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Abstract 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in equine 
veterinary practice. These drugs exert their effect by inhibiting 
cyclooxygenase (COX) enzymes, which control prostaglandin production, a 
major regulator of tissue perfusion. Two isoforms of COX enzymes exist: 
COX-1 is physiologically present in tissues, while COX-2 is up-regulated 
during inflammation and has been indicated as responsible for the 
negative effects of an inflammatory response. Evidence suggests that 
NSAIDs that inhibit only COX-2, preserving the physiological function of 
COX-1 might have a safer profile. Studies that evaluate the effect of 
NSAIDs on COX enzymes are all performed under experimental conditions 
and none uses actual clinical patients. The biochemical investigations in 
this work focus on describing the effect on COX enzymes activity of 
flunixin meglumine and phenylbutazone, two non-selective COX inhibitors 
and firocoxib, a COX-2 selective inhibitor, in clinical patients undergoing 
elective surgery. A separate epidemiological investigation was aimed at 
describing the impact that the findings of biochemical data have on a 
large population of equids. Electronic medical records (EMRs) from 
454,153 equids were obtained from practices in the United Kingdom, 
United States of America and Canada. Information on prevalence and 
indications for NSAIDs use was extracted from the EMRs via a text mining 
technique, improved from the literature and described and validated 
within this Thesis. Further the prevalence of a clinical sign compatible 
with NSAID toxicity, such as diarrhoea, is reported along with analysis 
evaluating NSAID administration in light of concurrent administration of 
other drugs and comorbidities. This work confirms findings from 
experimental settings that NSAIDs firocoxib is COX-2 selective and that 
flunixin meglumine and phenylbutazone are non-selective COX inhibitors 
and therefore their administration carries a greater risk of toxicity. 
However the impact of this finding needs to be interpreted with caution as 
	 3	
epidemiological data suggest that the prevalence of toxicity is in fact 
small and the use of these drugs at the labelled dose is quite safe. 
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CHAPTER 1 – Review of the Literature 
1.1 General non-steroidal anti-inflammatory drug history: from 
aspirin to coxibs 
 
The earliest recorded usage of a non-steroidal anti-inflammatory drug 
(NSAID) dates back to over 3500 years ago, from Ebers papyrus, 
Hippocrates, Celsus, Pliny the elder, Dioscorides and Galen, which all 
recommended preparations containing salicylate for the treatment of pain 
(Vane, 2000). The modern era of anti-inflammatory drug usage starts 
about 250 years ago with the study by Reverend Edward Stone who 
described the beneficial properties of willow bark (containing "salicine") to 
treat pain (Stone, 1763). Initially isolated in 1828 by Buchner, salicine was 
first synthesised in 1853 by Gerhardt and finally in 1897, in Bayer's 
laboratories, by Felix Hoffman, who also demonstrated its anti-
inflammatory efficacy (Botting, 2010; Jerie, 2006). After two years of 
clinical trials with low doses, Bayer's management decided to start the 
production and launched aspirin, as an analgesic drug, worldwide in 
summer 1899 (Vane, 2000).  The introduction of aspirin in the market was 
a major breakthrough economically and socially in human medicine. 
Recent reports suggest that the average worldwide consumption of aspirin 
is approximately 80 tablets/person/year (total production of 50,000 tons a 
year)(Vane, 2000). Although these numbers refer only to aspirin, they 
suggest how NSAIDs are part of everyday life for most and that they are 
among the most frequently administered medications in people.  	
Although aspirin had been marketed from the start as an anti-
inflammatory drug, its mode of action remained elusive for 74 years until 
the break-through discovery that these drugs act by inhibiting 
prostaglandin (PG) synthesis (Vane, 1971). Whilst researching the actions 
of the newly discovered prostaglandins, the same group of authors 
demonstrated that aspirin interferes with their production in vitro 
(Ferreira et al., 1971; Smith and Willis, 1971). The existence of the 
	 26	
cyclooxygenase (COX) enzyme family, also known as prostaglandin 
endoperoxide synthase enzymes, was for the first time demonstrated by 
three independent research groups in the late 1980s (DeWitt and Smith, 
1988; Merlie et al., 1988; Yokoyama et al., 1988). For a few years the 
knowledge was limited to a single enzyme (COX-1), until a second, 
inducible form of cyclooxygenase (COX-2) was identified (Laneuville et al., 
1994).
 
As the roles of the constitutively expressed isoform of 
cyclooxygenase (COX-1), and the inducible isoform (COX-2) were 
investigated the deleterious effects associated with NSAID use were 
attributed to the inhibition of COX-1 (Bakhle and Botting, 1996; Vane et 
al., 1998). Although the mechanism of action will be further discussed in 
Chapter 2 of this Thesis, the undesirable side-effects resulting from the 
use of these drugs is considered to be strongly related to the inhibition of 
prostaglandin production. In people these include gastrointestinal 
irritation, renal and hepatic toxicity, interference with haemostasis and 
reproductive tract problems (Bergh and Budsberg, 2005). It has been 
estimated that in the late 90s more than 30 million people would take 
NSAIDs daily and that of the approximately 100,000 humans that were 
treated for adverse gastrointestinal effects induced by NSAIDs 15% died as 
a consequence of toxicity (Singh, 1998; Singh and Triadafilopoulos, 1999). 
In 1999 the gastrointestinal side effects of NSAIDs were the 15th most 
common cause of death in the USA (Wolfe et al., 1999). These figures may 
explain why both human and veterinary researchers have recently focused 
on the production of new NSAIDs, which specifically inhibit the COX-2 iso-
enzyme, whilst allowing the physiologic regulation of prostaglandin 
production by COX-1 iso-enzyme. These so called “selective COX-2 
inhibitors” may maximize the beneficial anti-inflammatory effects, with 
reduced potential for development of side-effects. Drugs that emerged 
from this work include celecoxib, valdecoxib and rofecoxib. These are 
often referred to as the coxibs and they have been among the top-selling 
prescription drugs of any category in human medicine (FitzGerald and 
Patrono, 2001). 
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Up to just over a decade ago, non-selective NSAIDs (flunixin meglumine 
and phenylbutazone) were reported as most commonly used veterinary 
analgesics in Australia and South Africa (Joubert, 2001; Watson et al., 
1996). More recently, coxibs have also been evaluated in veterinary 
medicine for the treatment of pain and inflammation in dog, cat, and 
horse (Brideau et al., 2001; Giraudel et al., 2009; Kvaternick et al., 2007; 
Marshall et al., 2011; Orsini et al., 2012; Punke et al., 2008).  
 
1.2 Structure and function of cyclooxygenase enzymes 	
Despite the different physiologic functions, COX-1 and COX-2 enzymes 
share a rather similar structure with 61% amino acid homology (Appleby et 
al., 1994). Their structure constitutes approximately 600 amino acids 
organized to form a long hydrophobic channel with a hairpin turn at the 
end (Picot et al., 1994). The change with a valine residue in place of an 
isoleucine at the position 434 and 523 results in a 25% enlargement of the 
hydrophobic channel and active site of COX-2 due to a conformational 
change in phenylalanine 518. This larger diameter allows larger molecules, 
such as coxibs, to selectively bind to COX-2 but not to COX-1 (Kurumbail 
et al., 1996; Luong et al., 1996). 
 
Currently, three isoforms of COX enzymes have been identified, namely 
COX-1, COX-2 and COX-3. The COX-3 enzyme is a variant of COX-1 rather 
than a distinct isomer, but is expressed mainly in the cerebral tissue and 
only to a minor extent in other tissues (Chandrasekharan et al., 2002) and 
will not be mentioned further in this review. The localization and activity 
of COX-1 and COX-2 enzymes have been investigated intensely since the 
early 1990s (Vane et al., 1998). COX-1 is present under basal conditions in 
many cells, including mucosal cells of the gastrointestinal tract, 
endothelial cells, platelets and the renal medullary collecting ducts and 
interstitium (Harris et al., 1994; Kargman et al., 1996). The COX-2 isoform 
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is physiologically present in low concentrations in monocytes, 
macrophages, smooth muscle cells, fibroblasts and chondrocytes (Smith, 
1998), but is also constitutive in some tissues, such as kidney, brain or in 
canine pyloric and duodenal mucosa (Mitchell and Warner, 1999; Vane and 
Botting, 1995; Wooten et al., 2008). While COX-1 is considered a 
constitutive isoform, expressed mainly during physiological conditions, the 
expression of COX-2 is induced in determinate conditions, such as after 
stimulation of inflammatory cytokines or exposure to toxins, such as 
lipopolysaccharide (LPS). Further differences include a TATA box sequence 
located 25 base pairs upstream of the transcriptional start site, which is 
present in COX-2 but not in COX-1 enzyme (Appleby et al., 1994). The 
COX-2 gene also contains several potential transcription regulatory 
sequences (Appleby et al., 1994). During inflammation and injury, these 
elements allow COX-2 to respond to a wide variety of stimuli through up-
regulation of protein expression. In contrast, the COX-1 gene lacks these 
elements and possesses the characteristics of a ‘housekeeping’ gene 
(Garavito and DeWitt, 1999; Luong et al., 1996). Although the genes, 
mRNA transcripts, and protein structures of the COX enzymes differ, the 
COX enzymes both use the same substrate to produce an identical product 
(Garavito and DeWitt, 1999). The first reaction catalysed by the COX 
enzymes is the oxidation and cyclization of arachidonic acid to 
prostaglandin G2 (PGG2) at the COX site. This is followed by the reduction 
of PGG2 to prostaglandin H2 (PGH2) at the peroxidase site (Tazawa et al., 
1994). The final product of the COX enzymes, PGH2, is subsequently 
metabolized further into products with a wide range of biological 
activities (Garavito and DeWitt, 1999). Thromboxane synthase in platelets 
converts PGH2 into thromboxane A2 (TXA2), essential for platelet 
aggregation (Garavito and DeWitt, 1999; Tazawa et al., 1994).  
 
During inflammation, at the site of injury, the expression of COX-2 leads 
to increased PGE2, while inhibition of COX-2 results in a decreased 
inflammatory response (Vane et al., 1998). However, the perception that 
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COX-2 is a “bad” enzyme and COX-1 is a “good” enzyme is probably overly 
simplistic as there is some overlap in the functions of these isoforms and 
COX-2 has been shown to have physiologic function in certain tissues such 
as pyloric and duodenal mucosa in the dog (Wooten et al., 2008). 
 
1.3 Evaluation of cyclooxygenase selectivity 
 
Selectivity of COX-2 versus COX-1 is often expressed as the COX-1 to COX-
2 inhibitory ratio (COX-1:COX-2), usually expressed as the concentration 
necessary to inhibit 50% of COX activity (IC50), usually measured by 
stimulating cells capable of expressing products of these enzymes (Streppa 
et al., 2002). Recently it has been debated whether using IC50 is an 
accurate reflection of selectivity ratio and of concentrations and activity 
in vivo and that IC80 (the concentration that inhibits 80% of COX activity) 
would be more appropriate for this purpose (Furst, 1999; Hinz and Brune, 
2008; Kay-Mugford et al., 2000; Warner et al., 1999). In general terms, 
the higher the value, the more selective for COX-2 the drug is. In relation 
to their effect on COX-1 and COX-2 activity, NSAIDs are included in one of 
four categories (Frölich, 1997). The first of these includes the so called 
selective COX-1 inhibitors, routinely used in clinical settings to reduce 
platelet aggregation (e.g. aspirin) (Heath et al., 1994; Warner et al., 
1999). At higher doses these drugs may exert an effect at sites other than 
the vascular bed and may result in severe gastrointestinal and renal 
toxicity (Frölich, 1997). The second group includes NSAIDs that non-
selectively inhibit both isoforms of the COX isoenzymens and include the 
drugs most commonly used in equine medicine such as flunixin meglumine 
and phenylbutazone, but also other drugs routinely used in human as well 
as veterinary patients such as indomethacin, piroxicam, ibuprofen and 
ketoprofen (Frölich, 1997; Lees et al., 2004b).  The third group of NSAIDs 
includes drugs with a higher affinity for COX-2 but that still induce some 
degree of COX-1 inhibition (COX-2 preferential inhibitors). Meloxicam, 
nimesulide and carprofen are the most popular of these drugs. Meloxicam 
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has been evaluated in double blinded studies with a significant reduction 
in the number of gastrointestinal complications in comparison to non-
selective NSAIDs (Valat et al., 2001; Yocum et al., 2000) and these 
findings support the increased safety of NSAIDs with increased COX-2 
selectivity. However a study on meloxicam showed that this drug might 
have variable effect on prostanoid production despite serum concentration 
well within the therapeutic range for this drug (Blain et al., 2002). The 
last group includes drug with a high affinity for COX-2 and are called 
selective COX-2 inhibitors (FitzGerald and Patrono, 2001). Drugs of this 
group include the coxibs and their potent inhibition of COX-2 along with a 
normal function of COX-1 has been shown to offer significant 
improvements compared with NSAIDs of the previous three groups in 
veterinary studies (Beretta et al., 2005; FitzGerald and Patrono, 2001; 
Lees et al., 2004b; Punke et al., 2008). These NSAIDs are also referred to 
as COX-1 sparing, COX-2 specific, COX-2 preferential or COX-2 selective 
without however any true definition of the magnitude of the ratio used to 
define each term (Papich, 2008).  
 
1.4 Cyclooxygenase selectivity among species, in vivo and ex vivo 
 
Some disagreement between studies with respect to COX selectivity for 
different NSAIDs is present in the peer reviewed veterinary literature. 
Whilst earlier studies using purified enzymes in vitro reported a COX-
1:COX-2 ratio of 1275 (Gierse et al., 2002) for deracoxib in dogs, 
subsequent studies performed on a whole blood model had a ratio of only 
12 (McCann et al., 2004). For carprofen the measured COX selectivity was 
~100 fold different using purified canine enzyme systems compared to 
canine macrophages (Kay-Mugford et al., 2000; Ricketts et al., 1998) or 
~1000 fold difference comparing whole blood with cell culture methods 
(Wilson et al., 2004). These findings suggest that COX selectivity may vary 
significantly depending not only on the assay used but also on the model 
adopted (e.g. in vitro or ex vivo) (Vane and Botting, 1995). Further, COX 
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selectivity for various NSAIDs varies widely among species and data 
regarding one species may not necessarily apply to another (Brideau et 
al., 2001). Marked difference in carprofen selectivity has been reported in 
studies using canine cell lines (COX-1:COX-2 IC50 ratio of 129) (Ricketts et 
al., 1998) compared to sheep and rodent cell lines (COX-1:COX-2 IC50 ratio 
of 1) (Vane and Botting, 1995). Further, COX-2 selectivity of etodolac, an 
acetic acid derivative NSAID, is 10 times greater in people than in dogs 
(Glaser, 1995; Gierse et al., 2002). While a COX-2 preferential inhibitor 
(IC50 of 16.6) in the dog (Streppa et al., 2002), carprofen is non-selective 
in the horse (IC50 of 1.9) (Beretta et al., 2005). In conclusion these studies 
evidence not only the importance of assessing species-specific COX 
selectivity but also that evaluating ex vivo as well as in vivo models is of 
pivotal importance to assess the effect that these drugs have on a clinical 
patient. 
 
1.5 Assays for cyclooxygenase activity determination 
 
It is relatively well accepted that whole blood assays are the gold standard 
for the determination of COX selectivity in vitro (Patrignani et al., 1994) 
compared to other models using isolated cells or enzyme systems (Li et 
al., 1995; Noreen et al., 1998; Ogino et al., 1997; Pairet, 1998; Vago et 
al., 1995).  In fact, whole blood assays include most of the components 
that may normally affect drug activity such as proteins, cells, platelets 
and circulating enzymes all at physiological concentrations. Whole blood 
assay measures thromboxane (TXB2) produced by stimulated platelets 
which is a product proportional to the activity of COX-1 enzyme, whilst 
COX-2 activity is inferred from the amount of prostaglandin E2 produced 
by leukocytes (Brideau et al., 2001). Non-steroidal anti-inflammatory 
drugs are usually highly protein bound which in turn means that only a 
small amount of free active drug is present in blood, which is better 
expressed in whole blood assays compared to cell cultures or purified 
enzyme assays (Wilson et al., 2004).  
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Whole blood ex vivo models are considered most clinically relevant as the 
blood samples for COX activity assays are obtained following drug 
administration and therefore account for differences in drug metabolism, 
pharmacokinetic variables and drug accumulation in tissues and are more 
likely to reflect physiologic and pathologic conditions and predict clinical 
outcome (Blain et al., 2002). 
 
Pharmacokinetic-pharmacodynamic studies have also been performed to 
derive the clinically most appropriate dosage for each NSAID (Giraudel et 
al., 2005; Lees et al., 2004a, 2004b). An inhibition of COX-2 of about 80% 
(IC80) is necessary to predict a clinical effect and drugs producing 50% of 
inhibition may not produce a significant therapeutic effect (Hinz and 
Brune, 2008). 
 
1.6 Non-steroidal anti-inflammatory drug toxicity in horses 
 
Phenylbutazone, an NSAID, is one of the most commonly used drugs for 
treatment of equine athletes with signs of musculoskeletal pain (Soma et 
al., 2012), and it is generally believed to be reasonably tolerated in horses 
when administered at the recommended dosage and dosing interval. In 
1979 and again in 1981, two separate research groups (Lees and Michell, 
1979; Snow et al., 1981, 1979) demonstrated that administration of this 
drug to horses (4–8 mg/kg /day) can cause severe adverse effects, 
including gastric ulceration, renal dysfunction and inflammation and 
ulceration of the mucosa of the large colon, particularly of the right dorsal 
colon. These effects have subsequently been confirmed by several other 
studies (Cohen et al., 1995; Collins and Tyler, 1985, 1984; Hough et al., 
1999; Karcher et al., 1990; MacAllister et al., 1993; MacKay et al., 1983; 
Meschter et al., 1990a, 1990b, 1984; Simmons et al., 1990).  	
Earlier studies on phenylbutazone used high dosages that today would be 
beyond what are considered safe. Dosages at 10mg/kg daily for 14 days 
(Snow et al., 1979) or 13.5mg/kg daily (Meschter et al., 1990a, 1984) were 
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administered and very frequently resulted in significant renal, gastric and 
colonic damage. In a study, overdosing phenylbutazone (4.4mg/kg TID) 
and flunixin meglumine (1.1mg/kg IV TID) and ketoprofen (2.2mg/kg IV 
TID) for 12 days resulted in gastric glandular ulceration in all treated 
horses, whilst colonic ulceration was present only in phenylbutazone 
treated horses (MacAllister et al., 1993). The study by Collins and Tyler 
(1984) determined that total daily doses up to 8.8mg/kg were generally 
safe while toxicity was more likely to ensue at higher doses. The findings 
of this study determined the currently recommended dose for 
phenylbutazone in horses.  
 
Albeit side effects are generally rare when NSAIDs are administered at 
labelled doses, concurrent dehydration has also been shown to increase 
the risk for renal medullary crest necrosis in horses (Gunson and Soma, 
1983), which appear to be a species more susceptible to this side effect 
than others, such as dogs and rabbits (Black, 1986; Faulkner et al., 1984; 
Read, 1983). Overdosing has also shown to cause renal crest necrosis in 
horses receiving either phenylbutazone and flunixin meglumine, while 
horses receiving ketoprofen did not (MacAllister et al., 1993). 	
The gastrointestinal system is also sensitive to NSAID toxicity and gastric 
mucosa and the right dorsal colon appear to be most susceptible (Hough et 
al., 1999). A decrease in mucosal blood flow secondary to prostaglandin 
production inhibition by COX-1 enzyme has been suggested as the main 
mode of action (Richter et al., 2002). A study looking at the effect of 
flunixin meglumine on renal plasma and blood flows failed to find a 
significant effect (Held and Daniel, 1991), but the concurrent effect on 
gastrointestinal blood flow remains undetermined. The study by Meschter 
and colleagues (1984) described that overdosing of phenylbutazone caused 
wall degeneration of small mucosal veins, with dilation and hyaline 
degeneration resulting in erythrodiapedesis and leukodiapedesis, 
submucosal oedema and ulceration. Another study has documented an 
increase in gastrointestinal mucosa permeability, particularly at gastric 
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level (D’Arcy-Moskwa et al., 2012). In that study sucrose permeability test 
(Hewetson et al., 2006; O’Conner et al., 2004) was used to ascertain the 
permeability of the gastric epithelium and found that the effect of 
phenylbutazone was significantly greater than that of meloxicam (D’Arcy-
Moskwa et al., 2012). Another study comparing the effect of 
phenylbutazone to that of suxibuzone on the gastric mucosa found that 
both drugs induced gastric ulcers but phenylbutazone much more so than 
suxibuzone, compared to a placebo group (Monreal et al., 2004). That 
study aimed to compare the effect of these two drugs and concluded that 
suxibuzone is generally safer than phenylbutazone. However, significant 
flaws in study design make the results of that study difficult to interpret. 
The study consisted of a comparison of gastric ulceration score in three 
groups of horses receiving either a placebo, phenylbutazone or suxibuzone 
(Monreal et al., 2004). Whilst the study found that the majority of horses 
with gastric ulceration had received phenylbutazone and only a small 
proportion suxibuzone, none of the horses had undergone gastroscopy 
before the start of the study. Therefore the prevalence of gastric 
ulceration in the population before the study commenced was unclear. 
This was a major limitation since gastric ulceration is often present 
without clinical signs (Murray et al., 1989). Further, once metabolized by 
the liver, suxibuzone is converted to active phenylbutazone and released 
in the blood stream. Ultimately the effect of suxibuzone is similar to that 
of oral phenylbutazone without the “topical” direct effect on the gastric 
mucosa after ingestion and could therefore be comparable to intravenous 
phenylbutazone (Andrews et al., 2009). Some argued that suxibuzone may 
be more palatable than phenylbutazone, but a study found that a 
commercial preparation of suxibuzone has similar palatability to that of 
phenylbutazone (Longhofer et al., 2008) while others found that 
acceptability was better with suxibuzone (Sabaté et al., 2009). Another 
later study that compared these drugs at label doses but examined the 
gastric mucosa before and after the administration of these drugs found 
no difference between drugs or the placebo (Andrews et al., 2009). 	
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The potential for hepatotoxicity of NSAIDs has also been described in many 
species (Lee, 2003), including horses although this appears to be less 
common than gastrointestinal and renal toxicity (Lees et al., 1983). In 
humans, hepatotoxicity from NSAIDs administration has been described as 
an intrinsic, dose related reaction but also as an idiosyncratic reaction 
(Bjorkman, 1998; Tolman, 1998). Most of NSAIDs undergo some degree of 
hepatic metabolic pathway and severe liver disease might affect drug 
metabolism. However, the concern of using NSAIDs in patients with liver 
disease is more focused on the excessive active drug that remains 
available once the liver is unable to metabolise it effectively (Papich, 
2008; Sanchez, 2010). 
 
1.7 Knowledge discovery in databases 
 
Medical record computerisation has been introduced since the mid-1960s 
(Salton, 1971; Salton and Lesk, 1968). Initially information was stored 
using one of two main types of systems. The first used a rigid but 
structured protocol that offered optimal retrievability of the stored 
information. However, it lacked flexibility and limited the freedom of 
expression of clinicians storing the information and poorly adapted to 
unique characteristics of certain clinical cases. The alternative system 
allowed the storage of free unstructured text in a manner similar to paper 
records. Although this did not restrict freedom of expression it made data 
retrieval rather troublesome (De Bruijn and Martin, 2002; Garten et al., 
2010).  	
Systems for the automated retrieval of information from these databases 
have also been developed for 40 years (Anholt et al., 2014a; Harman, 
1996; Heinze et al., 2001; Krallinger et al., 2008; Salton, 1971). For 
unstructured free-text database most effective systems involve keyword 
frequency analysis (Anholt et al., 2014a; Kreis and Gorman, 1997; Petrova 
et al., 2012). The main goal of these retrieval systems is to find the right 
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index terms so that a query will identify and retrieve the most appropriate 
documents, cases or records (Kreis and Gorman, 1997).  	
Tools for text-based data mining have proved useful in human medicine 
for over a decade in knowledge discovery in databases (KDD) which has 
been defined as the use of systems to seek and extract similarities of 
documents in a collection automatically or determine what is unusual 
about a particular collection (Frawley et al., 1992). A pattern that is 
interesting according to predefined criteria and certain enough is defined 
as “knowledge”, whilst “discovered knowledge” is the output of a program 
that monitors the patterns of a set of facts in a database (Frawley et al., 
1992).  
 
Automated KDD uses Artificial Intelligence (AI) to discover useful 
knowledge from a collection of data. Data mining, referred to as the 
analysis step of KDD, aims to extract information of interest from a 
dataset and transform this information into an understandable structure 
for further use (Piatetsky-Shapiro 2000). A practical application of KDD has 
been described by Goldman and colleagues (1999). In their study these 
authors, through the use of Term Domain Distribution Analysis (TDDA), 
identified that human thoracic lung cancer tumours affect more 
frequently the right rather then the left lung with a ratio of 3:2 in a small 
dataset (178 cases, with records of ~250 words/case and a total collection 
size of 321kbytes). The TDDA used in that study consisted of the 
automated tracking of the frequencies for specific predefined terms and 
subsequently highlighting any significant difference from the expected 
term distribution and frequency (Goldman et al., 1999). 	
Current research of KDD is focused on methodologies to structure the 
unstructured textual information to conform free-text information to a 
predefined format (Garten et al., 2010). Traditional information retrieval 
systems simply rank documents relevant to a given query, mostly using a 
threshold function based on keyword frequency analysis with the ultimate 
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goal of identifying similar documents (Garten et al., 2010). The Electronic 
Medical Record (EMR) has been a major goal in Health Information 
Management for decades (Heinze et al., 2001). Heinze and colleagues 
(2001) reported the findings of LifeCode®, a project using a state-of-the-
art Natural Language Processing (NLP) search engine, designed to mine the 
transcriptions of dictated clinical records from a wide range of medical 
specialties to facilitate clinical and epidemiological studies on topics of 
interest for both medical and pharmaceutical industries. The success of 
previous systems had been seriously limited due to the relative 
inaccessibility of the information in free-text clinical documentation 
(Heinze et al., 2001). Attempts to change the documentation habits of 
physicians have not had significant success largely due to the increased 
time and inconvenience associated with using computer interfaces that 
require formatted input. Further, numerous consultations with practicing 
physicians have taught us that there is a basic inability of fully structured 
systems to fully adapt to the unique characteristics of each case (Garten 
et al., 2010). Nowadays the most common applications of these systems in 
medical research are represented by Medline or Pubmed, which enhance 
the role of NLP by integrating statistical algorithms to refine search results 
(Workman and Stoddart, 2012). 	
The biomedical literature holds almost all our understanding on a wide 
variety of topics, but remains dispersed across many journals. In order to 
integrate medical knowledge, connect important facts across publications 
and generate new hypotheses, authors must organize and encode the 
contents of the literature. By creating databases that structure the 
knowledge available on a specific topic, the value of the literature 
becomes much greater than the sum of the individual reports (Garten et 
al., 2010). 						
	 38	
1.8 Text mining in knowledge discovery in databases 
 
Recent work in biomedical text mining has focused on techniques 
developed for NLP, and text mining can be thought of as a subset of NLP, 
which is defined as a conversion of human language into computable 
formats (Garten et al., 2010). However, text mining also uses techniques 
developed in the field of machine learning that automatically recognize 
complex patterns in large text datasets (Garten et al., 2010). Text mining 
consists of two main steps: identification of documents that may contain 
the desired information, and subsequent extraction of the information 
from this set of documents (Krallinger et al., 2008). Text mining is the 
automated equivalent of reading for people, as just like a reader, the 
machine selects what they will read, then identifies important entities 
and relations amongst these entities and finally combines the new 
information to other parts of the article (De Bruijn and Martin, 2002). The 
identification process, or “automated reading” can also be subdivided in 
four general subtasks: text categorization, named entity tagging, fact 
extraction and collection-wide analysis (De Bruijn and Martin, 2002). The 
process of text categorisation is an information retrieval process that 
divides the document into separate subsets belonging to predetermined 
categories (Iliopoulos et al., 2001). Named entity tagging processes use 
character-by-character or word-by-word pattern analysis to identify 
entities fitting a named category (De Bruijn and Martin, 2002). Fact 
extraction is the identification of entities and their interactions or 
relationships, which is hardly achievable by an automated process, but can 
somewhat be obtained by statistical co-occurrence, imperfect parsing or 
co-reference resolution (De Bruijn and Martin, 2002). Collection-wide 
analysis includes the processes of integrating information between 
documents to discover new knowledge (De Bruijn and Martin, 2002; 
Weeber et al., 2000). This process is summarised in Figure 1.1. 
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1.9 Electronic medical records in medical practice 
 
The National Health Service (NHS) is the publicly funded health care 
system in place in the United Kingdom. In April 2004 the United Kingdom 
department of Health formed NHS Connecting for Health, a group that 
among it’s aims had that of creating a centralised electronic clinical 
record system that connects practice management systems software 
(PMSS) of general practitioners and hospitals. 	
	
	
Figure 1.1: Text mining as a modular process (adapted from De Bruijn & Martin 
2002) 
 
Among many other benefits, it was envisaged that this could ultimately 
provide an invaluable pool of information suitable for epidemiological 
research for authorized health professionals. Due to several political, 
social and ethical reasons the aims of this project have proved 
Collection-wide analysis 
Combines facts that were extracted from various text into inferences, 
ranging from combined probabilities to newly discovered knowledge 
Fact extraction, information extraction 
Extraction of more elaborate patterns out of the text 
Named entity tagging 
eg. protein/gene names 
Document categorisation 
Division of the document in disjoint subjects 
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problematic to achieve and at a great cost as the initial budget of £2.3 
billion over three years have been revised to £12.4 billion over 10 years 
according to the Department of Health’s National Program for IT in the 
NHS of 2006. The project aimed to provide integrated care records 
services, electronic prescribing and appointments booking, integrating the 
use of software for access of digital medical imaging and to improve 
performance management of primary care, but also to provide a central 
email and directory service. In 2007 the Public Accounts Committee (PAC) 
expressed some serious concerns that the project would not result in any 
significant clinical benefit for the patients and in 2011 a lack of significant 
progress of the project was still noted by PAC (House of Commons 
Committee of Public Accounts, 2011; House of Commons Health 
Committee, 2007). 	
The current record systems adopted by the NHS include entries that are a 
mixture of text and “Read codes”. General practitioners (GPs) are free to 
adopt whichever PMSS they think would best suit the needs of their 
practice, which complicates how data can be accessed for research 
purposes. It is interesting to note that EMR are assessed to see if general 
practitioners meet NHS targets through qualitative outcome frameworks 
(QOF) and GPs’ good compliance with read codes is followed with a 
financial incentive. Previously the validity and utility of the information of 
preliminary electronic patient record systems have been subject to 
validation against paper records or patient surveys (Pringle et al., 1995; 
Whitelaw et al., 1996; Wilson et al., 1995). In Britain the Primary Care 
Information Service (PRIMIS), developed by the University of Nottingham in 
2000, was designed to assist general practitioners to effectively use their 
PMSS to optimize clinical record management and ultimately improve 
patient care. This software package contains an internal toolkit for 
measuring reliability of data collection, which offers a form of internal 
validation system regarding patient clinical and personal data (reference 
website www.primis.nottingham.ac.uk) (Hassey, 2001).  Currently the 
EMIS system is one of the most common PMSS (53% of general practitioners 
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in 2011) in use in the United Kingdom that allows storage of data including 
medical history, acute and repeat medication records and results of blood 
and radiology investigations posted back to a surgery from a hospital 
(www.emishealth.com). In September 2014 the system was connected 
online linking 3750 general practices out of the approximately 9800 
present in the United Kingdom and enables other connected medical 
practices and patients to access their medical records online. The validity 
of this clinical record system was evaluated by comparing the stored data 
with information obtained directly from the patients through a 
questionnaire and results have shown that the information retrieved by 
this system is valid, complete and accurate (Hassey, 2001). SystemOne is 
also a commonly used system, available since 2008, which also uses Read 
codes extensively, but unlike other systems, all data is stored on remote 
servers. In 2015 the company IMS MAXIMS released a free PMS, which is 
pioneering open-source software usage in the NHS and might offer a more 
cost effective alternative for the future. Clinical Practice Research 
Datalink (CPRD) is a governmental, non-profit research service funded by 
the NHS National Institute for Health Research (NIHR) and the Medicines 
and Healthcare products Regulatory Agency (MHRA), a part of the 
Department of Health. This service provides anonymised primary care 
records for public hearth research since 1987. In Scotland the Primary 
Care Clinical Information Unit (PCCIU) was founded in 1999 to collect data 
from and provide a reporting service to general practice in Scotland. 	
One of the main issues with these systems relates to the confidentiality of 
patient data shared by General Practitioners who are obliged to follow the 
law in the Data Protection Act, but at the same time have the “duty to 
share” when this is in the best interest of the patient. 	
In 2013 the Department of Health created the Health and Social Care 
Information Centre (HSCIC) as an initiative aimed at gathering and 
analysing data from general medical practice clinical systems in NHS 
England to help decision makers improve the quality and efficiency of 
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frontline medical care. The program was called care.data and is managed 
by Atos, a French company, which has received controversial criticism for 
the lack of clarity around the ability for patients to opt out the project so 
that the project was stopped in May 2014, only to be resumed for few 
months in 2015 before being again paused due to the confidentiality 
concerns still remaining unresolved. The project was very expensive and 
data acquisition was mostly suitable for the industry and not for public 
health research. 
 
1.10 Electronic patients records in companion animal and equine 
veterinary practice 
 
Compared to the human health sector, the veterinary market lacks a 
centralised body such as the NHS that attempts to govern patient data 
management. Although several PMSS are available to veterinary practices, 
there has been little attempt to centralize the stored information and no 
attempt has been made to validate these systems for their usefulness in 
using the stored information for epidemiological research. Further the 
many available systems seldom allow a simple transfer of patient clinical 
detail between practices. This offers several challenges to data collection 
and the gathering of specific clinical information regarding the animal 
population in a specific country such as the United Kingdom or worldwide.  
 
Recent efforts have focused on the prospective collection of data from 
veterinary practices selected on the criteria of using a certain PMSS and 
being willing to participate. The Veterinary Companion Animal 
Surveillance System, also known as VetCompass, is a project operated by 
the Royal Veterinary College, University of London in collaboration with 
the University of Sydney in Australia, to investigate the range and 
frequency of small animal health problems seen in veterinary practice 
(http://www.rvc.ac.uk/vetcompass). This project uses a predefined 
coding system (VeNom – Veterinary Nomenclature) that Veterinary 
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surgeons from participating practices must utilise to classify each case 
they deal with into one of these categories. In March 2015 the project 
included data from over four million small animal patients, from 450 
veterinary practices in the UK. The Small Animal Veterinary Surveillance 
Network (SAVSNET) project is another initiative born from the 
collaboration between the British Small Animal Veterinary Association 
(BSAVA) and the University of Liverpool to monitor the current and future 
disease status, gather data for research and educate public and 
professionals to improve the management of disease in the small animal 
population in the United Kingdom (http://www.savsnet.co.uk/). The 
project in late 2015 involved over 50 small animal veterinary practices. 
Data is collected using a point-and-click application integrated in the 
practice’s PMSS. Veterinary surgeons from participating practices must 
then use this application to classify cases they see under a certain 
category (e.g. body system involved) (Radford et al., 2011). For a random 
subset of the clinic population a further set of detailed questions are 
asked to further describe/fit the case into a predetermined category. Both 
these projects offer the advantage that data are classified in 
predetermined categories by the veterinary clinicians that input the 
clinical data to the PMSS and therefore data is already ordered and ready 
for research. The downside is that clinicians are forced to fit the finding 
of a clinical case to a certain category, even though the clinical case they 
are evaluating might subsequently turn out to belong to another category 
or might just not fit well into any of the categories available. Also these 
processes require a serious long-term commitment by clinicians that are 
required to learn these coding systems. Ultimately, to date no validation 
has been performed comparing the free-text clinical records to that of 
these ad-hoc categorisations and their sensitivity and specificity remain 
undetermined. 	
These projects will offer an excellent support in infectious disease 
surveillance as they aim to provide veterinary surgeons with real-time 
information regarding disease outbreaks which would result in prompt 
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patient testing and effective implementation of preventive strategies 
(O’Neill et al., 2012a; Radford et al., 2011; Ward and Kelman, 2012). As in 
human medicine, this could have positive repercussions on both animal 
welfare and economically for society and veterinary practice (Erstad, 
2003). However, these projects suffer significant limitations at the 
present time, such that only practices using PMSS that allow third parties 
to access the clinical records in real time can be included. 	
Other examples utilizing computer-based patient record analysis for 
retrospective descriptive studies are sparse in veterinary medicine 
although they have been published in increasing number over the past few 
years (Boden et al., 2005; Boden and Parkin, 2008; Cameron et al., 2014; 
Lam et al., 2007a; Ortiz-Pelaez and Pfeiffer, 2008; Oswald et al., 2010).  
 
Another example includes ProActive Insight, a service sponsored by Merial 
offered to veterinary practices using Merial vaccines since 2013, which 
uses large datasets from equine practices in the United Kingdom. This 
service does not aim to use clinical data for epidemiological research, but 
has the sole intent to maximise income generation while reducing costs 
for veterinary practices (http://www.proactiveinsight.co.uk). This service 
is run by a third party company, Veterinary Insights ltd., partly supported 
by Merial and works by identifying areas that might improve business 
efficiency and profitability. This is achieved by analysis of key 
performance indicators aimed at building a picture of how the practice is 
performing compared to other similar practices throughout the country. 
This service aims to provide veterinary practices with business intelligence 
to exploit market trends and support better business decision-making. 
Since this project is aimed at improving the business aspect of veterinary 
practice, data has not been used for scientific knowledge advancement to 
date. 	
Like in human public health, there are limitations to collection of 
representative data samples from veterinary practice as it would be 
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difficult, if at not impossible, to convince the vast majority of veterinary 
practices to conform to a universal format for data storage. A solution 
might be to have a ruling institution, such as the Royal College of 
Veterinary Surgeons in the United Kingdom, to guide this process. 
Although this may seem logical in general terms, such a process would be 
impossible to impose as it would effectively limit the freedom of 
veterinary practices to choose one PMSS system over another. Further, an 
agreement between research groups would be necessary to decide what 
the most appropriate system would be in terms of providing data suitable 
for research. Ultimately, the lack of compliance by veterinary surgeons 
that often do not wish to share the clinical information of their patients 
with external investigators is also a major limiting factor. In fact many see 
disclosing anonymous clinical details to third parties, even if for the 
simple scope of scientific research, as a breach of client confidentiality. 
This is why clients enrolled in recent prospective projects are given the 
opportunity to opt out of these studies when their animal presents for 
clinical evaluation (O’Neill et al. 2011). Whilst this is going to be gold 
standard for data acquisition and real time disease surveillance, this is not 
possible for the studies that use a retrospective analysis of clinical 
records. However, secure handling of large anonymised datasets is 
unlikely to ever be a threat to confidentiality between veterinary surgeons 
and their clients (Balas et al., 2015).  	
An alternative strategy might consist of convincing veterinary practices of 
the importance of collecting good quality data suitable for epidemiological 
research, as the results of such research might in return provide 
veterinary practice with useful information to improve patient care, 
owner satisfaction and ultimately increasing client trust and yearly 
revenues. This approach might pay in the longer term, but its 
implementation is expected to be slow and would require a significant 
effort in terms of public engagement and advertising with veterinary 
practices.  
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1.11 Non-steroidal anti-inflammatory drugs in veterinary practice 	
Most information on the preferences of NSAID choice by veterinary 
surgeons has been obtained through questionnaire-based studies (Dujardin 
and van Loon, 2011; Hubbell et al., 2010; Joubert, 2001; Watson et al., 
1996). Although this may give information on what veterinary surgeons 
know and think about these drugs, none of these studies provide objective 
details on what is actually used in practice. Because of their nature, 
questionnaires may be subject to bias as interviewed subjects are likely to 
give answers that are more compliant with official recommendations for 
the topic investigated so that the reliability is usually moderate at best 
(Helmerhorst et al., 2012). The results of questionnaire-based studies 
applied to drug usage should therefore be interpreted more as reflection 
of veterinary surgeon’s knowledge rather than an indication of what is 
actually being administered to the patients.  One of the earliest surveys 
came from Australia from nearly 20 years ago and describes the use of 
analgesics, including corticosteroids and opioids along with NSAIDs, in dogs 
and cats (Watson et al., 1996). In that study descriptive statistics were 
applied to describe preferences by veterinary surgeons to treat a variety 
of conditions. A similar study was performed in South Africa a few years 
later and reported similar findings with phenylbutazone and flunixin 
meglumine being the NSAIDs of choice (Joubert, 2001). It is interesting to 
note how phenylbutazone was the drug of choice for many 
musculoskeletal conditions in these studies. It is legitimate to hypothesize 
that the type of NSAIDs used have largely changed since those studies 
were performed, as a wide variety of newer NSAIDs with fewer side 
effects have become available over the past decade, especially for use in 
small animal practice. Several studies have provided evidence of a lower 
potential for side effects (King et al., 2010; Moreau et al., 2003; Slingsby 
and Waterman-Pearson, 2001). Ideally this type of survey should be 
repeated periodically to ensure that an up-to-date evaluation of drug 
preferences is provided. In fact, newer drugs such as meloxicam, 
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carprofen and ketoprofen were reported as those being most frequently 
prescribed to small animal patients in a survey conducted a few years 
later among French veterinarians (Hugonnard et al., 2004). However, a 
similar more recent survey performed among equine veterinary surgeons 
in the Netherlands reported that phenylbutazone and flunixin meglumine 
were most used (Dujardin & van Loon 2011). This lack of change in the 
type of NSAID prescribed is not entirely surprising as the number of new 
NSAIDs licensed for horses remains limited to meloxicam and only more 
recently to firocoxib. A list of veterinary products containing NSAIDs in 
United Kingdom, United States of America and Canada is available in 
Appendix 1.11). 
 
Despite the significant effort required to obtain data through survey-based 
research projects, the results obtained should be interpreted as reflection 
of veterinary knowledge and experience rather that an actual direct 
assessment of what is actually used. This is where automated mining of 
digital clinical records has great potential, as it allows a direct objective 
measurement of amount and type of drug prescribed. A recent study has 
described a practical application of this methodology to describe the 
usage of corticosteroids in small animals (O’Neill et al., 2012b). 
Descriptive statistics were applied to a large dataset of over 30,000 
clinical records from three small animal practices in England. The results 
of that study provided evidence of a significant difference in prescription 
patterns between practices, which may be a reflection of several factors 
including personal experience and preference by veterinary surgeons from 
different practices (O’Neill et al., 2012b). The authors concluded that this 
was a preliminary study that although including a relatively large number 
of clinical records, was unlikely to be reflective of the overall population 
due to the limited number of veterinary practices and veterinary surgeons 
involved. While these studies include often thousands of medical records 
it is relevant to consider that, particularly when looking at prevalence of 
drug usage, there remains a potential effect of practice, which should be 
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accounted for during analyses. It is therefore important that the number 
of practices is as large as possible to minimise the intrinsic bias of large 
veterinary practices. 
 
1.12 Aims of the overall study 
 
This study aims to provide an insightful investigation of the role of COX 
selectivity in the development of NSAID toxicity in equine clinical 
practice.  
 
Biochemical investigations in Chapter 2 aim to provide evidence that COX 
selectivity can affect the potential development of toxic side effects in 
actual equine clinical patients. 
  
Epidemiological investigations in Chapters 3 to Chapter 5 look at the 
impact that NSAID usage has on equine practice. This is achieved by 
interrogating hundreds of thousands of patients’ medical records to 
describe how often NSAIDs are used, for which conditions, and how often 
toxicity is actually encountered in every day practice and also if there is 
evidence that administration of COX-2 selective NSAIDs carry a lower risk 
of side effects. 
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CHAPTER 2 - Effect Of Flunixin Meglumine, 
Phenylbutazone And Firocoxib On Cyclooxygenase 
Activity In The Horse 
 
2.1 Introduction 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a common treatment 
for pain and inflammation in horses undergoing surgery. These drugs exert 
their effects mostly by regulating cyclooxygenase (COX) enzyme activity 
and subsequent tissue prostaglandin production. Two main COX isoforms 
have been identified: COX-1 is the constitutive form and regulates tissue 
blood flow in physiologic states, while COX-2 is mainly expressed during 
inflammatory states and its uncontrolled action is considered responsible 
for many of the undesired effects of the inflammatory process (Vane et 
al., 1998). In horses, a relationship has been described between the use of 
non-selective COX inhibitors, including phenylbutazone and flunixin 
meglumine, and development of significant gastrointestinal and renal 
toxicity (Hough et al., 1999; Jones et al., 2003; MacAllister et al., 1993; 
Snow et al., 1979). These adverse effects are the likely result of inhibition 
of mucosal and renal medullary perfusion by reducing COX-1 activity 
(Moses and Bertone, 2002). Selective COX-2 inhibitors have been 
evaluated in horses to ascertain whether they could reduce the risks of 
side toxic side effects subsequent to COX-1 inhibition (Davis et al., 2011; 
Doucet et al., 2008; Letendre et al., 2008; Marshall et al., 2011; 
Tomlinson and Blikslager, 2005). 
 
While traditional NSAIDs, phenylbutazone and flunixin meglumine, are not 
selective COX inhibitors (Doucet et al., 2008; Marshall et al., 2011), 
coxibs, such as robenacoxib and firocoxib, have recently been evaluated in 
horses (Davis et al., 2011; Doucet et al., 2008; Letendre et al., 2008; 
Marshall et al., 2011; Tomlinson and Blikslager, 2005) and were found to 
have high COX selectivity ratio in vitro (Marshall et al., 2011). Currently, 
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firocoxib is the only COX-2 selective drug licensed for use in the horse and 
its licencing covers the alleviation of pain and inflammation associated 
with osteoarthritis and reduction of associated lameness in horses. 
 
The COX selectivity of an NSAID may be vastly influenced by the assay 
used as well as the model adopted i.e. in vitro or ex vivo (Blain et al., 
2002; Vane and Botting, 1995). Whilst earlier studies using purified 
enzymes in vitro reported a COX selectivity ratio of 1275 (Gierse et al., 
2002) for deracoxib in dogs, subsequent studies performed on a whole 
blood model had a ratio of only 12 (McCann et al., 2004). Some studies 
have shown little difference in clinical effect or rate of side effects for 
NSAIDs with different COX selectivity in vitro (Borer et al., 2003) and 
discrepancies between in vitro and ex vivo COX inhibition (Blain et al., 
2002; Giuliano and Warner, 1999). These studies demonstrate not only the 
importance of assessing species-specific COX selectivity, but also that 
evaluating ex vivo as well as in vitro models is of pivotal importance to 
assess the effect that these drugs have on clinical patients (Lees et al., 
2004a). In vitro models allow determination of inhibition concentration 
curves, which illustrate well the effect of these drugs at different 
concentrations and provide useful data to predict COX-1 enzyme inhibition 
at a given concentration. In vitro data can be subsequently used to 
evaluate if any discrepancy exists between expected COX-1 inhibition as 
calculated from an in vitro model and the actual COX-1 inhibition 
obtained with the drug used at the labelled dose in an ex vivo model. The 
comparison of in vitro and ex vivo data would provide an objective insight 
of the reliability of in vitro models to assess in vivo COX inhibition. To the 
authors’ knowledge published equine studies assess the effects of NSAIDs 
only in vitro or ex vivo in experimental animals (Beretta et al., 2005; 
Cuniberti et al., 2012; Davis et al., 2011) and data obtained from ex vivo 
clinical models is greatly needed. 
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Several studies have described the pharmacokinetic and pharmacodynamic 
properties of NSAIDs in horses (Coakley et al., 1999; Gerring et al., 1981; 
Kvaternick et al., 2007; Lees et al., 2004a; Lees and Higgins, 1985; 
Letendre et al., 2008; Toutain et al., 1994). For phenylbutazone at the 
dose of 4.4mg/kg intravenously the serum concentration producing 50% of 
the maximal effect (EC50) was found to be 3.6±2.2µg/ml (Toutain et al., 
1994). For flunixin meglumine at the dose of 1.1mg/kg intravenously the 
EC50 was 0.93±0.35µg/ml (Toutain et al., 1994). To the authors knowledge 
no data is available of the EC50 of firocoxib in horses. However, a study 
comparing the efficacy of phenylbutazone and firocoxib in managing 
naturally occurring osteoarthritis in horses found no significant difference 
at label doses (Doucet et al., 2008). Since in vivo the EC50 of firocoxib in 
clinical patients cannot be determined for ethical reasons, as a study 
protocol would require several serial blood samples collection, describing 
the serum concentration of firocoxib at 2 and 24 hours would provide an 
indirect rough estimation of the drug’s EC50. These two time points 
correspond to when the drug has its maximum effect and the lowest effect 
prior to administration of the subsequent dose respectively. Also, from a 
practical point of view, residual blood samples could be available as these 
could be collected for intra- and post-anaesthetic monitoring purposes. 
 
These studies are conducted under controlled research conditions, where 
animals do not concurrently receive other medications nor undergo 
procedures that might interfere with drug metabolism. The effect of the 
concomitant use of other pharmaceuticals and concurrent undergoing of 
surgical procedures on drug metabolism, which is the typical scenario in 
clinical patients is unknown. To the best of the author’s knowledge the 
concentration of phenylbutazone, flunixin meglumine and firocoxib 
administered peri-operatively in actual clinical cases has not been 
described before. 
 
The aims of this chapter are to:  
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1. Compare the in vitro selectivity of a non-selective COX inhibitor 
such as flunixin meglumine and the COX-2 selective firocoxib  
2. Investigate the effect of phenylbutazone, flunixin meglumine and 
firocoxib on the activity of COX enzymes in equine clinical patients 
receiving these drugs for clinical reasons by use of an ex vivo 
method 
3. Describe the concentration of these drugs in horses undergoing 
elective surgery, which are also administered with other peri-
operative medications.  
 
2.2 Materials and methods 
 
2.2.1 Evaluation of cyclooxygenase-1 inhibition in vitro 
 
2.2.1.1 Animal selection 
 
A convenience population, the teaching and blood donation herd of the 
Weipers Centre Equine Hospital of the University of Glasgow, was included 
in the study on the basis of a history of having received no NSAIDs in the 
previous two weeks and having residual blood available collected for 
reasons unrelated to the study. None of these horses had a history of 
systemic disease or had received any medication in the 3 months prior to 
the study; all horses were up to date with regard to vaccination status, 
had no abnormal physical examination findings (Byars and Gonda, 2015) 
and had a blood total protein concentration and packed cell volume (PCV) 
within the respective reference ranges (Staempfli and Oliver-Espinosa, 
2015).  
 
2.2.1.2 Evaluation of cyclooxygenase-1 activity 
 
The effect of the firocoxib and flunixin meglumine on in vitro COX-1 
activity was determined by measuring coagulation-induced thromboxane 
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B2 (TXB2) as described elsewhere (Beretta et al., 2005; Brideau et al., 
2001). Briefly, whole blood (500µl) was added to polypropylene micro-
centrifuge tubes containing either firocoxib or flunixin meglumine at a 
final concentration ranging from 0.01µM and 1000µM for a total of six 
dilutions for each drug in duplicate. A 500µl sample of heparinized 
(uncoagulated) blood was collected to serve as a negative control. Whole 
blood (500µl) was treated with vehicle (positive) control in triplicate. The 
blood was allowed to clot for one hour at 37°C before being centrifuged at 
2000g for 10 minutes. Following centrifugation, 100µl of serum was added 
to 400µl of methanol, and the resulting solution was centrifuged at 6000g 
for 10 minutes. A 50µl aliquot of the supernatant was collected and 
diluted in 150µl of buffer from a commercially available TXB2 enzyme 
immunoassay (EIA) kit1. This kit was used to determine the amount of TXB2 
in each sample.  
 
Inhibition of COX-1 activity was calculated as the percentage change in 
TXB2 concentration compared to the result from the negative control 
sample. The percentage change was plotted against the corresponding 
drug concentration, and the best sigmoid curve fit was obtained by use of 
nonlinear regression using Sigmaplot2.  
 
2.2.2 Evaluation of cyclooxygenase activity ex vivo 
 
2.2.2.1 Animal selection, group allocation and sample collection 
 
Horses presenting to the Weipers Centre Equine Hospital, University of 
Glasgow, between April and September 2012 with no history of medication 
including NSAIDs for a minimum of two weeks prior to admission, that 
were systemically healthy and scheduled to undergo an elective surgical 
procedure were recruited. Only horses from which sufficient blood (2.5ml) 
																																																								1	Thromboxane	B2,	Express	EIA	kit-monoclonal,	Cayman	chemical	Europe,	Tallinn,	Estonia	2	Sigmaplot,	version	11.2,	Systat	Software	Inc.,	Chicago,	Ill.,	USA	
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was remaining from samples obtained prior to surgery, during surgery and 
the day after surgery for clinical reasons (i.e. pre-, intra- and post-
operative monitoring of blood parameters) were included in the study. 
Horses less than one year of age were excluded to minimise variability due 
to patient size and diet. 
 
Horses were allocated to one of three groups based on the NSAID chosen 
by the attending clinician before surgery. The choice of NSAID used was 
independent from the purposes of the study. These were phenylbutazone3 
(4.4.mg/kg IV BID, n=6), flunixin meglumine4 (1.1mg/kg IV BID, n=6) or 
firocoxib5 (0.09mg/kg IV SID, n=6). There was no standardisation of other 
medications administered to the horses included in the study. 
 
For each horse, blood samples were collected before NSAID administration 
(T0), 2 hours after administration (intra-operatively, T2) and 24 hours after 
the first administration (T24) before a further dose of NSAID was give the 
morning following surgery. The timing of sample collection is represented 
in Figure 2.1. Residual blood samples were retrieved within one hour of 
collection and transported immediately to the laboratory for preparation 
for COX-1 and COX-2 activity determination as previously described 
(Beretta et al., 2005; Brideau et al., 2001).  
 
 
Figure 2.1: Representation of the timing of sample collection for the study 
evaluating cyclooxygenase activity ex vivo.  																																																								3	Equipalazone,	Dechra	Veterinary	Products	Ltd,	Shrewsbury,	Shropshire,	England	4	Finadyne,	MSD	Animal	Health,	Milton	Keynes,	Buckinghamshire,	England	5	Equioxx,	Merial	Animal	Health	Ltd,	Harlow,	Essex,	England	
Surgery	
started	
T0	 T24	T2	
NSAID	
administra3on	
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24	hours	
Further	NSAID	
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	 55	
2.2.2.2 Determination of cyclooxygenase activity ex vivo 
 
Measurement of ex vivo COX-1 activity was performed as described in 
section 2.2.1.2 by measuring coagulation-induced TXB2 (Beretta et al., 
2005; Brideau et al., 2001).  
 
Measurement of ex vivo COX-2 activity was performed using a modification 
of a previously described technique (Beretta et al., 2005). Briefly, the 
heparinised blood (500µl) was transferred into 1.5ml polypropylene tubes 
and LPS (Escherichia coli 0111:B4) in 0.1% bovine serum albumin in PBS 
solution was added to a final concentration of 100µg/ml. A second aliquot 
of blood was used as the negative (un-stimulated) control specimen. 
Samples were incubated at 37°C for 24 hours. Following incubation, 
samples were centrifuged at 2000g for 5 minutes to harvest plasma and 
100µl of plasma was added to 400µl of methanol and centrifuged at 6000g 
for 10 minutes. A 50µl aliquot of the supernatant was collected and 
diluted in 150µl of Prostaglandin E2 (PGE2) enzyme immunoassay (EIA) kit 
buffer. The amount of PGE2 in each sample was determined using a 
commercially available PGE2 EIA kit
6. 
 
The amount of prostaglandin E metabolites (PGEM) in plasma collected at 
each time point was measured as an indicator of COX-2 activity using a 
commercially available PGEM EIA kit as previously described (Cook et al., 
2009a). Briefly, all unstable metabolites of PGE2 were converted to the 
stable 13,14-dyhydro-15-keto PGA2 for quantification by means of a 
commercial ELISA kit 7  following manufacturer’s instructions. Each 
measurement was performed in triplicate on a 96-well plate and the 
average of the three measurements was subsequently used for the 
analysis. The R-square of each calibration curve was >99%, indicating the 
assay was reliable. 																																																								6	Prostaglandin	E2	EIA	kit-monoclonal,	Cayman	Chemical	Europe,	Tallinn,	Estonia	7	Prostaglandin	E	Metabolite	EIA	kit-monoclonal,	Cayman	Chemical	Europe,	Tallinn,	Estonia	
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2.2.2.3 Data analysis 
 
The relative change in concentration of TXB2, PGE2 and PGEM between the 
baseline sample (T0) and T2 and T24 samples was calculated. The effect of 
time and treatment on COX-1 (TXB2) and COX-2 (PGE2 and PGEM) activity 
and drug metabolites concentration was determined by Mann-Whitney 
test. Bonferroni corrections were used to account for multiple 
comparisons. The relationship between drug concentration and COX 
activity overall and at each time point was determined by Spearman’s 
rank correlation (significance set for p<0.05). Analysis was performed 
using Rv.3.0.0 software 20138.  
 
2.2.3 Determination of ex vivo non-steroidal anti-inflammatory serum 
concentration 
 
Aliquots of serum obtained at each time point were submitted to an 
external laboratory 9 . Flunixin meglumine, phenylbutazone and its 
metabolite oxyphenbutazone and firocoxib concentrations were 
determined by use of high performance liquid chromatography (HPLC) 
(Cox and Yarbrough, 2011; Higgins et al., 1987). 
 
2.2.4 Comparison of in vitro and ex vivo cyclooxygenase inhibition 
 
The relationship between drug concentration and COX activity overall and 
at each time point was determined by Spearman’s rank correlation 
(significance set for p<0.05).	 On the basis of the drug concentrations 
obtained by use of HPLC, the predicted percentage inhibition of COX-1 
activity was calculated from in vitro inhibition-concentration curves and 
compared with the ex vivo inhibition of COX-1 activity. Bland-Altman 
analysis was performed to determine the level of agreement between the 																																																								8	R,	version	3.0.0,	R	Foundation	for	Statistical	Computing,	Vienna,	Austria	9	UNIRELAB	srl,	Unipersonale,	Rome	Italy	
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in vitro and ex vivo methods of measuring inhibition of COX activity (Bland 
and Altman, 1986). Analysis was performed using Rv.3.0.0 software 2013. 
 
All procedures were approved by the Ethics and Welfare Committee of the 
School of Veterinary Medicine at the University of Glasgow. 
 
2.3 Results 
 
2.3.1 Evaluation of cyclooxygenase-1 inhibition in vitro 
 
2.3.1.1 Animal selection 
 
Animals included in the in vitro study were two mares and two geldings; 
two Thoroughbreds, one Warmblood and one pony; ages were 8, 23, 19 
and 28 years and each animal weighed 563kg, 534kg, 615kg and 296kg 
respectively.  
 
2.3.1.2 Evaluation of cyclooxygenase-1 inhibition 
 
The equation that best predicted the relative inhibition of COX-1 activity 
expressed as the change in TXB2 concentration relative to the 
concentration of the drug was as follows: 
 !"#$"%&'(" !"ℎ!"!#!$% = !! + !/[1 + !!!(!!!!)/!] 
 
where !! is the minimum COX activity, ! is the difference between the 
maximum and minimum COX activity, !  is the base of the natural 
logarithm, ! is the concentration of the drug, !! is the drug concentra- 
tion required for 50% inhibition of COX activity, and ! is the slope. 
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For flunixin meglumine, the best fit (r2 = 0.999) of the inhibition-
concentration curve was obtained by use of a 4-point sigmoid function 
represented by the following equation (Figure 2.2): 
 !"#$"%& !"ℎ!"!#!$%!"#$%&%$ = – 11.4541 + [111.509/ (1 + !–(! – !".!"#)/!!.!""#)] 
 
 
Figure 2.2: 4-point sigmoid curve representing the best fit of the inhibition-
concentration curve of COX-1 activity measured as TXB2 concentration for flunixin 
meglumine calculated from in vitro data for concentrations ranging from 0.01µM and 
1000µM; dotted lines represent 95% confidence interval limits. 
 
For firocoxib, the best fit (r2 = 0.952) of the inhibition-concentration curve 
was obtained by use of a 3-point sigmoid function represented by the 
following equation (Figure 2.3): 
 !"#$"%& !"ℎ!"!#!$%!"#$%$&"' =  46.7088/(1 + !–(! – !.!"#$")/!.!"#$) 
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Figure 2.3: 3-point sigmoid curve representing the best fit of the inhibition-
concentration curve of COX-1 activity measured as TXB2 concentration for firocoxib 
calculated from in vitro data for concentrations ranging from 0.01µM and 1000µM; 
dotted lines represent 95% confidence interval limits. 
 
2.3.2 Evaluation of cyclooxygenase activity ex vivo 
 
2.3.2.1 Animal selection and group allocation 
 
Horses in the phenylbutazone group had a median age of seven years 
(mean: nine years) and a median weight of 536kg (range: 260-759kg) and 
included two Warmbloods, one Thoroughbred and three ponies of which 
there were three geldings, one mare and two stallions. Horses in the 
flunixin meglumine group had a median age of eight years (range: 1-17 
years), median weight of 588kg (range: 350-636kg) and included three 
Warmbloods and three Thoroughbreds (four geldings, one mare and one 
stallion), which underwent elective soft tissue (n=4) or orthopaedic 
surgical procedures (n=2). Horses in the firocoxib group had a median age 
of four years (range: 1-10 years), median weight of 538kg (range: 323-
651kg) and included two Warmbloods, two Thoroughbreds and two ponies 
(five mares and one stallion), which underwent elective orthopaedic 
surgical procedures (n=6). 
 
A more detailed description of horses and procedures is included in Table 
2.1. 
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Table 2.1. Summary of the demographic information of the study population and 
procedures performed for horses in each group. 
 
PBZ: phenylbutazone; FM: flunixin meglumine; FIR: firocoxib; WB: warmblood; TB: 
thoroughbred; G: gelding; F: female; S: stallion; DDFT: deep digital flexor tendon; OCD: 
osteocondrosis dissecans; PSD: proximal suspensory desmitis; GCT: granulosa cell tumor; 
DSP: dorsal spinous processes; MT3: metatarsal 3; Age in years; Weight in kilograms. 
 
2.3.2.2 Determination of cyclooxygenase activity ex vivo 
 
The concentrations of PGE2 and TXB2 varied widely among horses. 
Therefore, the results are expressed also as the percentage change from 
the baseline concentration. At T2 and T24, COX-1 activity was reduced 
compared to baseline in horses receiving phenylbutazone or flunixin 
meglumine (Fig 2.4). At T2 and T24, the relative COX-1 activity was 
significantly greater in horses receiving firocoxib compared to horses 
receiving phenylbutazone (p=0.008) or flunixin meglumine (p=0.005) 
(Figure 2.4). The effect on COX-2 activity was not significantly different 
between drugs (p=0.5; Figure 2.5 and Figure 2.6). 
 
Group Horse Age Breed Gender Weight Diagnosis Procedure 
PBZ 
1 5 WB G 580 DDFT tear Tenoscopy 
2 16 Pony G 468 DDFT tear Tenoscopy 
3 5 WB F 573 OCD Hock Arthroscopy 
4 9 Pony S 499 - Castration 
5 14 TB G 759 PSD Neurectomy fasciotomy 
6 5 Welsh B S 260 Cryptorchid Castration 
FM 
7 1 TB S 350 - Castration 
8 4 WB G 625 Sarcoids Surgery+Cryo+Chemo 
9 8 TB F - GCT Ovariectomy 
10 8 WB G 636 Over-riding DSP DSP resection 
11 17 TB G 588 Echinococcosis Cyst lavage 
12 9 WB G 566 Suspensory Desmitis Neurectomy 
FIR 
13 7 Highland S 651 OCD Arthroscopy 
14 1 Trakhener F 323 MT3 Cyst Arthroscopy 
15 4 WB F 528 OCD Arthroscopy 
16 1 WB F 323 OCD Arthroscopy 
17 4 TB F 549 OCD Arthroscopy 
18 10 TB F 578 OCD Arthroscopy 
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Considering the samples as a whole without dividing by time point the 
results of Spearman’s rank analysis evidenced one significant correlation 
that was between phenylbutazone and absolute TXB2 concentrations 
(p=0.03). No other significant correlations were present when considering 
the overall samples without dividing in time-points. 
 
When subdividing the samples by time-point at T2 the relative 
concentration of PGE2 was significantly correlated to the concentration of 
oxyphenbutazone (p=0.03). When considering the absolute TXB2 and PGEM 
concentration they were significantly correlated to flunixin meglumine 
concentration (p=0.02) and firocoxib concentration (p=0.02) respectively. 
 
At the third time-point the relative phenylbutazone concentration was 
significantly correlated with the absolute TXB2 and PGEM concentrations 
(p=0.01). Flunixin meglumine was significantly correlated with absolute 
TXB2 (p=0.03) and PGEM (p=0.04) concentrations. 
 
Spearman’s rank analysis of all samples revealed no significant correlation 
between flunixin meglumine, phenylbutazone or firocoxib concentration 
and either TXB2, PGE2 or PGEM relative or absolute concentrations. At T2, 
the absolute metabolite concentration TXB2 and PGE2 were significantly 
correlated to flunixin meglumine concentration (p=0.02) and firocoxib 
concentration (p=0.02) respectively. At the third time-point flunixin 
meglumine concentration was significantly correlated with absolute TXB2 
(p=0.03) and PGEM (p=0.04) concentrations. 
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Figure 2.4: Box-and-whiskers plots of the percentage change in the amount of 
coagulation-induced TXB2 representing COX-1 activity, compared with the value 
before NSAID administration (baseline; value set at 100% - horizontal dotted line), in 
horses at 2 and 24 hours after treatment with phenylbutazone (n=6), flunixin 
meglumine (n=6) or firocoxib (n=6).  
Each box represents the second and third quartile ranges, the solid horizontal line in 
each box represents the median, the whiskers represents first and fourth quartile 
ranges, and the circles represent outlier data points. *: relative COX-1 activity differs 
significantly (p<0.05) between treatment groups. PBZ: phenylbutazone; FM: flunixin 
meglumine; FIR: firocoxib 
 
 
 
Figure 2.5: Box-and-whiskers plots of COX-2 activity expressed as the percentage 
change in LPS stimulated PGE2 concentration, compared with the baseline value (set 
at 100% - horizontal dotted line). 
PBZ: phenylbutazone; FM: flunixin meglumine; FIR: firocoxib 
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Figure 2.6: Box-and-whiskers plots of COX-2 activity expressed as the percentage 
change in plasma PGE metabolite concentration, compared with the baseline value 
(set at 100% - horizontal dotted line). 
PBZ: phenylbutazone; FM: flunixin meglumine; FIR: firocoxib 
 
 
2.3.3 Determination of ex vivo non-steroidal anti-inflammatory drug 
serum concentration 
 
The concentration of phenylbutazone at T0 was 0µg/ml for all but one 
horse that had a concentration of 1.30µg/mL. The median phenylbutazone 
concentration at the second time-point two hours after drug 
administration was 28.88µg/mL (mean: 29.05µg/ml; range: 21.35-
37.40µg/mL). At the third time-point the median concentration of 
phenylbutazone was 24.02µg/mL (mean: 22.29µg/ml; range: 12.03-
34.26µg/mL). 
 
The baseline concentration of oxyphenbutazone prior to phenylbutazone 
administration was 0µg/ml for all but one horse that had a concentration 
of 0.18µg/ml. At the second time-point (2h after administration) the 
median oxyphenbutazone concentration was 1.19µg/mL (mean: 
1.15µg/ml; range: 0.59-1.66µg/mL). At the third time-point the median 
concentration of oxyphenbutazone was 3.32µg/mL (mean: 3.45µg/ml; 
range: 2.42-4.42µg/mL). 
0
10
0
20
0
30
0
40
0
50
0
Pe
rc
en
ta
ge
 ch
an
ge
 in
 P
GE
M
 co
nc
en
tra
tio
n
PBZ FM FIR PBZ FM FIR
2h 24h
	 64	
 
For flunixin meglumine the baseline concentration (before drug 
administration) was 0µg/ml for all horses. At the second time-point (2h 
after administration) the median flunixin meglumine concentration was 
2.55µg/mL (mean: 2.84µg/ml; range: 2.45-3.82µg/mL). At the third time-
point the median concentration of flunixin meglumine was 1.29µg/mL 
(mean: 2.60µg/ml; range: 0.18-8.74µg/mL). 
 
For firocoxib the baseline concentration (before administration) was 
0ng/ml for all horses. At the second time-point (2h after administration) 
the median firocoxib concentration was 53.00ng/mL (mean: 65.17µg/ml; 
range: 30.8-134.8ng/mL). At the third time-point the median 
concentration of firocoxib was 35.4µg/mL (mean: 33.33µg/ml; range: 
21.6-40.7µg/mL). 
 
These results are summarized in Figure 2.7, Figure 2.8 and Figure 2.9. 
 
 
Figure 2.7: Box-whiskers plot depicting the concentration of phenylbutazone and its 
metabolite oxyphenbutazone after 2 and 24 hours from intravenous administration 
of phenylbutazone at 4.4mg/kg BID. The horizontal dotted line represents the serum 
concentration of phenylbutazone at EC50 (Toutain et al., 1994). 
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Figure 2.8: Box-whiskers plot depicting the concentration of flunixin meglumine 
after 2 and 24 hours from intravenous administration at the dose of 1.1mg/kg BID. 
The horizontal dotted line represents the serum concentration of flunixin 
meglumine at EC50 (Toutain et al., 1994). 
 
 
 
 
Figure 2.9: Box-whiskers plot depicting the concentration of firocoxib after 2 and 24 
hours from intravenous administration at 0.1mg/kg SID. 
 
 
2.3.4 Comparison of in vitro and ex vivo cyclooxygenase inhibition 
 
In vitro and ex vivo COX-1 inhibition was significantly different for both 
flunixin meglumine (p<0.001, Figure 2.10) and firocoxib (p=0.04, Figure 
2.11). 
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Figure 2.10: Comparison of flunixin meglumine concentration and in vitro and ex 
vivo inhibition of COX-1 activity. The sigmoid curve represents the calculated in 
vitro concentration-inhibition curve and the dotted lines represent the 95% CIs. 
Circles represent ex vivo measurements of inhibition of COX-1 activity at known 
drug concentrations. Notice that inhibition of COX-1 activity is higher ex vivo than 
in vitro (p<0.001). 
 
 
 
Figure 2.11: Comparison of firocoxib concentration and in vitro and ex vivo 
inhibition of COX-1 activity. The sigmoid curve represents the calculated in vitro 
concentration-inhibition curve and the dotted lines represent the 95% CIs. Circles 
represent ex vivo measurements of inhibition of COX-1 activity at known drug 
concentrations. Notice that in some cases the ex vivo inhibition of COX-1 activity 
corresponds to inhibition expected from in vitro data, whereas in the remaining 
cases, COX-1 activity is not inhibited by firocoxib. Overall data obtained in vitro and 
ex vivo were significantly different (p=0.04). 
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Figure 2.12: Bland-Altman plots of in vitro and ex vivo COX-1 activity after 
administration of flunixin meglumine to 6 horses. The mean bias (solid line) is high 
and 95% CIs (dotted lines) is >0% which suggests poor agreement. Flunixin 
meglumine concentration was determined for ex vivo samples collected from 6 
horses and calculated from the inhibition concentration curve determined in vitro. 
 
Figure 2.13: Bland-Altman plots of in vitro and ex vivo COX-1 activity after 
administration of firocoxib to 6 horses. The mean 95% CIs (dotted lines) is extremely 
wide, which suggests that the in vitro curve for inhibition of COX-1 activity is not 
useful for predicting ex vivo inhibition of COX-1 activity. Firocoxib concentration 
was determined for ex vivo samples collected from 6 horses and calculated from the 
inhibition concentration curve determined in vitro. 
 
Bland-Altman analysis revealed a mean difference between in vitro and ex 
vivo COX-1 activity. The mean difference was 69.8% (95% CI, 37.0% to 
102.6%) for flunixin meglumine (Figure 2.12) and –42.0% (95% CI, –181.5% 
to 97.6%) for firocoxib (Figure 2.13). 
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2.4 Discussion and conclusions 
 
The investigations in this chapter provide a biochemical perspective of the 
potential for toxicity of NSAIDs in horses. Clinically, most severe side 
effects from their use mainly involve the gastrointestinal and urinary 
systems as these are more susceptible to changes in physiologic COX 
activity, which might affect mucosal blood flow (Cohen et al., 1995; Jones 
et al., 2003; Read, 1983; Warner et al., 1999). 
 
This chapter determined the effect of flunixin meglumine and firocoxib on 
COX activity in vitro as well as that of flunixin meglumine, 
phenylbutazone and firocoxib ex vivo in horses undergoing elective 
surgery. Comparison of in vitro data of COX-1 inhibition and ex vivo data 
highlights the importance in following up in vitro research with studies on 
ex vivo models, as highlighted in other species, as well as for other NSAIDs 
(Blain et al., 2002; Gierse et al., 2002; Giuliano and Warner, 1999). 
 
Section 2.3.1 describes the inhibition of COX-1 activity by flunixin 
meglumine and firocoxib in horse’s blood in vitro. These data were 
obtained to calculate inhibition-concentration curves used to determine 
whether any significant discrepancy was present between in vitro and ex 
vivo COX-1 activity for the two drugs. The calculation of COX-2 activity in 
vitro was not performed. Assessing the effect on COX-2 activity would 
have been useful to calculate the IC50 or IC80 of these drugs (Beretta et 
al., 2005). However, this was not the goal of the study. This study was 
primarily to evaluate the potential for toxic side effects of these drugs 
arising from the excessive inhibition of COX-1. Further only IC50 and IC80 
were also not determined to reduce costs. 
 
Similarly no in vitro study on phenylbutazone was performed because of 
the similar COX inhibitory activity to flunixin meglumine, as illustrated in 
section 2.3.2 and to reduce the costs associated with the analysis.  
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The results of the study in section 2.2.2 show that firocoxib administration 
induced no significant inhibition of COX-1 activity in clinical patients, 
while flunixin meglumine and phenylbutazone administration induced 
profound inhibition of COX-1 activity. This supports the findings of another 
study (Cook et al., 2009a) in which investigators found less inhibition of 
COX-1 activity by firocoxib than by flunixin meglumine in small intestinal 
ischemia-reperfusion injury. No significant change in indicators of COX-2 
activity, LPS-stimulated PGE2 concentration, and PGEM concentration 
after surgery in either treatment group was present. Given that this was a 
clinical study, ethically it was not possible to include a control group 
without NSAID administration to quantify the effect of surgery on COX-2 
activity. However, our findings indicated that the effect of firocoxib on 
COX-2 activity was comparable to that of phenylbutazone and flunixin 
meglumine and all drugs prevented an increase in COX-2 activity in the 24 
hours after surgery.  
 
Whether firocoxib would have reduced COX-2 activity also in a population 
of clinical patients undergoing more invasive procedures remains 
undetermined. Horses in each group of this study were comparable for 
age, gender, weight and breed characteristics and the only difference was 
the type of elective procedure that each horse was undergoing. However, 
the effect of the type of procedure was not tested with formal statistics 
because the group sizes were so small that the likelihood of failing to 
identify a true significant difference would have been high. A limitation of 
the present study was the inability to match surgical procedures between 
groups, given that blood samples from clinical equine patients were used. 
Group allocation of horses was chosen independently from the scope of 
the study and no clinician was directly involved in performing the study. 
Veterinary surgeons chose which NSAID to administer independently, using 
their clinical judgment and following label recommendations.  
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All horses had no evidence of severe disease affecting more than one body 
system, and no horse included in the study had abnormal results for 
physical examination or hematologic evaluation. All procedures performed 
were considered elective. The commercial preparation of firocoxib, is 
licensed in the United Kingdom for the alleviation of pain and 
inflammation associated with osteoarthritis and alleviation of lameness in 
horses. Because of the narrow spectrum of conditions licensed for 
treatment with firocoxib, only horses with evidence of joint disease 
undergoing arthroscopy were included in the firocoxib group. This 
procedure is minimally invasive and unlikely to induce extensive systemic 
inflammation. In comparison, the flunixin meglumine group included 
horses undergoing soft tissue procedures that could potentially have 
resulted in greater COX stimulation than for arthroscopy (Jacobsen et al., 
2009). However, there was no significant difference in preoperative 
prostanoid concentrations between groups, and postoperative prostanoid 
concentrations were not increased in the flunixin meglumine group. A 
horse in the flunixin meglumine group underwent exploratory laparotomy 
to evaluate a hepatic mass that was confirmed to be a hydatid cyst, which 
likely constituted an incidental finding (Barton, 2010). A study conducted 
to examine the effect of surgery on the early inflammatory response (< 24 
hours) found a significant difference in serum amyloid A concentrations 
between procedures with minimal tissue injury (e.g., arthroscopies) and 
procedures with intermediate tissue injury (e.g., laryngeal surgeries and 
castrations), but no significant difference in serum amyloid A 
concentrations was found between surgeries involving minimal and major 
tissue injury (Jacobsen et al., 2009). In addition, investigators in that 
same study found no significant effect of tissue injury on other variables 
of inflammation, including white blood cell count and serum iron 
concentration (Jacobsen et al., 2009). These findings suggest that 
although there may be a difference in the degree of inflammation 
stimulated by surgery, it is minimal during the first 24 hours after surgery. 
In the study reported here, horses had no abnormal physical examination 
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findings or results for hematologic evaluation before surgery and did not 
develop complications after surgery. Therefore, this difference between 
groups was considered a minor issue. Further, when a more invasive 
procedure, such as midline laparotomy, was performed in healthy research 
horses, the effect of firocoxib on COX activity was not significantly 
different from that of flunixin meglumine (Cook et al., 2009a). In light of 
these findings and the limitations imposed by the clinical study design, 
enrolling patients undergoing procedures that involved mild to moderate 
tissue damage was considered acceptable.  
 
Another limitation of the current study is that drug concentration was 
tested only for the NSAID used in the horse’s group. In theory, horses in 
the flunixin meglumine and firocoxib group could have received 
phenylbutazone shortly prior to admission. One horse in the 
phenylbutazone group had low but detectable serum phenylbutazone and 
oxyphenbutazone concentration suggestive of administration few days 
before presentation to the hospital, in face of a history of no drug being 
administered. Measuring concentration of each NSAID in each animal at 
the baseline sample was not performed as it would have been costly and 
at the time the samples were collected it appeared reasonable to rely on 
history collection to determine if a horse matched the inclusion criteria of 
no recent NSAID administration. It is also relevant to highlight that the 
concentration of phenylbutazone was 10-fold smaller than the lowest 
concentration of the drug at the third time point. Therefore it was 
decided that data from this horse could be included in the study. 
 
The present study was not designed to compare analgesic effects of these 
drugs. Despite the short half-life of flunixin meglumine (2.1 to 4.2 hours) 
(Pellegrini-Masini et al., 2004; Toutain et al., 1994) this drug can 
significantly reduce tissue production of prostaglandins in exudates for up 
to 24 hours, which is well after the elimination of flunixin meglumine from 
the blood stream (Higgins et al., 1987; Toutain et al., 1994). The 
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persistence of firocoxib at a peripheral site of inflammation remains 
undetermined. However, the long half-life (29 to 31 hours) after once-
daily administration should guarantee persistence of the inhibition of COX 
activity in peripheral tissues throughout the course of treatment (Cox et 
al., 2012; Kvaternick et al., 2007). Evidence suggests that firocoxib is 
effective for controlling orthopaedic pain in both experimental and 
clinical settings (McCann et al., 2002; Orsini et al., 2012). None of the 
clinical patients in the firocoxib group required further administration of 
analgesic by attending clinicians, who were not involved in the study, 
during the first 24 hours after surgery (i.e., after a single dose of 
firocoxib). The author’s subjective clinical impression was that firocoxib 
might offer adequate analgesia for minimally invasive elective surgical 
procedures such as arthroscopy in horses, but further studies would be 
required to enable objective assessment of the efficacy of firocoxib as a 
perioperative analgesic. Whether firocoxib would control inflammation 
and the associated pain from more severe conditions, remains 
undetermined and should be evaluated in future studies in patients with 
septic synovitis, colic and endotoxaemia. Results for experiments in one 
study revealed that firocoxib was as effective as flunixin meglumine for 
managing signs of pain in healthy horses undergoing ventral midline 
coeliotomy and an experimental model of jejunal ischemia-reperfusion 
injury without enterectomy (Cook et al., 2009a). In that study, firocoxib 
was also as effective as flunixin meglumine at inhibiting prostaglandin 
production driven by ischemia-reperfusion injury (Cook et al., 2009a). 
Whether firocoxib would control inflammation and the associated pain 
from more severe naturally occurring disease or colic remains 
undetermined and should be evaluated in ad hoc studies. 
 
The findings of this study supported the hypothesis that firocoxib has ex 
vivo COX-1–sparing effects. However, further studies with more 
homogeneous groups would yield more conclusive evidence. Firocoxib did 
not inhibit ex vivo COX-1 activity in equine patients that underwent 
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elective surgery and could potentially offer an alternative for the 
treatment of pain and inflammation in patients for which the use of non-
selective NSAIDs is contraindicated. Further studies are required to 
evaluate the use of firocoxib in patients with clinical conditions for which 
its use is not currently licensed, including intestinal ischemia, right dorsal 
colitis, or pre-renal or intrinsic acute renal failure, before it can be 
recommended for use in these conditions. 
 
The data combining the peri-operative serum concentrations of 
phenylbutazone, flunixin meglumine and firocoxib to COX activity in 
actual equine clinical cases undergoing elective surgery is also novel. As 
drugs such as anaesthetics, intravenous fluids and antimicrobials 
concurrently administered in surgery might share metabolic pathways with 
NSAIDs, the way pharmacodynamic and pharmacokinetic data obtained in 
research settings relate to real-life clinical scenarios remains 
undetermined. The findings in this study show that the drug concentration 
for phenylbutazone and flunixin meglumine at two hours is much higher 
than the expected EC50 (Toutain et al., 1994) and that confirms the 
expectation that these drugs used at the label dose maintain therapeutic 
concentrations for at least two hours. At 24 hours the concentration of 
these drugs was generally still above EC50, with the exception of two cases 
where the concentration of flunixin meglumine had dropped below the 
EC50 threshold of 0.93µg/ml for this drug. The reason for this finding in 
these two horses remains unclear. It is possible that another drug was 
administered in place of flunixin meglumine for the second dose. While 
there is no record of this happening, this occurrence cannot be entirely 
discounted. Alternatively, it is also possible that in some clinical cases 
flunixin meglumine undergoes faster metabolism and clearance than 
expected. This finding requires further evaluation as a better 
understanding of drug clearance in these cases might affect the dose 
regimen administered and would ultimately enhance drug efficacy and 
patient welfare. At 24 hours, therefore after the second dose given at 12 
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hours after the initial dose, phenylbutazone and flunixin meglumine 
concentrations were generally still similar to the concentration at two 
hours. The higher variability at 24 hours is likely a reflection of the 
variable time the third sample was obtained. Sample collection was 
unrelated to the study and entirely clinician dependent. Horses were 
included if samples were available at the three time-points. The first 
sample was collected prior to NSAID administration and the second 
invariably two hours after NSAID administration (eg. during surgery, during 
anaesthesia monitoring). As surgery started at different times of the day 
(between 8am and 3pm) and it was hospital practice that from the day 
following surgery drugs for twice daily administration (such as 
phenylbutazone and flunixin meglumine) were to be given at ~8am and 
8pm, the “24 hour” sample could have been obtained anywhere between 
17 and 24 hours from the first NSAID administration. This variability might 
explain greater variability at the third time-point. While this was a 
shortcoming of the study it was not possible for the investigators to 
control drug administration or sample collection on real clinical cases. 
None of the horses was systemically ill following surgery and all samples 
were obtained for post-operative monitoring. Inclusion of the actual time 
between drug administration and third sample could also have been 
recorded to be included in the analysis, but addition of this variable would 
have required a much larger group size. Ultimately the overall aim of the 
study was to compare the effect of these drugs on COX activity and the 
data collected was adequate to achieve this goal. Extending this to a 
larger number of cases would have been economically beyond the funds 
available for this study. 
 
The lower concentration of firocoxib at 24 hours is not unexpected as this 
drug is administered only once a day and no additional dose was given 
before the last time-point. To the author’s knowledge no study exists to 
determine the EC50 of firocoxib in horses. However a study comparing 
phenylbutazone (4.4mg/kg PO BID) and firocoxib (0.1mg/kg PO SID) found 
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similar clinical efficacy between the two drugs to manage pain associated 
with osteoarthritis in horses (Doucet et al., 2008). Although the present 
study did not look at the clinical efficacy of these drugs the doses used 
were comparable to that study. A translational comparison between that 
and the present study would suggest that the EC50 of firocoxib is at least 
as low as the median firocoxib concentration of 53µg/ml. However, this 
statement is simply speculative and further studies on firocoxib efficacy 
are required. Significant correlations between indicators of COX activity 
and flunixin meglumine concentration were identified at the 2-hour and 
24-hour time points, and between indicators of COX activity and firocoxib 
concentration at the 2-hour time point only. The correlation was present 
only in a few of the combinations tested and this was likely a result of the 
effect of multiple factors including short metabolite half-life, difference 
in drug half-life between groups, and individual patient differences. It is 
possible that the lack of recognition of correlation in some cases was a 
consequence of the heterogeneous small group sizes. Group size was 
determined based on the predicted difference in the drugs COX 
selectivity. Involving more horses might allow detection of other 
significant relationships between drug and metabolites concentrations and 
enzyme activity, disease states and age or breed differences and warrants 
future investigations. 
 
Section 2.3.4 describes the relationship between in vitro COX inhibition 
and ex vivo inhibition in horses. Available in vitro data indicate an 
approximately 265-fold difference in selectivity between firocoxib and 
non-selective COX inhibitors (McCann et al., 2002). Drug concentrations in 
the present study were in the range expected on the basis of 
pharmacokinetic parameters reported for these drugs (Letendre et al., 
2008; Toutain et al., 1994). Pharmacokinetic studies are performed on 
healthy animals and the applicability of these parameters to clinical 
patients is debatable. Patients often have serious chronic or acute disease 
or receive multiple drugs (e.g., anaesthetics, antimicrobials, or 
	 76	
prokinetics) simultaneously. In the study reported here, all horses 
received antimicrobials peri-operatively and anaesthetics (general 
anaesthesia). These could potentially have interfered with metabolism 
and efficacy of the drugs of interest. No difference was expected between 
the predicted drug concentrations calculated from the pharmacokinetic 
parameters and the actual drug concentrations, considering that these 
patients had no abnormal findings for physical examination or results for 
hematologic evaluation. This would suggest that pharmacokinetic 
parameters for these NSAIDs determined in experimental animals are 
applicable to clinical patients undergoing elective surgery. 
 
Studies conducted to examine the inhibitory effects of NSAIDs on COX in 
horses are based on in vitro methods (Beretta et al., 2005; Davis et al., 
2011). In the present study, we examined the ability of in vitro methods 
to predict ex vivo inhibition of COX-1 activity by flunixin meglumine and 
firocoxib in horses. The function best fitting the in-vitro concentration-
inhibition curve was used to predict the relative inhibition expected for 
the actual drug concentrations measured by use of HPLC in the samples 
obtained ex vivo. Results of Bland-Altman analysis revealed a high bias, 
particularly for flunixin meglumine (95% CIs for flunixin meglumine were 
both > 0 and indicated that ex vivo inhibition of COX activity was more 
efficient than in vitro inhibition), which suggested very poor agreement 
between the ex vivo and in vivo methods (Bland and Altman, 1986). The 
wide 95% CIs (> 100%) for firocoxib suggested that estimation of ex vivo 
inhibition of COX-1 activity by use of in vitro data was highly variable. 
Other authors have described the manner by which in vitro data on 
inhibition of COX activity in humans differs between NSAIDs (Blain et al., 
2002). Investigators of that study found that the overall value of in vitro 
assays to predict ex vivo inhibition of COX activity differed among drugs: 
the ex vivo effect of diclofenac was reliably predicted in vitro, whereas ex 
vivo and in vitro inhibition differed significantly for ibuprofen on COX-2 
activity and meloxicam on COX-1 activity (Blain et al., 2002). Investigators 
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of another study  found that eltenac was preferentially selective for COX-2 
in vitro but not ex vivo in horses (Cuniberti et al., 2012). In veterinary 
species, studies have detected significant differences in the in vitro and 
ex vivo COX selectivity ratio (concentration required to inhibit enzyme 
activity by 50%) of NSAIDs (Cuniberti et al., 2012; Schmid et al., 2010). 
Calculation of the in vitro COX selectivity ratio has been reported 
previously and was not an objective of the present study; calculation of an 
ex vivo COX selectivity ratio is not possible in clinical patients. The 
significant difference between calculated and actual measurements in 
COX-1 activity further supports the need to assess NSAID efficacy ex vivo 
as well as in vitro in horses. However, it is also possible that variability in 
procedures performed in the flunixin meglumine group could have caused 
variable degrees of inflammation and might have contributed to the bias 
to some extent. In addition, the in vitro and ex vivo experiments were 
conducted in separate populations of horses. However, the comparison of 
in vitro and ex vivo methods warrants further investigation and 
comparison for COX-2. 
 
In conclusion firocoxib behaves as a selective COX-2 inhibitor ex vivo. This 
might provide the prospect of a safer profile for this drug when compared 
with flunixin meglumine and phenylbutazone and might provide an 
alternative for the treatment of inflammation in patients for which the 
use of non-selective NSAIDs is contraindicated. Further studies are 
required to evaluate the use of firocoxib in clinical cases for which its use 
is not currently licensed, including intestinal ischaemia, right dorsal colitis 
or pre-renal or intrinsic acute renal failure before it can be recommended 
for use in these conditions.  
 
While the safer profile of firocoxib compared to non-selective COX 
inhibitors has been demonstrated in this chapter the actual clinical 
relevance of this information needs to be assessed further. A different 
approach is necessary to describe how frequent NSAID toxicity is and if 
horses receiving non-selective COX inhibitors are more at risk of 
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developing clinical signs of toxicity compared to those receiving COX-2 
selective NSAIDs. This could be performed by assessing the clinical records 
of a large population of equine patients to identify the prevalence of 
toxicity, compare different NSAIDs and account for usage of other drugs 
and comorbidities (Chapter 5). Such type of analysis is unknown on a large 
scale in equine medicine and therefore the technique would require to be 
thoroughly validated (Chapter 3). 
 
A study looking at the overall effect on the population from the usage of 
NSAIDs will provide a different perspective on severity and frequency of 
toxicity in the horse population.  
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CHAPTER 3  - Text Mining Big Data From Equine Medical 
Practice 
 
3.1 Construction of a large equine electronic medical records 
database 
 
3.1.1 Introduction 
 
The number of projects that have been developed in the last few years to 
collect data from veterinary practice to look at large EMRs datasets both 
retrospectively as well as prospectively is on the increase (Jones et al., 
2014; Lam et al., 2007b, 2007c; Mattin et al., 2014; O’Neill et al., 2012a, 
2012b, 2013; Oswald et al., 2010; Radford et al., 2011). Much of these 
data are obtained from first opinion veterinary practice for disease 
surveillance but also to evaluate disease prevalence, risk factors and 
inform survival analysis. Those that obtain data prospectively are mostly 
focused on small animal practice and require variable commitment to 
produce reliable data as a conscious effort is required by veterinary 
surgeons to classify clinical cases for further analysis. In the case of 
SAVSNET (Small Animal Veterinary Surveillance Network), an initiative by 
the British Small Animal Veterinary Association and the University of 
Liverpool, a point and click application allows a reasonably quick 
classification by syndrome/body system and detailed information is only 
obtained for a random subsample of cases (Jones et al., 2014; Radford et 
al., 2011). With this system the effort is minimal for the operator, but as 
only a small subsample of cases (10%) are classified in detail the potential 
to draw conclusions, that may be non-representative of the wider dataset 
or population, is significant. The VetCompass project run by the Royal 
Veterinary College, is based on the use of a predetermined coding system, 
VeNom (Veterinary Nomenclature), which allows precise classification of 
most conditions (Mattin et al., 2014; O’Neill et al., 2012a). The VeNom 
system contains several hundreds of possible codes, which requires 
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considerable compliance from clinicians who need to learn to use the 
VeNom coding system in order to provide accurate and complete data. 
This might induce errors as it is foreseeable that clinicians might learn to 
use a set of the most commonly used terms and not commit to use the 
most appropriate code in the nomenclature for each case or not classify 
conditions that they see less commonly as they might not have the 
inclination to look up the most appropriate code. The use of a restricted 
coding system might limit the freedom of expression of the clinician and 
should probably be combined with free-text mining techniques (Heinze et 
al. 2001). Whilst providing a way of validation of a coding system, free 
text mining would also be a complementary and/or supplementary 
alternative for data extraction to semi-structured systems such as 
SAVSNET and VeNom. These systems rely on veterinary practitioners to be 
committed in learning these coding systems in order to use the most 
appropriate term and a validation process would allow understanding how 
classification by the coding system fits the clinical data described in the 
text. 
 
Free-text mining techniques are suitable for analysis of prospective as 
well as retrospective data as they do not require any specific co-operation 
by clinicians other than the completion of the EMR for each of their 
patients (Lam et al., 2007c). This is usually done for management and 
billing reasons so the data used are what would be produced by each 
practice regardless of involvement in a research study. On the other hand, 
data analysis becomes more laborious as the data are less structured and 
come in different forms from different practices, making the combination 
of data from multiple practices cumbersome. 
 
Data for this study originates from two main areas: United Kingdom and 
North America (United States of America and Canada). Each dataset was 
obtained retrospectively using two different strategies from each main 
continental area. This section of this chapter describes the two strategies 
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used to create a multi-centre equine EMR database and compares the data 
obtained by each strategy.  
 
3.1.2 Materials and methods 
 
3.1.2.1 Strategy in the United Kingdom 
 
A total of 86 veterinary first-opinion equine practices based in the United 
Kingdom were contacted. For each practice the goal was to get in touch 
with at least one of the partners to discuss and clarify the aims of study 
and details concerning client confidentiality and data anonymisation. A 
single partner (representing the views of his or her co-partners) was 
targeted as the ultimate decision-makers as to whether their practice 
could take part in the study.  
  
In all cases a leaflet to briefly explain the aim of the study was sent by 
email along with a draft of the confidentiality agreement (Appendix 3.1). 
Veterinary surgeons of local Scottish equine first-opinion practices were 
also contacted in person at a local veterinary continuing professional 
development (CPD) meeting organised by the Weipers Centre Equine 
Hospital at the University of Glasgow in April 2012. For non-local 
veterinary practices contact details were obtained from each practice’s 
web-site, the initial contact was made with the administrative staff of the 
practice (both by email and phone), who were relied upon to forward the 
message to one of the partners (previously selected from their web-site). 
 
Of the 86 practices that were approached, 51 were a convenience sample 
selected from the list of practices that had referred at least one case to 
the Weipers Centre Equine Hospital in the previous decade. Also 35 were 
members of an established UK-based group of equine veterinary practices 
(GEP) spread throughout the country committed to work together to 
achieve the highest standard of veterinary care and to provide continuing 
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professional education to their members. Member practices were initially 
approached by the GEP group director and data was subsequently 
obtained directly from those member practices that agreed to participate. 
All practices willing to participate were subsequently included in the 
study. 
 
Of the 51 practices approached directly, a partner could be contacted 
directly in 23 practices. For non-replying practices it is not known whether 
there was a lack of interest from the partner in participating or whether 
the message ever reached the partners (the administrative staff might 
have not passed the message on as requested). 
 
For those 12 practices that agreed to participate, after the initial contact, 
subsequent communication was with a member of the administrative staff 
designated by the partner, who would then help to extract data from the 
practice management software system. Instructions on how to extract the 
information in a format suitable to the aims of the study were obtained 
directly from the PMSS provider of each practice. Where the software 
could not produce anonymous data, instruction on how to substitute 
patient details with a unique numeric anonym using Microsoft Access10 was 
provided to the practice (Appendix 3.2). Once each dataset was created, 
it was then shared with our research group via a free web-based file 
hosting service.   
 
The minimum inclusion criteria for the database from the United Kingdom 
were as follows:  
• A column with an anonymous unique identifier for each individual 
animal was required in order to track EMRs for each individual 
animal throughout the dataset over time.  
																																																								
10 Microsoft, Thames Valley Park, Reading, Berkshire, U.K. RG6 1WG  	
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• A date of data entry for each EMR was required to assess temporal 
relationships, for example between drug administration and certain 
clinical signs that could indicate toxicity. 
• Clinical notes (including free text notes and laboratory results 
where available). 
 
Other desirable, but not essential, information included: 
• Demographic or signalment information (including anonymous id, 
species, breed, gender, date of birth).  
• Codes to differentiate first opinion and referral work for practices 
where both were present. 
• Details of the quantity as well as type of drug administered or 
dispensed.  
 
3.1.2.2 Strategy in North America 
 
Data collection in North America was performed by approaching PMSS 
providers directly. Initially three main companies were approached to 
obtain data, only one of which was open to discuss participation.  
 
The standard contract of this company with its client practices specified 
that the company had the right to use/sell EMRs information for other 
purposes (marketing and research) as long as patient/client details 
remained anonymous. This company agreed to anonymise, clean and 
format the data in order to be compatible with our research. It was 
agreed that the dataset should contain at least 150,000 equids from North 
America and that this should represent at least eight equine practices with 
a relevant first opinion workload with good geographical spread through 
the North American continent.  
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The minimum and desirable inclusion criteria for the North American 
database were the same required for the data from the United Kingdom 
described in section 3.1.2.1. Further desirable information required also:  
• Approximate practice location (i.e. State) 
• Approximate owner location (i.e. State) 
We were able to include more required criteria in the North American 
datasets because they were coming from the same PMSS provider and 
because we were paying for the provision of these data. 
 
3.1.2.3 Data formatting 
 
Where data format provided by each practice did not match that of a pre-
established format suitable for analysis, dataset manipulation was 
performed using Rv.3.0.0. The pre-established format included a 
datasheet organised into seven columns (anonymous patient identification 
number, practice, date of birth, breed, gender, date, clinical text) with a 
row of data for each EMR entry. The date column included the date data 
was entered in the system. The clinical text column included all the text 
present in the EMR entry in one single text cell, including details of 
clinical examination, procedures, laboratory results, prescribing and 
invoicing. 
 
The study was approved by Ethics and Welfare Committee of the School of 
Veterinary Medicine at the University of Glasgow. 
 
3.1.3 Results 
 
3.1.3.1 United Kingdom dataset 
 
Of the total of 86 practices contacted initially, twelve agreed to 
participate in the study. Of these, five practices were included through 
GEP and the remaining seven practices had been included by directly 
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approaching the practice. For the vast majority of the 63 practices 
contacted directly that did not participate (42), no partner Veterinary 
Surgeon responded to any of the initial and following contact efforts (a 
total of three phone calls and emails over a period of two to three weeks). 
Of the practices approached indirectly through GEP, 29 out of 35 did not 
wish to participate. 
 
Each dataset included the minimum database described in section 3.2.2.1. 
The format was very variable between systems and also within the same 
system, resulting in practices using the same PMSS providing datasets with 
different structure. Data from some PMSS required significant 
manipulation of variable technical difficulty to become suitable for 
analysis as highlighted by the following examples.  
 
The first example is from the PMSS of one practice, which stored all 
veterinary reports and discharge instructions in a sequence of sub-folders 
each named with a number and the concatenation of number in the 
folder’s name would provide the unique numeric identification for the 
animals. This numeric identification matched other data (e.g. day to day 
hospitalisation findings or billing information such as drugs dispensed) for 
that animal stored in other spreadsheets. Further, some of the first 
opinion cases (as well as most of the referral cases of this practice) had 
veterinary reports and discharge instructions that were stored as MS Word 
documents and were converted as unformatted text strings and added into 
a spreadsheet with their unique identification obtained from the 
concatenation of sub-folders names. This dataset included also patients 
from the small animal branch of the practice combined with the equine 
practice and a large amount of time and effort had to be spent in the 
identification and removal of non-equine patients. This was achieved by 
searching for documents that included other animal species. Further the 
date was automatically extracted from each document’s name where 
available as a proportion of these include the date in the document’s 
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name. For those where the date was not available in the file name, 
information about date was extracted from within the documents’ as the 
date was usually included in the first row of data in most of the remaining 
cases. The remaining few hundred cases had to be edited manually 
individually as the date was present randomly within the text of the 
document so the process could not be easily automated.  
 
Another first opinion equine practice included also data from the farm 
animal branch, which was removed by mining rows where words from 
other species were identified (the PMSS of that particular practice had no 
column to identify the species).  
 
Data from two practices, using different PMSSs, was organised in multiple 
tables but a cross-referencing column was available to merge the two 
tables.  
 
For two practices using the same PMSS there was the need by one of the 
technicians of the PMSS Company to write a script to specifically extract 
the information of interest and attach it to the demographic patient 
details.  
 
Two practices had both first opinion and referral services included within 
the same dataset. For one of these the PMSS allowed differentiation 
between referral and first opinion cases. For the second practice, 
differentiation of first opinion and referral cases was performed by 
identification of the primary first opinion and referral veterinary surgeon. 
For both practices first opinion and referral services were well separated 
and although some veterinary surgeons from the referral service might 
have examined some first opinion case, this would have been a rare 
occurrence. 
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Data from two practices, that had agreed to participate, was unsuitable, 
having been provided in an unstructured spreadsheet. Ultimately data 
from 10 veterinary practices was available for use during the rest of the 
project. 
 
These examples highlight the complexity of the process required for data 
cleaning and preparation for the subsequent analysis. This process 
required a significant effort and time, although could have been 
somewhat faster if performed by an experienced programmer. The 
remaining practices provided data that was readily usable. 
 
The complete final dataset from the United Kingdom included a total of 
2,653,695 rows (overall size 462.1MB) of data from 141,543 equine 
patients attended by the first opinion service of 10 equine practices 
between 1987 and 2013. The data is summarised in Table 3.1. Figure 3.1 
represents the distribution of the amount of data (actual rows of data) 
entered in the respective PMSS each year by each practice. Figure 3.2 
represents the number of new patients (i.e. patients not previously 
identified within the dataset) added to the dataset by practice each year. 
Figure 3.3 represents the total number of animals in the dataset by 
practice each year. 
 
Table 3.1:  Summary of the contribution of each practice to the dataset from the 
United Kingdom.  
Practice Region Rows  Animals Period Gender (F-M-U) 
A Scotland 30677 3828 1993-2012 1676/291/61 
B Scotland Unsuitable - - - 
C Scotland 7805 215 2007-2012 0/0/215 
D South East 779328 70487 1987-2012 16780/23895/123 
E East Midlands 662484 9401 2007-2012 0/0/9401 
F North East Unsuitable - - - 
G North West 54044 3248 1995-2012 681/149/0 
H East of England 202514 9745 1997-2013 2445/6013/1287 
I North West 15431 1552 2010-2012 626/209/0 
J York & Humber 59927 3273 1994-2008 1260/1402/611 
K South West 566083 26059 2007-2013 6002/9372/10651 
L East of England 275405 13735 2005-2013 3226/3875/6634 
Total   141,543   
Rows: rows of data; F/M/U: Female/Male/Unknown 
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Where the demographic details were available the dataset included 1,349 
rows from 94 Donkeys and 664,197 rows from 34,559 horses. Of the 
remaining records 1,122,465 rows of data were from 87,710 animals 
classified as equines. The remaining 865,684 rows of data from 20,698 
animals included no details of their species. In terms of breed 2,324 types 
of breed and breeds crosses were reported. These included also 
misspellings and different variations of abbreviations (eg. Thoroughbred, 
TB, Tb, tb, t/b, T/b, etc). The dataset included a total of 180,840 rows of 
data from 7618 Thoroughbreds (6.9% of the animals for which a breed was 
recorded), 44,520 rows of data from 1878 Warmbloods (1.7% of the 
animals for which a breed was recorded), 14,879 rows of data from 599 
Arabian horses (0.5% of the animals for which a breed was recorded), 
62,927 rows of data from 2941 draft horses (2.7% of the animals for which 
a breed was recorded), 117,738 rows of data from 4122 ponies (3.7% of 
the animals for which a breed was recorded) and 10,146 rows of data from 
960 miniature breeds (0.9% of the animals for which a breed was 
recorded). No data of breed was available in 566,796 rows of data from 
31,280 animals (22.2% of all animals). 
 
The remaining 1,655,849 rows of data from 91,663 (83.5% of the animals 
for which a breed was recorded) animals were a mixture of combinations 
of breed crosses or misspellings or unclassifiable abbreviations. Gender 
was recorded for 79704 (56.5%) animals. This dataset included 32,697 
females (41.0% of those for which gender was recorded; 541,366 rows of 
data), 27,778 geldings (34.9%; 410,318 rows) and 5,767 entire males (7.2%; 
95,062 rows).  
 
A further 13,462 animals (16.9%; 267,635 rows) was recorded as “male” 
with no specification to whether the patient was neutered or not. For 
61,357 animals (43.5%; 1,339,317 rows) no gender was recorded. 
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Age was calculated as the difference in number of days between date of 
birth and the date the record was entered in the system. Date of birth was 
available for 77,754 (55.1%) animals (1,308,001 rows of data; 49.3%). The 
maximum age recorded was 2013 years and the minimum age was -23 
years. As these were clearly mistaken dates entered in the system age was 
only included for those 1,115,060 (42.0%) entries where age was in the 
range 0 to 40 years. Of these the median record (or row of data) age was 9 
years and the mean age was 10.8 years (1st quartile five years, 3rd quartile 
15 years). A realistic age was not available in 1,538,635 (58.0%) rows of 
data of which 192,941 rows of data from 17,916 animals included an age 
that was likely wrong (less than 0 or greater than 40 years). 
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3.1.3.2 North America dataset 
 
The dataset from North America included data from nine practices 
including a total of 27 branches distributed throughout 16 states of 
Canada and the United States of America. The overall dataset included a 
total of 11,699,875 rows of data (overall data size 5.54Gb). Of the total of 
312,634 equids in the dataset, 256,069 (81.9%) equids had first opinion 
records only, 15,941 (5.1%) equids had referral records only and 40,624 
(13.0%) equids had records from both first opinion and referral services. 
The data spanned between 1994 and 2013. Figure 3.4 represents the 
distribution of the amount of data entered each year by each practice. 
Figure 3.5 represents the number of new patients by practice in each year 
and Figure 3.6 represents the number of horses in the dataset by practice 
each year. A proportion of data from three practices in North America 
prior to 2005, 2006 and 2007, respectively was known to have a wrong 
date of data entry to the system as a consequence of having imported 
data from a previous PMSS not compatible with the current PMSS. 
 
As data was prepared directly from the PMSS Company, it was organised in 
a consistent structured manner. Each of the nine datasets included a 
comma separated value spreadsheet with 50 columns with the following 
information: two Anonymous Patient Identification (one for the practice 
and one general id), demographic details (species, breed, gender, colour, 
date of birth), date of data entry, and 42 columns to structure the clinical 
notes (including free text notes, note type, lab results and reference 
ranges, drugs dispensed and amounts, diagnosis, owner and practice 
state). The detailed columns of the dataset are summarised in table 3.2.
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Table 3.2: Table summarising the contribution of each practice to the dataset from 
North America.  
Practice Region Br Rows Animals Period Gender (F/M/U) 
L Colorado 1 339476 9329 1994-2013 3569/4341/1419 
M 7 States 14 3880795 82431 2004-2013 20198/25204/37029 
N Virginia 1 847674 20483 1997-2013 7510/10924/2049 
O Alberta 2 1884163 37117 2006-2013 9789/13085/14243 
P Ontario 4 857020 60551 1996-2013 7977/10761/41813 
Q California 1 334532 11537 1999-2013 2184/2406/6947 
R 2 states 2 1311646 48369 1994-2013 9678/13627/25064 
S Tennessee 1 1108298 20580 2006-2013 3875/7637/9032 
T Wisconsin 1 1136271 22237 2004-2013 9057/10721/2459 
Total - 27 11699875 312634 117 years 73837/98742/140055 
Br: Branches; Rows: rows of data; 7 States: Texas, Arizona, N Mexico, Oklahoma 
Montana, Iowa and Florida; 2 States: Florida and New York; F/M/U: 
Female/Male/Unknown 
 
The last column included also the identification of the primary veterinary 
surgeon. This was requested to identify those veterinarians with high post-
graduate clinical qualifications (DACVS, DACVIM and DACVT) or that 
worked as part of the referral service. In fact, this PMSS had no inbuilt 
facility to differentiate between first opinion and referral caseloads in 
those practices where both services were available. Opposed to the 
dataset from the United Kingdom, for the dataset from North America the 
population was a mixture of first opinion and referral as it was not 
possible to distinguish between these two populations. 
 
While the PMSS data was well structured, the content of the clinical notes 
was extremely variable and reliant on veterinarians/veterinary 
technicians. For example a single visit would typically include data over 
several rows for which demographic information was repeated in each 
row. The clinical notes could be included in a single cell per row or in 
multiple cells per row. For cells where no data was available or applicable 
or entered in another row for that visit the cell would be filled as Not 
Available (NA). For example, if a horse had an orthopaedic examination 
and received some phenylbutazone and some blood work was performed 
then the clinical findings were included on one row and the lab-work 
results and reference ranges on another row or on the same row. Details 
of the drug dispensed would usually be reported in separate columns on 
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the same or on a different row such as “Invoice Item Description”, 
“Dispensed” or “Quantity”, but sometimes these details were included 
also, or just, in the free-text clinical notes columns. All these rows shared 
the same demographic information and date of data entry, which allowed 
identification of that particular examination on a patient. A list of the 
most relevant columns included in the dataset from North America is 
summarised in Table 3.3. 
 
Table 3.3: List of the most relevant columns including the clinical notes in the 
dataset from North America.  
Column name Content Rows with empty cell 
Note  Free-text notes 9,518,669 
Result type Description of Notes/Value column 8,505,189 
Value Free-text notes 8,529,218 
ResultDataType Invoice vs Appointment vs Result 635,672 
Result Units Units of parameter 11,333,279 
ResultRefRangeHigh Higher end of reference range 11,390,356 
ResultRefRangeLow Low end of reference range 11,390,356 
ResultComments Free-text notes 3,325,997 
InvoiceItemDescription Free-text notes 5,469,218 
ItemDescription Free-text 5,469,207 
ContainerDescription Dispensing code 8,754,044 
DiagnosticCategoryName Administrative code 11,446,396 
DiagnosticCodeName Administrative code 11,686,190 
DiagnosticSubCodeName Administrative code 11,697,864 
DiagnosisName Diagnosis 11,699,857 
DiagnosisPathString Pathological diagnosis 11,699,864 
IsPresentingComplaint Presenting complaint All Empty 
DiagnosisDifferentalDate Date differential diagnosis added 11,699,871 
DiagnosisTentativeDate Date tentative diagnosis added 11,688,874 
Physical  Quantity dispensed 6,230,050 
Dispensed Quantity dispensed 6,230,443 
Quantity Volume administered 5,470,720 
MeasurementName Administrative code 5,469,897 
DiagnositcClassName Administrative code code 11,375,708 
OwnerState Owner state 45,251 
PracticeState Branch location 1700 
RecordProviderName DVM identification 82,854 
Other columns missing are anomymous identifiers for who input the data, under who the 
data is invoiced to. 
 
As a significant degree of variability was present in the way practices and 
their veterinarians stored the information in the system and to account for 
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typing errors and data input mistakes (data added to the wrong columns) 
all the columns including clinical information other than identification, 
demographic information, date of data entry and practice location were 
merged in a single column of text. 
 
Where the demographic details were available the horse population 
dataset included 2,116 rows of data (0.02% of total) from 118 Donkeys, 
147 rows of data (>0.01% of total) from eight mules, 273 (<0.01% of total 
rows of data from two zebras and 11,697,339 rows of data (99.98% of 
total) from 312,506 animals classified as equines. In terms of breed 646 
types of breed and breeds crosses were reported. These included also 
different abbreviations and misspellings (eg. Warmblood, warm blood, 
Dutch WB, Begian Warmblood, Trakhener, VTrakhener, etc.). The dataset 
included a total of 3,817,733 rows of data from 66,960 quarter horses 
(34.5% of the animals for which a breed was recorded), 1,244,730 rows of 
data from 26,374 Thoroughbreds (13.6% of the animals for which a breed 
was recorded), 1,653,924 rows of data from 20,748 Warmbloods (10.7% of 
the animals for which a breed was recorded), 729,650 rows of data from 
15,444 horses of American breeds (Appaloosa, Paint, Peruvian Paso, 
Tennessee walking horse, etc.) (7.9% of the animals for which a breed was 
recorded), 260,330 rows of data from 5444 Arabian horses (2.8% of the 
animals for which a breed was recorded), 201,483 rows of data from 5632 
ponies (2.9% of the animals for which a breed was recorded), 80,121 rows 
of data from 1664 draft horses (Clydesdale, Percheron, etc.) (0.9% of the 
animals for which a breed was recorded), 37,912 rows of data from 849 
cobs (0.4% of the animals for which a breed was recorded) and 80,402 
rows of data from 2098 miniature breeds (1.1% of the animals for which a 
breed was recorded); 30,142, 12,866 and 26 rows of data were from 1038 
donkeys, 469 mules and 4 zebras respectively (0.5%, 0.2% and 0.002% of 
the animals for which a breed was recorded respectively). No data of 
breed was available in 2,326,650 rows of data from 118,487 animals 
(37.9% of all animals). The remaining 1,223,906 rows of data from 47,423 
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(24.4% of the animals for which a breed was recorded) animals were a 
mixture of combinations of breed crosses or misspellings or unclassifiable 
abbreviations.  
 
Data on gender was available for 172,579 animals (55.2% of total) and 
included 4,125,743 rows from 73,837 females (42.8% of those for which 
gender was recorded), 4,554,301 rows from 85,483 geldings (49.5% of 
those for which gender was recorded) and 876,618 rows from 13,237 
entire males (7.7% of those for which gender was recorded). A further 22 
(>0.1%) animals (447 rows) were recorded as “male” with no specification 
to whether the patient was neutered or not. For 140,055 animals (44.8% of 
total) no gender was recorded (2,142,766 rows). 
 
Age was calculated as the difference in number of days between date of 
birth and the date the record was entered in the system. Date of birth was 
available for 198078 (63.3%) animals (9,357,112 rows of data; 80.0%). The 
maximum age recorded was 253 years and the minimum age was -101 
years. As these were clearly mistaken dates entered in the system age was 
only included for those entries 9,235,185 rows from 189,311 animals 
(60.6% of the total) in the range 0 to 40 years, resulting in the exclusion of 
age in 121,927 rows of data (1.3% of those with a date of birth available) 
from 8767 animals (4.4% of those with a date of birth). Of these with a 
plausible age the median age was eight years and the mean age was 9.1 
years (1st quartile four years, 3rd quartile 13 years) and this reflected the 
age at the time each row of data was entered in the system.  
 
3.1.4 Discussion 
 
The aim of this work was to assemble databases compatible with text 
mining. The practice-by-practice approach implemented in the United 
Kingdom offered no practical advantage other than being more 
economical. Data collection was completed at virtually no cost as data 
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was voluntarily provided free of charge by participating veterinary 
practices. These practices pay significant annual fees to their PMSS 
Companies, which often include basic technical support as part of the 
standard assistance contract. Data extraction can often be obtained using 
in-built search functions to create a comprehensive spreadsheet including 
all the information in the EMRs. However, assistance was required on two 
occasions from the PMSS Company to create queries to obtain the data 
required. In both cases the cost was affordable (£200) and provided data 
of suitable quality. 
 
The greatest shortcoming of this approach was related to the time and 
effort required to gather data. A large number of practices had to be 
contacted at the start to include only few (17% of the 86 initially 
approached provided data) in the end and the response rate was similar to 
that of another similar study in small animals (Cameron et al., 2014). 
Previous studies requiring private equine practices to share client data 
reported a comparable low response rate of 23% (Hotchkiss et al., 2007). 
The overall process, including data cleaning, required more than 18 
months to complete.  
  
Approaching GEP proved helpful as partners of veterinary practices 
appeared more likely to reply to a message from a known contact such as 
the GEP group director, particularly when they had not previously been in 
touch with a member of our research group from the University of 
Glasgow. Collaboration with GEP worked as a mutual benefit as provision 
of data was obtained in exchange for free-of-charge presentations at one 
of their CPD events. Provisional results of data analysis were presented at 
GEP meeting in October 2013. 
 
The variability in dataset format provided by each practice as well as the 
difference in PMSS used by participating practices also required significant 
efforts to obtain a dataset suitable for analysis. This required also a 
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significant amount of time and effort, including lengthy communication 
with some practices and their PMSS Company to clarify technical 
characteristics of their datasets and avoid data format misinterpretation.  
 
The dataset obtained from North America was provided in a format ideal 
for analysis as cleaning and formatting was performed directly by the 
PMSS provider company. The dataset obtained in this manner was costly 
(about £9,000), but the cost was reflected in quality and quantity of data 
provided. This approach proved faster as data was obtained within weeks 
of finalising an agreement with this PMSS Company and was immediately 
ready for analysis. 
 
Both United Kingdom and North American approaches produced final 
datasets with structures meeting the minimal requirements for our 
research. However, a large amount of desirable data was missing from 
both dataset, as much of the demographic details were not available as 
they were not recorded in the system by administrative staff, veterinary 
technicians/nurses or veterinary surgeons. Missing data is often a 
significant issue in retrospective studies and little (if anything) can be 
done to retrieve missing information, particularly where patient and 
owner’s identities are masked. Nevertheless the amount of information 
available in the dataset was still sufficient for significant analyses. 
 
A major limitation of both datasets was that there was no way to check 
correctness of data added to the PMSS due to the retrospective data 
collection. Although the vast majority of the information contained is 
assumed to be correct, errors are bound to be present for any of the 
information entered either automatically or manually. Correctness of 
patient identification is of pivotal importance for PMSS as this allows 
longitudinal tracking of patients through time and it is therefore created 
automatically. However, animals sharing first and last names might be 
confused by a member of staff entering the information in the PMSS. 
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While this is possible in theory when adding new information to the 
system, the amount of this type of incorrect data is likely to be minimal as 
the correctness of this information is essential to correct billing and the 
heart of practice-client trust and the importance of allocating the 
information to the correct patient would be emphasised to all staff 
working at these practices. Data referring to date of examination were 
added to the PMSS automatically so mistakes might arise through two 
mechanisms. The main mechanism is by importing old data from previous 
PMSS not compatible with the current system. A proportion of data from 
three practices in North America prior to 2005, 2006 and 2007, 
respectively was known to be wrong due to the incorrect importing of data 
from a previous not compatible PMSS. For one practice this was reflected 
by a very large number of cases seen in 2007 (~20,000) while the following 
years this practice had a caseload of roughly 5,000 cases per year. For all 
remaining practices from North America there was little change in the 
number of cases between years prior and following the introduction of the 
current PMSS. The second mechanism that might lead to recording an 
incorrect date may be due to systems failure where the date of the system 
is reset. Because it is a legal requirement for practices to keep accurate 
medical records, it is likely that any effect of system dates would be short 
lived and would have a minimal impact on the overall correctness of the 
data. 
 
Date of birth, species, breed and gender were entered manually in the 
system and the amount of incorrect data is unknown. Age at the time of 
the veterinary consultation was calculated from the record date and date 
of birth. In some instances, the recorded date of birth was obviously 
erroneous (e.g. after the date of data entry or even of the year 1899), 
leading to ages of less than zero or more than forty years. These age 
values were removed before analysis, however an unknown proportion of 
retained ages (between zero and forty years) may have also been 
incorrect for the same errors in manual entry.  Unfortunately there is no 
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way of retrospectively confirming the validity of these dates and related 
age, therefore age-related findings from the data should always be 
interpreted with some caution. However, there is no reason to suspect a 
systematic bias in manual errors in that manual errors would have been 
likely to cancel each other out and therefore have minimal impact on the 
overall results. Only if the error were systematic (eg. repeated shifting of 
decimal points) would the results have been seriously compromised. 
 
As to the free-text clinical notes, these included any information deemed 
worth recording by the attending veterinarian. It is likely that some detail 
is missing due to forgetfulness or lack of commitment to keeping good 
records under different circumstances. Finally errors in clinical judgment 
(wrong diagnoses, diagnoses not supported by appropriate evidence) are 
also possible and simply reflect the nature of equine practice, particularly 
for ambulatory first opinion equine practice. 
 
In conclusion, two possible strategies to create a large dataset of EMR 
have been described. While one method is cheaper, the other provided a 
larger amount of better quality data in a much more timely fashion. A 
limitation of both methods reflects the bias of using only practices willing 
to participate (United Kingdom data) or only using the one PMSS providing 
the data (North American data). Future efforts should aim to provide 
equine practices with good quality studies aiming to improve decision-
making in equine practice as this might in return raise awareness in 
veterinary practice of the need for more good quality data to perform 
more studies, which would benefit both research and veterinary practice. 
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3.2 Text-mining electronic medical records from equine medical 
practice: methodology validation 
 
3.2.1 Introduction 
 
3.2.1.1 Free-text mining in the veterinary literature 
 
The widespread use of electronic medical records (EMR) by private 
veterinary practices could support large epidemiological studies by 
providing large datasets of clinical records without the manual labour 
required to access traditional paper records. Automation of this process 
should significantly increase speed of data extraction. However, the 
technique used to extract the information of interest should be thoroughly 
validated to illustrate the reliability of the automated process. Electronic 
medical records are often stored as free-text with minimal structure and 
practice management software systems (PMSS) seldom offer means to 
search these records adequately (Anholt et al., 2014b; Erstad, 2003).  
 
The potential applications of text mining in clinical research are multiple 
and include retrospective analysis of data to describe changes in disease 
prevalence, relationships between treatments and side effects, treatment 
outcomes, risk factor analysis and survival analysis. Prospective studies 
could combine the use of coding systems with text mining for syndromic 
surveillance (Anholt et al., 2014b), as has been successfully accomplished 
in human medicine (Brossette et al., 1998; Gerbier et al., 2011).  
 
Text mining to retrieve targeted electronic medical records has been used 
in some veterinary studies in recent years (Anholt et al., 2014b; Lam et 
al., 2007a, 2007b; Oswald et al., 2010). Lam and colleagues (2007) have 
described a methodology to mine free-text clinical records using the 
software package SimStat/WordStat by Provalis Research. In that study 
the authors describe the reasons for retirement from racing for racehorses 
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in a dataset from the Hong Kong Jockey Club. This software has 
subsequently been used in risk factor analysis for retirement following 
tendon injuries or to determine the prevalence of cervical vertebral 
stenotic myelopathy in a thoroughbred breeding farm (Lam et al., 2007b; 
Oswald et al., 2010). A study by Anholt and colleagues (2014) reported its 
use in small animal veterinary practice in Canada to illustrate the 
frequency of antimicrobial usage in pets with diarrhoea demonstrating the 
potential of this methodology for disease surveillance. 
 
Technique validation is extremely important for any assay or analysis in 
research. This applies also to text mining of EMRs. A recent study aimed to 
validate the use of WordStat for text mining veterinary EMRs against 
manual classification (Anholt et al., 2014a). This study describes in detail 
how analysis is performed using the software manufacturer’s 
recommendations. The dataset was imported as a comma separated value 
file format and included 25,000 records from 12 first opinion small animal 
practices in Canada. The dataset included a column for the anonymised 
identification number of each animal, patient species, breed, gender and 
date of birth plus a rough indication of the owner post-code area and also 
a column with the free-text clinical notes (including chief complaint, 
history, physical examination findings, procedures performed and relevant 
results) added by the attending clinicians. The dataset did not include any 
standardised diagnostic coding or fixed vocabulary. The analysis was 
performed to automatically characterise the text contained within the 
free-text notes and resulted in high sensitivity (87%) and specificity (99%) 
proving that WordStat can be a useful tool in clinical epidemiologic 
research. These authors elected to sacrifice the identification of some 
true positives in order to minimise the number of false positives. 
However, while their specificity was excellent, sensitivity might be 
improved further with a substantial change in the methodology to improve 
identification and exclusion of falsely positive and falsely negative cases. 
A similar approach is described by Lam and colleagues (2007) with the 
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addition of a review process of the data incorrectly classified and update 
of the search dictionaries in an iterative manner. However, this study did 
not report sensitivity and specificity of this technique (Lam et al., 2007a)  
 
3.2.1.2 Text-mining software 
 
Documents to be searched can be imported into WordStat11 after being 
processed in SimStat 12 . Simstat will support files of several formats 
including csv, xls, xlsx and xml. For the purposes of this study data was 
imported as csv. Import was achieved by following the path “file -> Data -
> Import”. The import process requires a variable amount of time 
depending on the file size (number of columns and rows imported) and 
machine power. 
 
Once imported in SimStat, the menu driven command: “Statistics -> 
Choose X and Y” opens a “Choices Dialogue” window that will allow the 
user to determine which columns of the dataset are to be used as 
reference (e.g. row numbers) and which contain the text to be mined. The 
reference column is to be entered in the tab labelled “Independent:” and 
the column or columns containing the text to be mined are to be entered 
in the tab labelled as “Dependent:”. Once each column of interest has 
been added, WordStat can be launched by selecting “Statistics -> Content 
Analysis”. 
 
WordStat is a linguistic based program that allows identification of 
predetermined words or compound phrases included in a user-defined 
categorisation dictionary within a given free-text, returning all rows of 
data (“cases”) matching any word in said dictionary. The software 
includes a feature to exclude terms of little semantic value (561 terms 
between pronouns, conjunctions and adverbs) unless these are included in 
the categorisation dictionary. This feature simplifies and speeds up the 																																																								11	WordStat	v6.1.20,	Provalis	Research,	Montreal,	Canada	12	SimStat	v2.6.2,	Provalis	Research,	Montreal,	Canada	
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process by removing a large number of terms repeated throughout the 
text and that likely have little, or no significant, bearing on the 
interpretation of the text.  
 
The “Frequency tab” in WordStat then produces a list of all remaining 
words within the dataset and this list can be used to further define the 
categorisation “inclusion dictionary” and increase the sensitivity including 
misspellings and abbreviations actually included in the dataset. This list of 
words can be exported as a spreadsheet and evaluated using other 
software such as MS Excel or Numbers. The software also offers some 
syntax shortcuts to include words with a similar root by adding the 
character “*” at the end of the common root. For example “abd*” would 
identify all cases including a word starting as “abd”, which includes 
“abdomen”, “abdominal”, “abd.”, etc. Nevertheless unique or rare 
spellings that do not follow a specific rule would still need to be included 
individually as specific words. The word list is a very useful tool as it 
provides the user with the means to produce a dictionary that includes all 
relevant terms and their variations that are actually present in the 
dataset.  
 
As identification of a specific word within the text might not always 
correctly classify a case as part of the appropriate category, negations 
must be taken into account. For instance if the characterisation dictionary 
includes the word “diarrhoea”, a sentence such as “the horse does not 
have diarrhoea” would be classified as positive, whilst clearly the horse 
“does not have diarrhoea” and therefore should be classified as negative. 
Efficient identification of such false positives maximises the specificity of 
the analysis. WordStat supports the creation of semantic rules using 
boolean functions (“and”, “or”, “not”) or other modifiers (“no”, “if”, 
“watch”) and proximity operators (“near”, “before”, “after”) to further 
categorise cases. For example an operator might specify that any case for 
which the word “not” is present within three words of the word “colic” 
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than the case is to be classified as a “not colic” rather than in the “colic” 
group. This is done using a specific but simple syntax. For this example 
the rule to obtain this result should be coded as “not BEFORE colic/C 5”. A 
list of rules to exclude false positive cases could be included in an 
“exclusion dictionary” that could then provide a list of those cases that 
should be removed from the more comprehensive “inclusion dictionary”. 
All rules in the exclusion dictionary are created starting from words or 
combinations of words included in the inclusion dictionary. Creating these 
rules in the exclusion dictionary will remove false positive cases ultimately 
optimising specificity. However, the linguistic variability of free-text 
records is immense and creating rules that fit all data is often not possible 
and a degree of error is likely to be present, so that in the end finding the 
right balance between cases to be included or removed becomes a 
subjective process partly based on trial and error, running analysis, 
examining the output, updating dictionaries and re-running the output 
(Lam et al., 2007a). For example the rule “not BEFORE colic/C 5” might 
identify as false negative the sentence “do not call if the horse does not 
colic again” as the horse is likely to have shown abdominal discomfort at 
some point. However, the sentence “the horse did not colic again in this 
occasion, but has foot pain” similarly would also be incorrectly identified 
if the rule were removed. Therefore if the methodology used for text-
mining includes pre-set rules to identify false positive cases, it is 
appropriate to report sensitivity and specificity of the inclusions-exclusion 
dictionary combination against the dataset being mined. 
 
An alternative, which may be more time-consuming, but might ultimately 
offer better results, is that of searching for relatively complete sentences 
identifying false positive cases and adding those directly to the exclusion 
dictionary. This is laborious as the output search from the inclusion 
dictionary is to be evaluated manually. However, this would allow 
extraction only of truly false positives improving sensitivity, specificity 
and positive and negative predictive values. 
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This study describes the validation of a text-mining method depicting 
exclusion terms individually rather than by rules and compares the results 
to the literature (Anholt et al., 2014a) 
 
3.2.2 Materials and Methods 
 
3.2.2.1 Data used for validation 
 
Lifelong clinical records were extracted from a random sample of patients 
from the United Kingdom dataset described in the Chapter 3 using R 
v3.0.2. Some patients were randomly selected from a group for which the 
records mentioned colic (50 animals). Patients for which conditions with 
an expected very low prevalence such as right dorsal colitis (3 animals) 
and renal failure (17 animals) were mentioned at some point during their 
life were identified using the search feature of a text editor software13 
and were subsequently added to the population to ensure that cases with 
a very low prevalence were included in the validation process. Finally 
records from a subset of 265 animals randomly selected from the overall 
population 141,543 animals from the United Kingdom, excluding those 70 
already included, were also included. The random selection of patients 
was programmed so that the final number of rows of data from each 
practice would reflect in the validation dataset the overall proportion of 
rows of data from each practice as closely as possible. The obtained 
dataset is from now referred to as “validation dataset”. Columns for 
patient identification, date and free-text clinical notes were also 
included. There was no standardised diagnostic coding, fixed vocabulary in 
the dataset.  
 
 
 																																																								13	TextEdit,	version	1.9,	Apple	Inc.,	Cupertino,	CA,	USA	
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3.2.2.2 WordStat settings  
 
The validation dataset was imported into SimStat by classifying the 
patient identification and note columns as the independent and 
dependent variables, respectively in the “Statistics -> Chose X-Y” tab.  
WordStat was launched by clicking on “Content Analysis” under the 
“Statistics” tab. Wordstat first view is at the tab named “Dictionaries”. In 
this, the “Exclusions:” option is to be unselected while the tab “English - 
Lemmatization” is selected in the scroll down menu by “Substitution:”.  
Under the “Options” tab the following boxes were selected. Under the 
sub-tab “Text Processing” no option was ticked other than “Accept 
numeric character” under the “Characters:” section. In the box “Add 
characters appearing:” box, a string including all punctuation characters 
such as: !?-+:”;’,.<> was added to both boxes labelled as “Anywhere”. 
Under the “Speller/Thesaurus” tab, in the box “Active spell checking 
dictionaries:” the “American.adm” and “British.adm” options were 
selected, whilst “Ignore words containing numbers” and “Ignore words in 
uppercase” were deselected.  
 
3.2.2.3 Inclusion dictionary 
 
After selecting the WordStat settings highlighted in the previous section, 
clicking on the tab “ Frequencies” WordStat created a list of all terms 
included in the dataset, which was then exported into a MS-Excel 
spreadsheet to be evaluated manually word-by-word. Any term that might 
have been of interest was then included in an appropriate categorization 
dictionary. This included terms spelled correctly as well as words that 
identify terms of interest spelled incorrectly or abbreviated. Also words 
which could be part of combinations of words identifying conditions of 
interest (eg. “right” as part of “right dorsal colitis”) were included.  
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3.2.2.4 WordStat search 
 
After each categorization dictionary was created from the list of words 
produced in the “Frequency” tab, the rows of data (cases) that included 
the terms contained in the categorization dictionary were identified by 
clicking on the “keyword-in-context” tab. The result produced a 
spreadsheet with five columns including the position (row number) of that 
row of data in the original dataset, three columns with text including all 
text immediately before the searched term, the searched term and all 
text immediately after the searched term, respectively and the last 
column identifying the animal identification number. The result of the 
search was then saved as a “.csv”. This procedure was performed for each 
of the dictionary terms of interest selected in the “Keyword:” scroll down 
menu under the “Keyword-in-context” tab. 
 
3.2.2.5 Exclusion dictionary 
 
The output of the search obtained from the characterization dictionary 
(inclusion dictionary) was subsequently evaluated manually to identify 
false positive cases. Each exclusion dictionary was created with 
combinations of words identifying false positive terms. 
 
Once a comprehensive exclusion dictionary had been created, the cases 
that contained the exclusion terms were identified by scanning the 
dataset against the exclusion dictionary and the result was then exported 
as a “.csv” file. This output included the original data row number, three 
text columns and the animal identification number.  
 
3.2.2.6 Removal of false positive terms 
 
Both search results from inclusion and exclusion characterisation 
dictionaries were imported into R v3.0.2 so that the false positive terms 
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identified by the exclusion dictionary could be removed from the search 
results of the inclusion dictionary. This was achieved in R v3.0.2 by the 
one-line command:  
 
true.pos<-inclusion[!inclusion$rowames%in%exclusion$rownames,] 
 
where “inclusion” is the dataset including the rows of data extracted from 
the original dataset as containing terms in the inclusion dictionary, and 
“exclusion” is the dataset including the cases matching terms within the 
exclusion dictionary. 
The row numbers (“rownames”) in the resulting “true.pos” dataset were 
then used to extract the row of data from the original dataset with the 
command: 
 
result<-orig.data[orig.data$rownames%in%true.pos$rownames,] 
 
where “orig.data” is the original dataset including all the records. The 
dataset “result” included all the rows of data from the original dataset 
that included terms in the inclusion dictionary but that also excluded the 
cases containing terms specified in the exclusion dictionary. 
 
3.2.2.7 Re-inclusion dictionary 
 
The output search of the exclusion dictionary was also evaluated manually 
to identify whether it included any row of data identifying a false negative 
term. Combinations of words uniquely identifying these false negative 
rows of data were included in the re-inclusion dictionary. Mining for terms 
in the re-inclusion dictionary within data obtained from the exclusion 
dictionary identified truly positive terms, which were subsequently re-
added to the “result” dataset obtained in section 3.3.2.6.  
 
The whole mining procedure is summarised in Figure 3.7. 
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3.2.2.8 Characterisation dictionaries used for validation 
 
For technique validation four dictionaries were searched. The first 
characterisation dictionary included a class of drugs such as “NSAIDs”. The 
second dictionary included a condition of an expected relatively high 
prevalence, such as “colic”, while third and fourth dictionaries included 
conditions at expected low prevalence such as “renal failure” and “right 
dorsal colitis”. Preparation of inclusion, exclusion and re-inclusion 
dictionaries was performed as described in sections from 3.2.2.2 to 
3.2.2.7. 
 
3.2.2.9 Manual classification as “gold standard” 
 
The validation dataset was classified manually only after the automated 
classification process as described between sections 3.3.2.1 and 3.3.2.7.  
Manual classification was performed using MS Excel on the same file that 
had been imported into WordStat for analysis, including two columns, one 
for the animal identification and one for the free-text records. A third 
column was then used to encode each row of data according to one of the 
categories: “NSAIDs”, “colic”, “renal failure”, “right dorsal colitis”. Rows 
of data were included in each of the four categories if an NSAID was 
administered/prescribed, a horse exhibited signs of abdominal discomfort, 
or a diagnosis of renal failure or right dorsal colitis was made, 
respectively. The dataset including the manual classification column was 
saved as a “.csv”. 
 
The text-mining process is summarised in Figure 3.7. 
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Figure 3.7: Flow chart summary of the text-mining process adopted in the study.	
Inclusion and re-inclusion dictionaries defined analysis sensitivity; Exclusion 
dictionary defined analysis specificity. The tree datasets are then imported in R 
v3.0.2 to remove rows from the Exclusion dataset from the Inclusion dataset and to 
then re-include those in the Re-inclusion dataset. The lower portion of the picture 
summarises how the final dataset (dark grey) resulted from the subtraction of the 
exclusion dataset from the inclusion dataset and the final addition of re-inclusion 
dataset obtained from the exclusion dataset. 
 
3.2.2.10 Comparison between manual and automated classification 
 
The search output for each of the four characterization dictionaries as 
well as the validation dataset including the column with the manual 
classification were imported into R v3.0.2. The row number obtained from 
automated and manual classification was compared and any discrepancy 
recorded and subsequently re-evaluated manually to investigate the 
source of the disagreement. A note was made as to whether the mistake 
was made by the automated or manual analysis. 
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3.2.3 Results 
 
3.2.3.1 Data 
 
A subsample of clinical records from 335 animals was selected with a total 
of 17,561 rows of data. The number of cases and rows of data per practice 
are summarised in Table 3.4. 
 
Table 3.4: summary of cases used for validation from the original dataset for the 
validation dataset. Data obtained from the United Kingdom. 
Practice Total patients (%) 
Total rows of 
data (%) 
Validation 
patients (%) 
Validation rows 
of data (%) 
A 3828 (2.7%) 30,677 (1.2%) 6 (1.8%) 89 (>0.5%) 
C 215 (0.2%) 7,805 (0.3%) 3 (0.9%) 100 (0.6%) 
D 70487 (49.8%) 779,328 (29.4%) 115 (34.3%) 2960 (16.9%) 
E 9401 (6.6%) 662,484 (25.0%) 79 (23.6%) 10513 (59.9%) 
G 3248 (2.3%) 54,044 (2.0%) 12 (3.6%) 492 (2.8%) 
H 9745 (6.9%) 202,514 (7.6%) 26 (7.8%) 826 (4.7%) 
I 1552 (1.1%) 15,431 (0.6%) 4 (1.2%) 40 (0.2%) 
J 3273 (2.3%) 59,927 (2.3%) 8 (2.4%) 215 (1.2%) 
K 26059 (18.4%) 566,083 (21.3%) 51 (15.2%) 1608 (9.2%) 
L 13735 (9.7%) 275,405 (10.4%) 31 (9.3%) 718 (4.1%) 
Total 141,543 2,653,698 335 (0.2%) 17561 (0.7%) 
Values in brackets refer to proportion of animals and rows of data from that practice 
from total and of the respective proportions of animals and rows of data from each 
practice in the validation dataset compared to the total dataset. The validation dataset 
included 0.2% of all animals and 0.7% of all rows of data of the data from the United 
Kingdom. 
 
3.2.3.2 Inclusion Dictionary 
 
The inclusion dictionary for “NSAIDs” included 53 terms, 58 for “colic”, 13 
terms for “renal failure” and 6 terms for “right dorsal colitis”.  
 
Following data extraction of the total of 17,561 rows of data in the 
validation dataset, terms in the NSAIDs inclusion dictionary were present 
1562 times in 1181 rows for NSAIDs, 356 times in 295 rows for colic, 23 
times in 23 rows for renal failure and seven times in seven rows for right 
dorsal colitis. 
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3.2.3.3 Exclusion Dictionary 
 
The exclusion dictionary for “NSAIDs” included four terms, 131 for “colic”, 
four terms for “renal failure” and no terms for “right dorsal colitis”.  
 
Following data extraction of the total of 17,561 rows of data in the 
validation dataset, terms in the NSAIDs exclusion dictionary were present 
125 times in 112 rows, 63 times in 57 rows for colic, twice in two rows for 
renal failure and no term for right dorsal colitis. 
 
3.2.3.4 Re-inclusion Dictionary 
 
The re-inclusion dictionary for “NSAIDs” included 4 terms, five for “colic” 
and no terms for “renal failure” and “right dorsal colitis”.  
 
Following data extraction of the total of 17,561 rows of data in the 
validation dataset, terms in the NSAIDs exclusion dictionary were present 
79 times in 78 rows, twice in two rows for colic. No term was present for 
both renal failure and right dorsal colitis. 
 
The full list of terms in these dictionaries is reported in Appendix 3.3. 
 
3.2.3.5 Result dataset 
 
Rows of data including false positive terms consistent with an erroneous 
classification of unaffected patients as affected were removed as 
described in section 3.2.2.6 and the few false negative terms identified by 
the re-inclusion dictionary were re-included in the “result” dataset. This 
resulted in 1149 rows for NSAIDs, 239 rows for colic, 23 rows for renal 
failure and seven rows for right dorsal colitis. 
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3.2.3.6 Comparison between manual and automated classification 
 
There was good agreement between manual and automated search 
methods for each of the four dictionaries evaluated in the study.  
 
Manual search identified 1132 cases out of 17,561 rows of data that had 
included a record referring to administration of NSAIDs, while automated 
analysis identified 1149 cases. Sensitivity, specificity and positive and 
negative predictive values were 99.8%, 99.9%, 98.3% and 100.0%, 
respectively. Manual classification missed 19 instances where NSAIDs had 
in fact been administered that were correctly classified by automated 
analysis. Two further cases were false negative cases incorrectly classified 
by the automated process, but correctly identified in the manual 
processing. This included words within the dictionary that had also been 
included in the exclusion dictionary as part of the sentence referred to a 
possible future use of the drug (so drug was not administered yet), while a 
previous sentence in the same case referred to the current use of the 
drug. For example a horse “has been evaluated for lameness. Horse also 
has copd with dry hay and has diarrhoea after bute.” In this example a 
horse might be included as it has had diarrhoea with an inclusion 
dictionary for diarrhoea. However, the exclusion dictionary might include 
lameness terms, such as “lameness” as many cases that had receive 
phenylbutazone might contain several variations of a sentence intimating 
that if the horse develops diarrhoea whilst being administered an NSAIDs 
to manage a lameness then the owner should call immediately. The re-
inclusion dictionary would include again the specific word combination 
that identifies this row of data “Horse also has copd with dry hay and 
diarrhoea after bute” so this row is not misclassified by the exclusion 
dictionary alone, without including other cases referring only to the 
hypothetical development of diarrhoea. 
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Manual search identified 226 rows of data referring to colic out of 17,561, 
while automated analysis identified 239 cases. Sensitivity, specificity and 
positive and negative predictive values were 100.0%, 99.9%, 94.6% and 
100.0% respectively. Similarly, manual classification missed 13 cases 
identifying a colic episode that were correctly classified by automated 
analysis. The automated process did not produce any false negative result.  
 
Regarding the conditions of expected low prevalence there was perfect 
agreement between manual and automated analysis. The dataset included 
22 cases referring to renal failure and seven cases referring to right dorsal 
colitis and were all identified correctly by both methodologies. Sensitivity, 
specificity and positive and negative predictive values were all 100.0%. All 
the results are summarised in table 3.5. 
 
Table: 3.5: Sensitivity, specificity, positive and negative predictive values (PPV and 
NPV respectively) of automated analysis compared to manual analysis reported as 
per cent values.  
  Manual Sensitivity Specificity PPV NPV   + - 
Colic + 226 13 100 99.9 94.6 100 - 0 17322 
NSAIDs + 1130 19 99.8 99.9 98.3 100 
- 2 16410 
Ren 
fail 
+ 22 0 100 100 100 100 - 0 17539 
RDC + 7 0 100 100 100 100 - 0 17554 
In the 2x2 tables comparing automated and manual classification, rows are conditions 
identified by the software and columns correspond to manual classification. +/- in the 
manual “Manual” column identifies the number of positive and negative terms classified 
manually in each category (Colic, NSAIDs, Ren Fail and RDC). The +/- of each category 
identifies the number of positive and negative terms classified automatically. NSAIDs: 
non-steroidal anti-inflammatory drugs; Ren fail: renal failure; RDC: right dorsal colitis 
 
3.2.4 Discussion 
 
The findings of this study highlight that the free-text mining methodology 
here described can achieve excellent results, comparable to that of the 
current “gold standard” which is manual analysis. It is arguable whether 
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manual analysis is really the “gold standard” as it has not been validated 
being for years the only method available to classify free-text medical 
records. While this method yielded acceptable results for its intended 
purpose so far, one must acknowledge that there are some limitations in 
manual evaluation of medical records as this method is based on the 
assumption that an operator will limit classification mistakes to a 
minimum. Nevertheless evaluation of human/operator error should be an 
integral part of any validation process (Huber, 1998). Furthermore, one 
might expect that operator induced errors might increase with operator 
fatigue, which increases along with the length of the dataset. In the 
current study a total of 32 errors were produced by the operator, by 
missing the presence of a term, which had otherwise been identified by 
the automated analysis. Even though these errors were present after a 
single manual analysis, likely consequence of operator fatigue, the 
difference with automated analysis was minimal and most importantly, 
the automated analysis yielded a better result than manual analysis. 
Manual classification also has considerable room for improvement. In the 
present study one operator read and classified the validation dataset 
once. Employing two or more operators to read the same text and reading 
the text more than once could improve significantly sensitivity of manual 
analysis. This however yields the drawback of becoming then more time 
consuming and to require twice the manual effort with doubling of the 
costs required. 
 
The technical time required to automatically mine the information of 
interest from the dataset is negligible in comparison to that of manual 
analysis (few seconds with the automated process, depending on machine 
power, compared to ~80 man/hours for the manual analysis for a dataset 
of 17,561 rows of data). However, it is important to point out that a large 
amount of time was necessary initially to create adequately 
comprehensive characterisation dictionaries. In fact dictionary creations 
required a much longer time (~300man/hours) than manual classification 
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for this small dataset of 17,561 rows of data. This highlights that the 
benefits of using automated analysis are directly proportional to the size 
of the dataset as the time required for analysis would mostly then be 
dependent on computer processing power. Further the dictionary could be 
used as a starting point to analyse different dataset examining the same 
conditions; however, ideally one should create a dictionary starting from 
the word frequency list and ensure that no new term is lost. Also a 
dictionary from a previous dataset used for a new dataset could include 
several terms not present in the new dataset, affecting the time required 
for analysis as several terms not in new dataset would be searched, even 
if not there. The analysis results would be unaffected if a dictionary 
contained terms not present in the data, however. 
 
Excellent specificity and sensitivity were expected as each dictionary was 
created including all possible words that would have identified a certain 
category starting from the list of words actually present in the dataset. 
This included misspelled and abbreviated terms. Although browsing 
through the word list was a time consuming but pivotal step of the 
analytic process, it also means that the dictionary is very dataset-specific 
and if new data is added then the dictionary may need to be updated to 
include new terms that might be only present in the new data.  
 
Sensitivity was higher than that of the study by Anholt and colleagues 
(2014a) preserving similar specificity. In that study specificity was as high 
as 99.3%, but the authors commented that this high specificity was 
obtained only by sacrificing sensitivity (87.6%). This discrepancy originates 
in the different approach used to create the exclusion dictionaries. Anholt 
and colleagues (2014a) defined the characterisation dictionary by setting 
semantic rules to identify false positive terms as described in section 
3.3.1.2, but recognised that when numerous rules were developed to 
correctly classify all of the possible variations of a sentence, the process 
would improve either only sensitivity or specificity at the expense of the 
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other. False positive terms included sentences where the operator meant 
to report that a particular term was not present, for example that “the 
patient did not have colic”. Alternatively false positive terms could occur 
for single words with multiple meanings; for example “displacement” 
could identify a “colonic displacement” in the dictionary “colic” or 
“fracture displacement” in the dictionary “fractures”, or “dorsal 
displacement of the soft palate” in the dictionary “respiratory”, etc. For 
the example of colic, comprehensive sentences including negative 
expressions identified from the inclusion dictionary search output 
(“doesn’t have colic”, “not have colic”, “no colic”, “no sign of colic”, 
etc.) were included in the exclusion dictionary. In the case of words 
compatible in more than one inclusion dictionary, comprehensive word 
combinations were used for the exclusion and re-inclusion dictionaries. 
For example, the “exclusion colic” dictionary included terms such as 
“dorsal displacement of the soft palate”, “fracture displacement”, etc, 
whilst the re-inclusion dictionary included combination of words (down to 
the complete sentence) to identify terms that where truly positive 
enlisted in the exclusion list search. 
 
As that study focused on syndrome surveillance, the authors elected to 
maximise specificity to ensure that the largest proportion of cases 
identifying a particular syndrome were correct (Anholt et al., 2014a). The 
authors also commented that their study’s findings were strictly setting 
specific and clarified how the process should be re-evaluated on a 
different dataset (Anholt et al., 2014a). For example, linguistic 
differences may reflect different geographical regions as well as temporal 
differences from where and when data had been generated. The 
methodology used in the current study differs in that false positive cases 
were identified manually by the definition of specific word combinations 
in place of construction of automated rules. Further, the method by 
Anholt and colleagues (2014a) identified a subset of cases that were 
positive in some instances and negative in others. This difficulty was 
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overcome also by adopting the re-inclusion dictionaries to ultimately 
correctly classify those ambiguous terms. This process was more laborious 
as it added several steps to the analysis process and was ultimately more 
time consuming but was justified by the resulting excellent sensitivity and 
specificity. 
 
In the current study inclusion of all terms and their variations, 
abbreviations and misspellings was of pivotal importance to maximise 
sensitivity of the analysis process. Despite the effort to include all 
appropriate terms actually present in the dataset, sensitivity was not 100% 
as some positive cases where still misclassified after subtraction of terms 
in the exclusion characterisation dictionary. Mostly this occurred when 
true positive terms were present along with terms included in the 
exclusion dictionary in the same case, as described in the results section. 
For example a sentence that said: “this horse suffered abdominal pain 
today, but did not colic after administration of a NSAID”, would be 
initially detected by the inclusion dictionary as including the words 
“abdominal pain” and “colic”, but would be then excluded as containing 
the word combination “did not colic”, whilst it is clearly a colic case. 
Fortunately this was a rather rare occurrence in the dataset and the use of 
a re-inclusion dictionary provided an efficient solution to this problem. 
The use of an exclusion and re-inclusion dictionary appeared more useful 
for dictionaries identifying clinical syndromes, such as colic. Clinicians 
might discuss a differential diagnosis so exclusion and re-inclusion 
dictionaries might be helpful to differentiate between true and false 
positive cases. However, for the identification of drug usage the adoption 
of exclusion and re-inclusion dictionaries is of arguable benefit. Drugs are 
recorded when they are administered or dispensed for billing purposes or 
when the clinician wishes to record that treatment has commenced. In the 
present study, adoption of exclusion and re-inclusion dictionaries for 
“NSAIDs” was necessary only because of the ambiguity intrinsic to 
Buscopan® (Buscopan Compositum and Buscopan 20), since this name 
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identifies two commercial preparations, one with and one without an 
NSAID. So these dictionaries allowed identification of terms referring to 
the formulation actually containing the NSAID. Since this ambiguity is 
unusual with pharmaceutical products, in the investigator experience the 
use of an inclusion dictionary alone might suffice and yields excellent 
specificity and sensitivity to identify drug usage. The investigator 
experience for drug categories other than NSAIDs is that no false negative 
terms are generally present therefore only the inclusion dictionary could 
be used for the analysis. 
 
In the present study it was noticed that in most cases a relatively small 
number of word combinations identified the vast majority of false positive 
cases, which made exclusion dictionary definition somewhat faster. This is 
explainable by the fact that the person entering the text records might 
tend to use similar word combinations to describe similar scenarios. 
Nevertheless, great effort was required to include a large number of false 
positive cases in the exclusion dictionary and false negative cases in the 
re-inclusion dictionary. The vast majority of discrepancies between 
automated and manual classification was for terms classified as false 
positives, which were in fact found to be correctly classified by the 
automated analysis and had been missed on the first manual evaluation. 
The results of this study show that automated analysis of free-text clinical 
records is possible and can offer results at least as good as manual 
classification. In fact, our analysis shows that automated analysis has 
slightly better sensitivity than manual analysis as operator errors due to 
tiredness are minimised by the automation, which prevents missing some 
truly positive terms. However, sensitivity and specificity of automated 
analysis are still greatly dependent on an operator related process in the 
process of dictionaries’ creation. 
 
In terms of data handling, R v3.0.2 was used to remove false positive 
cases and to re-include truly positive cases that were initially excluded. 
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This was achieved by subtracting the rows of data identified from the 
exclusion dictionary search from the inclusion dictionary search output 
and to subsequently re-include those in the re-inclusion dictionary. This 
procedure could have been performed using other commercial software 
packages, such as MS Excel or MS Access, but R v3.0.2 was chosen because 
this software is an open source software and is not limited by the size of 
the dataset and therefore the methodology tested is also suitable also for 
larger datasets, exceeding the limits of 1.4 million rows of data or the 2Gb 
file size imposed by MS Excel or MS Access. Ultimately, the code written 
for R v3.0.2 was relatively simple and fast and produced the desired result 
in very little time for a dataset of this size. Nevertheless other software 
packages might have been used such as SQL or Stata. The decision of using 
R v3.0.2 was fundamentally based on the investigator’s preference. 
 
When comparing the efficiency of manual classification to that of the 
automated analytic process this study does not account for time and effort 
required to develop the skills necessary to set up and run the analysis in 
WordStat and R v3.0.2. A significant effort was put in place before 
starting the study to understand in depth how these software packages 
work and how they might assist this type of analysis. However, section 
3.3.2 of this chapter describes in detail how the analysis has been done 
and should assist others wishing to use this technique on a different 
dataset. While following these instructions the use of WordStat is 
relatively straight forward, using a programming language like R v3.0.2 
remains more challenging and would require further training in this 
programming environment, which is outwith the scope of this manuscript. 
 
In conclusion, the automated process is significantly faster, once 
inclusion, exclusion and re-inclusion classification dictionaries are 
prepared on a dataset of this size. As all words present in the dataset are 
used, sensitivity does not appear to be an issue for this method of 
analysis. In terms of optimised specificity, the use of exclusion and re-
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inclusion dictionaries is useful in situations where there are many false 
positive and subsequently false negative cases. This is achieved simply by 
evaluating the output search of the inclusion dictionary to identify any 
significant proportion of erroneous classifications. False positive and 
negative cases appeared proportionally more common when trying to 
identify general syndromes, such as colic, but less common when focusing 
on specific diagnosis or when looking at drug administration.  
 
In the future this type of analysis may aid several applications, from the 
retrospective analysis of EMRs, to prospective studies for syndromic 
surveillance or to monitor changes in caseload in veterinary practice. 
Alternatively, EMRs can offer clues to compare treatment outcomes and 
efficacy or identify the prevalence and significance of side effects 
following drug administration on large patient populations.  
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CHAPTER 4 – Non-Steroidal Anti-Inflammatory Drug Usage 
In Equine Practice 
 
4.1 Introduction 
 
Knowing the prevalence of drug usage might provide useful information to 
understand the behaviour of veterinary practitioners. Despite economical 
and research efforts necessary to demonstrate safety and efficacy of new 
drugs that undergo an arduous licensing process years might pass by 
before practitioners embrace regular use of new pharmaceuticals. This is 
understandable as practitioners are responsible for using these drugs and 
some time is required to develop a personal experience with their use, 
switching from a well-established practice with older, known substances 
to new ones. 
 
Further, every country has its own official body responsible to define 
appropriate drug usage within its jurisdiction. Our data was obtained from 
the United Kingdom, United States of America and Canada and in each of 
these countries veterinarians must, by law, prescribe drugs licensed for 
use in the species they are treating, as these drugs have been tested for 
safety and efficacy in these species. However, clinical practice often 
requires veterinary staff to treat patients when no drug is licensed for use 
in that species, but alternative drugs are licensed for use in other species 
with a similar condition or even in human patients. 
  
In the United Kingdom, veterinary surgeons are allowed off-label use of 
some drugs under the “Cascade”, which is an official legislative provision 
in the Veterinary Medicine Regulations that allows veterinary surgeons to 
prescribe unauthorised medicine that would not otherwise be permitted 
for use in some species (www.vmd.degra.gov.uk).  
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The principle of the Cascade is that if no suitable veterinary medicine, 
authorised in the United Kingdom, is available to treat a condition in a 
determined animal species, the veterinary surgeon responsible for the 
animal may still be able to treat that animal by using drugs licenced in 
other species or for human patients if no veterinary product is available, 
to avoid causing unnecessary and unacceptable suffering. Similar 
legislations are enforced in the countries of North America. Describing the 
prevalence of off-label use of a certain drug in a certain species might 
also highlight the need for a licensed product containing that drug in that 
species. Ultimately, analysis of prevalence of drug usage in veterinary 
practice might assist governing bodies to prioritise drugs that require more 
urgent evaluation under the legal licensing process. 
 
Analysis of the context of drug usage might also provide information for 
clinical research providing evidence to support current practice where 
such evidence is currently lacking. For example, in horses phenylbutazone 
is commonly used to treat pain and inflammation associated with 
orthopaedic disease and flunixin meglumine is generally used for 
inflammation and pain associated with soft tissue conditions (Sanchez and 
Robertson, 2014), despite convincing evidence of a very similar mode of 
action, both being nonselective COX inhibitors (Beretta et al., 2005). 
 
In the United Kingdom, as well as United States and Canada, 
phenylbutazone is licensed exclusively for the treatment of 
musculoskeletal disorders, while flunixin meglumine is licensed for 
treatment of both musculoskeletal disorders and visceral pain. Therefore, 
use of phenylbutazone for the treatment of colic would be an off-label use 
in these countries, particularly when a suitably licensed alternative, such 
as flunixin meglumine, is readily available. If the practice of using 
phenylbutazone to treat patients with visceral pain is somewhat frequent, 
legislative bodies might consider extending authorization to treat visceral 
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pain with this drug should they consider it appropriate, as long as no 
evidence of unwanted side effects is identified. 
 
The aims of this study are to describe the prevalence of usage of the most 
commonly used non-steroidal anti-inflammatory drugs (NSAIDs) in equine 
practice in the United Kingdom as well as in North America. Further, the 
NSAID choice for colic and orthopaedic disease will also be described. 
 
The final section of this chapter will include an overall discussion and 
conclusion, comparing differences in NSAID use in veterinary practices 
between the United Kingdom, USA and Canada. 
 
4.2 Non-steroidal anti-inflammatory drug usage in the United 
Kingdom 
 
4.2.1 Introduction 
 
The prevalence of NSAID usage has not been previously described in a 
multicentre large population of horses in the United Kingdom. Several 
pharmaceutical substances containing NSAIDs licensed for use in horses are 
available in this country. These include phenylbutazone, suxibuzone, 
flunixin meglumine, ketoprofen, carprofen, vedaprofen, metamizole, 
meloxicam and firocoxib. Flunixin meglumine, meloxicam and ketoprofen 
are licensed in horses to treat pain and inflammation associated with 
musculoskeletal disorders and alleviation of visceral pain associated with 
colic. Metamizole is available in the United Kingdom in a formulation with 
a butylscopolamine (Buscopan Compositum), a spasmolytic, for the 
treatment of pain associated with colic. Phenylbutazone, suxibuzone, 
carprofen are licensed for the treatment of pain and inflammation 
associated with musculoskeletal disorders in horses. Firocoxib is only 
licensed for treatment of pain and lameness associated with osteoarthritis 
for up to 14 days. Vedaprofen is available as an oral gel preparation, 
licensed for treatment of pain associated with musculoskeletal and soft-
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tissue disorders and trauma, including preventative treatment before 
surgical trauma. 
 
Other NSAIDs currently not licensed in horses but seldom used in equine 
practice include meclofenamic acid, eltenac and aspirin. Meclofenamic 
acid and eltenac were once available for use in the horse but their 
licenses have now been expired for over a decade. There is no licensed 
equine product containing aspirin, but acetylsalicylic acid is often used for 
treatment of hypercoagulative conditions which result in intravascular 
thrombus formation. Common conditions include thrombophlebitis 
following catheterisation and laminitis and therefore aspirin is used by 
some to prevent platelet aggregation, one of the mechanisms that lead to 
clotting. 
 
The present study describes the use of these types of NSAIDs in a 
population of equids from the United Kingdom. The overall prevalence 
estimate and 95% confidence intervals (95% CIs) are determined and the 
yearly and mean prevalence of use for each drug is reported for the 5-year 
period between 2008 and 2012. 
 
4.2.2 Materials and methods 
 
The dataset of EMRs from 141,543 animals (between 1987 and 2013; 
2,653,695 rows of data) was analysed with the methods described in detail 
in Chapter 3. Briefly, the list of the words included in the dataset was 
used to identify terms that might identify a NSAID. This included 
commercial brand names of NSAIDs as well as pharmaceutical names and 
colloquial names. The NSAIDs inclusion dictionary included a total of 232 
words (Appendix 4) covering both brand and pharmaceutical names as well 
as various misspellings and abbreviations. The words included in the 
dataset were selected to identify NSAIDs in general and also in particular 
the following drugs: flunixin meglumine, phenylbutazone, suxibuzone, 
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ketoprofen, carprofen, vedaprofen, metamizole, meloxicam, firocoxib, 
meclofenamic acid, eltenac and aspirin. 
 
Prevalence of NSAID usage and 95% CIs were then calculated as previously 
described (Wilson, 1927) for the equine population in the whole dataset 
while the yearly prevalence of drug usage was calculated between 2008 
and 2012, inclusive. 
 
Finally, NSAIDs usage was also investigated concurrently with colic and 
orthopaedic disease, to describe which NSAIDs are most commonly used 
with these conditions. The dataset was subsequently searched using the 
methodology described in Chapter 3 to identify records referring to colic 
and orthopaedic disease. A colic episode was defined as such when colic 
was reported on a given day for a give animal. When colic was reported in 
two consecutive days in the same animal, these were counted as two colic 
episodes as these could have required a repeated administration of 
NSAIDs. Administration of each drug was classified as related to the 
relevant disease episode if given on the same day that the disease was 
reported. Similarly an orthopaedic episode was defined as such when an 
orthopaedic condition or procedure was reported for a given animal. When 
the orthopaedic condition was reported in two consecutive days in the 
same animal, these were counted as two episodes as these could have 
required a repeated administration of NSAIDs. Administration of each drug 
was classified as related to the relevant orthopaedic episode if given on 
the same day that the disease was reported. 
 
The study was approved by Ethics and Welfare Committee of the School of 
Veterinary Medicine at the University of Glasgow. 
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4.2.3 Results 
 
4.2.3.1 General prevalence of non-steroidal anti-inflammatory drug 
usage 
 
The prevalence of horses receiving a NSAID at least once in the records, 
during the 27 year period, was calculated. A total of 40,350 (28.6%; 95% 
CIs: 28.4-28.8%) animals received NSAIDs at least once out of the total of 
141,543 individual animals included within the dataset. 
 
The NSAIDs most frequently used were phenylbutazone/suxibuzone and 
flunixin meglumine. The prevalence of usage was 18.2% (95% CIs: 18.0-
18.4%) for phenylbutazone and 6.1% (95% CIs: 6.0-6.2%) for suxibuzone. 
For flunixin meglumine estimated prevalence of use was 8.3% (95%CIs: 8.1-
8.4%). Other NSAIDs that were less frequently used included metamizole 
(1.82%, 95% CIs: 1.75-1.89%) and meloxicam (1.05%, 95% CIs: 1.00-1.10%). 
Prevalence of use for ketoprofen, meclofenamic acid, eltenac, carprofen, 
aspirin, firocoxib and vedaprofen was less than 1% for each of these drugs 
and altogether accounted for 1.1% of all NSAIDs administered. Precise 
details on prevalence of use are reported in Table 4.1. 
 
Table 4.1: Prevalence of NSAIDs usage in an equine population between 1987 and 
2013 in the United Kingdom. Column “animals” refers to number of equids receiving 
each drug in the population of 141,543 equids. 
Drug Animals Prevalence 95%CIs 
Phenylbutazone 25626 18.17 17.97-18.37 
Flunixin Meglumine 11649 8.26 8.12-8.40 
Suxibuzone 8578 6.08 5.96-6.21 
Metamizole 2565 1.82 1.75-1.89 
Meloxicam 1484 1.05 1.00-1.11 
Ketoprofen 796 0.56 0.53-0.60 
Meclofenamic Acid 432 0.31 0.28-0.34 
Eltenac 108 0.08 0.06-0.09 
Carprofen 102 0.07 0.06-0.09 
Aspirin 72 0.05 0.04-0.06 
Firocoxib 40 0.03 0.02-0.04 
Vedaprofen 31 0.02 0.02-0.03 
TOTAL 40350 28.6 28.37-28.84 
TOTAL: horses receiving any NSAID in the dataset. 
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Records between 2008 and 2012, the period to determine yearly 
prevalence of NSAID use, were available for a total of 80,083 animals of 
which NSAID usage was recorded in 23,328 patients (prevalence: 29.1%; 
95% CIs: 28.8-29.4%). The number of horses receiving each drug in each 
year is summarised in Table 4.2. 
 
The prevalence of usage for each year (Table 4.3) highlights that 
phenylbutazone/suxibuzone and flunixin meglumine remain the NSAIDs 
most commonly used. The prevalence of use has not changed substantially 
over this 5-year period despite firocoxib being added to the market in 
2008. Meloxicam was also introduced to the British veterinary market in 
2001 and between 2008 and 2010 its use slowly increased, before the 
annual prevalence seems to have plateaued at around 1.4%. 
 
Table 4.2: Number of animals receiving NSAIDs between 2008 and 2012 in the 
United Kingdom (please note that a horse could have received more than one NSAID 
in the same year and its records could span over multiple years) 
Drugs 2008 2009 2010 2011 2012 2008-2012 
Phenylbutazone 3741 3361 3375 3403 3353 13859 
Flunixin Meglumine 1850 2023 2090 1977 1748 8417 
Suxibuzone 1692 1821 1969 2083 1784 7552 
Metamizole 518 492 496 546 504 2271 
Meloxicam 105 217 353 392 351 1330 
Ketoprofen 116 102 78 79 64 419 
Meclofenamic Acid 0 0 0 0 0 0 
Eltenac 0 0 0 0 0 0 
Carprofen 23 9 3 5 3 42 
Aspirin 3 12 15 22 10 60 
Firocoxib 1 6 5 12 12 36 
Vedaprofen 1 0 4 1 0 6 
NSAIDs 6063 6012 6314 6385 5867 23328 
TOTAL 27266 25946 27195 27245 24805 80083 
NSAIDs: total number of animals receiving at least one NSAID in each year; TOTAL: total 
number of animals in each year.  
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Table 4.3: Prevalence (%) of usage for each NSAID in each year between 2008 and 
2012 in the United Kingdom.  
Drug 2008 2009 2010 2011 2012 2008-2012 
Phenylbutazone 13.72 12.95 12.41 12.49 13.52 17.31 
Flunixin Meglumine 6.79 7.8 7.69 7.26 7.05 10.51 
Suxibuzone 6.21 7.02 7.24 7.65 7.19 9.43 
Metamizole 1.95 1.90 1.82 2.00 2.03 2.84 
Meloxicam 0.39 0.84 1.3 1.44 1.42 1.66 
Ketoprofen 0.43 0.39 0.29 0.29 0.26 0.52 
Meclofenamic Acid 0 0 0 0 0 0 
Eltenac 0 0 0 0 0 0 
Carprofen 0.08 0.03 0.01 0.02 0.01 0.05 
Aspirin 0.01 0.05 0.06 0.08 0.04 0.07 
Firocoxib 0 0.02 0.02 0.04 0.05 0.04 
Vedaprofen 0 0 0.01 0 0 0.01 
NSAIDs 22.24 23.17 23.22 23.44 23.65 29.13 
NSAIDs: prevalence of any NSAID in each year. 
 
4.2.3.2 Prevalence of non-steroidal anti-inflammatory drug use with 
colic and orthopaedic disease 
 
The database included a total of 38,720 days on which colic was 
mentioned in a clinical record (colic days) from 15,747 animals and 
260,989 days on which orthopaedic was mentioned in a clinical record 
(orthopaedic days) from 55,728 animals (Table 4.4). The most frequently 
used NSAID for colic cases was flunixin meglumine (3830 days) followed by 
phenylbutazone (2578 days) and metamizole (2552 days). For orthopaedic 
disease the most commonly used NSAID was phenylbutazone (20079 days), 
but a large proportion of cases received also suxibuzone (7586 days) and 
flunixin meglumine (5290 days). Meloxicam was administered for 2552 
colic days and 295 orthopaedic days, while ketoprofen was administered 
on 310 colic days and on 210 orthopaedic days. Firocoxib was administered 
only in 2 colic days and 19 times for orthopaedic days. These results are 
summarised in Table 4.4. 
 
The prevalence of use of other NSAIDs licensed for use in veterinary 
patients was low (1.1% of the total usage of NSAIDs) and little inferences 
can be made on use of these drugs. 
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Table 4.4: NSAIDs usage in colic and orthopaedic cases; Prevalence values are 
reported as % of the affected population 
 Colic n=38,720 Orthopaedic n=260,989 
Drug Episodes Prevalence (95%CIs) Episodes Prevalence (95%CIs) 
Phenylbutazone 2578 6.66 (6.41-6.91) 20079 7.69 (7.59-7.80) 
Suxibuzone 490 1.27 (1.16-1.38) 7586 2.91 (2.84-2.97) 
Flunixin meglumine 3830 9.89 (9.6-10.19) 5290 2.03 (1.97-2.08) 
Firocoxib 2 0.01 (0.00-0.02) 19 0.01 (0.00-0.01) 
Ketoprofen 310 0.80 (0.72-0.89) 210 0.08 (0.07-0.09) 
Metamizole 2552 6.59 (6.35-6.84) 295 0.11 (0.10-0.13) 
Meloxicam 379 0.98 (0.89-1.08) 816 0.31 (0.29-0.33) 
Colic: number of total days on which colic is mentioned; Orthopaedic: number of total 
days orthopaedic disease is mentioned; Episodes: number of days on which each drug 
was mentioned in the clinical record at the same time as colic and orthopaedic disease 
respectively; 95% CIs: 95% Confidence Intervals. 
 
4.2.4 Discussion 
 
The results of this study demonstrate that phenylbutazone and 
suxibuzone, followed by flunixin meglumine were the most commonly used 
NSAIDs in the United Kingdom equine veterinary practices used in the 
current study between 2008 and 2013. The use of different types of 
NSAIDs remained relatively constant. Only a slight increase in the use of 
meloxicam between 2008 and 2010 was identified, which although it was a 
3-fold increase, accounted for only 246 administrations. 
 
Suxibuzone, although more palatable, is similar to but generally slightly 
more expensive than phenylbutazone. Both drugs are licensed in the 
United Kingdom for treatment of inflammation and pain associated with 
musculoskeletal disease. Suxibuzone is converted to phenylbutazone and 
oxyphenbutazone once absorbed and has been found to be bioequivalent 
to phenylbutazone (Jaraiz et al., 1999). The prevalence of use of 
phenylbutazone and suxibuzone together accounted for 24.3% of all NSAIDs 
in this study. These drugs were commonly used to treat pain and 
inflammation associated with orthopaedic disease. However, a significant 
proportion of cases with visceral pain also received phenylbutazone. This 
finding was somewhat unexpected as the use of phenylbutazone in colic 
cases is off-label. Nevertheless, it appears that many equine practitioners 
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prefer to use phenylbutazone despite the fact that several other NSAIDs 
are licensed for the management of colic in the horse. These include 
metamizole, flunixin meglumine, meloxicam and ketoprofen. The reason 
for choosing phenylbutazone might be due to a blander, but effective 
inhibition, of clinical signs compared to flunixin meglumine, and therefore 
use of phenylbutazone would be less likely to delay referral of colic cases 
requiring surgical intervention. While peer-reviewed evidence to support 
this belief is lacking, practice of off-label administration of 
phenylbutazone to colic cases appears well established in the United 
Kingdom. Perceived lack of efficacy, availability and cost of meloxicam 
and ketoprofen might explain their reduced use.  
 
Flunixin meglumine was the second most common NSAID used in the 
United Kingdom equine population that was studied and was a common 
choice for treatment of visceral pain but also to a lesser extent to treat 
musculoskeletal pain and inflammation. While phenylbutazone is 
advocated for treatment of orthopaedic pain, flunixin meglumine is 
generally preferred for the management of abdominal discomfort 
(Dowling, 2010). In the United Kingdom Veterinary Surgeons are obliged to 
follow the cascade by which the off-label use of phenylbutazone for the 
management of colic could be justified only in the scenario where other 
licenced products would not be available in an emergency situation, such 
as with some colic cases. 
 
“Buscopan Compositum” is the only preparation containing metamizole 
available for use in horses in the United Kingdom, which is a combination 
with the spasmolytic butylscopolamine. Since a few preparations under 
the brand name of “Buscopan” have been available in the United 
Kingdom, precise estimation of metamizole usage was troublesome. In 
colloquial terms veterinary surgeons might refer to the use of “buscopan” 
regardless of whether this was the formulation including metamizole 
(“Buscopan Compositum”) or just butylscopolamine (“Buscopan 20”, 
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“Buscopan Ampoules”). These preparations differ in the volume to be 
administered so that for a typical 500kg horse the volume of “Buscopan 
Compositum” should be 25ml and for “Buscopan 20” only 7.5ml. 
“Buscopan Ampoules” have now been removed from the United Kingdom 
market. For the construction of the inclusion dictionary for metamizole, 
only the formulation referring to “Buscopan Compositum” was considered. 
This might have resulted in the underestimation of the use of metamizole 
in our population. In fact, in several instances where the volume of drug 
administered was recorded, this appeared too large to be just the single 
butylscopolamine preparation (i.e. more than 20ml) in cases where the 
veterinary surgeon simply referred to the preparation as “Buscopan”. 
However, in first opinion ambulatory settings, and indeed in many of the 
clinical records available for this study, information is often not available 
regarding the precise weight of the animal and it would be difficult to use 
the dose as an indicator to which “Buscopan” preparation the veterinary 
surgeon was referring. The lack of clarity between preparations recorded 
as being used in the EMRs suggests that data on the prevalence of use of 
metamizole is to be interpreted with caution. 
 
Meloxicam was introduced to the equine veterinary market in 2001 and 
the data presented here appear to suggest that its use remains limited in 
the United Kingdom. Meloxicam is licensed for treatment of pain from 
both musculoskeletal and visceral in origin as an oral and intravenous 
preparation. The oral preparation licensed for use in horses is licensed 
only for treatment of orthopaedic conditions. The licenced dose is 
0.6mg/kg every 24 hours while pharmacokinetic studies suggest that a 
twice daily administration would be more appropriate due to a faster 
plasma clearance in the horse than in other species (Toutain et al., 2004). 
The recommendation of using a sub-optimal dose interval might have 
resulted in a reduced efficacy and loss of faith in this drug by veterinary 
surgeons, which might explain the overall low prevalence of use. The fact 
that meloxicam has been used more frequently with orthopaedic cases 
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than with colic cases might also reflect the perception of the drug being 
less effective than other NSAIDs and therefore less suitable for an 
emergency situation, when controlling pain and inflammation might be 
more critical. Alternatively this might also reflect the use of the oral 
preparation, which is licensed only for orthopaedic disease. 
Differentiating oral and intravenous preparations from the dataset would 
have been troublesome because of the lack of a persistent definition of 
either product in the data. Therefore only the total use of meloxicam was 
included. 
 
Ketoprofen is licensed for treatment of pain associated with 
musculoskeletal disorders and colic in the horse in the United Kingdom. 
This drug was also used in a smaller proportion of cases, only slightly more 
frequently for the treatment of visceral pain than orthopaedic disease. 
 
Since a firocoxib preparation licenced for use in the horse was introduced 
in March 2008 use of firocoxib has seen a limited increase in the United 
Kingdom. This drug is licensed for treatment of pain and inflammation 
associated with osteoarthritis in horses and the course of administration 
should not exceed 14 days. In our dataset the use of firocoxib was limited 
to a total of 40 animals and few conclusions can be drawn from the data, 
other than it does not yet seem to have been well accepted in equine 
practice in this country, at least in the practices that contributed to the 
data investigated during the current study. 
 
Aspirin is used mostly to control hypercoagulative states, particularly in 
association with thrombophlebitis or for the treatment of laminitis. The 
use of aspirin appeared to be very minor in this first opinion population 
from the United Kingdom and mostly focused in the data from two 
practices (84% of all aspirin used), which likely reflects practice protocol 
rather than an overall use. This might suggest that in the United Kingdom 
aspirin might be perceived as ineffective by veterinary surgeons in first 
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opinion equine practice or that conditions that might require treatment 
with aspirin are referred to referral centres.  
 
Preparations of Carprofen and Vedaprofen are also available for use in 
horses in Britain but their use also remains minimal. Other drugs such as 
meclofenamic acid, eltenac are not available for use in the horse in the 
United Kingdom anymore and any appearance in the data used in the 
current study referred to older records so their use is of no relevance 
today. 
 
Since the analysis aimed at detecting presence of colic or orthopaedic 
disease in the records on the same day that each NSAID was administered 
one might argue that a relationship between drug administration and 
development of clinical signs exists. It was not possible to confirm that 
these drugs were administered exclusively after (i.e. as a treatment) the 
clinical signs in all cases. However, there was no record that veterinary 
surgeons were concerned that these drugs had induced abdominal 
discomfort or orthopaedic disease. If this was the case one might expect 
that a patient would be examined more than once on a given day. Since 
the date was used to differentiate appointments it was not possible to tell 
if horses received more than one visit on the same day. In the vast 
majority of these cases the record referred to the drug being dispensed 
after the episode of abdominal discomfort or to address an underlying 
concurrent orthopaedic condition. However it was not possible to identify 
cases when the horse received an NSAID in the morning to manage a 
certain condition and then developed colic or other clinical signs and had 
to be re-examined. With this scenario both examinations would have had 
the same date in the system and could have not been differentiated by 
the analysis. Due to the retrospective nature of the data it was not 
possible to make any inference about the temporal relationship between 
drug administration and recording of colic of orthopaedic conditions. It is 
most likely that data about drug administration and clinical signs were 
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added to the PMSS at the same point in time, most often after the 
veterinary surgeon had returned to their practice a few hours later. 
 
The overall dataset spanned a period of 26 years between 1987 and 2013. 
However, inter-year comparison of drug usage was performed only 
between 2008 and 2012, inclusive. This period included the largest 
amount of data (61.2% of the data with a valid date; 1,623,409 rows of 
data) and data was available from all practices so that inter-year 
comparison was less likely to be biased by the absence of one or more 
practices. Including only the later years reduced the bias that could have 
derived from behaviour changes present over a longer period, but might 
still reflect some individual practice behaviour, particularly that of the 
largest practices. 
 
This study did not aim to describe the prevalence of colic or orthopaedic 
disease in the United Kingdom horse population. The data on colic and 
orthopaedic disease refers to the number of times these conditions were 
mentioned on different days in the records. Therefore a horse could have 
been examined multiple times for a chronic lameness and this would have 
appeared as multiple lameness episodes rather than recurrence of an on-
going condition. The aim of this study was to describe NSAID usage and not 
the actual length or prevalence of a colic episode or of orthopaedic 
disease. 
 
In this study it was not possible to determine with a reasonable certainty 
the duration of NSAID treatment. The dataset contains details of when the 
veterinary surgeon inserted information in the PMSS about drug usage. For 
example, in the case where a 5-days course is prescribed, drugs may be 
dispensed to be administered by the owner; in such a scenario only the 
date the drugs are dispensed will be included in the record. Dates 
available referred to the date the drugs were dispensed to the owner but 
did not necessarily reflect the actual date of drug administration to the 
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animal. More precise information on length of treatment could have been 
mined from the free-text records, where available. This would have 
required the lengthy process of defining inclusion, exclusion and re-
inclusion dictionaries and would have required more time than was 
available for the study. Further, dictionaries definition is likely to be very 
time consuming as multiple drugs might be dispensed at the same time, 
with differing lengths of treatment, which could be recorded in the same 
row of data. This would translate in the need for the dictionary to include 
the wide range of combination of words necessary to minimize mixing 
drugs and course of treatment that are written in the same sentence. The 
same is true also for the amounts of drug being dispensed. In conclusions, 
time available for analysis limited the ability of the analysis to describe 
length of treatment or dosages used in practice, but this should be the 
aim of future studies. 
 
4.3 Non-steroidal anti-inflammatory drug usage in North America 
 
4.3.1 Introduction 
 
The prevalence of usage of NSAIDs in North America has not been 
described before in a large population of horses. Knowing the prevalence 
of usage of each NSAID could assist clinicians and researchers to interpret 
research data appropriately. For example, knowing how many horses 
receive NSAIDs, or combinations of NSAIDs, and approximately for how 
long NSAIDs are prescribed could help understand the significance of the 
prevalence of side effects in treated patients. Further, as a considerable 
effort, both economical and professionally, has been committed to 
develop new, safer drugs over the past decade evaluation of how drug 
usage has changed could provide some indication as to how veterinary 
practice has been modified to include their use. 
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The FDA14 (Food and Drug Administration) is the body responsible for the 
regulation of veterinary drug usage in the United States. In Canada this 
role is played by Health Canada15. The information on each drug and 
indication for their use in veterinary patients is easily obtainable from 
their respective websites. In these countries NSAIDs are prescription 
drugs, meaning that they can be only purchased under veterinary 
guidance. Nevertheless, they are often administered to horses without 
veterinary supervision directly by owners and trainers. 
 
The dataset described in Chapter 3 includes the EMRs from 225,777 
animals that have a correct date of data entry and provides a valuable 
insight of how NSAIDs have been used in equine practice in North America. 
 
4.3.2 Materials and methods 
 
The dataset of EMRs from 312,610 equids from North America between 
1994 and 2013, which include the 225,777 horses with a reliable date of 
data entry to the PMSS system and the 86,833 with a date that was not 
reliable, was analysed with the methods described in detail in Chapter 3. 
Briefly, the list of the words included in the dataset was used to identify 
terms that might identify NSAID usage. This included commercial brand 
names of NSAIDs as well as pharmaceutical names, colloquial names, 
financial codes and abbreviations. All NSAIDs were identified using the 
methodology described in Chapter 3. The inclusion dictionary was created 
using terms included in the dataset that identify NSAIDs in general and 
also in particular the following drugs: flunixin meglumine, 
phenylbutazone, suxibuzone, meloxicam, firocoxib, ketoprofen, 
metamizole, aspirin, diclofenac, meclofenamic acid, carprofen, deracoxib 
and vedaprofen (Appendix 4). 
 																																																								14	http://www.accessdata.fda.gov/scripts/animaldrugsatfda/	15	http://www.hc-sc.gc.ca/index-eng.php		
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Prevalence and 95% CIs were then calculated as previously described 
(Wilson, 1927) for the equine population in the whole dataset. The yearly 
prevalence of drug usage was calculated between 2008 and 2012, inclusive 
as this time period included the largest proportion of data (75.3%; 
8,807,287 rows of data). 
 
Finally NSAIDs usage was investigated concurrently with colic and 
orthopaedic disease, to describe which NSAIDs are most commonly used 
with these conditions. A colic day was defined as such when colic was 
reported in a given day for a given animal. When colic was reported in two 
consecutive days in the same animal, these were counted as two colic 
days as these could have required a repeated administration of NSAIDs and 
this study aimed to describe the NSAID used and not the actual length of 
colic. Administration of each drug was classified as related to the disease 
episode if given on the same day. 
 
4.3.3 Results 
 
The prevalence of horses receiving NSAIDs at least once in the records was 
calculated. A total of 115,446 (36.9%; 95% CIs: 36.8-37.1%) and 91,799 
(40.7%; 95% CIs: 40.5-40.9%) animals received NSAIDs at least once out of 
the total of 312,610 and 225,777 with a reliable date respectively. 
 
The NSAIDs most frequently used were phenylbutazone and flunixin 
meglumine. In the group of 225,777 the prevalence of usage was 28.5% 
(95% CIs: 28.4-28.7%) for phenylbutazone and 23.2% (95% CIs: 23.0-23.3%) 
for flunixin meglumine. Other NSAIDs that were seldom used included 
firocoxib, ketoprofen and metamizole. The prevalence for firocoxib and 
ketoprofen administration was 3.7% (95% CIs: 3.6-3.8%) and 3.7%(95% CIs: 
3.6-3.8%) respectively, while Diclofenac was used in 1.92% (95% CIs: 1.8-
2.0%) of horses, but this was only with a commercial topical preparation.  
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The prevalence of use for aspirin, metamizole, meclofenamic acid, 
vedaprofen, carprofen, meloxicam, deracoxib and suxibuzone was less 
than 1% for each of these drugs. These results are summarised in Table 
4.5. 
 
Table 4.5: Prevalence of NSAIDs usage in an equine population in North America. 
Column “Total” refers to number of horses receiving each drug in the population of 
312,610 equids, while the “Valid Date” refers to the population of 225,777 equids 
with EMRs with a valid date of data entry in the management system. Prevalence 
and 95% CIs data is calculated on the population with a valid date. 
Drug Total Valid Date Prevalence 95%CIs 
Phenylbutazone 82002 64450 28.55 28.36-28.73 
Flunixin Meglumine 63430 52287 23.16 22.99-23.33 
Firocoxib 8573 8375 3.71 3.63-3.79 
Ketoprofen 9437 8303 3.68 3.60-3.76 
Diclofenac 5045 4331 1.92 1.86-1.98 
Aspirin 2022 1631 0.72 0.69-0.76 
Metamizole 1767 1495 0.66 0.63-0.70 
Meclofenamic Acid 722 622 0.28 0.25-0.30 
Vedaprofen 532 443 0.20 0.18-0.22 
Carprofen 97 86 0.04 0.03-0.05 
Meloxicam 51 41 0.02 0.01-0.02 
Deracoxib 7 5 0 0.00-0.01 
Suxibuzone 0 0 0 0.00-0.00 
TOTAL 115,446 91,799 40.66 40.46-40.86 
TOTAL: horses receiving any NSAID in the dataset. 
 
Records between 2008 and 2012 were available for a total of 171,191 
animals of which NSAID usage was recorded in 68,339 patients 
(prevalence: 39.9%; 95% CIs: 39.7-40.1%). The number of horses receiving 
each drug in each year is summarised in Table 4.6. 
 
Table 4.7 summarises the prevalence of usage of each individual NSAID 
and of all NSAIDs altogether in each individual year and overall between 
2008 and 2012, inclusive. 
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Table 4.6: Number of animals receiving NSAIDs between 2008 and 2012 in North 
America (please note that a horse could have received more than one NSAID in the 
same year and its records could span over multiple years and the sum of horses in 
each individual years will be greater than the number of horses receiving the drugs 
in the 5 year period). 
Drugs 2008 2009 2010 2011 2012 2008-2012 
Phenylbutazone 8322 13432 14271 14024 14195 48899 
Flunixin Meglumine 7167 9880 9980 10138 10148 37067 
Firocoxib 795 1046 1541 2219 2865 6572 
Ketoprofen 1010 1143 1348 1565 1765 5571 
Diclofenac 465 641 787 797 819 3264 
Aspirin 238 359 359 306 218 1217 
Metamizole 134 235 274 265 267 1112 
Suxibuzone 63 90 123 112 107 468 
Meclofenamic Acid 39 69 78 80 91 336 
Vedaprofen 7 15 16 10 18 61 
Carprofen 1 8 16 8 4 30 
Meloxicam 0 1 2 1 0 3 
Deracoxib 0 0 0 0 0 0 
NSAIDs 13150 19470 20157 20290 20967 68568 
TOTAL 42862 59221 58109 56844 57073 171191 
NSAIDs: total number of horses receiving at least one NSAID in each year; TOTAL: total 
number of horses in each year. 
 
Table 4.7: Prevalence of usage for each NSAID in each year between 2008 and 2012 
in North America. 
Drug 2008 2009 2010 2011 2012 2008-2012 
Phenylbutazone 19.42 22.68 24.56 24.67 24.87 28.56 
Flunixin Meglumine 16.72 16.68 17.17 17.83 17.78 21.65 
Firocoxib 1.85 1.77 2.65 3.9 5.02 3.84 
Ketoprofen 2.36 1.93 2.32 2.75 3.09 3.25 
Diclofenac 1.08 1.08 1.35 1.4 1.44 1.91 
Aspirin 0.56 0.61 0.62 0.54 0.38 0.71 
Metamizole 0.31 0.4 0.47 0.47 0.47 0.65 
Meclofenamic Acid 0.15 0.15 0.21 0.2 0.19 0.27 
Vedaprofen 0.09 0.12 0.13 0.14 0.16 0.2 
Carprofen 0.02 0.03 0.03 0.02 0.03 0.04 
Meloxicam 0 0.01 0.03 0.01 0.01 0.02 
Deracoxib 0 0 0 0 0 0 
Suxibuzone 0 0 0 0 0 0 
NSAIDs 30.68 32.88 34.69 35.69 36.74 40.05 
NSAIDs: prevalence of any NSAID in each year. 
 
The database of records from the 225,777 equids, with a valid date in the 
dataset, included a total of 96,614 single days on which colic was 
recorded affecting 21,682 animals and 346,165 days on which an 
orthopaedic condition was recorded affecting 94,840 animals. The most 
used NSAID for colic cases was flunixin meglumine, followed by 
phenylbutazone (Table 4.8). For orthopaedic disease the most commonly 
used NSAID was phenylbutazone, but a large proportion of cases received 
flunixin meglumine. Firocoxib and ketoprofen were administered 
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predominantly on the same day of an orthopaedic episode and only to a 
lesser extent on the same day of a colic episode.  
 
The prevalence of use of other NSAIDs approved for use in equine patients 
was minor (0.3% of the total usage of NSAIDs). 
 
Table 4.8: NSAIDs usage on the same day of colic and orthopaedic cases in North 
America; Prevalence values are reported as % of the affected population. Not all 
episodes of colic or orthopaedic disease received a NSAID 
 Colic 96614 Orthopaedic 346165 
Drug Episodes Prevalence (95%CIs) Episodes Prevalence (95%CIs) 
Phenylbutazone 3422 3.54 (3.43-3.66) 65550 18.94 (18.81-19.07) 
Flunixin meglumine 20723 21.45 (21.19-21.71) 39542 11.42 (11.32-11.53) 
Firocoxib 796 0.82 (0.77-0.88) 8878 2.56 (2.51-2.62) 
Ketoprofen 259 0.27 (0.24-0.30) 8745 2.53 (2.47-2.58) 
Colic: number of total colic episodes; Orthopaedic: number of total orthopaedic disease 
episodes; Episodes: each number of episode treated with a specific NSAID; 95% CIs: 95% 
Confidence Intervals. 
 
4.3.4 Discussion 
 
The findings of this study indicate that phenylbutazone and flunixin 
meglumine are the most commonly used drugs in equine veterinary 
practice in North America.  
 
Between 2008 and 2012, the use of phenylbutazone had increased by 5%. 
This might be consistent with the reduced cost associated with this drug, 
which may have influenced choice of NSAID during the concurrent difficult 
economic conditions. Compounded phenylbutazone can be very cheap 
(~10¢ per 1 gram/dose or even less). During a period of economic 
recession a greater proportion of owners might prefer to manage non-life 
threatening conditions with phenylbutazone rather than spending money 
on more expensive investigations and treatments. Alternatively other 
unidentified factors might have contributed to the increase in use of 
phenylbutazone in North America in this time period. A relatively large 
proportion (13.6%) of horses received phenylbutazone on the same day of 
colic and this could be the result of some veterinarians preferring 
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phenylbutazone in colic cases as well as cases that had by chance received 
phenylbutazone on the same day to treat another condition (eg. 
orthopaedic disease) but before the start of the colic signs. 
 
The use of flunixin meglumine remained otherwise unchanged despite the 
higher cost of this drug in comparison to phenylbutazone. This might be 
because, despite the increased cost of this drug, its perceived efficacy 
makes it the best choice in situations where pain or inflammation is 
severe. Flunixin meglumine was by far the most common drug selected for 
treatment of abdominal discomfort of those horses receiving NSAID on the 
same day as colic over 80% received the drug. This may be because 
flunixin meglumine is the only drug licensed for the management of colic 
in the United States of America and Canada.  
 
Since the introduction of firocoxib as a licensed preparation for equine use 
in 2006 its use has seen a steady increase. This drug is licensed (Equioxx, 
Merial Limited, USA) in the United States for treatment of pain and 
inflammation associated with osteoarthritis in horses and the course of 
administration should not exceed 14 days. In Canada, no product approved 
for use in the horse is available, but veterinarians often resorted to a 
product (Previcox®, Merial Limited, Canada) licensed for use in dogs. Of 
the horses that suffered colic, some had also received firocoxib on the 
same day and this summed up to 8.2% of the total of those that had 
received this drug. Firocoxib is licensed for treatment of pain associated 
with osteoarthritis in the horse in North America. This drug was also used 
in 0.9%of cases, on the same day as a colic episode. Following manual 
evaluation of those records revealed that the drug had been dispensed for 
treatment of a concurrent underlying orthopaedic problem on the day 
colic was then diagnosed. 
 
Ketoprofen is licensed for treatment of pain associated with 
musculoskeletal disorders in the horse in North America. This drug was 
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also used in a smaller proportion of cases, particularly in orthopaedic 
cases, but in a number (2% of those receiving ketoprofen) of cases it had 
also been administered on the same day as an episode of colic. Following 
manual evaluation of those records it was apparent that almost invariably 
these records refer to instances where these drugs had been dispensed for 
treatment of a concurrent underlying orthopaedic problem at the time the 
mild/transient episode of colic was diagnosed.  
 
Aspirin is used mostly to control hypercoagulative states, particularly in 
association with thrombophlebitis or for the treatment of laminitis. In our 
dataset further common use of aspirin appeared to be treatment of 
inflammation and pain associated with ophthalmic disease. The use of 
aspirin appeared mostly focused in the data from two practices (70% of all 
aspirin used), which likely reflects practice protocol rather than an overall 
use. Aspirin acts by irreversibly preventing arachidonic acid-induced 
platelet aggregation and therefore prevents intravascular thrombus 
formation (Cambridge et al., 1991). Since aspirin has been shown to 
prevent platelet aggregation in horses (Heath et al., 1994) a theoretical 
beneficial effect of aspirin in cases of laminitis and thrombophlebitis has 
been proposed (Sellon and Wise, 2010). Nevertheless, evidence that 
aspirin improves outcome in cases of laminitis or thrombophlebitis in 
horses remains scarce. This might, in part, explain the variable use of 
aspirin between practices. 
 
The prevalence of use of metamizole is also lower in this part of the world 
compared with Europe. In the past metamizole was used as an antipyretic 
(eg. dipyrone), but in the United Kingdom it is still available in 
combination with a spasmolytic, butylscopolamine bromide (Buscopan® 
Compositum, Boehringer Ingelheim, United Kingdom), licensed for the 
treatment of abdominal pain in horses. This combined preparation is not 
licensed in North America and since 1995 metamizole has been withdrawn 
from the US market. In Canada, metamizole is licensed for use in the 
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horse as an antispasmodic, analgesic, antipyretic and anti-inflammatory 
(Dipyrone 50%, Vétoquinol, Canada). Nevertheless, Canadian practices 
accounted only for 5.5% of the overall amount of metamizole recorded in 
the North American database. Therefore, it appears that the supposition 
that old stockpiles of the drug occasionally appear in US practices may be 
true (Payne et al., 1999); alternatively veterinary practices might import 
this drug from other neighbouring countries, such as Canada. In fact, 
products containing metamizole were referred to in data from all 
practices, although the vast majority (86.7%) of the metamizole used was 
from 3 practices, which were all in the United States. 
 
The prevalence of use of other NSAIDs for the veterinary market was low 
(<1%). The preparation of diclofenac is a topical preparation (Surpass®), 
which is used for treatment of musculoskeletal disorders and it is used 
mostly in the scenario of superficial inflammatory conditions, such as 
muscle or tendinous injuries.  
 
Treatment with suxibuzone saw a peak (81% of total usage) in 
administration in 2009. The use of this drug was recorded almost entirely 
at one practice (96% of all recorded uses). Suxibuzone is not licensed in 
North America and the use of this drug might just reflect that one practice 
had imported some suxibuzone from abroad. 
 
4.4 Discussion 
 
These two studies report the prevalence of use of NSAIDs in two different 
continents, which include countries with socio-economic as well as 
legislative differences. Socio-economic differences might affect the 
preference of certain drugs over others, as well as acceptance of 
innovation such as new drugs being licensed with different safety profiles. 
Cost and tradition might also have played a role in the comparative 
differences in use of NSAIDs in the United Kingdom and North America.  
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The prevalence of usage for each year (Tables 4.3 and 4.7) highlights that 
phenylbutazone and flunixin meglumine remain the most commonly used 
NSAIDs in both the United Kingdom and North America. In relative terms 
phenylbutazone is used more commonly in North America than it is in the 
United Kingdom. The explanation for this finding may lay in the 
availability of Suxibuzone only in the United Kingdom. Suxibuzone is very 
similar to phenylbutazone and prevalence of use of phenylbutazone in 
North America should be compared to the combined prevalence of the use 
of phenylbutazone and suxibuzone in the United Kingdom. Further social 
factors might contribute to the different prevalence of use of 
phenylbutazone between countries. Compared to North America, owners 
or veterinary surgeons in the United Kingdom might be more inclined to 
determine the cause of disease, and treat conditions appropriately, or 
equally opt for non-conventional treatments for palliative care to use in 
place of phenylbutazone. These theories remain unconfirmed and further 
studies would be required to explain this finding. Also the finding of the 
off-label use of phenylbutazone to manage visceral pain in horses is in line 
with the author’s personal experience of first opinion practice in the 
United Kingdom and United States. The finding of this study could prompt 
legislative bodies of each country to re-evaluate the labelled use of 
phenylbutazone if appropriate. If the use of phenylbutazone were to be 
considered contra-indicated for the management of abdominal discomfort 
in horses, then a campaign aimed at educating veterinary surgeons and 
limit this practice would be warranted. 
 
Firocoxib was used comparatively more in North America than in the 
United Kingdom where its use appears vey limited despite being available 
for use in horses since 2008. Firocoxib was introduced to the North 
American veterinary market in 2006 and has seen a 2.7-fold increase 
between 2008 and 2012. However it still remains far less commonly used 
than phenylbutazone or flunixin meglumine.  
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Ketoprofen is also used more commonly in North America than in the 
United Kingdom. The reason for this finding is difficult to explain 
particularly as ketoprofen is only licensed for musculoskeletal disease in 
North America while it is licensed for both musculoskeletal disease and 
colic in the United Kingdom.  
 
Diclofenac is also commonly used in North America, and this is in the form 
of a topical preparation, which is not licensed in the United Kingdom 
where no diclofenac is available. 
 
Legislative differences certainly influenced which drugs were available for 
veterinary surgeons in each country. For example, metamizole was 
removed from the market in the United States, while in Canada the 
preparation is still available as an antipyretic and anti-inflammatory. In 
the United Kingdom it is available only in combination with 
butylscopolamine. 
 
The overall scarce usage of meloxicam in both countries might result from 
a perceived lack of efficacy of this drug explained by current evidence 
suggesting that the labelled once-a-day administration results in sub-
therapeutic serum concentrations of the drug (Lees et al., 1991; Toutain 
et al., 2004) and that more frequent administration might be more 
efficacious while maintaining safety (Naylor et al., 2014). The evidence of 
a reduced of usage of this drug with a safer profile in vitro compared to 
phenylbutazone and flunixin meglumine should prompt legislative bodies 
to reconsider and up-date the instructions for its use. Updating the dosing 
interval would improve drug efficacy and could help reduce the 
prevalence of toxicity (Naylor et al., 2014). This process would be 
expensive (at least in the United Kingdom) and currently other drugs 
licensed for once a day administration (many formulations of trimethoprim 
sulphonamide) are generally administered twice daily to respect the 
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pharmacokinetic of this antimicrobial (Peck et al., 2002), despite the lack 
of up-to-date legislation. 
 
While the use of carprofen is negligible in the United Kingdom, in North 
America the relative usage of carprofen has doubled between 2008 and 
2012. This is surprising as there is no carprofen preparation licensed for 
the use in horses in either Canada or in the United States. While this 
increase might seem conspicuous, it is explained overall by the very small 
number of horses treated with this drug (<1%) and has little clinical 
relevance. 
 
Aspirin also was relatively more used in North America than it was in the 
United Kingdom. Aspirin is generally limited to treat or prevent diseases 
resulting from increased platelet aggregation such as thrombosis. Common 
pathological conditions resulting from thrombus formation include jugular 
thrombophlebitis and laminitis (Sellon and Wise, 2010). This limited 
spectrum of conditions combined with the fact that no licensed aspirin 
preparation is present in any of these countries might explain the low 
prevalence of use of this drug. 
 
Comparison between North America and United Kingdom suggests that 
NSAIDs usage in general is more common in United States and Canada than 
in the United Kingdom. While over 40% of horses in the North American 
dataset appear to have received NSAIDs at some point, in the United 
Kingdom this figure reached 28%. The reason for increased NSAID usage in 
North America might be a reflection of a different attitude of equine 
veterinary practice between continents. Similar to the difference in 
phenylbutazone usage between United Kingdom and North America, it is 
possible that the greater NSAID usage in North America is explained by a 
different attitude of clients towards disease. It is possible that in the 
United Kingdom clients request veterinary assistance only when required 
or British owners and veterinary surgeons might tend to investigate the 
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cause of disease for a more targeted treatment rather than opt for 
palliative care with NSAIDs. Alternatively in North America clients may be 
more proactive in seeking veterinary advice and treatment or veterinary 
surgeons might simply have the tendency to prescribe NSAIDs even when 
the animal does not have overt signs of discomfort. The real cause for this 
difference remains however undetermined. 
 
The data also allows comparison of the attitude of the veterinary market 
towards new medications. The study offers a good example of how 
veterinary surgeons adapt their clinical practice to the introduction of 
new pharmaceuticals such as firocoxib and how this might vary between 
countries. In North America, the use of firocoxib has increased rapidly and 
was still on the increase in 2012, while in the United Kingdom this drug is 
still rarely used. Reasons for this difference are likely to be multiple and 
include social differences, as veterinary surgeons in the United Kingdom 
might be more conservative and less prone to embrace new products. 
Further, different marketing strategies from the producer of firocoxib also 
might have played a role, if product promotion in North America had been 
more pressing. Costs also might play a role, as firocoxib is more expensive 
than some of the alternative products (including phenylbutazone and 
suxibuzone), the concurrent difficult economic climate might have limited 
the willingness to try new, but more expensive drugs in the United 
Kingdom. 
 
This study provides data that was then used to ascertain the relationship 
between usage of these drugs and the risk of developing side effects. This 
was the aim for the following Chapter 5. 
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CHAPTER 5 - Use Of Big Data To Describe Relevance Of 
Non-Steroidal Anti-Inflammatory Drug Toxicity In Equine 
Practice 
 
5.1 Introduction 
 
5.1.1 Non-steroidal anti-inflammatory drugs toxicity 
 
Current evidence is consistent with an increased risk of potentially life-
threatening side effects with NSAIDs administration in horses, involving 
mainly the gastrointestinal tract and the urinary system. (Hough et al., 
1999; Jones et al., 2003; Lees and Michell, 1979; Read, 1983; Snow et al., 
1981, Snow et al., 1979). Inhibition of physiologic prostaglandin 
production that regulates tissue blood flow is believed to be the main 
pathophysiologic mechanism (Lees and Higgins, 1985). 
 
Little information is available on the prevalence of side effects and 
whether there is any significant difference between NSAIDs with different 
COX selectivity. Even though these drugs are generally well tolerated, 
toxicity frequently occurs at the labelled dose (Andrews and McConnico, 
2009; Cohen et al., 1995), therefore current recommendations are to 
closely monitor all equids receiving NSAIDs for early signs of toxicity 
(Andrews and McConnico, 2009; Jones et al., 2003). Life-threatening 
complications related to NSAID toxicity include right dorsal colitis and 
renal medullary crest necrosis (Snow et al., 1979), but these are relatively 
uncommon considering how frequently these drugs are used (Cohen et al., 
1995; Gunson and Soma, 1983; Jones et al., 2003; Read, 1983). A post-
mortem survey between 1979 and 1981 at the College of Veterinary 
Medicine of Texas A&M University identified 35 cases of renal medullary 
necrosis. All of the horses in this study had received phenylbutazone for 
periods ranging from 6 months to 12 years. Of these 20 were subjected to 
euthanasia for unreported reasons, whilst the remainder died from natural 
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causes. The overall prevalence of this condition cannot be estimated from 
that study as no information is available on the total number of equine 
post-mortem examinations performed in that period (Read, 1983). 
Another study from the same institution was aimed at describing the 
outcome with medical management of right dorsal colitis within the 
referral population of the local teaching hospital (Cohen et al., 1995). In 
that study only 5 cases were included in a 9-year period. The study by 
Jones and colleagues (2003), aimed at describing the use of 
ultrasonography to detect cases of right dorsal colitis, includes 5 cases in 
a 2 year period at the teaching hospital of the college of veterinary 
medicine of North Carolina State University. Although a figure for the 
overall populations of these two hospitals during the period of these 
studies is not provided, it appears reasonable to assume that the 
prevalence of this condition is generally low. 
 
5.1.2 Detection of non-steroidal anti-inflammatory drugs toxicity from 
Electronic Medical Records 
 
The widespread use of EMRs in veterinary practice provides an opportunity 
to describe drug usage, as detailed in the previous chapter, but also to 
estimate the prevalence of side effects. 
 
Informatics is “the application of information and computer science 
technology to public health practice, research and learning” (Friede et 
al., 1995) and has been applied in human as well as veterinary medicine to 
extract information from unstructured or semi-structured free-text 
clinical records (Anholt et al., 2014b; Chapman et al., 2005; Chen et al., 
2008; Friedlin et al., 2008; Heinze et al., 2001; Lam et al., 2007c; Roque 
et al., 2011; Sager et al., 1994). 
 
To detect cases with a specific diagnosis from free text EMR, one must 
search for all combinations of words that might identify that diagnosis. 
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This approach relies on a correct diagnosis being made by the veterinarian 
entering the data into the EMR and therefore is likely to underestimate 
the real prevalence in first opinion settings, where reaching a definitive 
diagnosis via appropriate testing is often not feasible. However, while for 
this same reason it is possible that the prevalence of toxicity in some 
cases may be overestimated, because of the difficulty to confirm the 
diagnosis, some also suffer toxicity without overt clinical signs (Read, 
1983). A correct diagnosis might not be reached due to either a failure to 
recognise toxicity or if clinical data is not recorded in the EMR. On the 
other hand, clinical signs identified during the clinical examination can be 
relatively non-specific and if used as a marker for this disease could result 
in an overestimation of the prevalence. This is a problem particularly in 
conditions for which a diagnosis cannot be easily confirmed ante-mortem 
such as renal medullary crest necrosis (Gunson and Soma, 1983), 
particularly when necropsy and histopathology is often not performed for 
cases subjected to euthanasia in the field. Right dorsal colitis is diagnosed 
ante-mortem in cases with characteristic clinical signs, clinical-
pathological picture, evidence of thickened right dorsal colon with 
abdominal ultrasonography, history of NSAIDs administration and after the 
exclusion of other major causes of diarrhoea, such as bacterial colitis and 
antimicrobial induced diarrhoea (McGorum and Pirie, 2009; Sanchez, 
2010).  
 
Right dorsal colitis may present with one or more of several non-specific 
clinical signs including anorexia, weight loss, lethargy, intermittent or 
sporadic episodes of acute abdominal pain, pyrexia, ventral oedema and 
diarrhoea (Cohen et al., 1995). Even though clinical signs such as 
anorexia, lethargy and weight loss are most predominant (Sanchez, 2010) 
these are more easily recorded in hospitalised patients compared with 
ambulatory first opinion settings, unless they are very severe or 
specifically noted and reported by the owner. Episodes of abdominal pain 
and pyrexia are often sporadic, while ventral oedema is a feature of a 
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more advanced stage of the disease (Cohen et al., 1995). Abnormal faecal 
consistency is noticeable at the time the bedding is cleaned and is likely 
to be reported by owners. Therefore, diarrhoea might arguably be a more 
sensitive marker for this condition in first opinion ambulatory settings. 
Therefore, it might be a reasonable approach to identify episodes of 
diarrhoea that owners considered severe enough to require a veterinary 
examination in order to detect cases of NSAID toxicity. Finally diarrhoea 
may be a more suitable outcome variable to detect NSAID toxicity as it is 
relatively more sensitive than confirmed right dorsal colitis in first opinion 
settings. 
 
It is important to note that diarrhoea is a non-specific clinical sign and 
many conditions are included in a differential diagnosis list for diarrhoea 
such as most gastrointestinal diseases, infectious colitis, parasitic disease, 
excessive ingestion of sand, inflammatory or infiltrative disorders of the 
intestine, sudden dietary change, carbohydrate overload, anaphylaxis and 
ingestion of other toxic substances (arsenic, cantharidin, etc.). Further, 
several non-gastrointestinal conditions can result in loose faecal 
consistency and include any condition reducing blood oncotic pressure, 
either from protein and albumin loss within a body cavity, such as 
peritonitis, pleuropneumonia or pericarditis, or outwith the body such as 
protein loosing nephropathy or severe dermatological conditions or burns, 
or from increased vascular hydrostatic pressure, in case of uncompensated 
congestive heart failure, intrinsic renal failure or over-zealous intravenous 
fluid therapy. Finally administration of other drugs, within or outwith 
labelled doses might also induce diarrhoea. Antimicrobials, very 
frequently administered to equids under veterinary care, are also a well-
documented contributing factor to the development of diarrhoea 
(Sanchez, 2010). Therefore using diarrhoea to identify cases of right dorsal 
colitis would result in obtaining several false positive cases, as many cases 
with diarrhoea would not have right dorsal colitis. Diarrhoea also yields 
low specificity to identify NSAID toxicity as it presents with a wide range 
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of conditions resulting in a high false positive rate. On the other hand 
while right dorsal colitis would be very specific, therefore with a low false 
positive rate, many cases with mild right dorsal colitis could remain 
unidentified with a higher false negative rate. This highlights the 
importance of accounting for confounding factors, such as other conditions 
leading to diarrhoea, via multiple logistic regression analysis. Confounding 
factors should include administration of other drugs such as antimicrobials 
as these drugs are often administered concurrently with NSAIDs and are 
also a relatively common cause of diarrhoea in the horse (McGorum and 
Pirie, 2009). Corticosteroids share a common pathway with NSAIDs to 
inhibit prostaglandin production (Vane et al., 1998) and represent a 
confounding factor for the development of diarrhoea. However, 
corticosteroids are often used as a treatment for conditions inducing 
diarrhoea in horses as they modulate the inflammatory component that 
leads to diarrhoea (Barr, 2006; Mair, 1993) and corticosteroid 
administration should therefore be accounted for in the logistic regression 
analysis. Administration of laxatives and intravenous fluids should also be 
included as these are often administered to soften faeces (Sanchez, 2010). 
Some anthelmintic drugs, particularly those from the avermectin family 
and benzimidazole derivatives, have also been associated with colic and 
diarrhoea after administration (Barrett et al., 2005). As abdominal pain is 
a rather common clinical sign of these gastrointestinal diseases in horses, 
colic should also be included in the analysis to account for underlying 
conditions that could predispose a horse to develop diarrhoea. Further, 
diseases leading to colic might result in an altered barrier function of the 
intestinal mucosa and ultimately result in diarrhoea (Sanchez, 2010).  
 
Renal medullary crest necrosis is often present sub-clinically and only 
severe cases develop severe clinical renal failure (Gunson and Soma, 
1983). Further, the diagnosis is generally only confirmed during post-
mortem examination, suggesting that the condition is likely not to be 
commonly recognised in the vast majority of cases (Gunson and Soma, 
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1983), particularly in first opinion practice. Semantically, renal NSAID 
toxicity might be described simply as renal failure in many cases and 
therefore detection of this condition by text-mining EMRs would be 
potentially insensitive. Several conditions can induce renal failure in 
horses. Renal failure is generally classified as (i) pre-renal, mostly due to 
decreased renal perfusion secondary to hypovolaemia and reduced cardiac 
output; (ii) intrinsic renal disease, including NSAID toxicity, but also 
nephritis, nephropathies, nephrolithiasis, kidney neoplasia; (iii) post-renal 
causes, generally including cystitis, urolithiasis, rupture or trauma to the 
bladder or urethra. While the mere presence of renal disease is generally 
easy to detect by the increase in creatinine and BUN concentration in 
blood biochemistry, confirming the origin (pre-renal, intrinsic or post-
renal) is more difficult particularly in ambulatory first opinion settings, 
where appropriate tools to further investigate the condition may not be 
readily available. These include cystoscopy, a laboratory to perform 
urinalysis and good quality ultrasonography. Furthermore, with cases of 
renal medullary necrosis, it would be very difficult to reach this definitive 
diagnosis, as post-mortem and histopathology of the renal medullary crest 
are not readily available. As with diarrhoea, searching for renal failure 
might also have a higher sensitivity but a lower specificity and accounting 
for confounding comorbidities is also appropriate.  
 
The studies in this chapter might also highlight how differences in drug 
usage between countries might also affect the results. For example, as 
highlighted in Chapter 4, some NSAIDs are available only in certain 
countries and their availability might influence the usage of other drugs as 
well as the condition for which these drugs are used. This might be the 
case for NSAIDs such as metamizole, which is available in Canada but not 
in the US, but in the United Kingdom it is available only in combination 
with a spasmolytic as a treatment of visceral pain. As equids with colic 
might be predisposed to develop gastrointestinal signs such as diarrhoea, 
it might be speculated that diarrhoea would be more common with a drug 
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licensed solely for gastrointestinal disease. In other words, this could be a 
reflection of the intrinsic increased risk for diarrhoea in this population, as 
well as an increased prevalence of the drug’s side effects. The true 
contribution of the drug to the development of diarrhoea would be very 
difficult to estimate in these circumstances. 
 
Further, regional differences towards usage of certain drugs might also 
affect the prevalence of side effects and highlight how confounding 
factors intrinsic to a certain geographical region influence the results of 
studies on a drugs’ safety profile. For example, legislative differences 
between countries that control drug licensing might highlight differences 
in the safety profile of these drugs in these different countries. Ultimately 
this highlights the importance of interpreting research findings with 
caution when data is obtained from a population from a different country, 
with different drug licensing regulations. 
 
The aim of this chapter was to describe the prevalence of side effects, 
such as diarrhoea, that might be attributed to NSAIDs administration, 
accounting for the administration of several other pharmaceuticals, from 
data obtained from two different geographical regions, the United 
Kingdom and North America (U.S.A. and Canada). 
 
5.2 Non-steroidal anti-inflammatory drug toxicity in the United 
Kingdom 
 
5.2.1 Introduction 
 
The prevalence of toxicity related to NSAID administration is unknown in 
the United Kingdom. Two clinical studies that describe NSAID toxicity are 
from North America (Cohen et al., 1995; Jones et al., 2003). The only 
study from the British Isles is from Ireland, reporting three cases of right 
dorsal colitis over an unspecified period of time (Galvin et al., 2004). 
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Considering the frequent use of NSAIDs in equine practice, as described in 
Chapter 3, and the scarcity of reports of toxicity, the prevalence of side 
effects is expected to be very low. This might be for a number of reasons 
beyond a true low prevalence including difficulty in confirming the 
diagnosis in vivo, particularly in less severe cases. This is particularly true 
in a first opinion population, as mild cases might not be reported by the 
owners or because of lack of the means necessary to reach a diagnosis in a 
field setting. 
 
The aim of this study was to report the prevalence of suspected NSAID 
toxicity. Since the prevalence of diagnosis of NSAID toxicity was expected 
to be very low (<1% of equids receiving NSAIDs) the study focused not only 
on determining the prevalence of toxicity but also on documenting if a 
relationship exists between a common clinical sign that could be 
consistent with toxicity, such as diarrhoea, and the administration of 
these drugs. Diarrhoea was ideal for the purpose of the study as it is easily 
detected by owners and is generally a cause of concern that results in a 
veterinary surgeon’s opinion being sought. 
 
5.2.2 Materials and methods 
 
5.2.2.1 Prevalence of reported non-steroidal anti-inflammatory drug 
toxicity 
 
The United Kingdom first opinion dataset described in Chapter 3, which 
included 141,543 animals (between 1987 and 2013; 2,653,695 rows of 
data) was analysed with the methods described in detail in Chapter 3. 
Briefly, the list of the words included in the dataset was used to identify 
terms that might identify NSAID toxicity; including cases where toxicity 
was suspected but not necessarily confirmed. 
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5.2.2.2 Diarrhoea and control population 
 
Diarrhoea was defined as a case where decreased faecal consistency was 
such a concern to warrant being mentioned in the EMR. Different cut-offs 
in number of days from a previous episode were evaluated at 90 and 180 
days to define a case of diarrhoea as a “new case”. 
 
Text mining was performed on the dataset from the United Kingdom and 
all cases for which at least one episode of diarrhoea was recorded in the 
EMR were extracted from the dataset using the methodology described in 
Chapter 3. A comprehensive inclusion characterisation dictionary was 
created to detect all cases referring to faeces from soft to watery. A 
comprehensive exclusion dictionary was also used, to exclude for 
example, the frequent recommendation included in clinical records, to 
‘monitor a patient for diarrhoea’ or ‘discontinue a treatment in case of 
the development of diarrhoea’. 
 
A control population was selected at random from those horses matching 
each diarrhoea episode by date and practice for which diarrhoea was 
never mentioned in the EMR. Control equids were selected from the same 
practice and if they had received an examination on the same date of the 
episode of diarrhoea; where no equid was examined on the same date of 
the diarrhoea episode, a case with the closest date available was chosen. 
For each episode of diarrhoea, even if from an equid that had multiple 
episodes, a new control subject was selected so that the number of 
control equids matched exactly the number of episodes of diarrhoea. 
 
The dataset, including all cases with diarrhoea and their matched 
controls, was used for the following analysis. 
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5.2.2.3 Diarrhoea prevalence determination 
 
The results of data mining were imported in R to calculate the difference 
in days between episodes, for equids in which more than one episode of 
diarrhoea was recorded. A dataset was created including all episodes of 
diarrhoea, date and practice. The prevalence estimate for diarrhoea and 
confidence intervals were calculated using the formula: 
 ! = !! !!/!!!! ±  !!!! !!!!/!!!!    
 
In this equation p is the probable prevalence, p0 is the observed 
prevalence, t is the square of the distribution divided by the sample size 
and q0 is the coefficient used to calculate the standard deviation in 
(p0q0/n)
1/2 where n is the sample size (Wilson, 1927). This formula is 
appropriate for the determination of prevalence estimates as the 
confidence intervals are bound to be greater than or equal to zero. 
 
5.2.2.4 Explanatory variable: non-steroidal anti-inflammatory drugs 
 
All cases included in the dataset described in the previous section 
receiving NSAIDs were identified in R. The date of recorded usage of an 
NSAID was used to determine if drugs were administered in the two weeks 
preceding the development of diarrhoea. 
 
The data was obtained for all NSAIDs together and was subsequently 
looked at more specifically for the five NSAIDs (phenylbutazone, 
suxibuzone, flunixin meglumine, metamizole and meloxicam), which were 
more commonly used in this country, as highlighted in Chapter 4. In 
addition to these, ketoprofen and firocoxib were also evaluated. 
 
Ultimately 16 binary variables (“true” or “false” depending on whether 
use of the drug was recorded) were created to describe if usage of NSAIDs 
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as a whole, or of specific drugs, was recorded within 14 or seven days 
prior to the development of diarrhoea. 
 
For the control animals these 16 variables were “true” or “false” 
depending on whether use of each drug was recorded within 14 or seven 
days prior to the date the matched horse in the diarrhoea group had 
developed diarrhoea. 
 
5.2.2.5 Explanatory variable: Antimicrobials 
 
Antimicrobial administration was defined as all antimicrobial agents for 
systemic administration. All cases included in the dataset described in the 
previous section receiving antimicrobials were identified in R. The date of 
recorded usage of an antimicrobial was used to determine when drugs 
were administered in the two weeks preceding the development of 
diarrhoea. Contemporary drug administration in the matched control 
animals was also identified. Ultimately two binary variables were created 
depending on whether use of antimicrobials was recorded within 14 or 
seven days prior to the development of diarrhoea. 
 
5.2.2.6 Explanatory variable: Corticosteroids 
 
Corticosteroids administration was also evaluated and included 
corticosteroids for systemic administration such as dexamethasone, 
prednisolone and prednisone. All cases included in the dataset described 
in the previous section receiving corticosteroids were identified in R. The 
date of recorded usage of a corticosteroid was used to determine when 
drugs were administered in the two weeks preceding the development of 
diarrhoea. Contemporary drug administration in the matched control 
animals was also identified. Ultimately four binary variables were created 
depending on whether use of any corticosteroid, or just systemic 
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corticosteroid, was recorded within 14 or seven days prior to the 
development of diarrhoea. 
 
5.2.2.7 Explanatory variable: Laxatives 
 
Laxatives were defined as drugs administered to reduce faecal 
consistency. Typically these included magnesium sulphate (Epsom salts) or 
liquid paraffin. All cases included in the dataset described in the previous 
section receiving laxatives were identified in R. The date of recorded 
usage of a laxative was used to determine if the treatment was 
administered in the two days preceding the development of diarrhoea. 
Contemporary laxative administration in the matched control animals was 
also identified. Ultimately one binary variable was created for when 
administration of a laxative treatment was recorded within the 48 hours 
prior to the development of diarrhoea. 
 
5.2.2.8 Explanatory variable: Intravenous fluids 
 
Intravenous fluid therapy was defined as the parenteral administration of 
fluids. It did not account for quantity administered, administration rate or 
treatment length. All cases included in the dataset described in the 
previous section undergoing intravenous fluid therapy were identified in R. 
The date of recorded parenteral administration of fluids was used to 
determine if the treatment occurred in the two days preceding the 
development of diarrhoea. Contemporary fluid administration in the 
matched control animals was also identified. Ultimately one binary 
variable was created when intravenous fluid administration was recorded 
within the 48 hours prior to the development of diarrhoea. 
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5.2.2.9 Explanatory variable: Anthelmintic drugs 
 
All cases included in the dataset described in the previous section 
receiving anthelmintic drugs were identified in R. The date of recorded 
usage of an anthelmintic was used to determine if drugs were 
administered in the two weeks preceding the development of diarrhoea. 
Contemporary drug administration in the matched control animals was 
also identified. Ultimately two binary variables were created depending 
on whether use of anthelmintic drugs was recorded within 14 or seven 
days prior to the development of diarrhoea. 
 
5.2.2.10 Statistical analysis 
 
Multivariable conditional logistic regression modelling was selected for the 
analysis to evaluate the effect of multiple, potentially inter-related 
explanatory variables. The outcome variable was binomial in nature, e.g. 
presence or absence of diarrhoea.  
 
Logistic regression models the natural logarithm (ln) of the odds of an 
outcome for a given value of explanatory variable(s). The odds are defined 
as the probability of having an outcome (diarrhoea) divided by the 
probability of not having the outcome (no diarrhoea).  
 
The general formula depicting a logistic regression model is as follows: 
 ! = !" !1 − ! = ! + !!!! + !!!! +⋯+ !!!! 
 
where the first term of the equation is the log transformation of the odds 
of the outcome, with p being the probability of that outcome actually 
happening, α is the intercept term, β1 to βi are the regression coefficients 
which represent the change of y for a unit change in the outcome x.  
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Logistic regression also allows determination of interactions between 
explanatory variables. Interactions should be evaluated to ascertain that 
the effect of two variables on the outcome is not simply additive, as the 
two variables might enhance or moderate each other’s effect (Dohoo et 
al., 2010). For example, NSAIDs and antimicrobials are well recognised 
causes of diarrhoea in the horse (Sanchez, 2010). Physiologically this is 
explainable as flunixin meglumine weakens the intestinal lining by 
reducing mucosal blood flow. Antimicrobials increase the number of toxins 
released with bacterial death within the intestinal lumen, which also 
often results in diarrhoea. However, the effect of each drug combined 
might be expected to be greater as the effect of the increased quantity of 
bacterial toxins produced as a consequence of antimicrobial 
administration could have a greater effect on a mucosa weakened by 
flunixin meglumine. This example highlights the possible pathogenic 
mechanism through which the combination of both drugs might cause a 
greater effect than the additive effect of each individual drug. Potential 
interaction terms were chosen based on those that might make sense 
pharmacologically. Another reason for testing certain interaction terms 
was that they reflect common clinical practice as drugs are often 
administered in combination. This is the case for example with 
antimicrobials and NSAIDs, different NSAIDs together (flunixin meglumine 
and phenylbutazone), or antimicrobials and corticosteroids as these 
scenarios reflect common clinical practice. Conditional logistic regression 
is used for binary data with one or more predictors, where observations 
are not independent but are matched or grouped in some way. 
 
Odds ratio (OR) calculation is also affected when including interaction 
terms in the regression model. The OR for each single first term is 
obtained by multiplying the OR, as if there was no significant interaction, 
with the OR of the interaction. The OR of the interaction is obtained by 
the multiplication of the OR of each single term, as if there was no 
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significant interaction, with the OR of the interaction alone (Dohoo et al., 
2010). The OR for interaction terms was then calculated with the 
following formula: 
 ! !!!!!!!!∗!  ±!.!" !!!!!!!!!!∗!!  
 
where β1 and β2 are the coefficient of each single variables and β1*2 is the 
coefficient of the interaction term and σ is the standard error. 
 
For example, in the output of the logistic regression model the coefficient 
calculated for flunixin meglumine was 1.04, for phenylbutazone was -0.59 
and for the interaction term flunixin*phenylbutazone was -0.69. From this 
the resulting OR was obtained as the exponential of -0.24 obtained from 
the sum of the coefficients of each term (e.g. (1.04+(-0.59)+(-0.69)=-
0.24). 
 
Univariable logistic regression was used initially to evaluate the 
significance, and the size of the effect, of each explanatory variable on its 
own and to evaluate whether each variable should be considered for 
inclusion in the multivariable analysis. 
 
The Akaike Information Criterion (AIC) was used to select the regression 
model best fitting the data. The AIC provides an index to compare the 
quality of each model, by estimating the amount of information lost by 
each model (Akaike, 1998, 1974). The AIC value is calculated by the 
following formula: 
 !"# = 2! − 2 !" !  
 
where K is the number of parameters in the model and L is the likelihood 
function of the model. From this formula it is clear that the AIC can be 
used only to compare models that use the same number of observations, 
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e.g. K, so that the AIC varies only along with the log likelihood. In this 
study the AIC was used as every explanatory variable had a complete set 
of data points. The dataset used had no missing data. In fact all 
explanatory variables were binary and if a drug was used then it was 
classified as “true”, otherwise as “false”. 
 
Conditional logistic regression analysis was performed in R using the 
function “clogit” of the package “survival” and the best fitting model was 
obtained by adding and removing different variables using a forward and 
backwards approach. The term defining the matching was added as 
“+strata(set)” where “set” was a variable assigning each diarrhoea 
positive case to its own control.  
 
AIC was used to evaluate whether the addition of an interaction term 
improved significantly the fit of the model to the data. The suitability of 
each model was evaluated using relative likelihood of the model 
calculated by the formula: 
 !!"#!"#!!"#!!  
 
where AICmin is the smallest AIC, AICi is the one being tested. A commonly 
accepted cut-off AIC difference is four which means that the model with 
the higher AIC of the two is 0.135 times as likely to minimise information 
loss by addition of an explanatory variable to the model (Steyerberg, 
2009) 
 
5.2.2.11 Post-hoc analysis to account for comorbidities 
 
Other comorbidities were also included post-hoc to further explain the 
findings of the initial analyses and account for the possible confounding 
effect of comorbidities that could also have triggered diarrhoea and that 
might have required treatment with some of the drugs included as 
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explanatory variables in the initial model. The EMR referring to colic and 
orthopaedic disease, referred to in Chapter 4, were included in the model. 
These were used to identify patients suspected, investigated or treated 
for abdominal discomfort or an orthopaedic condition in zero to seven 
days or seven to 14 days, or at any other point in the EMRs, preceding the 
development of diarrhoea. These variables were mutually exclusive. 
Conditional logistic regression was then used to evaluate whether 
inclusion of one or both comorbidities altered the statistical significance 
and odd ratios of variables included in the model.  
 
Inclusion, exclusion and re-inclusion dictionaries used for the analysis are 
available in Appendix 5. 
 
The study was approved by Ethics and Welfare Committee of the School of 
Veterinary Medicine at the University of Glasgow. 
 
5.2.3 Results 
 
5.2.3.1 Prevalence of reported non-steroidal anti-inflammatory drug 
toxicity 
 
Of the total of 2,653,695 rows of data from 141,543 equids from the 
United Kingdom, NSAID toxicity was suspected or diagnosed in only eight 
animals. The demographic details of the population in this dataset are 
described in Chapter 3. The overall prevalence of NSAID toxicity in this 
population from the United Kingdom was therefore 0.01% (95% CIs:  0.00-
0.01%). 
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5.2.3.2 Diarrhoea and Control population 
 
A 90 day cut-off was arbitrarily chosen based on the author’s expert 
opinion. Longer cut-offs (up to 180 days) were also evaluated and would 
have changed the number of diarrhoea episodes by a maximum of 0.8%.  
 
Of the 141,543 equine patients in the dataset, a total 2,427 equids 
suffered at least one episode of diarrhoea with a total of 2,589 episodes of 
diarrhoea, of which 432 were recorded as horses whereas the rest were 
recorded as equine.  
 
Of all equids, 2,327 had a single episode of diarrhoea recorded, 70 had 
two episodes, 14 had three episodes, seven had four episodes, five had 
five episodes, two had six episodes and the last two equids had seven and 
eight episodes each. The mean age of the population that suffered 
diarrhoea was 13.5 years (median 12 years, range: 0-40 years), while a 
plausible age was not available for 1,310 equids of those with diarrhoea. 
Diarrhoea was reported in 687 females and 613 males, of which 531 were 
geldings, 82 entire males. Gender had not been recorded in 1,127 equids 
with diarrhoea. The control population included a total of 2,589 animals, 
of which 434 were recorded as being horses, and the remaining simply as 
equines. No control animal appeared more than once in the dataset. The 
mean age of the control population was 12.6 years (median 11.3 years, 
range: 0-40 years), while age was not available for 1,315 control animals. 
Control animals for which gender had been recorded included 656 females 
and 652 males, of which 562 were geldings and 90 entire males. 
 
The dataset including all cases with diarrhoea and their matched control 
animals is from now on referred to as the “diarrhoea dataset” and 
included a total of 5016 equids, 2427 that suffered at least one episode of 
diarrhoea and 2589 equids that never had diarrhoea reported in the 
record. 
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5.2.3.3 Diarrhoea prevalence determination 
 
A total of 2427 equids from the population of 141,543 animals suffered at 
least one episode of diarrhoea severe enough to be mentioned in the EMR 
(diarrhoea prevalence: 1.71%; 95% CIs: 1.65-1.78%).  
 
5.2.3.4 Explanatory variable: non-steroidal anti-inflammatory drugs 
 
From the total of 141,543 animals, administration of NSAIDs was recorded 
at least once in the EMR of 39,816 patients, with a calculated prevalence 
for NSAIDs usage of 28.13% (95% CIs: 27.9-28.36%). 
  
A total of 794 animals, out of the total of 5016 equids in the diarrhoea 
dataset, received NSAIDs in the preceding 14 days. Of these, 583 were 
from the diarrhoea group and 211 were from the control group. The 
overall prevalence of NSAID usage in the 14 days preceding the 
development of diarrhoea was 22.52% (CIs: 21.0-24.20%), while in the 
control group this was 8.15% (95% CIs: 7.16-9.27%).  
 
The prevalence of phenylbutazone usage within 14 days of the ‘case date’ 
was 11.32% (293 animals; 95% CIs: 10.15-12.6%) in those with diarrhoea 
(n= 2427) and 4.87% (126 animals; 95% CIs: 4.10-5.76%) in control animals 
(n= 2589). The prevalence of suxibuzone usage with 14 days of the ‘case 
date’ was 4.83% (125 animals; 95% CIs: 4.07-5.72%) in those with diarrhoea 
and 1.74% (45 animals; 95% CIs: 1.30-2.32%) in control animals. The 
prevalence of flunixin meglumine usage within 14 days of the ‘case date’ 
was 5.95% (154 animals; 95% CIs: 5.10-6.93%) in those with diarrhoea and 
2.16% (56 animals; 95% CIs: 1.67-2.80%) in control animals. The prevalence 
of ketoprofen usage within 14 days was 0.19% (5 animals; 95% CIs: 0.08-
0.45%) in those with diarrhoea and no animal received ketoprofen in the 
control group (0.00%; 95%CIs: 0.00-0.15%). Prevalence of meloxicam usage 
within 14 days of the ‘case date’ was 1.04% (27 animals; 95% CIs: 0.72-
		
173	
	
1.51%) in equids with diarrhoea and 0.35% (9 animals; 95% CIs: 0.18-0.66%) 
in the control group. Prevalence of metamizole usage within 14 days of 
the ‘case date’ was 2.05% (53 animals; 95% CIs: 1.57-2.67%) in equids with 
diarrhoea and 0.30% (8 animals; 95% CIs: 0.16-0.61%) in the control group. 
Finally firocoxib was administered to only one horse, which suffered 
diarrhoea within 14 days (prevalence of use 0.04%; 95% CIs: 0.01-0.22%). 
 
When including only NSAIDs administered seven days from the ‘case date’, 
the prevalence of NSAIDs usage was 19.16% (496 animals; 95% CIs: 17.69-
20.72%) in equids with diarrhoea and 6.1% (158 animals; 95% CIs: 5.24-
7.09%) in the control group. The prevalence of phenylbutazone usage 
within 7 days from the ‘case date’ was 9.39% (243 animals; 95% CIs: 8.32-
10.57%) in equids with diarrhoea and 3.44% (89 animals; 95% CIs: 2.80-
4.21%) in the control group. The prevalence of suxibuzone usage within 7 
days from the ‘case date’ was 3.75% (97 animals; 95% CIs: 3.08-4.55%) in 
equids with diarrhoea and 1.35% (35 animals; 95% CIs: 0.97-1.87%) in the 
control group. The prevalence of flunixin meglumine usage within 7 days 
from the ‘case date’ was 5.25% (136 animals; 95% CIs: 4.46-6.18%) in 
equids with diarrhoea and 1.66% (43 animals; 95% CIs: 1.24-2.23%) in the 
control group. The prevalence of ketoprofen usage within 7 days from the 
‘case date’ was 0.19% (5 animals; 95% CIs: 0.08-0.45%) in equids with 
diarrhoea and no animal in the control group had received ketoprofen 
(prevalence 0.00%; 95% CIs: 0.00-0.15%). Prevalence of meloxicam use 
within 7 days from the ‘case date’ was 0.81% (21 animals; 95% CIs: 0.53-
1.24%) in equids with diarrhoea and 0.35% (9 animals; 95% CIs: 0.18-0.66%) 
in the control group. The prevalence of metamizole use within 7 days from 
the ‘case date’ was 1.89% (49 animals; 95% CIs: 1.43-2.49%) in equids with 
diarrhoea and 0.19% (5 animals; 95% CIs: 0.08-0.45%) in the control group. 
Finally firocoxib was administered only to one horse, which suffered 
diarrhoea within 7 days (prevalence of use 0.04%; 95% CIs: 0.01-0.22%) and 
no equid in the control group received firocoxib (prevalence 0.00%; 95% 
CIs: 0.00-0.15%). 
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These results are summarised in Table 5.1. 
 
Table 5.1: Prevalence of NSAIDs usage 14 and 7 days before a ‘case date’ from 2427 
equids that suffered 2589 episodes of diarrhoea and 2589 control animals that never 
had diarrhoea in the United Kingdom. 
Drug Days Total D Prevalence (95% CIs) C Prevalence (95% CIs) 
NSAIDs 14 794 583 22.52 (20.95-24.17) 211 8.15 (7.16-9.27) 7 654 496 19.16 (17.69-20.72) 158 6.1 (5.24-7.09) 
       
Phenylbutazone 14 419 293 11.32 (10.15-12.60) 126 4.87 (4.10-5.76) 7 332 243 9.39 (8.32-10.57) 89 3.44 (2.80-4.21) 
       
Suxibuzone 14 170 125 4.83 (4.07-5.72) 45 1.74 (1.30-2.32) 7 132 97 3.75 (3.08-4.55) 35 1.35 (0.97-1.87) 
       
Flunixin 
meglumine 
14 210 154 5.95 (5.10-6.93) 56 2.16 (1.67-2.80) 
7 179 136 5.25 (4.46-6.18) 43 1.66 (1.24-2.23) 
       
Ketoprofen 14 5 5 0.19 (0.08-0.45) 0 0.00 (0.00-0.15) 7 5 5 0.19 (0.08-0.45) 0 0.00 (0.00-0.15) 
       
Meloxicam 14 36 27 1.04 (0.72-1.51) 9 0.35 (0.18-0.66) 7 30 21 0.81 (0.53—1.24) 9 0.35 (0.18-0.66) 
       
Metamizole 14 61 53 2.05 (1.57-2.67) 8 0.30 (0.16-0.61) 7 54 49 1.89 (1.43-2.49) 5 0.19 (0.08-0.45) 
       
Firocoxib 14 1 1 0.04 (0.01-0.22) 0 0.00 (0.00-0.15) 7 1 1 0.04 (0.01-0.22) 0 0.00 (0.00-0.15) 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group. 
 
5.2.3.5 Explanatory variable: Antimicrobials 
 
From the total of 141,543 animals, administration of antimicrobials was 
recorded at least once in the EMR of 34,102 patients with a prevalence for 
antimicrobial usage of 24.09% (95% CIs: 23.87-24.32%).  
 
The prevalence of antimicrobial usage within 14 days from the ‘case date’ 
was 16.26% (421 animals; 95% CIs: 14.89-17.73%) in those with diarrhoea 
and 7.34% (190 animals; 95% CIs: 6.40-8.41%) in control animals. 
 
In the 7 days before the ‘case date’, the prevalence of antimicrobial usage 
was 13.56% (351 animals; 95% CIs: 12.29-14.93%) in the equids with 
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diarrhoea and 5.68% (147 animals; 95% CIs: 4.85-6.64%) in the control 
group. 
 
5.2.3.6 Explanatory variable: Corticosteroids 
 
Of the total of 141,543 animals, administration of corticosteroids was 
recorded at least once in the EMR of 10,518 patients with a prevalence for 
corticosteroids usage of 7.43% (95% CIs: 7.30-7.57%).  
 
The prevalence of corticosteroid administration in the 14 days preceding 
the ‘case date’ was 4.36% (113 animals; 95% CIs: 3.64-5.22%) in the equids 
with diarrhoea and 1.74% (45 animals; 95% CIs: 1.3-2.32%) in the control 
group. 
 
The prevalence of corticosteroid administration in the 7 days preceding 
the ‘case date’ was 3.51% (122 animals; 95% CIs: 2.87-4.30%) in the equids 
with diarrhoea and 1.20% (31 animals; 95% CIs: 0.84-1.69%) in the control 
group. 
 
When looking specifically at usage of systemic corticosteroid 
(dexamethasone, prednisolone, prednisone), the prevalence over the total 
population of 141,543 equids was 4.26% (6007 animals; 95% CIs: 4.15-
4.37%), which accounted for 57.11% (95%CIs: 56.16-58.05%) of all 
corticosteroids. 
 
The prevalence of systemic corticosteroid administration in the 14 days 
preceding the ‘case date’ was 2.16% (56 animals; 95% CIs: 1.67-2.80%) in 
the equids with diarrhoea and 0.70% (18 animals; 95% CIs: 0.44-1.10%) in 
the control group. 
 
The prevalence of systemic corticosteroid administration in the 7 days 
preceding the ‘case date’ was 1.82% (47 animals; 95% CIs: 1.37-2.41%) in 
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the equids with diarrhoea and 0.58% (15 animals; 95% CIs: 0.35-0.95%) in 
the control group. 
 
5.2.3.7 Explanatory variable: Laxatives 
 
Of the total of 141,543 animals, administration of laxatives was recorded 
at least once in the EMR of 5850 patients with a prevalence for laxative 
usage of 4.15% (95% CIs: 4.04-4.25%). 
 
The prevalence of laxative usage in the 2 days preceding a ‘case date’ was 
1.04% (31 animals; 95% CIs: 0.72-1.51%) in the equids with diarrhoea and 
0.15% (4 animals; 95% CIs: 0.06-0.40%) in the control group. 
 
 
5.2.3.8 Explanatory variable: Intravenous fluids 
 
Of the total of 141,543 animals, administration of intravenous fluids was 
recorded at least once in the EMR of 2122 patients with a prevalence of 
fluid administration intravenously of 1.50% (95% CIs: 1.44-1.57%).  
 
The prevalence of fluid therapy usage in the 2 days preceding a ‘case 
date’ was 3.51% (91 animals; 95% CIs: 2.87-4.30%) in equids with diarrhoea 
and 0.58% (15 animals; 95% CIs: 0.35-0.95%) in the control group. 
 
5.2.3.9 Explanatory variable: Anthelmintic drugs 
 
Of the total of 141.061 animals, administration of anthelmintic drugs was 
recorded at least once in the EMR of 9835 patients with a prevalence for 
anthelmintic drug usage of 6.97% (95% CIs: 6.84-7.11%).  
 
The prevalence of anthelmintic drug usage in the 14 days preceding the 
‘case date’ was 3.94% (102 animals; 95% CIs: 3.26-4.76%) in equids with 
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diarrhoea and 1.31% (34 animals; 95% CIs: 0.94-1.83%) in the control 
group.  
 
The prevalence of anthelmintic drug usage in the 7 days preceding the 
‘case date’ was 3.05% (105 animals; 95% CIs: 2.46-3.79%) in equids with 
diarrhoea and 1.00% (26 animals; 95% CIs: 0.69-1.47%) in the control 
group. 
 
Prevalence data on drug usage is summarised in Table 5.2. Prevalence 
data of equids in the diarrhoea dataset is summarised in Table 5.3. 
 
Table 5.2: Prevalence of drug usage in 141,543 equids from the United Kingdom. 
The data reflects usage of each drug at some point in the animal EMR. 
Drug Equids Prevalence (%) 95% CIs (%) 
Antimicrobials 34,102 24.09 23.87-24.32 
Corticosteroids 10,518 7.43 7.30-7.57 
Systemic corticosteroids 6007 4.26 4.15-4.37 
Laxatives 5850 4.15 4.04-4.25 
Intravenous fluids 2122 1.50 1.44-1.57 
Anthelmintic drugs 9835 6.97 6.84-7.11 
 
 
Table 5.3: Prevalence of drug usage 14 and 7 days before a ‘case date’ from 2427 
equids that suffered 2589 episodes of diarrhoea and 2589 control animals that never 
had diarrhoea in the United Kingdom. 
Drug Days Total D Prevalence (95% CIs) C Prevalence (95% CIs) 
Antimicrobials 14 611 421 16.26 (14.89-17.73) 190 7.34 (6.40-8.41) 7 498 351 13.56 (12.29-14.93) 147 5.68 (4.85-6.64) 
       
Corticosteroids 14 158 113 4.36 (3.64-5.22) 45 1.74 (1.30-2.32) 7 153 122 3.51(2.87-4.30) 31 1.20 (0.84-1.69) 
       
Systemic 
corticosteroids 
14 74 56 2.16 (1.67-2.80) 18 0.70 (0.44-1.10) 
7 62 47 1.82 (1.37-2.41) 15 0.58 (0.35-0.95) 
       
Laxatives 2 35 31 1.04 (0.72-1.51) 4 0.15 90.06-0.40) 
       
Intravenous fluids 2 106 91 3.51 (2.87-4.30) 15 0.58 (0.35-0.95) 
       
Anthelmintic 
drugs 
14 136 102 3.94 (3.26-4.76) 34 1.31 (0.94-0.83) 
7 184 105 3.05 (2.46-3.79) 26 1.00 (0.69-1.47) 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group. 
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5.2.3.10 Statistical analysis 
 
Univariable logistic regression 
 
When looking at drug administration in the 14 days preceding the 
development of diarrhoea, NSAIDs usage was 3.72 (95% CIs: 3.06-4.51; 
p<0.001) times more likely in equids that had diarrhoea. Equids with 
diarrhoea were 2.74 times more likely to have received phenylbutazone 
(95%CIs: 2.16-3.48; p<0.001) and 3.16 (95%CIs: 2.18-4.59; p<0.001) times 
more likely to have received suxibuzone. Equids with diarrhoea were 3.13 
(95% CIs: 2.24-4.39; p<0.001) times more likely to have received flunixin 
meglumine. Equids with diarrhoea were 7.76 (95% CIs: 3.56-16.89; 
p<0.001) times more likely to have received metamizole, while equids 
with diarrhoea were 3.23 (95% CIs: 1.44-7.26; p=0.004) times more likely 
to have received meloxicam. The presence of diarrhoea was not 
significantly associated with the administration of ketoprofen (p=0.931) or 
firocoxib (p=0.953). 
 
Equids with diarrhoea were 2.67 (95% CIs: 2.18-3.26; p<0.001) times more 
likely to have received antimicrobials and 2.84 (95% CIs: 1.95-4.16; 
p<0.001) times more likely to have received corticosteroids and 3.5 (95 
CIs: 1.97-6.19; p<0.001) times more likely to have received systemic 
corticosteroids and 3.39 (95% CIs: 2.22-5.16; p<0.001) times more likely to 
have received anthelmintic drugs in the 2 weeks before the development 
of diarrhoea. 
 
Equids with diarrhoea were 4.18 (95% CIs: 3.37-5.17; p<0.001) times more 
likely to have received some NSAIDs in the seven days prior to the 
development of diarrhoea administration. Equids with diarrhoea were 3.25 
(95% CIs: 2.47-4.27; p<0.001) times more likely to have received 
phenylbutazone, 3.14 (95% CIs: 2.06-4.79; p<0.001) times more likely to 
have received suxibuzone, 3.64 (95% CIs: 2.50-5.30; p<0.001) times more 
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likely to have received flunixin meglumine, 11.59 (95% CIs: 4.48-29.98; 
p<0.001) times more likely to have received metamizole and 2.52 (95% 
CIs: 1.08-5.86; p=0.032) times more likely to have received meloxicam. 
There was no significant relationship between the administration of either 
ketoprofen (p=0.31) or firocoxib (p=0.953) in the week before 
development of diarrhoea and diarrhoea.  
 
Equids with diarrhoea were 2.85 (95% CIs: 2.29-3.56; p<0.001) times more 
likely to have received antimicrobials, 3.36 (95 CIs: 2.16-5.23; p<0.001) 
times more likely to have received corticosteroids, 3.54 (95 CIs: 1.90-6.62; 
p<0.001) times more likely to have received systemic corticosteroids and 
3.45 (95% CIs: 2.14-5.58; p<0.001) times more likely to have received 
anthelmintic drugs in the 2 weeks before the development of diarrhoea. 
Equids with diarrhoea were also 7.81 (95% CIs: 2.61-23.31 p<0.001) times 
more likely to have received a laxative and 7.26 (95% CIs: 4.08-12.93; 
p<0.001) times more likely to have received intravenous fluid therapy in 
the 2 days preceding the development of diarrhoea. These results are 
summarised in Table 5.4. 
 
 
Multivariable conditional logistic regression 
 
The best fitting model without inclusion of interaction terms included the 
following parameters (Table 5.5):  
i. Drugs dispensed two days before diarrhoea: intravenous fluids 
ii. Drugs dispensed seven days before diarrhoea: phenylbutazone, 
metamizole, corticosteroids 
iii. Drugs dispensed 14 days before diarrhoea: suxibuzone, 
antimicrobials, anthelmintic drugs. 
 
An interaction term between phenylbutazone and antimicrobials also 
improved model fit significantly and was therefore included. 
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Table 5.4: Univariable logistic regression of variables considered for the 
multivariable conditional logistic regression. The number of diarrhoea episodes and 
matched controls is 2589 each in the dataset from the United Kingdom. 
Treatment Days Total D C P-value OR 95% CIs 
NSAIDs 7 654 496 158 <0.001 3.80 3.10-4.63 14 794 583 211 <0.001 4.18 3.37-5.17 
        
Phenylbutazone 7 332 243 89 <0.001 2.90 2.25-3.73 14 419 293 126 <0.001 3.25 2.47-4.27 
        
Suxibuzone 7 133 97 35 <0.001 2.88 1.94-4.28 
14 170 125 45 <0.001 3.14 2.06-4.79 
        
Flunixin meglumine 
7 179 136 43 <0.001 3.45 2.40-4.95 
14 210 154 56 <0.001 3.64 2.50-5.30 
        
Metamizole 
7 54 49 5 <0.001 15.67 4.88-50.33 
14 61 53 8 0.032 11.59 4.48-29.98 
        
Meloxicam 7 30 21 9 0.033 2.33 1.07-5.09 14 36 27 9 <0.001 2.52 1.08-5.86 
        
Ketoprofen 7 5 5 0 0.991 1.08x10
7 0-Infinite 
14 5 5 0 0.310 2.87x105 0-Infinite 
        
Firocoxib 7 1 1 0 0.991 1.47x10
6 0-Infinite 
14 1 1 0 0.953 1.05x105 0-Infinite 
        
Antimicrobials 7 498 351 147 <0.001 2.77 2.24-3.43 14 611 421 190 <0.001 2.85 2.29-3.56 
        
Corticosteroids 7 122 91 31 <0.001 3.07 2.01-4.67 
14 158 113 45 <0.001 3.36 2.16-5.23 
        
Systemic 
corticosteroids 
7 62 47 15 <0.001 3.29 1.81-5.98 
14 74 56 18 <0.001 3.54 1.90-6.62 
        
Laxatives 2 35 31 4 <0.001 7.81 2.61-23.31 
        
Intravenous fluids 2 106 91 15 <0.001 7.26 4.08-12.93 
        
Anthelmintic drugs 7 105 79 26 <0.001 3.00 2.03-4.42 14 136 102 34 <0.001 3.45 2.14-5.58 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group; OR: odds ratio. 
 
Equids with diarrhoea were 2.75 (95% CIs: 1.86-4.07; p<0.001) times more 
likely to have received phenylbutazone in the preceding 7 days, 1.83 (95% 
CIs: 1.23-2.73; p=0.003) times more likely to have received suxibuzone in 
the preceding 14 days, 6.84 (95% CIs: 2.57-18.21; p<0.001) times more 
likely to have received metamizole in the preceding 7 days, 1.89 (95% CIs: 
1.47-2.39; p<0.001) times more likely to have received antimicrobials in 
the preceding 14 days, 1.89 (95% CIs: 1.18-3.02; p=0.008) times more 
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likely to have received corticosteroids in the preceding 7 days, 4.44 (95% 
CIs: 2.43-8.09; p<0.001) times more likely to have received intravenous 
fluids in the preceding 2 days and 2.20 (95% CIs: 1.41-3.41; p=0.001) times 
more likely to have received anthelmintic drugs in the preceding 14 days. 
Further the only significant interaction term tested was that between 
phenylbutazone and antimicrobials, as equids with diarrhoea were 2.44 
(95%CIs: 1.06-5.63; p=0.006) times more likely to have received both 
phenylbutazone and antimicrobials in the 7 and 14 days preceding 
diarrhoea respectively. 
 
Table 5.5: Multivariable conditional logistic regression model showing variables 
significantly associated with the risk of developing diarrhoea in the United Kingdom. 
The number of diarrhoea episodes and matched controls is 2589 each. 
Treatment Days Total D C P-value OR 95% CIs 
Phenylbutazone 7 332 243 89 <0.001 2.75 1.86-4.07 
Suxibuzone 14 170 125 45 0.003 1.83 1.23-2.73 
Metamizole 7 54 49 5 <0.001 6.84 2.57-18.21 
Antimicrobials 14 611 421 190 <0.001 1.87 1.47-2.39 
Corticosteroids 7 122 91 31 0.008 1.89 1.18-3.02 
Intravenous fluids 2 106 91 15 <0.001 4.44 2.43-8.09 
Anthelmintic drugs 14 136 102 34 0.001 2.20 1.41-3.41 
Phenylbutazone*Antimicrobials 7*14 169 124 45 0.006 2.44 1.06-5.63 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group; OR: odds ratio 
 
 
Other variables, such as flunixin meglumine (p=0.19), ketoprofen (p=0.93), 
meloxicam (p=0.58), firocoxib (p=0.96) and laxatives (p=0.054) were not 
significant at any time before diarrhoea and were not included in the final 
model. An interaction term between suxibuzone and antimicrobials was 
tested but found not to be significant (p=0.07). The interaction between 
metamizole and antimicrobials was significant (p=0.041) but improved the 
AIC by less than two units and therefore was not retained in the final 
model. An interaction term between phenylbutazone and suxibuzone was 
also tested and shown not to be significant (p=0.45).  
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5.2.3.11 Post-hoc analysis to account for co-morbidities 
 
The dataset of 141,543 animals included a total of 15,747 equids suffering 
at least one episode of abdominal discomfort at some point in the EMRs 
dataset with a total prevalence of 11.1% (95% CIs: 11.0-11.3%). In the 
diarrhoea dataset the number of equids suffering at least one episode of 
colic was 1,872 of which 1,151 (1236 episodes) were in the diarrhoea 
group and 721 (721 episodes) in the control group. 
 
The dataset of 141,543 animals included a total of 55,728 equids in the 
orthopaedic group with a total prevalence of 39.37% (95% CIs: 39.12-
39.63%). In the diarrhoea dataset the number of equids suffering at least 
one episode of orthopaedic disease was 3,470 of which 1,638 (1763 
episodes) were in the diarrhoea group and 1,832 (1832 episodes) in the 
control group. 
 
The best fitting multivariable conditional logistic regression model with 
co-morbidities included the following parameters (Table 5.6):  
i. Drugs dispensed two days before diarrhoea: intravenous fluids 
ii. Drugs dispensed seven days before diarrhoea: phenylbutazone 
iii. Drugs dispensed 14 days before diarrhoea: suxibuzone, 
antimicrobials, anthelmintic medications 
iv. Colic seven days before diarrhoea 
v. Orthopaedic disease seven days before diarrhoea 
vi. Orthopaedic disease at any point before 14 days before diarrhoea 
 
With the addition of colic and orthopaedic disease to the logistic 
regression analysis the effects of corticosteroids (p=0.06) and metamizole 
(0.1) became not significant in the post-hoc analysis. Further, in equids 
with diarrhoea the odds of having received phenylbutazone and 
intravenous fluids had decreased remarkably (>30%). Addition of colic at 
seven to 14 days before diarrhoea or any other time during the lifetime 
before that or orthopaedic disease at 14 days before diarrhoea did not 
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improve the AIC of the model significantly. Finally for equids with 
diarrhoea the odds of having received both phenylbutazone and 
antimicrobials had also dropped remarkably. The interaction term 
between antimicrobials and phenylbutazone did not improve the AIC 
significantly once colic and orthopaedic disease variables were added to 
the model and was therefore excluded from the final model. 
 
Table 5.6: Post-hoc multivariable conditional logistic regression model showing 
variables significantly associated with the risk of developing diarrhoea in the United 
Kingdom. The number of diarrhoea episodes and matched controls is 2589 each. 
Treatment Days Total D C P-value OR 95% CIs 
Phenylbutazone 7 332 243 89 0.001 1.64 1.21-2.24 
Suxibuzone 14 170 125 45 0.018 1.67 1.09-2.54 
Antimicrobials 14 611 421 190 <0.001 1.68 1.33-2.13 
Intravenous fluids 2 106 91 15 0.030 2.10 1.09-4.07 
Anthelmintic drugs 14 136 102 34 0.003 1.97 1.26-3.07 
Colic 7 855 714 141 <0.001 6.53 5.21-8.18 
Orthopaedic disease 7 1426 834 592 0.003 1.26 1.08-1.46 
Orthopaedic disease life 1981 871 1110 <0.001 0.62 0.54-0.71 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group; OR: odds ratio; life: orthopaedic disease at any point in life other than 14 
days before an episode of diarrhoea. 
 
5.2.4 Discussion 
 
This study presents several other interesting findings such as prevalence 
data, which were not within the main objective of the study. Prevalence 
of diarrhoea has not been reported before on such a large population in 
first opinion equine veterinary practice in the United Kingdom. Prevalence 
data is extracted from the EMRs stored in the PMSS and therefore is 
strictly influenced by veterinary surgeons commitment to record clinical 
data complete with details. The prevalence of diarrhoea reported in this 
study needs to be interpreted in light of the first opinion nature of the 
data. In the authors knowledge little data is available to compare disease 
prevalence between first opinion and referral equine practice. First 
opinion data is likely to include proportionally more cases of mild 
diarrhoea that require little clinical intervention, whilst referred cases are 
more likely to be a selection of more severe cases requiring more 
intensive management and treatment. Also the prevalence reported in this 
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study refers only to the prevalence of reported diarrhoea, so the actual 
prevalence of diarrhoea is likely to be higher. Reasons for not reporting 
diarrhoea might generally include mild, self-limiting episodes or cases 
with extreme financial limitations for which the owner would perceive 
that seeking veterinary advice would be too costly. Finally cases that 
suffered per-acute death could also have been missed, in which case a 
veterinary surgeon would have not been consulted. However, from a 
veterinary point of view the figure is interesting as it reflects the real 
prevalence of diarrhoea in equids under veterinary care. Another factor 
that might have contributed to underestimating diarrhoea prevalence is 
the definition of “diarrhoea episode” adopted for the study. It is possible 
that some equids could have had two episodes of diarrhoea from two 
different causes within 90 days. It is also important to point out that, 
while some animals with diarrhoea had multiple episodes recorded in the 
EMR the cut-off of 90 diarrhoea-free days between episodes was 
arbitrarily chosen to ensure that if a new episode was recorded this was 
unlikely to be a continuation of the previous episode. A shorter cut-off 
would have led to an overestimation of diarrhoea prevalence due to cases 
being examined more than once for the same disease process. While a 
patient might have chronic intermitted diarrhoea for several months, in 
such cases examinations would be expected to be more frequent than 
every three months. 
 
Other conditions, which might be consistent with NSAID toxicity, include 
renal failure and gastric ulceration. However, since these are not clinical 
signs per se, but rely on further testing to be identified (haematology and 
urinalysis and gastroscopy), the risk for under-diagnosis is high, 
particularly for mild cases and their detection would certainly be an 
underestimation of the true prevalence. Therefore these conditions were 
deemed not suitable for the purpose of this study. 
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The present study did not evaluate whether practice played an effect on 
the prevalence of diarrhoea and drug usage. Diarrhoea and control cases 
were matched by date and practice in order to minimise the effect of a 
local outbreak of certain conditions leading to diarrhoea that could have 
affected the results. Therefore no difference in practice of origin would 
have been present between diarrhoea and control patients. This could 
have accounted for the different ability of veterinary surgeons to identify 
and report certain conditions such as diarrhoea, colic and orthopaedic 
disease and also drug usage patterns. However, identification for 
veterinary surgeons was available only in two of the datasets from the 
United Kingdom. 
 
For a discussion on the prevalence of NSAID usage, colic and orthopaedic 
disease please refer to Chapter 4. 
 
This study also reports the prevalence of the use of several variables in 
the general population, as well as in equids with diarrhoea. The use of 
antimicrobials in about a quarter of the general equine population 
highlights that they are frequently used in equine practice and this figure 
is potentially alarming in light of the recent threat to public health posed 
by antimicrobial resistance (Weese et al., 2015). The present study did 
not evaluate the use of each antimicrobial category or the use of 
protected antimicrobials as this was beyond the scope of the study. 
Differentiation in each antimicrobial category would be complicated and 
time consuming. Although this could provide a useful insight into the 
relationship between different antimicrobial classes and diarrhoea, the 
current study was focused on NSAIDs and further differentiation of 
antimicrobials by class was not performed. 
 
The variable corticosteroids included all corticosteroids, which in equids 
mainly include those for intra-articular, inhaled or systemic 
administration. As intra-articular corticosteroids include a large proportion 
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of corticosteroids used in equine first opinion practice and their 
relationship with diarrhoea is currently unknown, a further variable 
including only systemic corticosteroids was created. From this data it 
appears that the systemic corticosteroids account for 57.1% of all 
corticosteroids used in our population.  
 
Data on the prevalence of use of laxatives is in line with the overall 
prevalence of colic as these drugs are likely to be used in a proportion of 
colic cases suffering from impactions. The prevalence of intravenous fluid 
administration includes all cases receiving fluids for the management of 
hypovolaemia or dehydration. However the prevalence of hypovolaemia or 
dehydration was not investigated in the study so its prevalence cannot be 
compared to that of intravenous fluid usage. 
 
Anthelmintic drugs are often administered to equids for treatment, as well 
as prevention of intestinal parasitic infections, which could result in 
diarrhoea. This study reported a relatively low prevalence of anthelmintic 
usage in the overall equine population (6.97%). It is important to highlight 
that in the United Kingdom anthelmintic drugs are POM-VPS drugs. This 
means that anthelmintic drugs can be purchased not only from veterinary 
surgeons but also from SPQs (“suitably qualified persons”) as defined in 
the Veterinary Medicine Regulations. This means that owners can purchase 
anthelmintic drugs from people other than a veterinary surgeon, which 
could result in a serious underestimation of their use. Undoubtedly, 
explanatory variables consisting of drugs that are not under the exclusive 
control of veterinary professional, pose a serious challenge to 
epidemiologic research, as there would be no reliable way to assess their 
actual usage. 
 
The results of this study support existing evidence that a significant 
relationship exists between administration of NSAIDs and development of 
diarrhoea in equine species. Conditional logistic regression analysis 
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confirms there was a statistically significant association between 
phenylbutazone, suxibuzone and metamizole administration and the 
development of diarrhoea. In the multivariable conditional logistic 
regression analysis, previous administration of flunixin meglumine, 
ketoprofen, meloxicam or firocoxib was not significantly associated with 
diarrhoea.  
 
The lack of relationship between diarrhoea and administration of flunixin 
meglumine in the multivariable logistic regression analysis was somewhat 
surprising. Previous studies, including the findings of Chapter 2 of this 
manuscript have suggested that flunixin meglumine induced profound 
inhibition of COX activity in horses and can affect gastrointestinal mucosal 
blood-flow and healing (Cook et al., 2009a; Duz et al., 2015). In theory, 
this might result in diarrhoea, particularly in cases where underlying 
gastrointestinal disease could contribute to diarrhoea development. The 
only NSAIDs licenced in the United Kingdom for treatment of abdominal 
discomfort include flunixin meglumine, ketoprofen, meloxicam and 
metamizole (in combination with the spasmolytic butylscopolamine). The 
findings of Chapter 4 showed that flunixin meglumine and metamizole, 
along with phenylbutazone, were the most commonly used for treatment 
of abdominal discomfort. As cases with colic are likely to suffer abdominal 
disease that may lead to diarrhoea, it was expected that at least some of 
these cases receiving flunixin meglumine might have then developed 
diarrhoea. The results of univariable logistic regression show that equids 
with diarrhoea are 3.64 times more likely to have received flunixin 
meglumine compared to control animals. Nevertheless multivariable 
conditional logistic regression analysis failed to identify a significant 
relationship between administration of flunixin meglumine and diarrhoea. 
The reason for this finding remains undetermined, but it is possible that 
the concomitant use of other drugs or treatments included in the 
multivariable analysis could have affected this finding. Flunixin meglumine 
is often used, along with other medications, to manage conditions such as 
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colic and orthopaedic disease. Some of these, including intravenous fluids, 
antimicrobials and corticosteroids, might have a greater effect on the 
development of diarrhoea thus explaining the lack of significance of 
flunixin meglumine in both multivariable logistic regression models. 
 
In the post-hoc analysis inclusion of colic and orthopaedic disease did not 
change the significance of the association of flunixin meglumine with the 
development of diarrhoea. These results suggest that, while in the 
univariable analysis equids with diarrhoea appear more likely to have 
received flunixin meglumine, other confounding factors, such as 
administration of other drugs or concurrent diseases processes including 
colic, are more likely determinants in cases of diarrhoea. The contribution 
of other factors not accounted for in this study, such as dosage of flunixin 
meglumine, route of administration and length of treatment also remain 
undetermined. However, from the results of this analysis it appears that 
this drug might be relatively safe, assuming it is used at label doses. More 
data is necessary including that of dose used and course length to actually 
confirm that veterinary surgeons and owners keep within the 
recommended dose regimens. 
 
The odds for drug administration preceding an episode of diarrhoea were 
by far the highest with metamizole but the effect of this drug became 
non-significant once the co-morbidity of colic was included in the analysis. 
Similarly the inclusion of colic to the multivariable analysis affected 
negatively the odds ratio of phenylbutazone. However, this was to a lesser 
extent than metamizole, as phenylbutazone was used for a wide array of 
conditions and not only for colic. These results highlight the confounding 
effect that the variable colic had on other variables such as 
phenylbutazone and metamizole. This effect is the consequence of the 
fact that these variables are not entirely independent as these drugs are 
often used for the management of this condition as shown in Chapter 4. 
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The fact that in the multivariable conditional logistic regression analysis 
there was no significant relationship between diarrhoea and previous 
administration of ketoprofen, meloxicam and firocoxib is not surprising, as 
only a few animals in the dataset had received these drugs, so the 
statistical power to identify such an association, if it exists, would be 
limited in this study. Similarly, no significant relationship was present in 
the univariable conditional logistic regression analysis for ketoprofen and 
firocoxib. While the effect of meloxicam appeared significant in the 
univariable conditional logistic regression analysis, the effect of this small 
group was likely diluted in the multivariable logistic regression analysis 
and became then non-significant. Similar to flunixin meglumine, 
meloxicam is often used along with other medications, which might act as 
a confounding effect and have a greater effect on the development of 
diarrhoea. 
 
In first opinion equine practice, antimicrobials are often administered in 
combination with NSAIDs, to treat bacterial infections and the associated 
inflammatory response. Since both classes of drugs have been well 
documented to induce diarrhoea in equids it seemed appropriate to 
include antimicrobials in the model and to investigate a possible 
interaction with NSAIDs. However, a significant interaction term was only 
identified between phenylbutazone and antimicrobials, suggesting that 
equids with diarrhoea were 2.4 times more likely to have been 
administered this drug combination. The odds ratio of the interaction 
term indicates that combination of phenylbutazone and antimicrobials 
worsens slightly the odds for development of diarrhoea than if 
antimicrobials were administered alone, while the odds for both drugs 
being administered together being associated with diarrhoea is lower than 
if phenylbutazone was used alone. However, this interaction term had to 
be dropped once colic and orthopaedic disease were accounted for in the 
post-hoc model. 
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Orthopaedic disease was also added to the model because affected 
patients often received NSAIDs as part of the management. Moreover, 
orthopaedic disease is unlikely to have any effect on the gastrointestinal 
tract and therefore orthopaedic patients might represent a selection of 
the overall population that is at a normal risk of developing diarrhoea. 
Interestingly orthopaedic procedures were 1.3 times more likely to have 
been carried out in the week preceding diarrhoea in this first opinion 
population. The reason for this remains undetermined, but could be 
related to the stress of being generally unwell or undergoing a veterinary 
lameness investigation. Horses with diarrhoea were 0.6 times as likely to 
have undergone an orthopaedic investigation at some point in life before 
the two weeks prior to diarrhoea. 
 
The confounding effect on diarrhoea of underlying gastrointestinal 
disease, was somewhat accounted for by the colic variable. A colic 
episode was 6.5 times more likely in the week preceding the development 
of diarrhoea in a patient that then went on to develop diarrhoea than in 
one that did not. This demonstrated that diarrhoea is more likely in equids 
that have suffered gastrointestinal disease from infectious, inflammatory, 
ischaemic or dietary cause, manifested as abdominal discomfort, as all are 
known potential causes of colic in equids.  
 
It was also somewhat surprising that no significant interaction was present 
between colic and NSAIDs administration since NSAIDs might reduce blood 
flow to the intestine, which might result in mucosal damage and 
diarrhoea, particularly if other concurrent gastrointestinal disease is 
present.  
 
A significant relationship existed between corticosteroid administration 
and diarrhoea both in the single as well as multivariable conditional 
logistic regression analyses. Corticosteroids are often used intra-articular 
in equids to modulate inflammation associated with arthritis. But these 
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became non-significant with the addition of other co-morbidities, such as 
orthopaedic disease. Further, corticosteroid administration is not a 
common cause of diarrhoea at label doses in equids. In fact 
dexamethasone treatment is often warranted in cases of diarrhoea 
associated with cyathostomiasis as well as infiltrative bowel disease (Barr, 
2006). The effect of corticosteroids became not significant once 
comorbidities such as orthopaedic disease were added to the analysis so 
the variable was dropped by the final model. 
 
The time elapsed between the date of data entry in the EMR, 
corresponding to the drugs being dispensed, and the actual length of 
treatment was summarily accounted for by the use of the seven or 14 days 
period. The explanatory variables evaluated in this study include drugs 
administered or dispensed zero to seven and seven to 14 days prior to the 
development of diarrhoea. The use of either the seven or 14 days cut-off 
was determined on the basis of clinical relevance, AIC and significance in 
the model. Other variables such as laxatives and intravenous fluids were 
included only when administered up to two days before the development 
of diarrhoea. The two-day period for intravenous fluid and laxative 
administration was chosen because both treatments would be expected to 
affect faecal consistency within 48 hours of administration. Further, both 
treatments are usually administered directly by the veterinary surgeon on 
a single administration and therefore the date of data entry in records 
likely reflects the actual date of administration. This differs from the 
other explanatory variables, which include drugs often dispensed for 
administration by the owner over multiple days, hence evaluating 
generally a period of one to two weeks from the data being entered in the 
PMSS. For this reason no continuous variable was created to document the 
number of days between drug administration and development of 
diarrhoea. In fact, having included the number of days this would likely 
reflect the days between the drug being sold and the diarrhoea being 
noticed, with no information on treatment regimen.  
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It is important to point out that the findings of this study are applicable to 
a first opinion population and the findings do not apply to a referral 
population. First opinion cases vary more in the severity of the condition 
than referral cases, as cases are usually referred if they require more 
intensive management and exhaustive investigations. Therefore in a first 
opinion caseload, many cases might be very mild. Owner perception of 
disease severity might vary significantly and also plays a major role in the 
type of cases included.  
 
Extraction of data regarding drug dosages and length of course of 
administration recommended is problematic and time consuming if at all 
achievable from free-text EMRs and was not performed in this study. This 
is a significant shortcoming of the study, as reliable information on doses 
as well as length of course of treatment prior to the development of 
diarrhoea could improve model fit as well as clinical relevance of the 
results substantially. 
 
The post-hoc analysis was performed to further investigate some of the 
findings of the initial analysis. For example, while phenylbutazone is 
widely used to treat visceral pain in the horse in the United Kingdom, this 
use is off-label. Further, phenylbutazone and suxibuzone are also widely 
used to manage pain associated with the musculoskeletal system. 
Therefore, addition of colic and orthopaedic disease to the multivariable 
logistic regression model could have clarified further the relationship 
between diarrhoea and usage of these drugs. 
 
In conclusion, it appears from the analysis of the data that while a 
significant relationship exists between diarrhoea and NSAID 
administration, the overall risk appears in fact to be very low. The data 
was obtained from a real population where veterinary clinicians are 
generally aware of the risk of side effects related to the use of this drug 
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and therefore are likely to judiciously observe label doses. Further work is 
required to assess whether label doses are observed in equine practice. 
 
5.3 NSAID toxicity in North America 
 
5.3.1 Introduction 
 
The prevalence of toxicity related to NSAID administration is unknown in 
the North America. The clinical studies that describe NSAID toxicity that 
are from North America include only a total of 8 cases from 2 academic 
institutions collected over a period of years (Cohen et al., 1995; Jones et 
al., 2003). Even though the frequency of case reports in the peer reviewed 
literature is hardly a representative estimate of the true prevalence of 
disease, the rarity of these reports suggests that recognised clinically 
significant toxicity might be rare.  
 
Toxicity from NSAIDs usage might manifest clinically as diarrhoea, gastric 
ulceration and renal disease. While diarrhoea is a clinical sign relatively 
easy to detect, gastric ulceration and renal disease, which are not clinical 
signs but a diagnosis, rely on further testing to be identified (Sanchez, 
2010). Therefore the risk for under-diagnosing is high in first opinion 
settings and their detection would certainly be an underestimation of the 
true prevalence. For this reason identifying these conditions to determine 
the prevalence of side effects from NSAIDs usage is not ideal. 
 
The aims of this study are the same as those in section 5.2, but applied to 
the data from North America described in Chapter 3. These briefly include 
describing the prevalence of diarrhoea and documenting whether a 
relationship exists between diarrhoea and the administration of drugs 
commonly used in equine practice.  
 
 
		
194	
	
5.3.2 Materials and methods 
 
5.3.2.1 Prevalence of reported non-steroidal anti-inflammatory drug 
toxicity 
 
The dataset of EMR from first opinion equine practice in North America, 
described in Chapter 3 was used. The dataset of EMRs from 312,634 
animals (between 1994 and 2013; 11,699,875 rows of data) was analysed 
with the methods described in detail in Chapter 3. Briefly, the list of the 
words included in the dataset was used to identify terms that might 
identify NSAID toxicity, including also cases where toxicity was suspected 
but not necessarily confirmed. 
 
5.3.2.2 Diarrhoea and control population 
 
Like in section 5.2.2, diarrhoea was defined as a case where faeces had 
such decreased consistency as to worry an owner enough to seek 
veterinary advice and also to warrant it being mentioned in the EMR by 
the attending clinician. Different cut-offs in number of days from a 
previous episode were evaluated at 90 and 180 days to define a case of 
diarrhoea as a “new case”. 
 
Analysis was performed on the dataset from North America, after removal 
of cases for which the date of data input was considered unreliable as 
instructed by the PMSS Company. This was the case when data was 
imported to the current system directly from the previous incompatible 
PMSS. A diarrhoea dataset, including cases of diarrhoea and animals 
matched by practice and date from North America was created with the 
same methodology described in section 5.2.2.2. 
 
A control population was selected at random from those horses matching 
each diarrhoea episode by date and practice for which diarrhoea was 
never mentioned in the EMR. Control equids were also picked from the 
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same practice and also if they received an examination on the same date 
of the episode of diarrhoea. Where no equid was examined on the same 
date of the diarrhoea episode, a case with the closest date available was 
chosen. For each episode of diarrhoea, even if from an equid that had 
multiple episodes, a new control subject was selected so that the number 
of control equids matched exactly the number of episodes of diarrhoea. 
 
5.3.2.3 Diarrhoea prevalence determination 
 
The prevalence estimate for diarrhoea and relative confidence intervals 
on the dataset from North America were calculated using the methodology 
described in section 5.2.2.3.  
 
The prevalence for first opinion and referral caseloads was also assessed, 
using the possession of specialist qualifications as the criteria to 
differentiate first opinion and referral cases. 
 
5.3.2.4 Explanatory variable: non-steroidal anti-inflammatory drugs 
 
All cases from North America receiving NSAIDs were identified in R with 
the methods described in Chapter 4. Instances of drug administration 
contemporary to recorded clinical signs of diarrhoea were identified with 
the same methodology described in section 5.2.2.4. For the data from 
North America this was obtained for all NSAIDs together and was 
subsequently looked at more specifically for 3 particular drugs: flunixin 
meglumine, phenylbutazone and firocoxib. Ultimately 8 binary variables 
(“true” or “false” depending on whether use of the drug was recorded) 
were created to describe if usage of NSAIDs as a whole, flunixin 
meglumine, phenylbutazone and firocoxib was recorded within 14 or 7 
days prior to the development of diarrhoea for the data from North 
America. Contemporary drug administration in the matched control 
animals was also identified. 
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5.3.2.5 Explanatory variable: Antimicrobials 
 
With the same methodology described in section 5.2.2.5, 2 binary 
variables were created depending on whether use of antimicrobials was 
recorded within 14 or 7 days prior to the development of diarrhoea in the 
data from North America. Contemporary drug administration in the 
matched control animals was also identified. 
 
5.3.2.6 Explanatory variable: Corticosteroids 
 
Using the same methodology as in section 5.2.2.6, 4 binary variables were 
created depending on whether use of corticosteroids, systemic 
corticosteroids and corticosteroids as a whole, was recorded within 14 or 7 
days prior to the development of diarrhoea in the dataset from North 
America. Contemporary drug administration in the matched control 
animals was also identified. 
 
5.3.2.7 Explanatory variable: Laxatives 
 
Using the same methodology as in section 5.2.2.7, one binary variable was 
created when administration of a laxative treatment was recorded within 
the 48 hours prior to the development of diarrhoea in the dataset from 
North America. Contemporary drug administration in the matched control 
animals was also identified. 
 
5.3.2.8 Explanatory variable: Intravenous fluids 
 
Using the same methodology as in section 5.2.2.8, one binary variable was 
created when intravenous fluid administration was recorded within the 48 
hours prior to diarrhoea development in the dataset from North America. 
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Contemporary drug administration in the matched control animals was 
also identified. 
 
5.3.2.9 Explanatory variable: Anthelmintic drugs 
 
Using the same methodology as in section 5.2.2.9, 2 binary variables were 
created depending on whether use of anthelmintic drugs was recorded 
within 14 or 7 days prior to the development of diarrhoea in the dataset 
from North America. Contemporary drug administration in the matched 
control animals was also identified. 
 
5.3.2.10 Statistical analysis 
 
Data analysis was repeated on the data from North America following the 
methodology described in depth in section 5.2.2.10. 
 
5.3.2.11 Post-hoc analysis to account for comorbidities 
 
Similar to section 5.2.2.11, the effect of comorbidities was evaluated 
post-hoc to further explain some of the findings of the initial analysis and 
account for the possible confounding effect of comorbidities such as colic 
and orthopaedic disease. These were used to identify patients suspected, 
investigated or treated for abdominal discomfort or an orthopaedic 
condition in zero to seven days or seven to 14 days, or at any other point 
in the EMRs, preceding the development of diarrhoea. These variables 
were mutually exclusive. Conditional logistic regression was then used to 
evaluate whether inclusion of one or both comorbidities altered the 
statistical significance and odd ratios of variables included in the model. 
 
Inclusion, exclusion and re-inclusion dictionaries used for the analysis are 
available in Appendix 5. 
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The study was approved by Ethics and Welfare Committee of the School of 
Veterinary Medicine at the University of Glasgow. 
 
5.3.3 Results 
 
5.3.3.1 Prevalence of reported non-steroidal anti-inflammatory drugs 
toxicity 
 
Of the total of 11,699,875 rows of data from 312,634 equids from North 
America, NSAID toxicity was suspected or diagnosed in only 19 animals. 
The demographic details of the population in this dataset are described in 
Chapter 3. The overall prevalence of NSAID toxicity in this population from 
North America was therefore 0.007% (95% CIs: 0.00-0.01%). 
 
5.3.3.2 Diarrhoea and Control population 
 
The overall dataset from North America included records from 312,634 
equids, which were then narrowed down to a total of 225,777 equids with 
a reliable date of data entry to the PMSS between 1998 and 2013 
(10,483,807 rows of data). 
 
A 90 day cut-off was arbitrarily based on the expert opinion of the author. 
Interestingly a longer cut-off (e.g. 6 months) would have decreased the 
number of diarrhoea episodes by approximately 1% and the overall 
diarrhoea prevalence by 0.3%.  
 
The dataset with valid dates included a total 4741 equids that suffered at 
least one episode of diarrhoea for a total of 5122 episodes of diarrhoea. 
Of these, 4430 had reported a single episode of diarrhoea, 259 reported 2 
episodes, 38 reported 3 episodes, 12 reported 4 episodes and the 
remaining 2 equids reported 5 and 7 episodes respectively. The mean age 
of the population that suffered diarrhoea was 10.4 years (median 9 years, 
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range: 0-40 years), while age was not available for 454 equids. All cases 
were equids from a total of 265 breeds or crosses. Diarrhoea was reported 
in 1991 females and 2671 males of which 2208 were geldings, 462 entire 
males and 1 was recorded simply as male. Gender had not been recorded 
in 460 equids with diarrhoea. 
 
The control population included a total of 5122 equids and no control 
animal appeared more than once in the dataset. The mean age of the 
control population was 11.0 years (median 10 years, range: 0-40 years), 
while age was not available for 982 animals. All cases were equids from a 
total of 282 breeds or crosses. Control equids included 1843 females and 
2346 males of which 2132 were geldings, 212 entire males and 2 were 
recorded simply as male. Gender had not been recorded in 982 equids. 
 
The dataset including all cases with diarrhoea and their matched control is 
from now on referred to as the “diarrhoea dataset” and included a total of 
9863 equids, 4741 that suffered at least one episode of diarrhoea and 5122 
equids that never had diarrhoea reported in the records. 
 
5.3.3.3 Diarrhoea prevalence determination 
 
A total of 4741 equids from the population of 225,777 individuals with a 
valid date of data entry suffered at least one episode of diarrhoea severe 
enough to be mentioned in the EMR (diarrhoea prevalence: 2.10%; 95% CIs: 
2.04-2.16%). 
 
Using possession of a specialist diploma to differentiate first opinion from 
referral caseload, the dataset included 211,614 equids from the first 
opinion population from which 5058 episodes of diarrhoea were detected 
from 4682 equids, with a prevalence estimate of reported diarrhoea in 
first opinion practice of 2.39% (95% CIs: 2.33-2.46%). The referral 
population included a total of 51,111 equids with 64 episodes of diarrhoea 
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from only 63 equids (prevalence 0.13% - 95% CIs: 0.09-0.16%). The data to 
differentiate first opinion and referral caseloads was not considered 
reliable and not included in the following analysis. 
 
5.3.3.4 Explanatory variable: non-steroidal anti-inflammatory drugs 
 
Of the 225,777 that had valid dates recorded, administration of NSAIDs 
was recorded at least once in 90,886 equids, with a calculated prevalence 
of NSAIDs usage of 40.25% (95% CIs: 40.05-40.46%).  
 
A total of 2596 animals, out of the total of 9862 equids in the diarrhoea 
dataset from North America, received NSAIDs in the preceding 14 days. Of 
these, 1608 were from the diarrhoea group and 988 were from the control 
group. The overall prevalence of NSAID usage in the 14 days preceding the 
development of diarrhoea was 33.92% (CIs: 32.58-35.28%), while in the 
control group this was 19.29% (95% CIs: 18.23-20.39%).  
 
The prevalence of NSAIDs usage within 14 days of the ‘case date’ was 
33.92% (1608 animals; 95% CIs: 32.58-35.28%) in equids with diarrhoea and 
19.29% (988 animals; 95% CIs: 18.23-20.39%) in equids in the control 
group. The prevalence of phenylbutazone usage within 14 days of the 
‘case date’ was 9.98% (473 animals; 95% CIs: 9.16-10.86%) in equids with 
diarrhoea and 11.32% (580 animals; 95% CIs: 10.48-12.22%) in equids in the 
control group. The prevalence of flunixin meglumine usage within 14 days 
of the ‘case date’ was 26.62% (1262 animals; 95% CIs: 25.38-27.90%) in 
equids with diarrhoea and 10.39% (532 animals; 95% CIs: 9.58-11.25%) in 
equids in the control group. The prevalence of firocoxib usage within 14 
days of the ‘case date’ was 1.48% (74 animals; 95% CIs: 1.17-1.86%) in 
equids with diarrhoea and 1.44% (74 animals; 95% CIs: 1.15-1.81%) in 
equids in the control group.  
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The prevalence of NSAIDs usage within 7 days of the ‘case date’ was 
31.51% (1494 animals; 95% CIs: 30.21-32.85%) in equids with diarrhoea and 
15.13% (775 animals; 95% CIs: 14.18-16.14%) in equids in the control 
group. The prevalence of phenylbutazone usage within 7 days of the ‘case 
date’ was 8.46% (401 animals; 95% CIs: 7.70-9.28%) in equids with 
diarrhoea and 8.77% (449 animals; 95% CIs: 8.02-9.57%) in equids in the 
control group. The prevalence of flunixin meglumine usage within 7 days 
of the ‘case date’ was 25.06% (1188 animals; 95% CIs: 23.84-26.31%) in 
equids with diarrhoea and 7.91% (405 animals; 95% CIs: 7.20-8.68%) in 
equids in the control group. The prevalence of firocoxib usage within 7 
days of the ‘case date’ was 1.24% (59 animals; 95% CIs: 0.97-1.60%) in 
equids with diarrhoea and 0.82% (42 animals; 95% CIs: 0.61-1.11%) in 
equids in the control group. 
 
Results of prevalence of drug usage are summarised in Table 5.7. 
 
Table 5.7: Prevalence of NSAIDs usage 14 and 7 days before a ‘case date’ from 4741 
equids from North America that suffered 5122 episodes of diarrhoea and 5122 
control equids that never had diarrhoea. 
Drug Days Total D Prevalence (95% CIs) C Prevalence (95% CIs) 
NSAIDs 14 2596 1608 33.92 (32.58-35.28) 988 19.29 (18.23-20.39) 7 2269 1494 31.51 (30.21-32.85) 775 15.13 (14.18-16.14) 
       
Phenylbutazone 14 1053 473 9.98 (9.16-10.86) 580 11.32 (10.48-12.22) 7 850 401 8.46 (7.7-9.28) 449 8.77 (8.02-9.57) 
       
Flunixin 
meglumine 
14 1794 1262 26.62 (25.38-27.9) 532 10.39 (9.58-11.25) 
7 1593 1188 25.06 (23.84-26.31) 405 7.91 (7.2-8.68) 
       
Firocoxib 14 144 70 1.48 (1.17-1.86) 74 1.44 (1.15-1.81) 7 101 59 1.24 (0.97-1.6) 42 0.82 (0.61-1.11) 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group; OR: odds ratio. 
 
5.3.3.5 Explanatory variable: Antimicrobials 
 
Of the total of 312,634 animals administration of antimicrobials was 
recorded at least once in the EMR of 79,301 patients with a prevalence for 
antimicrobial usage of 25.37% (95% CIs: 25.22-25.52%). Of the 225,777 that 
		
202	
	
had valid dates recorded, administration of antimicrobial was recorded in 
61,644 equids with a prevalence of 27.30% (95% CIs: 27.12-27.49%).  
 
A total of 1797 animals, out of the total of 9862 equids in the diarrhoea 
dataset, received antimicrobials in this timeframe with an overall 
prevalence of 18.22% (95% CIs: 17.47-19.00%). The prevalence of 
antimicrobial usage within 14 days of the ‘case date’ was 24.80% (1176 
animals; 95% CIs: 23.60-26.05%) in equids with diarrhoea and 12.12% (621 
animals; 95% CIs: 11.26-13.05%) in equids in the control group.  
 
In the 7 days before the reference date, a total of 1610 equids received 
antimicrobials with an overall prevalence of 16.33% (95% CIs: 15.61-
17.07%) in this week period. The prevalence of antimicrobial usage within 
7 days of the ‘case date’ was 23.14% (1097 animals; 95% CIs: 21.96-
24.36%) in equids with diarrhoea and 10.02% (513 animals; 95% CIs: 9.22-
10.87%) in equids in the control group. 
 
5.3.3.6 Explanatory variable: Corticosteroids 
 
Of the total of 312,634 animals administration of corticosteroids was 
recorded at least once in the EMR of 75,391 patients with a prevalence for 
corticosteroids usage of 24.12% (95% CIs: 23.97-24.27%). Of the 225,777 
that had valid dates recorded administration was recorded in 57,521 
equids with a prevalence of corticosteroid usage of 25.48% (95% CIs: 
25.30-25.66%).  
 
A total of 730 animals, out of the total of 9862 equids in the diarrhoea 
dataset, received corticosteroids in the 14 days preceding the ‘case date’ 
with an overall prevalence of 7.40% (95% CIs: 6.90-7.94%). 
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The prevalence of corticosteroids usage within 14 days of the ‘case date’ 
was 6.12% (290 animals; 95% CIs: 5.47-6.84%) in equids with diarrhoea and 
8.59% (440 animals; 95% CIs: 7.85-9.39%) in equids in the control group.  
 
In the 7 days before the reference date, a total of 535 equids received 
corticosteroid with an overall prevalence of 5.42% (95% CIs: 4.99-5.89%). 
The prevalence of corticosteroid usage within 7 days of the ‘case date’ 
was 4.64% (220 animals; 95% CIs: 4.08-5.28%) in equids with diarrhoea and 
6.15% (315 animals; 95% CIs: 5.52-6.84%) in equids in the control group. 
 
When looking specifically at usage of systemic corticosteroid 
(dexamethasone, prednisolone, prednisone), the prevalence over the total 
population of 312,634 equids was 14.65% (95% CIs: 15.52-14.77%) and in 
the subpopulation of 225,777 animals the prevalence was 15.40% (95% CIs: 
15.25-15.55%), with a total number of treated animals of 45,792 and 
34,772 respectively. 
 
In the 14 days period preceding the reference date, a total of 475 equids 
received corticosteroids systemically with an overall prevalence of 4.82% 
(95% CIs: 4.41-5.26%). The prevalence of systemic corticosteroids usage 
within 14 days of the ‘case date’ was 4.35% (206 animals; 95% CIs: 3.80-
4.96%) in equids with diarrhoea and 5.25% (269 animals; 95% CIs: 4.67-
5.90%) in equids in the control group. 
 
In the 7 days before the reference date, a total of 356 equids received 
corticosteroids systemically with an overall prevalence of 3.61% (95% CIs: 
3.26-3.40%) in this timeframe. The prevalence of corticosteroids usage 
within 7 days of the ‘case date’ was 3.40% (161 animals; 95% CIs: 2.92-
3.95%) in equids with diarrhoea and 3.81% (195 animals; 95% CIs: 3.32-
4.37%) in equids in the control group. 
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5.3.3.7 Explanatory variable: Laxatives 
 
Of the total of 312,634 animals administration of laxatives was recorded 
at least once in the EMR of 20,572 patients with a prevalence for laxative 
usage of 6.58% (95% CIs: 6.49-6.67%). Of the 225,777 that had valid dates 
recorded administration of laxatives was recorded in 16,925 equids with a 
prevalence of 7.50% (95% CIs: 7.39-7.61%).  
 
In the diarrhoea dataset laxative treatment was included if administered 
in the 2 days preceding the reporting of diarrhoea. A total of 538 animals, 
out of the total of 9862 equids in the diarrhoea dataset, received at least 
one laxative treatment in this timeframe with an overall prevalence of 
5.46% (95% CIs: 5.02-5.92%). The prevalence of laxative treatment within 
2 days of the ‘case date’ was 10.08% (478 animals; 95% CIs: 9.26-10.97%) 
in equids with diarrhoea and 1.17% (60 animals; 95% CIs: 0.91-1.50%) in 
equids in the control group. 
 
5.3.3.8 Explanatory variable: Intravenous fluids 
 
Of the total of 312,634 animals administration of intravenous fluids was 
recorded at least once in the EMR of 26,642 patients with a prevalence of 
fluid administration intravenously of 8.52% (95% CIs: 8.43-8.62%). Of the 
225,777 that had valid dates recorded administration of fluids parenterally 
was recorded in 24,090 equids with a prevalence of 10.67% (95% CIs: 
10.54-10.80%).  
 
In the diarrhoea dataset intravenous fluid administration was included if it 
occurred in the 2 days preceding the reporting of diarrhoea. A total of 642 
animals, out of the total of 9862 equids in the diarrhoea dataset, received 
fluid intravenously in this timeframe with an overall prevalence of 6.51% 
(95% CIs: 6.04-7.01%). The prevalence of intravenous fluids administration 
in the 2 days preceding the ‘case date’ was 10.80% (512 animals; 95% CIs: 
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9.95-11.71%) in equids with diarrhoea and 2.54% (130 animals; 95% CIs: 
2.14-3.01%) in equids in the control group. 
 
5.3.3.9 Explanatory variable: Anthelmintic drugs 
 
Of the total of 312,634 animals administration of anthelmintic drugs was 
recorded at least once in the EMR of 45,368 patients with a prevalence for 
anthelmintic drug usage of 14.51% (95% CIs: 14.39-14.64%). Of the 225,777 
for which the date was valid, administration of anthelmintic drug was 
recorded in 31,998 equids with a prevalence of 14.17% (95% CIs: 14.03-
14.32%).  
 
A total of 246 animals, out of the total of 9862 equids in the diarrhoea 
dataset, received anthelmintics in this timeframe with an overall 
prevalence of 2.49% (95% CIs: 2.20-2.82%). The prevalence of anthelmintic 
usage within 14 days of the ‘case date’ was 2.19% (140 animals; 95% CIs: 
1.81-2.65%) in equids with diarrhoea and 2.77% (142 animals; 95% CIs: 
2.36-3.26%) in equids in the control group.  
 
In the 7 days before the reference date, a total of 1153 equids received 
anthelmintic with an overall prevalence of 1.55% (95% CIs: 1.33-1.81%). 
The prevalence of anthelmintic usage within 7 days of the ‘case date’ was 
1.62% (77 animals; 95% CIs: 1.30-2.03%) in equids with diarrhoea and 1.48% 
(76 animals; 95% CIs: 1.19-1.85%) in equids in the control group. 
 
 
Table 5.8: Prevalence of drug usage in 225,777 equids from North America. The 
data reflects usage of each drug at some point in the animal EMR. 
Drug Equids Prevalence (%) 95% CIs (%) 
Antimicrobials 61644 27.30 27.12-27.49 
Corticosteroids 57,521 25.48 25.30-25.66 
Systemic 
corticosteroids 34,772 15.40 15.25-15.55 
Laxatives 16,925 7.50 7.39-7.61 
Intravenous fluids 24,090 10.67 10.54-10.80 
Anthelmintic drugs 31,998 14.17 14.03-14.32 
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Prevalence data for drug usage is summarised in Table 5.8. Prevalence 
data on drug usage in the diarrhoea dataset is summarised in Table 5.9. 
 
 
Table 5.9: Prevalence of drug usage 14 and 7 days before a ‘case date’ from 4741 
equids from North America that suffered 5122 episodes of diarrhoea and 5122 
control equids that never had diarrhoea. 
Drug Days Total D Prevalence (95% CIs) C Prevalence (95% CIs) 
Antimicrobials 14 1797 1176 24.8 (23.6-26.05) 621 12.12 (11.26-13.05) 7 1610 1097 10.02 (9.22-10.87) 513 10.8 (9.95-11.71) 
       
Corticosteroids 14 730 290 6.12 (5.47-6.84) 440 8.59 (7.85-9.39) 7 535 220 4.64 (4.08-5.28) 315 6.15 (5.52-6.84) 
       
Systemic 
corticosteroids 
14 475 206 4.35 (3.8-4.96) 269 5.25 (4.67-5.9) 
7 356 161 3.4 (2.92-3.95) 195 3.81 (3.32-4.37) 
       
Laxatives 2 538 478 10.08 (9.26-10.97) 60 1.17 (0.91-1.5) 
       
Intravenous fluids 2 642 512 10.8 (9.95-11.71) 130 2.54 (2.14-3.01) 
       
Anthelmintic 
drugs 
14 246 104 2.19 (1.81-2.65) 142 2.77 (2.36-3.26) 
7 153 77 1.62 (1.3-2.03) 76 1.48 (1.19-1.85) 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group. 
 
5.3.3.10 Statistical analysis 
 
Univariable logistic regression 
 
When looking at drug administration in the 14 days preceding the 
development of diarrhoea, development of diarrhoea was 2.04 (95% CIs: 
1.84-2.26; p<0.001) times more likely with NSAIDs administration. 
Diarrhoea was 0.78 times as likely with phenylbutazone administration 
(95%CIs: 0.68-0.90; p<0.001). Equids with diarrhoea were 3.13 (95% CIs: 
2.76-3.555; p<0.001) times more likely to have received flunixin 
meglumine. The presence of diarrhoea was not significantly associated 
with the administration of firocoxib (p=0.737). Diarrhoea was 0.52 
(95%CIs: 0.35-0.75; p<0.001) times as likely with administration of 
ketoprofen. 
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Diarrhoea was 2.34 (95% CIs: 2.07-2.63; p<0.001) times more likely with 
antimicrobial administration. Diarrhoea was 0.61 (95 CIs: 0.52-0.72; 
p<0.001) times as likely with corticosteroids administration, 0.73 (95 CIs: 
0.60-0.90; p=0.003) times as likely with systemic corticosteroids and 0.7 
(95% CIs: 0.53-0.92; p=0.012) times as likely with the administration of 
anthelmintic drugs. 
 
When looking at drug administration in the 7 days preceding the 
development of diarrhoea, development of diarrhoea was 2.51 (95% CIs: 
2.25-2.80; p<0.001) times more likely with NSAIDs administration. Equids 
with diarrhoea were 3.98 (95% CIs: 3.46-4.56; p<0.001) times more likely 
to have received flunixin meglumine. There was no significant relationship 
between the administration of either phenylbutazone (p=0.08) or firocoxib 
(p=0.09) in the week before development of diarrhoea. Equids with 
diarrhoea were 0.58 (95% CIs: 0.38-0.87; p=0.009) times as likely to have 
received ketoprofen than control animals. Equids with diarrhoea were 
2.68 (95% CIs: 2.36-3.05, p<0.001) times more likely to have received 
antimicrobials than controls in the 7 days preceding the development of 
diarrhoea. Diarrhoea was 0.66 (95% CIs: 0.54-0.80; p<0.001) times as likely 
following corticosteroid administration. There was no significant 
relationship between development of diarrhoea and administration of 
either systemic corticosteroids (p=0.07) or anthelmintic treatment (p=0.9) 
in this 7-day period. 
 
Diarrhoea was significantly more likely with administration of laxatives 
(OR: 10.18; 95% CIs: 7.64-13.57; p<0.001) and intravenous fluid therapy 
(OR: 4.89; 95% CIs: 3.94-6.06; p<0.001) in the previous 2 days. 
 
Univariable logistic regression results are summarised in Table 5.10. 
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Table 5.10: Univariable logistic regression of variables considered for the 
multivariable conditional logistic regression. The dataset includes 4741 equids from 
North America that suffered 5122 episodes of diarrhoea and 5122 control equids 
that never had diarrhoea 
Treatment Days Total D C P-value OR 95% CIs 
NSAIDs 
14 2596 1608 988 <0.001 2.04 1.84-2.26 
7 2269 1494 775 <0.001 2.51 2.25-2.80 
        
Phenylbutazone 
14 1053 473 580 <0.001 0.78 0.69-0.90 
7 850 401 449 0.08 0.97 0.93-1.01 
        
Flunixin meglumine 
14 1794 1262 532 <0.001 3.13 2.76-3.55 
7 1593 1188 405 <0.001 3.98 3.46-4.56 
        
Firocoxib 
14 144 70 74 0.74 0.99 0.91-1.07 
7 101 59 42 0.09 1.09 0.99-1.20 
        
Ketoprofen 
14 122 42 80 <0.001 0.52 0.35-0.75 
7 98 36 62 0.009 0.58 0.38-0.87 
        
Antimicrobials 
14 1797 1176 621 <0.001 2.34 2.07-2.63 
7 1610 1097 513 <0.001 2.68 2.36-3.05 
        
Corticosteroids 
14 730 290 440 <0.001 0.61 0.52-0.72 
7 535 220 315 <0.001 0.66 0.54-0.80 
        
Systemic corticosteroids 
14 475 206 269 0.003 0.73 0.60-0.90 
7 356 161 195 0.07 0.95 0.90-1.01 
        
Laxatives 2 538 478 60 <0.001 10.18 7.64-13.57 
        
Intravenous Fluid Therapy 2 642 512 130 <0.001 4.89 3.94-6.06 
        
Anthelmintic drugs 
14 246 104 142 0.012 0.7 0.53-0.92 
7 153 77 76 0.9 1.01 0.93-1.09 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group; OR: odds ratio. 
 
Multivariable conditional logistic regression 
 
The best fitting model without inclusion of interaction terms included the 
following parameters (Table 5.11):  
iv. Drugs dispensed 2 days before diarrhoea: laxatives, intravenous 
fluids 
v. Drugs dispensed 7 days before diarrhoea: flunixin, antimicrobials 
vi. Drugs dispensed 14 days before diarrhoea: phenylbutazone, 
ketoprofen, corticosteroids and anthelmintic drugs. 
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The interaction terms between corticosteroids and antimicrobials, flunixin 
and phenylbutazone and antimicrobials and phenylbutazone also improved 
model fit significantly and were therefore included.  
 
Table 5.11: Multivariable conditional logistic regression model showing variables 
significantly associated with the risk of developing diarrhoea in North America. The 
dataset includes 4741 equids that suffered 5122 episodes of diarrhoea and 5122 
control equids that never had diarrhoea 
Treatment Days Total D C P-value OR 95% CIs 
Flunixin meglumine 7 1593 1188 405 <0.001 2.84 2.32-3.48 
Phenylbutazone 14 1053 473 580 <0.001 0.56 0.44-0.71 
Ketoprofen 14 122 42 80 <0.001 0.10 0.04-0.24 
Corticosteroids 14 730 290 440 <0.001 0.34 0.27-0.45 
Antimicrobials 7 1610 1097 513 <0.001 1.63 1.33-1.99 
Anthelmintic drugs 14 246 104 142 <0.001 0.58 0.43-0.79 
Laxatives 2 538 478 60 <0.001 4.57 3.33-6.28 
Intravenous fluid therapy 2 642 512 130 <0.001 2.30 1.80-2.94 
Corticosteroids*Antimicrobials 14*7 303 173 130 0.022 0.89 0.58-1.38 
Antimicrobials*Phenylbutazone 7*14 546 311 235 0.017 1.39 0.93-2.07 
Flunixin*Phenylbutazone 7*14 342 185 157 <0.001 0.79 0.52-2.07 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group; OR: odds ratio; Corticosteroids*Antimicrobials: interaction term true if an 
equid received both corticosteroids 14 days before the ‘case date’ and antimicrobials 7 
days before the ‘case date’; Antimicrobials*Phenylbutazone: interaction term true if an 
equid received antimicrobials 7 days and phenylbutazone 14 days prior to the ‘case 
date’ respectively; Flunixin*Phenylbutazone: interaction term true if an equid received 
flunixin meglumine 7 days and phenylbutazone 14 days prior to the ‘case date’ 
respectively. 
 
Equids with diarrhoea were 2.84 (95% CIs: 2.31-3.48; p<0.001) times more 
likely to have received flunixin meglumine in the 7 days preceding the 
development of diarrhoea, 0.56 (95% CIs: 0.44-0.71; p<0.001) times as 
likely to have received phenylbutazone in the preceding 14 days, 0.10 
(95% CIs: 0.04-0.24) times as likely to have received ketoprofen in the 
preceding 14 days, 0.34 (95% CIs: 0.27-0.45; p<0.001) times as likely to 
have received corticosteroids in the preceding 14 days, 1.63 (95% CIs: 
1.33-1.99; p<0.001) times more likely to have received antimicrobials in 
the preceding 7 days, 0.58 (95% CIs: 0.43-0.79; p<0.001) times as likely to 
have received an anthelmintic drug in the preceding 14 days, 4.57 (95% 
CIs: 3.33-6.28; p<0.001) times more likely to have received a laxative in 
the preceding 2 days and 2.30 (95% CIs: 1.80-2.94; p<0.001) times more 
likely to have received intravenous fluid therapy in the 2 days preceding 
the development of diarrhoea. Further, three interaction terms were 
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significant and were included in the model. Equids with diarrhoea were 
0.89 (95% CIs: 0.58-1.38; p=0.022) times as likely to have received both 
corticosteroids in the 14 days and antimicrobials in the 7 days prior to the 
development of diarrhoea. Equids with diarrhoea were 1.39 (95% CIs: 0.93-
2.07; p<0.017) times more likely to have received both antimicrobials in 
the 7 days and phenylbutazone in the 14 days prior to the development of 
diarrhoea. Equids with diarrhoea were 0.79 (95% CIs: 0.52-2.07; p<0.001) 
times as likely to have received both flunixin meglumine in the 7 days and 
phenylbutazone in the 14 day prior to the development of diarrhoea. For 
all significant interaction terms the 95% confidence intervals spanned 
across 1. This makes interpretation of their overall clinical meaning 
troublesome, but they were still included in the final model as their 
inclusion significantly improved the AIC. 
 
The variable for firocoxib was tested and not significant (p=0.5). Several 
interaction terms between the included explanatory variables were tested 
and those that were not significant included flunixin meglumine and 
antimicrobials (p=0.4), corticosteroids and phenylbutazone (p=0.4) and 
corticosteroids and flunixin meglumine (p=0.7), ketoprofen and 
corticosteroids (p=0.9) and ketoprofen and antimicrobials (p=0.7). 
 
5.3.3.11 Post-hoc analysis to account for comorbidities 
 
The dataset of 312,634 animals from North America included a total of 
27,166 equids suffering at least one episode of abdominal discomfort at 
some point in the EMRs dataset with a total prevalence of 8.7% (95% CIs: 
8.6-8.8%). Of the 225,777 equids with a valid date 21,682 equids suffered 
at least one episode of colic; prevalence of colic was 9.6% (95% CIs: 9.5-
9.7%). In the diarrhoea dataset the number of equids suffering at least one 
episode of colic was 4669 of which 3215 (3541 episodes) were in the 
diarrhoea group and 1454 (1454 episodes) in the control group. 
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The dataset of 312,634 animals included a total of 128,384 equids in the 
orthopaedic group for a total prevalence of 41.1% (95% CIs: 40.9-41.2%). 
Of the 225,777 equids with a valid date 94,840 suffered at least one 
episode of orthopaedic disease; prevalence of orthopaedic disease was 
42.0% (95% CIs: 41.8-42.2%). In the diarrhoea dataset the number of equids 
suffering at least one episode of orthopaedic disease was 7063 of which 
3375 (3717 episodes) were in the diarrhoea group and 3688 (3688 
episodes) in the control group. 
 
The best fitting model included the following parameters:  
vii. Drugs dispensed 2 days before diarrhoea: intravenous fluids 
viii. Drugs dispensed 7 days before diarrhoea: antimicrobials 
ix. Drugs dispensed 14 days before diarrhoea: corticosteroids, 
phenylbutazone, anthelmintic drugs 
x. Colic 7 days before diarrhoea 
xi. Orthopaedic disease 7 and 14 days before diarrhoea 
xii. Colic and/or orthopaedic disease at some point in the EMR database 
before diarrhoea from 14 days before diarrhoea developed. 
 
All previous interaction terms became non-significant once colic and 
orthopaedic variables were added to the model and have therefore not 
been included. The only significant interaction terms between drugs 
included administration of corticosteroids and antimicrobials in the week 
prior to diarrhoea (p<0.001). The only significant interaction terms 
between drug and comorbidity terms included administration of 
phenylbutazone and orthopaedic disease (p=0.004). Inclusion of any of 
these interaction terms did not improve the AIC sufficiently to be 
maintained in the final model. Interactions between phenylbutazone and 
colic in the first week (p=0.4) or at any time before diarrhoea (p=0.1) 
were not significant. The interaction between firocoxib and colic was also 
not significant (p=0.06). Odd ratios, confidence interval and level of 
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significance for all the variables in the post-hoc model are summarised in 
table 5.12. 
 
Table 5.12: Post-hoc multiple conditional logistic regression model showing 
variables significantly associated with the risk of developing diarrhoea in North 
America. The dataset includes 4741 equids that suffered 5122 episodes of diarrhoea 
and 5122 control equids that never had diarrhoea 
Treatment Days Total D C P-value OR 95% CIs 
Phenylbutazone 14 1053 473 580 <0.001 0.67 0.55-0.81 
Corticosteroids 14 730 290 440 <0.001 0.53 0.42-0.67 
Antimicrobials 7 1610 1097 513 <0.001 2.27 1.90-2.71 
Anthelmintic drugs 14 246 104 142 0.020 0.66 0.46-0.94 
Intravenous fluids 2 642 512 130 <0.001 2.09 1.52-2.89 
Colic 7 2927 2630 297 <0.001 17.5 14.60-21.04 
Colic life 1735 986 749 <0.001 1.43 1.23-1.68 
Ortho 7 3488 1986 1502 <0.001 1.54 1.37-1.74 
Ortho life 4458 1941 2517 <0.001 0.58 0.51-0.65 
Days: maximum number of days between drug administration and development of 
diarrhoea; Total: total number of equids receiving that drug; D: diarrhoea group; C 
control group; OR: odds ratio; Colic-life: true if at least one episode of colic is recorded 
in the EMR at any time from before 14 days from development of diarrhoea; Colic: true 
if an animal suffered an episode of colic in the 7 days preceding diarrhoea; Ortho-life: 
true if at least one orthopaedic investigation or treatment is recorded in the EMR at any 
time from before 14 days from development of diarrhoea; Ortho: true if an animal was 
investigated or treated for an orthopaedic related condition in the previous 7 days prior 
to diarrhoea. 
 
5.3.4 Discussion 
 
This study presents several other interesting findings, which were not 
within the main objective of the study. Prevalence of diarrhoea, colic and 
orthopaedic disease has not been reported before on such a large 
population in equine veterinary practice in North America. The prevalence 
estimate for diarrhoea reported in this study was 2.1% obtained from the 
population of 225,177 patients with a valid date of data entry to the PMSS. 
The overall population of 312,634 animals is more comprehensive but 
dates of the older data were wrong; in addition whether all patients seen 
by each practice in those years were actually entered in the system is 
unknown. However, the prevalence estimates from both populations were 
similarly around 2%. This value is the prevalence of diarrhoea requiring 
veterinary attention/intervention; the actual prevalence of diarrhoea in 
the population would be impossible to determine. However, the need for 
inclusion of cases so mild that they do not require veterinary intervention 
		
213	
	
would be also questionable. It is important to point out that while some 
animals with diarrhoea had more than one episode, the cut-off of 90 
diarrhoea-free days between episodes was chosen to ensure that if a new 
episode was recorded this was unlikely to be the continuation of the 
previous episode. While a horse might have chronic intermitted diarrhoea 
for several months, in such cases examinations would be expected to be 
more frequent than every 3 months. 
 
Further, prevalence data from this dataset from North America needs to 
be interpreted in light of the mixed first opinion and referral nature of the 
data. Since referral cases are for the vast majority hospitalised, they are 
intrinsically at a higher risk of developing nosocomial bacterial infections, 
which might lead to diarrhoea (Ekiri et al., 2010). Further, hospitalised 
patients are monitored more closely and even a single bout of diarrhoea is 
likely to be detected and recorded. For these reasons, one might argue 
that a referral population might present a higher prevalence of diarrhoea. 
The data did not allow a clear differentiation between first opinion and 
referral cases and therefore the results include both types of populations. 
Without a purpose built feature of the PMSS to differentiate first opinion 
from referral cases an alternative would be to assume that clinicians 
holding a post-graduate specialist diploma (ACVIM, ACVS, ACT, ECEIM, 
ECVS) might be the ones involved with a referral caseload. However, it has 
to be acknowledged that whilst this is true in many cases, a specialist 
qualification is not a mandatory requirement to accept referral cases. 
Further, a variable proportion of the caseload of many veterinary 
specialists in private practice might include cases that are not referred by 
another veterinary surgeon. Finally, cases referred internally from a 
veterinarian from the first opinion service to a specialist, depending on 
the practice’s standard operating procedures, might remain under the 
name of the first opinion veterinarian in the PMSS. This complicates the 
picture further and since no clear differentiation between first opinion 
and referral population was possible, this was not included in the analysis 
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and the population was treated as a whole. The discrepancy between first 
opinion and referral is large and unlikely to reflect the true prevalence of 
diarrhoea in a referral population. 
 
The effect of practice was not evaluated as practice was used as a 
criterion to match diarrhoea cases with their control for the conditional 
logistic regression analysis. It therefore would have been inappropriate to 
include practice as an explanatory variable in the analysis. North America 
is a vast continent and marked differences in temperature, humidity and 
precipitations exist between different geographical locations on the 
continent. These differences play a determinant role in infectious disease 
prevalence and might affect diarrhoea prevalence estimates. 
Local/seasonal outbreaks of diarrhoea might have affected the prevalence 
of diarrhoea in some areas. Further, different practices might have 
different expertise, standard operating procedures and protocols for 
disease diagnosis and treatment, which might also introduce bias. The 
effect of practice could be investigated by assessing whether the some 
practice was proportionally overrepresented in the diarrhoea group, but 
this was beyond the scope of this study and was not performed. 
 
The prevalence of NSAIDs usage in the 14 days prior to the development of 
diarrhoea was 33.9% (95% CIs: 32.6-35.3%) and 19.3% (95% CIs: 18.2-20.4%) 
in the control group. In fact the reported overall prevalence of NSAIDs 
usage was 36.9% (95% CIs: 36.8-37.1%) and 40.7% (95% CIs: 40.5-40.9%) for 
the overall population of 312,634 and 225,777 animals respectively. While 
this study seem to suggest a low prevalence of NSAIDs usage in the 
diarrhoea group, this actually refers to the use in a specific 14 day period 
prior to the development of diarrhoea and so it is not directly comparable 
to the overall prevalence which reflects the proportion of equids receiving 
the drug at some point throughout their lifetime in the EMR database. For 
a discussion on the overall prevalence of NSAIDs usage in the data from 
North America please refer to Chapter 4.  
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Similar to the study from the United Kingdom, this study from North 
America also reports the prevalence of use of several variables in the 
general population and in equids with diarrhoea. 
 
Antimicrobials are often administered in combination with NSAIDs, not 
only to treat on-going bacterial infections and the associated 
inflammatory response but also preventatively in the perioperative period 
in elective and emergency surgery cases. 
 
This study also reported a relatively high prevalence of corticosteroid 
usage in North America since at least one in four equids received 
corticosteroids at least once. The corticosteroid category includes all 
corticosteroids, from those for intra-articular administration to systemic 
treatments. However, treatment with both systemic and non-systemic 
corticosteroids is not mutually exclusive, as many equids had received 
either treatment, at different times during the course of their life. 
Differentiation between systemic corticosteroids and corticosteroids for 
intra-articular administration is relevant as systemic corticosteroids might 
affect the gastrointestinal tract to a greater extent (Sanchez, 2010). 
 
Data on the prevalence of use of laxatives is in line with the overall 
prevalence of colic as these drugs are likely to be used with a proportion 
of colic cases suffering from impactions. The prevalence of intravenous 
fluid administration includes all cases receiving fluids for the management 
of hypovolaemia or dehydration. However the prevalence of hypovolaemia 
or dehydration was not investigated in the study so its prevalence cannot 
be compared to that of intravenous fluid use. 
 
Anthelmintic drugs are often administered to equids, for treatment as well 
as prevention of intestinal parasitic infections, which could result in 
diarrhoea. This study also reported a relatively low prevalence of 
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anthelmintic usage. The prevalence of anthelmintic drug usage in the 14 
days prior to the development of diarrhoea was 2.2% (95% CIs: 1.8-2.7%) 
and 2.8% (95% CIs: 2.4-3.3%) in the control group. The overall prevalence 
of anthelmintic drug usage was 14.5% (95% CIs: 14.4-14.6%) and 14.2% (95% 
CIs: 14.0-14.3%) for the overall population of 312,634 and 225,777 animals 
respectively. This much lower prevalence of anthelmintic treatment in the 
diarrhoea group is a consequence of the inclusion of cases where the drug 
was administered only 14 days prior to diarrhoea. Overall, it is important 
to highlight that in North America owners can purchase anthelmintic drugs 
over the counter without the need for a prescription, which could result in 
a serious underestimation of the prevalence of their use. Undoubtedly, 
explanatory variables consisting of drugs that are not under the exclusive 
control of veterinary professional, pose a serious challenge to 
epidemiologic research, as there would be no reliable way to assess their 
actual usage. 
 
The results of this analysis supports existing evidence that development of 
diarrhoea is more likely following administration of NSAIDs than in equine 
patients not receiving these drugs, but also the OR close to 1 suggests that 
the risk is small. This applies as long as the currently widespread practice 
of observing recommended dose regimen is maintained. Data on dose used 
and course length is necessary to actually confirm that veterinary surgeons 
and owners keep within the recommended dose regimens to fully confirm 
that current dose recommendation are safe. Conditional logistic regression 
confirmed a statistically significant relationship between flunixin 
meglumine administration and development of diarrhoea. An unexpected 
finding was that development of diarrhoea had an odds ratio less than 1 
for the administration of non-selective COX inhibitors such as 
phenylbutazone and ketoprofen. The finding that there was no significant 
relationship between diarrhoea and previous administration of firocoxib 
was in line with the findings of the study described in Chapter 2 of this 
thesis, where this drug has been shown to have a safer profile in vitro as 
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well as ex vivo than other NSAIDs such as phenylbutazone or flunixin 
meglumine. Administration of other drugs was also included in the model 
as these could act as a confounding as some are often administered in 
combination with NSAIDs in equine clinical practice.  
 
In North America it is common practice to use phenylbutazone to treat 
pain and inflammation as a consequence of orthopaedic disease. Equids in 
the orthopaedic group might also have a healthier gastrointestinal tract 
compared to that of a population with other diseases more likely to cause 
systemic illness. This theory is substantiated by the fact that diarrhoea is 
0.58 times as likely in patients suffering orthopaedic disease at any time 
in the dataset up to two weeks before the development of diarrhoea. 
Further, equids with diarrhoea were also 1.54 times more likely to have 
had an orthopaedic disease investigated or treated in the week before 
diarrhoea was reported. This difference might be explained as equids 
undergoing orthopaedic investigation or treatment often receive drugs 
which may not be accounted for in the analysis, such as sedatives or 
anaesthetics, or undergo the stress of travelling to the hospital and might 
then be more prone to diarrhoea. This effect might become less relevant a 
week later as the patient has time to recover. Finally, also other 
undetermined comorbidities might also be involved but were not 
accounted for in the post-hoc model, however the ones included were 
judged to be the most relevant clinically. 
 
The confounding effect on diarrhoea of underlying gastrointestinal 
disease, was somewhat accounted for by the colic variables. Diarrhoea 
was 17 times more likely after a recent (<7 days) episode of colic, or 1.5 
times more likely in horses that had previously suffered of colic at any 
time during life. This suggests that diarrhoea is more likely in equids that 
are more susceptible to gastrointestinal disease, either infectious, 
inflammatory or dietary in origin, manifested by discomfort at some point 
in life. 
		
218	
	
 
No significant interaction was present between colic and NSAIDs 
administration. Inclusion of colic to the model changed the significance of 
the effect of flunixin meglumine in the post-hoc analysis (p=0.2). This 
suggests that diarrhoea was not significantly more likely in equids that 
received flunixin meglumine in the previous week than in those that did 
not. Abdominal pain plays a confounding role and the perceived increased 
risk of diarrhoea by clinicians with administration of flunixin meglumine in 
many cases is secondary to administration of these drugs to patients that 
might have an unhealthy gastrointestinal tract so intrinsically predisposed 
to develop diarrhoea. Also equids with diarrhoea were 0.1 times as likely 
to have received ketoprofen. An explanation of the low odds ratio of 
ketoprofen administration in relation to diarrhoea may lay in the fact that 
in North America ketoprofen is used almost exclusively to treat equids 
examined for orthopaedic disease as shown in Chapter 4. In the post-hoc 
analysis the effect of ketoprofen administration became non-significant 
(p=0.07) when colic and orthopaedic disease were added to the 
conditional logistic regression model suggesting perhaps the influence that 
orthopaedic disease had on the effect of ketoprofen. 
 
Since antimicrobials have been well documented to induce diarrhoea in 
equids, and since they are often used in combination with NSAIDs in 
equine practice, it seemed appropriate to include antimicrobials in the 
model and to investigate a possible interaction with NSAIDs. The only 
significant interaction term was between phenylbutazone and 
antimicrobials and the odds ratio for their concurrent administration was 
higher in equids with diarrhoea. The odds ratio for administration of both 
drugs in cases with diarrhoea was lower than when antimicrobials where 
considered on their own and this finding might result from the low odds 
for diarrhoea along with phenylbutazone administration. 
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It appears that diarrhoea is 0.3 times as likely with administration of 
corticosteroids. Initially it was hypothesised that orthopaedic cases 
receiving intra-articular corticosteroids could have explained this finding: 
however, inclusion of the orthopaedic variables did not change the 
significance of corticosteroid treatment in the model and only induced a 
slight increase in the odds ratio. Corticosteroid administration, both 
systemically or intra-articular, is not a well-recognised cause of diarrhoea 
at label doses in equids. In fact dexamethasone treatment is often 
warranted in cases of diarrhoea associated with cyathostomiasis as well as 
infiltrative bowel disease (Barr, 2006) to ease the inflammatory response 
associated with these conditions. 
 
Other variables such as laxatives and intravenous fluids were included only 
when administered up to 2 days before the development of diarrhoea. The 
2-day period for intravenous fluid and laxative administration was chosen 
because both treatments would be expected to reduce faecal consistency 
within 48 hours of administration. Further, both treatments are usually 
administered directly by the veterinary surgeon on a single administration 
and therefore the date of data entry in PMSS likely reflects the actual 
date of administration. This differs from the other explanatory variables, 
which include drugs often dispensed for administration by the owner over 
multiple days, hence evaluating a period of 1 to 2 weeks from the data 
being entered in the PMSS. Diarrhoea was significantly more likely with 
administration of these drugs, however when colic was included in the 
model, the use of laxative became non-significant (p=0.4) while the odds 
for diarrhoea with use of intravenous fluids were only marginally 
decreased. 
 
Anthelmintic administration was 0.6 times as likely in the 14 days 
preceding the development of diarrhoea. This did not change significantly 
in the post-hoc analysis.  
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The time elapsed between the date of data entry in the PMSS, 
corresponding to the drugs being dispensed, and the actual length of 
treatment was summarily accounted for by the use of the 7 or 14 days 
period. The explanatory variables evaluated in this study include drugs 
administered or dispensed 7 to 14 days prior to the development of 
diarrhoea. The use of either the 7 or 14 days cut-off was determined on 
the basis of clinical relevance and AIC and significance in the model. Also, 
as a significant proportion of the data was derived from first opinion 
ambulatory practice, there was no guarantee that owners completed the 
course of administration or followed precisely the instructions regarding 
dose and dose interval given by their veterinarian. Information on dosage, 
or total quantity of drug used, was not directly available in the data and 
extraction of this information would have required knowledge of the 
weight of every animal to be available to calculate the dosage used. In 
first opinion equine ambulatory settings a scale to determine the precise 
weight of a patient is not available and therefore weight is generally 
obtained by rough estimation. Extraction of dosages and length of course 
of administration recommended is hard to achieve from the free-text EMR 
data and was not performed in this study. This is a major shortcoming of 
the study, as including dosages and length of course of treatment prior to 
the development of diarrhoea could substantially improve the model fit as 
well as the clinical relevance of the results. This could be achieved only 
by systematically and prospectively including this information in the EMR. 
These are the main reasons as to why all variables were binary (“true” or 
“false”) and no continuous variable was created to document the number 
of days between drug administration/prescription and development of 
diarrhoea or the total amount of drug used before the development of 
diarrhoea. 
 
The post-hoc analysis was performed to investigate some unexpected 
findings produced by the initial model accounting for the effect of 
confounding factors often associated with administration of NSAIDs, such 
		
221	
	
as colic and orthopaedic disease. These included the low odds ratios for 
phenylbutazone and ketoprofen and an odds ratio for flunixin lower than 
expected from clinical experience. Including comorbidities in the model 
complicated the analytic process, but at the same time the large 
population of the study allowed this process without a significant drop in 
study power.  
 
Logistic regression was used as it provides information on the association 
between binary explanatory and binary outcome variables (Thrusfield, 
2007, Dohoo et al., 2010). Evaluating differences between single and 
multiple logistic regression analysis allows understanding of how variables 
influence each others’ effect over the outcome. Akaike Information 
Criterion (AIC) has been used to select the linear regression model best 
fitting the data in multiple conditional logistic regression analysis. The AIC 
provides an index to compare the quality of each model, by estimating the 
amount of information lost by each model (Akaike, 1998; Akaike, 1974). 
The best fitting model was selected manually trying different 
combinations of explanatory variables and interaction terms.  
 
In conclusion, it appears from the analysis of the data that, while flunixin 
meglumine and ketoprofen might increase the risk for diarrhoea in a 
statistically significant manner, this increase is actually non-significant 
once episodes of abdominal pain are accounted for. The data is obtained 
from a real population where veterinary clinicians are usually aware of the 
risk of side effects related to the use of this drug and therefore judiciously 
observe label doses. However, further evidence on whether veterinary 
surgeons truly observe recommended dose regimens is needed. 
 
The role of phenylbutazone remains puzzling as this drug, like flunixin 
meglumine and ketoprofen, also affect COX-1 activity. However, from the 
results of this analysis it appears that phenylbutazone administration is 
less likely to be associated with diarrhoea. However, other not evaluated 
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confounding factors might be relevant and the ex vivo data should warrant 
a judicious use of these drugs. Firocoxib on the other hand appeared safer 
ex vivo as well as from the results of this study. However, this drug is 
licenced for treatment of pain from osteoarthritis in horses and whether 
diarrhoea would occur more frequently if this drug was administered to 
patients with underlying gastrointestinal disease remains undetermined.  
 
5.4 Discussion 
 
This chapter has demonstrated some of the applications and analysis 
possible with the semi-structured free-text datasets assembled as 
described in Chapter 3 and analysed with the methods illustrated in 
Chapter 4. 
 
Interpretation of the results of the analysis in this chapter required deep 
understanding of how data was obtained and of veterinary practices in 
each continent. While the analysis of British and North American data 
provided different results, analyses of each dataset share overall similar 
conclusions. For both datasets the prevalence of reported NSAID toxicity is 
extremely low despite these drugs being commonly used in veterinary 
practice. This is likely a consequence of several factors including the 
difficulty in detecting low levels of toxicity, particularly in first opinion 
equine practice, as this is highly dependent on owners’ ability to 
recognise, or willingness to report, mild clinical signs. Also the difficulty in 
confirming the diagnosis ante-mortem poses a huge challenge particularly 
in first opinion ambulatory settings, which might result in a considerable 
proportion of the cases being unrecognised.  
 
In this study a total of 27 cases of suspected NSAID toxicity were 
identified, out of a total of 453,695 animals. It is important to point out 
that the clinical data was collected over a 25-year period and that the 
analysis was strictly retrospective. Also the extremely low prevalence of 
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toxicity likely could reflect the judicious usage of these drugs by 
veterinary surgeons, who are aware of the risks associated with their 
administration and therefore adhere to the recommended dose and length 
of treatment. However, the present study did not evaluate the dosage 
used and no evidence that clinicians adhered to labelled doses is 
available. Despite all these limitations related to the retrospective nature 
of the study, including lack of data on dosages and length of treatment 
used, the prevalence of toxicity appears to be extremely low. This finding 
suggests that NSAIDs are safe to use, provided one avoids overdosing and 
monitors closely for side effects in order to discontinue administration 
before toxicity becomes severe and life threatening. 
 
The findings of logistic regression analysis highlight that diarrhoea is 
slightly more likely with NSAID administration, but as the prevalence of 
diarrhoea is low (1-2%) while prevalence of NSAID usage is high the slight 
increase in risk will have a minimal impact on the prevalence at the 
population level. Further, the search extracted records including a wide 
range of severity of this aspecific clinical sign, while the prevalence of 
extreme toxicity resulting in diarrhoea, such as life-threatening right 
dorsal colitis is extremely low. 
 
Several differences are present between the results of the multiple 
logistic regression analysis of the data from the United Kingdom and North 
America. These results should be interpreted in light of several 
differences in equine veterinary practice between the two continents and 
confirms how one should translate with caution to his/her own country 
studies obtained from different geographical regions. This is to account 
not only differences in legislation for drug usage, but also economic and 
social differences, which could affect not only how and when animals 
receive treatment but also how these animals are managed, including 
availability of pastures, distances travelled for competitions, etc. Further 
differences in climate and day-light hours could also affect findings 
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between countries or at different latitudes. In conclusion, this study 
highlights how findings from one country should be applied with caution to 
other countries. 
 
One of the main differences between countries is the availability of 
certain drugs. For example, metamizole is available in Canada but not in 
the United States, while in the United Kingdom it is available only in 
combination with a spasmolytic licensed for the treatment of visceral 
pain. This is a rather relevant difference as it may have a significant 
repercussion on how veterinarians manage visceral pain in these countries. 
As highlighted in Chapter 4, the use of the metamizole/butylscopolamine 
combination is very popular for the management of colic in the United 
Kingdom, while in North America flunixin meglumine is more widely used 
for this condition. While flunixin is also commonly used with colic, 
proportionally a large amount of colic cases also received phenylbutazone 
in the United Kingdom. It is possible that veterinary surgeons in the United 
Kingdom tend to select metamizole in cases that might be slightly more 
likely to then develop diarrhoea within the next 7 days (hence a markedly 
increased OR for previous metamizole administration in cases with 
diarrhoea). On the other hand in the US the vast majority of colic cases 
receive flunixin meglumine, which might then reflect in the increased 
odds ratio of previous flunixin meglumine administration in cases with 
diarrhoea in that country. While metamizole is available in Canada as a 
single drug, not many vets decided to use it for the treatment of colic, 
despite the drug being licensed for the treatment of this condition in this 
country, therefore little conclusion could be drawn from the use of 
metamizole on its own. Also the widespread use of phenylbutazone to 
manage visceral pain in the United Kingdom might have played a role in 
affecting the difference in flunixin meglumine and phenylbutazone’s odds 
ratios in the multivariable analysis. If a larger proportion of cases with 
gastrointestinal pain, which might therefore be at increased risk for 
diarrhoea development received phenylbutazone, then a positive 
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relationship between diarrhoea and phenylbutazone might be detected. At 
the same time, as similar cases received flunixin meglumine in North 
America, the same positive relationship exists between flunixin meglumine 
and diarrhoea. The post-hoc analysis was performed to account for this 
“drug selection bias”, and the results show a marked decrease in odds 
ratio for phenylbutazone usage in cases with diarrhoea once the analysis 
included the colic variable. The relationship between diarrhoea and 
flunixin meglumine became insignificant once colic was accounted for in 
North America and it remained non-significant in the United Kingdom. Also 
all instances where veterinary surgeons combined multiple NSAIDs were 
not significant in the analysis from both regions.  
 
The effect of firocoxib was also similar between United Kingdom and 
North America, but only one case receiving firocoxib was present in the 
dataset for analysis from the United Kingdom, so the data from this 
country was underpowered to assess the relationship between firocoxib 
and diarrhoea. In North America there was no significant relationship 
between diarrhoea development and firocoxib administration. 
 
Moreover it is also possible that either, other unforeseen conditions played 
a significant role, or that colic as a whole is too general and including only 
certain colic cases, such as those with more severe gastrointestinal 
disease requiring referral or emergency exploratory laparotomy, might 
change the significance of some variables in the analysis. Ultimately it is 
also possible that these drugs might truly increase the likelihood of 
diarrhoea and therefore the findings of this study are correct. 
 
Other differences between United Kingdom and North America might exist 
on the frequency with which veterinarians prescribe NSAIDs to their 
patients as discussed in Chapter 4. For example, in North America the 
prevalence of use of NSAIDs was higher than in the United Kingdom. This 
data suggests that veterinarians in North America use these drugs more 
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frequently than veterinary surgeons in the United Kingdom. The reason for 
this behaviour is unclear, but this behaviour might be reflective of what 
these clinicians are taught during the undergraduate years and at CPD 
events in their respective country. For example, it could be that in the 
United Kingdom more emphasis is placed on the severity of side effects 
from NSAID usage or that more emphasis is placed in North America on 
ensuring that pain and inflammation are managed appropriately. 
Alternatively, British clients might be less willing to spend money to treat 
their patients with NSAIDs, or alternatively prefer to have a condition 
investigated and treated, rather than simply managing signs of pain. 
Explaining this difference was not the aim of the study, but highlighting a 
difference was a first step. Further studies are required to evaluate this 
difference to understand how research findings from one continent apply 
to the other.  
 
Nevertheless this difference in prescribing habit might also have 
influenced the result. This might be particularly true if in the United 
Kingdom NSAIDs are used most commonly in cases that have more severe 
inflammation, so are more at risk of side effects. However, the overall 
prevalence of diarrhoea was very similar between datasets so this effect 
remains undetermined. 
 
A further, significant difference between United Kingdom and North 
America data is the type of cases included. While the British dataset 
included only first opinion cases, data from North America included a 
mixed population of first opinion and referral cases. Referral work 
includes generally first opinion cases, which are too complicated to be 
dealt with in ambulatory settings or that require advanced diagnostics and 
intensive care treatment. A proportion of the referral cases is also a sicker 
population and could therefore be more susceptible to develop drug 
toxicity, which might result in diarrhoea. 
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Other differences between the United Kingdom and North America are 
reflected in the role of corticosteroids. In the United Kingdom equids with 
diarrhoea were nearly twice as likely to have received corticosteroids in 
the preceding 7 days than controls, while in North America equids with 
diarrhoea were only 0.3 times as likely to have received corticosteroids 
than controls in the preceding 14 days. The current study did not aim at 
describing the prescription habits of corticosteroids and any difference 
between countries in usage of these drugs remains undocumented. 
However, a marked difference exists in NSAID usage in orthopaedic 
patients between United Kingdom and North America. Table 4.8 highlights 
a much greater proportion of orthopaedic examinations in North America 
documenting usage of NSAIDs than in the United Kingdom. A NSAID was 
used in ~35% of orthopaedic examinations/treatments in North America, 
while this was documented only for ~13% of orthopaedic cases in the 
United Kingdom. This difference might partially reflect inclusion of 
referral cases in the dataset from North America as well as different NSAID 
prescription habits between countries. This difference in drug usage 
suggests a difference in management of orthopaedic cases between 
countries and could well suggest a difference of attitude towards the use 
of intra-articular corticosteroids for orthopaedic disease, such as 
osteoarthritis. Data from the studies in this chapter also show that in the 
United Kingdom the use of corticosteroids is nearly 4 times smaller than in 
North America. Although the specific use of corticosteroids was not one of 
the aims of the study and it was not investigated further, the data 
supports the theory of a different attitude towards corticosteroids usage 
between countries.  
 
The effect of intravenous fluid therapy was similar between the two 
continents. It appears that equids with diarrhoea were more likely to have 
received intravenous fluids than control animals. This might reflect the 
habit of providing more fluids than the animal’s actual needs in equine 
practice, which might result in decreased faecal consistency. On the other 
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hand, in cases of large colonic impactions the aim of fluid therapy is to 
increase colonic secretions to soften the impacted faecal material in the 
colon, therefore cases of large colon impaction might have influenced this 
result. Administration of laxatives via the oral route is the currently 
recommended treatment for large colon impactions (Sanchez, 2010). 
Laxatives also yielded different results between continents. While no 
significant effect of laxatives over diarrhoea was detected in the 
multivariable regression analysis in the United Kingdom, previous laxative 
treatment was significantly more likely in equids with diarrhoea in North 
America. The reason for this difference also remains undetermined. This 
finding is puzzling, particularly as laxative administration was 7 times 
more likely in equids with diarrhoea in the univariable analysis in the 
United Kingdom. The relationship between diarrhoea and large colon 
impaction was not investigated, as this was not within the scope of the 
study. 
 
A further difference between United Kingdom and North America lies in 
the effect of anthelmintic drugs on the output of the analysis. The 
recorded use of anthelmintic drugs was two times greater in North 
America than in the United Kingdom. The interpretation of this finding is 
somewhat difficult. Possible explanations include that either in North 
America there is a greater tendency to blanket-treat herds while in the 
United Kingdom monitoring faecal egg counts to identify animals with 
higher counts that might require treatment may be more common. 
However, the American Association of Equine Practitioners (AAEP) has 
released and recently updated guidelines for parasite control, which 
suggest that deworming should be focused on certain animals (so called 
“high-shedders”) rather than treating the whole herd (Nielsen et al., 
2013). This is because in the past 40 years the population of equine 
intestinal parasites has shifted from the large strongyles being the most 
significant to the small strongyles, the cyathostomes, as the most 
significant clinically. Recent evidence suggests that cyathostome 
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populations are developing anthelmintic resistance and the best results 
are obtained by trying to control and not eliminate these parasites (Love, 
2003). These guidelines might have in some way affected attitude towards 
blanket worming in North America as well as in the United Kingdom. 
Analysis of frequency data shows that while the prevalence of deworming 
is substantially unchanged in the United Kingdom since 2008, anthelmintic 
usage in North America has seen a significant and steady decrease in the 
past 5 years. Despite this attempt to reduce the indiscriminate usage of 
anthelmintic drugs, that might predispose to development of resistance, 
the fact that dewormers are available over the counter in North America 
while in the United Kingdom they can be purchased only under the 
direction of a suitably qualified person needs to be kept in consideration. 
This suggests that an unknown proportion of anthelmintic drugs is 
administered directly by owners without any veterinary supervision. 
Further lay social attitudes towards resorting veterinary advice for 
deworming might also be different between countries. Therefore the 
effect of this variable is difficult, if not impossible, to interpret from the 
data. However, anthelmintic drug usage was still included in the analysis 
as it was important to account for at least a portion of the anthelmintic 
drugs used and unrecorded anthelmintic drug usage was expected to be 
uniform throughout the study population. 
 
The modelling approach adopted for both studies from the United 
Kingdom and North America presented several limitations. The variables 
included are simple and generic and not specific so may be difficult to 
relate the results to the specific practical clinical scenario. Further, 
residual confounding caused by unmeasured or imperfectly measured 
confounders is inherent to this type of analysis. Alternative approaches to 
a case-control design could include the complete dataset but would create 
further problems such as dealing with large amounts of missing data. 
 
In conclusion, the findings of these studies suggest that the prevalence of 
reported NSAID toxicity is very low. Also diarrhoea, used as a marker for 
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NSAID toxicity, is slightly more likely following administration of NSAIDs, 
even when the concurrent administration of other substances, well 
documented in causing diarrhoea, is accounted for. However the 
prevalence of reported diarrhoea was very low in our population and this 
risk is minimal; clinical evidence and intuition would suggest this provided 
that recommendations for NSAIDs dosage and frequency of administration 
are respected.	
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CHAPTER 6 – Discussion And Conclusions 
 
6.1 – Novelty of this work 
 
The two goals of this PhD were to evaluate the biochemical potential for 
side effects of NSAIDs with different COX selectivity using an ex vivo 
model of clinical patients and also to evaluate the prevalence and clinical 
relevance of these side effects in a horse population.  
 
The first goal was achieved using methodologies already validated in the 
literature (Beretta et al., 2005). The novelty of this work consisted of 
using samples from actual clinical patients and not experimental animals. 
This approach is relevant as it fills a gap in knowledge since, thus far, 
knowledge of COX-inhibition of NSAIDs has worked under the assumption 
that little difference would be present between experimental animals and 
actual clinical patients. While this assumption is understandable, scientific 
rigor requires that all assumptions should be examined and supported by 
evidence, hence the need for this study. The findings in this study on 
clinical patients clearly support the findings of previous studies performed 
on experimental animals (Barton et al., 2014; Cook et al., 2009a; 
Marshall, 2010). The biochemical investigations of Chapter 2 confirm the 
potentially deleterious effects of non-selective COX inhibitors such as 
flunixin meglumine and phenylbutazone and that using COX-2 selective 
drugs, such as firocoxib, spares COX-1 activity in clinical patients. While 
these findings indicate that firocoxib has a safer profile compared to 
flunixin meglumine and phenylbutazone, the impact on the horse 
population remained undetermined. The data from any biochemical 
investigation merely described the potential for toxicity from the use of 
NSAIDs, but does not provide any information as to what proportion of 
animals in the population actually experiences side effects in clinical 
practice and does not evaluate the confounding effect of other concurrent 
medications or comorbidities. 
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The second goal of this work was therefore to evaluate the impact that 
the side effects from the use of NSAIDs have on a clinical population of 
equids. The methodology implemented to achieve this goal was novel and 
opens a wide range of opportunities for future research studies, which go 
beyond the scope of this thesis. Electronic medical records from 
veterinary practice offer a goldmine of data for clinical epidemiologic 
research. The methods in Chapter 3 describe two different techniques 
that can be used to obtain retrospective data from the EMRs of equine 
veterinary practices. The advantages and disadvantages of each technique 
are discussed in detail and show how each technique can adapt to 
different circumstances. The technique applied to the United Kingdom is 
more labour intensive, collects data of variable quality that might require 
significant effort in data cleaning, but offers the advantage of being 
relatively cheap. On the other hand, the technique applied in North 
America quickly provided good quality data through the PMSS company, 
but incurred a significant financial expense. Equally, both techniques 
provided a great amount of data suitable for the scopes of the study.  
 
Another novel aspect of the thesis is the text mining methodology 
validation in Chapter 3. Although the use of text mining techniques of 
EMRs have been reported before in the veterinary literature (Anholt et al., 
2014a; Cameron et al., 2014; Lam et al., 2007a), their sensitivity and 
specificity has been shown to be good but not excellent and the 
methodology used for their validation has been suboptimal (Anholt et al., 
2014a). Chapter 3 describes how these techniques have been improved to 
achieve excellent agreement with manual classification to justify their 
wider use in the future. The methodology described highlights the 
importance of creating exhaustive dictionaries to achieve optimal 
accuracy of the mining process. The use of exclusion dictionaries and re-
inclusion dictionaries was novel and allows minimisation of false positive 
and false negative rates. This method is mostly automated with a minor 
		
233	
	
manual component necessary for dictionary definition. Certainly the 
improvement in sensitivity and specificity outweighs the time and effort 
required for the manual component of the analysis as it increases 
confidence in the results significantly.  
 
Chapter 4 and Chapter 5 are also innovative as they describe for the first 
time the prevalence of use of several drugs gathered from two large 
equine clinical populations, describing in detail the differences that occur 
in drug usage between the United Kingdom and North America. The 
prevalence of conditions such as diarrhoea, colic and orthopaedic disease 
was relatively similar between these regions while the pharmacological 
management of these conditions was different as highlighted in Chapter 4. 
These findings highlight the general importance of interpreting research 
findings in light of their geographical and legislative background. Clinical 
studies from one country should be interpreted with caution in relation to 
other countries.  
 
Finally, this work concludes with the investigation of the relationship 
between clinical signs consistent with NSAID toxicity, drugs administration 
and comorbidities. The use of such a large population provided sufficient 
statistical power to include several variables in the logistic regression 
analysis. Determination of odds ratio for NSAID administration in cases of 
diarrhoea provided an indication of the extent of the impact that the use 
of these drugs may have on these equine populations. 
 
6.2 Overall conclusions 
 
The overall conclusions of this Thesis are focused on whether NSAID 
administration is associated with significant side effect on equids and on 
the extent of this effect. While the findings in Chapter 2 show that there 
is a valid pharmacological basis to be concerned over NSAID toxicity, the 
epidemiological investigation highlights that the impact of these side 
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effects on the population is small. This conclusion needs to be interpreted 
in light of the fact that equine veterinary surgeons are generally well 
aware of the potential side effects of NSAIDs and therefore rarely exceed 
recommended dosages. However, data on dosages used in the datasets 
was not available and this is only a supposition based on the author’s 
personal experience. Studies including data on dosages should be highly 
encouraged to highlight the importance of following the legislation that 
regulates the use of these drugs and to promote alternative means of 
managing pain in equids where NSAIDs alone are not sufficient. On the 
other hand, from a population point of view, the impact of these NSAID-
related side effects is so limited that one might conclude that NSAIDs, 
including non-selective COX inhibitors, are generally quite safe to use. It 
remains undetermined whether an association exists between NSAID 
dosage and course length and the odds for diarrhoea development. As 
previously discussed, data on dosage has not been extracted from the 
free-text EMR. It remains unclear to what extent NSAIDs are used at 
dosages exceeding recommended dosages. Similarly, under-dosing could 
potentially have had an effect as under-dosing would be expected to 
result in reduced toxicity. These findings also challenge the need to spend 
significant financial resources to fund research aiming at identifying 
NSAIDs with a safer profile.  
 
6.3 Limitations of this work 
 
The conclusion that can be drawn from the results presented in this Thesis 
should be interpreted in light of their greater limitations.  
 
The biochemical investigation of COX activity was performed in clinical 
patients, undergoing procedures of variable clinical invasiveness that 
could have triggered an inflammatory response of variable degrees. Two 
main intrinsic limitations were bound to the clinical study design. The first 
one was that allocation of horses to either flunixin meglumine, 
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phenylbutazone or fircoxib group was not randomised or within the control 
of the investigator. Group allocation was determined by the attending 
clinician and could have depended on presenting clinical signs, diagnosis 
or degree of inflammation present. A non-randomised group allocation 
meant that group allocation may have not been independent from the 
outcome being measured. So horses with more severe inflammation might 
have been more likely to receive a more potent COX inhibitor such as 
flunixin meglumine. This might have ultimately affected the results, as 
other NSAIDs could have been less effective at reducing COX activity in 
horses suffering a more severe inflammatory response. The second 
limitation deriving from the study design and non-randomised group 
allocation was the lack of standardisation in term of surgical procedures 
performed. Different diagnoses also required treatment with different 
surgical procedures, which could have triggered inflammatory responses of 
variable severity. However, previous studies have shown that the 
inflammatory response following surgical trauma was minimal in the first 
24 hours and the inflammatory response was similar between minimally 
invasive and very invasive surgical procedures (Jacobsen et al., 2009). A 
further limitation of the study in Chapter 2 included sample size, which 
was determined based on the predicted difference in the drugs COX 
selectivity. Involving more horses might allow detection of other 
significant relationships between drug and metabolite concentrations and 
enzyme activity, disease states and age or breed differences and warrants 
future investigation. This would have been too costly and could not be 
performed. 
 
The epidemiological investigation in Chapters 4 and 5 also suffered a few 
limitations, which were mostly intrinsic to the retrospective nature of the 
data. Missing data could have affected the outcome of our analysis. 
Information about age and gender was not available for a significant 
proportion of the study population and these variables could have been 
used as matching criteria or added to the model as possible confounders. 
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Large amount of missing data could indicate that the data available is also 
of poor quality and may not reflect what is actually happening (Coleman 
et al., 2015) and future studies should aim to validate that what is in the 
records reflects what actually happened. Data was also missing from some 
veterinary practices for some of the early years in the database. Older 
data from the United Kingdom was available only from one practice while 
older data from North America included proportionally a very small 
amount of patients. How this could have biased the results of the study 
remains also unclear. Finally, data on patients migrated to another 
practice, or deceased, but not recorded in the system was also missing. 
This is reflection of the dynamic nature of veterinary practice, where 
equine patients might change practice as they are sold, momentarily or 
definitively relocated or if the owner decides to change veterinary care 
provider. The data used for this study has no information on animal 
movement and loss of information could be prevented in future 
prospective studies only if the vast majority of veterinary practices in one 
country contributing data using PMSS that permits tracking of patients 
between practices. Further, unreliable data, such as that with wrong 
dates of data entry limits the use of data migrated from older PMSS to the 
current and may result in loss of data. 
 
From a clinical standpoint it would have been very useful to have data 
regarding dosages to be able to evaluate any effect of dose on toxicity. 
The current analysis is performed under the assumption that overdosing of 
NSAIDs is a rather rare occurrence in veterinary practice, but the extent 
to which NSAID are used at inappropriate dosages remains currently 
undetermined. In ambulatory first opinion equine practice particularly, 
patient weight is often estimated and not directly measured and has been 
shown to affect the accuracy with which dosages are calculated (Ross et 
al., 2015). It is possible that in some cases some animals were 
administered amounts of certain drugs that were outside the 
recommended dose ranges. Also information on administration route, 
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course duration and clear definition of the indication for using the drug 
was also lacking. In a prospective study this information may be 
specifically requested to increase the precision of the information 
collected and limit the amount of missing data. 
 
Another limitation is the assumption that owners administered drugs as 
instructed by the prescribing veterinary surgeons. Monitoring owners’ 
compliance would be near to impossible even with a prospective study 
design. The data available for this study did not account for the difference 
between date of drug dispensation and actual date of drug administration 
and all analyses were done under the assumption that once a drug is 
dispensed administration would be on the same day. While this may be 
generally true for some drugs (e.g. antimicrobials, intravenous fluids, 
laxatives), which are generally prescribed to treat acute onset conditions 
requiring immediate care, this may not necessarily be the case for other 
drug categories, which may be dispensed to treat more recurrent disease, 
such as NSAIDs to manage chronic lameness or corticosteroids to use 
during exacerbation of a recurrent disease, or to fit a scheduled protocol, 
such as deworming. The effect that time elapsed between drug 
prescription and administration may have had on the overall results is 
unclear. In the future, collecting data where date of drug administration 
is recorded will be possible, but probably only for studies on hospitalised 
animals, since recording actual date of administration by owners is hardly 
feasible. 
 
Both dataset from United Kingdom and North America were obtained from 
a convenience sample of veterinary practices. This could have intrinsically 
introduced some bias. Whether the population included in the study was 
truly reflective of the overall veterinary population remains 
undetermined. Whether these veterinary practices worked at a higher 
standard than the general population or whether they had some 
purchasing deals with certain companies that could have biased towards 
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certain NSAIDs remains unclear. Ideally in future studies practices should 
be selected at random from the veterinary practice population. 
 
A final significant limitation of this study results from our ability to 
differentiate the type of comorbidities included. For example, including 
only certain types of colic or orthopaedic conditions might have affected 
the results significantly. For example, diarrhoea is considered generally a 
condition generated from the hindgut, or cases with endotoxaemia might 
be more prone to diarrhoea development. Similarly, some orthopaedic 
conditions require long term management that could result in an overall 
greater amount of NSAIDs administered which could result in a higher risk 
of toxicity. Therefore including more specific variables in place of the 
generic colic and orthopaedic terms could have affected the results 
significantly. This was not performed largely due to time constraints, but 
would be one of the logical next steps in this particular area of research. 
 
Performing these studies in a prospective manner would incur significant 
cost and time, necessary to develop a tool to allow communication 
between PMSS and obtain uniform data from different PMSS. Further, 
years would then be required so that enough data could be collected to 
perform some meaningful analysis. However, this process would provide 
several advantages, including data of better quality, minimising missing 
data and would hopefully include a sample of veterinary practices 
including a more representative sample of the equine population under 
veterinary care. 
 
6.4 Future work 
 
The work of this Thesis has laid the basis for several future studies. 
 
The biochemical investigation in Chapter 2 could include other drugs such 
as meloxicam and ketoprofen. Drug selection was not under the 
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investigator’s control and the clinicians responsible for these clinical cases 
did not use these two drugs to manage perioperative inflammation and 
pain of their patients. Further work could also aim at comparing the effect 
of these drugs in ischemia-reperfusion injury as done by Cook and 
colleagues (2009a). Flunixin meglumine has been shown to induce mucosal 
neutrophil infiltration after ischaemia-reperfusion insult and this might 
induce delayed return of normal peristalsis in some cases (Cook et al. 
2009b). Other non-selective COX inhibitors might have a lesser effect on 
neutrophil migration and could improve overall survival in these cases 
(Cook et al., 2009a). 
 
The epidemiological investigation started by creating a dataset of EMRs, 
which includes all the information stored in the PMSS, therefore the data 
can be used to evaluate the prevalence of any disease or usage of any 
drug. The relationship between administration of any drug and disease 
development could be investigated with the same methodology of Chapter 
5. Further the data could also be used to evaluate time to recovery after 
certain procedures or with a particular disease. Moreover investigation of 
how disease prevalence evolves overtime or varies geographically could 
also be investigated. The data offers the advantage of a very large 
population, which could be used to calculate a reliable prevalence even 
for very rare conditions, impossible with smaller datasets. 
  
A further development of this work would include prospective collection 
of data, from practices willing to collaborate. Data obtained prospectively 
for specific research purposes would offer the advantage of less missing 
information, for example regarding dosages used. Prospective data 
collection should be implemented by working with PMSS companies to 
improve the compatibility of their systems with the scope of 
epidemiological research, without altering the user interface of their 
software. A key component of a prospective study of this type would be 
developing software to support veterinary surgeons’ compliance. While 
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complex coding systems offer the advantage to provide a clear 
classification of the cases in a dataset (O’Neill et al., 2012a), they may 
result in poorer compliance by veterinary staff in the long run. To ensure 
the best compliance, complete data should be obtainable directly from 
the PMSS systems without requiring an effort by veterinary staff that goes 
much beyond the general record keeping tasks of everyday practice.  
Prospective data, as highlighted by studies in small animal species (Jones 
et al., 2014; O’Neill et al., 2012a; Radford et al., 2011), can provide 
useful information in disease surveillance and alert veterinary surgeons of 
disease outbreaks in the their area. Studies of this type could have a great 
impact on equine welfare. 
 
In conclusion, much more can be done to build on the work in this Thesis, 
both on the topic of NSAID toxicity but also by using the data for many 
other varied studies. 
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Appendices 
 
Appendix 1.11 
Table summary of products containing NSAIDs 
Summary of products containing NSAIDs licensed for use in horses in the United 
Kingdom, United States of America and Canada. 
Drug Brand name Form Route Available conc. MLD Indications Country YFM 
Phenylbutazone 
Butagran Equi 
Pwd PO 
 
200mg/1g 
4.4mg/kg BID 
 
MSK UK 
 
1994 
Pro-Dynam 1994 
Equipalazone 
1994 
Pst 1g 1994 
Inj IV 200mg/ml MSK, AP 2013 
Butazolidin 
B 
PO 1g 
4g/day MSK US 
 
Tab  
Grn  
Inj IV 200mg/ml 
 
Butatron 
Tab PO 1g  
B PO 1g 
 
Tevcodyne 
B PO 1g  
Inj IV 200mg/ml  
EquiBute 
Tab PO 1g 
 
Inj IV 200mg/ml  
Butasone 1000 Bolus  PO 1g 
  CA 
1999 
Butasone 400 Pwd PO 1g 1989 
Butasone Conc Pwd PO 1g 1989 
Butequine Pst PO  2014 
Buzone conc Pwd PO 1g 1997 
Buzone Inj Inj IV 200mg/ml 2012 
Phneylbutazone 
20% 
Inj IV 200mg/ml 2010 
Phenylbutazone 
concentrate Pwd PO  2005 
Phenylbutazone 
Inj 
Inj IV 200mg/ml 1974 
Phenylbutazone 
powder Pwd PO 1g 1993 
Phenylbutazone 
tab 
Tab PO 1g 1974 
Suxibuzone Danilon Equidos Grn PO 1.5g 6.26mg/kg/day MSK UK 2001 
Flunixin  
Meglumine 
Allevinix 
Inj 
 
IV 
 
50mg/ml 
 
1mg/kg 
 
MSK, Colic 
 
UK 
2013 
Cronixin 1996 
Flunixin 1998 
Meflosyl 1998 
Norixin 1997 
Pyroflam 2006 
Finadyne 1987 
Finadyne Paste Pst PO  
MSK 
1989 
Equinixin Gr PO 25mg/g 2006 
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Banamine-S 
Inj 
 
IV, IM 
 
50mg 
 
0.5mg/lb/day 
 
MSK, Colic 
 
US 
 
 
Banamine Inj  
Flu-nix 
 
Flunixin 
Meglumine Inj  
Flunixin 
Meglumine Sol  
Flunixin Inj  
Banamine 
Granules Grn PO 
 
MSK 
 
Banamine Paste Pst   
Banamine 
Inj IV, IM 50mg/ml   CA 
1979 
Cronyxin 1997 
Flunazine 2001 
Flunixin inj 1997 
Influx-50 1999 
Suppressor 2004 
Metamizole 
Buscopan 
Compositum Inj 
Inj 
IV 
 
5ml/100kg Dx, Colic, UO  UK 2001 
Dipyrone Inj IV, IM, SC 500mg/ml   CA 
1965 
Dipyrone 50 IV, IM   1997 
Meloxicam 
Animexolan Inj 
IV 
20mg/ml 
0.6mg/kg SID MSK, Colic UK 
2012 
Contacera 
Inj 15mg/ml 2014 
Inj 20mg/ml 2012 
Emdocam Inj 20mg/ml 2011 
Inflacam 
Inj 15mg/ml 2011 
Inj 20mg/ml 2011 
Grn PO 330mg 2011 
Loxicom 
Inj IV 20mg/ml 2009 
Pst PO 50mg/g 2009 
Melosolute 
Inj IV 
40mg/ml 2013 
Melovem 20mg/ml 2009 
Meloxidolor 20mg/ml 2013 
 40mg/ml 2013 
Meloxidyl 20mg/ml 2007 
Metacam 
OS PO 15mg/ml 2003 
Inj IV 
20mg/ml 2001 
40mg/ml 2015 
Novaquin OS PO 15mg/ml 2015 
Recocam Inj IV 20mg/ml 2011 
Rheumocam OS PO 15mg/ml 2008 
Recocam Inj IV 20mg/ml 2011 
Ketoprofen 
Dinalgen 
Inj IV 
150mg/ml 2.2mg/kg SID up 
to 3 days 
MSK, Colic,  
P-O 
UK 
2010 
Ketink 
100mg/ml 
 
2.2mg/kg SID up 
to 5 days 
 
MSK, Colic,  
P-O 
2012 
Ketodolor 2013 
Nefotek 2012 
Rifen MSK, Colic  
P-O, AP 
2010 
Comforion Vet 
MSK, Colic 
2005 
Ketofen 1992 
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MLD: maximum licensed dose; YFM: Year First Marketed; Pwd: powder; Pst: Paste; 
Inj: injectable; B: bolus; Tab: tablet; Grn: granules; OS: oral suspension; Crm: 
cream; PO: orally; IV: intravenous; IM: intramuscular; SC: sub-cutaneous; BID: 
twice daily; SID: once daily; MSK: muscleskeletal disorders; AP: antipyretic; Dx: as 
a diagnostic aid; UO: Urinary obstruction; P-O: peri-operatively; OA: osteoarthritis. 	
Kelaprofen 2012 
Ketofen 1mg/lb SID up to 5 days MSK US  
Anafen IV, IM 
  
CA 
1993 
Ketoprofen V IV, IM 2016 
Diclofenac Surpass Crm Topical 10mg/1g 
 
OA 
US 
 
Meclofenamic 
acid 
Arquel Granules Grn PO 1mg/lb 1g/1000lbs SID 
up to 7 days 
MSK 
 
Firocoxib Equioxx 
Inj IV 20mg/ml 
0.09mg/kg SID 
up to 14 days 
OA UK 
2008 
Pst PO 8.2mg/g 0.1mg/kg SID up 
to 14 days 
2008 
Inj IV 20mg/ml 
0.09mg/kg SID 
up to 5 days 
OA US 
2008 
Pst PO 8.2mg/g 
0.1mg/kg SID up 
to 14 days, or 9 
days after IV 
Equioxx 
2008 
Aspirin Acetylsalicylic 
acid bolus 
B  PO 15.6g 
  
CA 1996 
Vedaprofen Quadrisol Gel PO 100mg/ml 
 
MSK, P-O UK 1997 
Deracoxib No product currently licensed for use in equids 
Eltenac No product currently licensed for use in equids 
Carprofen No product currently licensed for use in equids 
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Appendix 3.1 – Letter for Veterinary Practices 
 
 
 
 
WEIPERS CENTRE EQUINE HOSPITAL 
Division of Companion Animal Sciences 
Faculty of Veterinary Medicine 
University of Glasgow 
Bearsden Road, Glasgow, G61 1QH 
Telephone: 0141-330 5999   Fax: 0141-330 6025   Email: equine@vet.gla.ac.uk 
University of Glasgow Charity Number: SC004401 
 
The$clinical$use$and$adverse$effects$of$
NSAIDs$in$the$UK$horse$population 
Marco Duz MedVet MVM(Res) MRCVS  
Tim Parkin BSc BVSc PhD DipECVPH FHEA MRCVS 
John Marshall BVMS DipACVS/ECVS PhD MRCVS 
 Non$steroidal- anti$inflammatory- drugs- (NSAIDs)- are- among- the- most- widely-used-medications-in-both-human-and-veterinary-medicine.-Phenylbutazone-and-flunixin- meglumine- have- been- associated- with- adverse- effects- in- horses-including- gastric- ulceration,- right- dorsal- colitis- and- renal- failure.- Recently,-NSAIDs- designed- to- reduce- adverse- effects- have- been- introduced- to- the-veterinary-market,- including-meloxicam-and- firocoxib,-but- their- level-of-use- in-the-UK-is-currently-unknown. 
AIMS:$Describe-the-use-of-NSAIDs-in-the-UK-horse-population.-Identify-the-true-prevalence- of- NSAIDs- induced- toxicity- and- whether- significant- differences-between-NSAIDs-exist. 
METHODS:$We-need- to-access- the- records-of-horses-under-your-care-over- the-years- through- the- practice- management- software- provider- or- locally- at- your-practice.-All-data-collected-will-be-handled-as-anonymously-as-possible-and-we-will- provide- a- signed- confidentiality- agreement- form- for- you.- Records-will- be-analysed- with- a- content- analysis- and- text- mining- software- to- automatically-extract-the-data-of-interest-to-be-included-in-the-statistical-analysis. 
WHAT$ARE$YOU$REQUIRED$TO$DO?$Only-sign-the-agreement-form.-Collection-of- digitally- stored- data- will- be- done- on$line- (through- an- agreement- with- the-management- software- company)- or- alternatively- at- your- practice.- You- can-withdraw-from-the-study-at-any-time. 
WHAT’S$ IN$ IT$ FOR$YOU?$You- have- the- opportunity- to- participate- in- a- large$scale-epidemiological-study.-The-results-may-guide-your-future-choice-of-the-best-NSAID/dosage-for-your-equine-patient. If-you-are-willing-to-participate,-or-simply-want-more-information,-please-contact-John- Marshall- or- Marco- Duz- at- the- Weipers- Centre- (0141- 330- 5999- –-equine@vet.gla.ac.uk). Best-regards,-Marco,-Tim-and-John 
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Consent for template for participating practices 
(Please	write	this	letter	on	your	practice	stationary	if	possible	-	with	letterhead/	name	of	practice)		To:		Tim	Parkin	BSc,	BVSc,	PhD,	DipECVPH,	MRCVS	Boyd	Orr	Centre	for	Population	and	Ecosystem	Health	School	of	Veterinary	Medicine	University	of	Glasgow	464	Bearsden	Road	Glasgow	–	G61	1QH			Dear	Tim,		
Regarding	the	use	of	clinical	data	for	the	study	of	the	clinical	use	and	adverse	effects	
of	NSAIDs	in	the	UK	horse	population	
	
	Our	usage	policy,	including	data	ownership,	anonymisation,	security	and	confidentiality	for	our	data	is	as	follows:		1. The	data	will	remain	property	of	(practice	name)		2. Any	costs	involved	with	providing	the	data	will	be	payable	by	the	investigators	of	the	study		3. Data	will	be	supplied	in	an	anonymised	format	wherever	possible		4. Confidentiality	will	be	maintained	and	secure	physical	and	electronic	storage	ensured		5. The	facilities	for	secure	and	physical	electronic	storage	of	the	data	may	be	scrutinized		6. Any	papers,	publication	or	presentations	resulting	from	the	data	will	be	made	available	to	(practice	name).		Please	sign	below	to	show	your	agreement	with	this	policy	for	this	project.			
Practice	representative	to	sign		 	 	 Date:	……………………………. 
	
Practice	representative	print	name	MRCVS,	Partner	at	(practice	name)	 	
	 		Please	sign	one	copy	of	this	letter	and	return	to	me	at	the	address	above		Signed:	……………………………………………		 	 	 Date:	……………………………		Name:	Tim	Parkin	 	 	 	 	 	
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Appendix 3.2 
 
Microsoft Access Instructions For Data Anonymisation 
 
 
!
MS#Access#(#assign#unique#ID#procedure#!
STEP#1##Open!dataset!with!excel.!!Add!new!column!by!RIGHT!clicking!on!letter!A!of!the!first!column!(see!Figure!1!–!black!arrow!–!this!will!highlight!the!whole!column)!and!selecting!Insert!in!the!menu!that!then!should!open!(with!the!RIGHT!click).!This!will!add!an!empty!column!and!shift!all!the!others!to!the!right.!!
!
Figure#1#!Then!one!LEFT!click!on!cell!A2!and!type!as!follows:!!
=concatenate(B2,G2,H2,I2)2Press!enter!to!confirm!!Please,!substitute!B2,!G2,!H2!and!I2!with!the!name!of!the!cells!that!contain!the!first!Last!Name,!Horse!Name,!Breed!and!DOB!–!please!do!not!include!the!address!column!(B,G,H,I!may!vary!but!should!always!be!followed!by!“2”!–!as!you!are!selecting!cells!in!row!2).!!!
!
Figure#2#!This!will!collate!all!the!information!in!the!cells!selected!into!one!string!in!one!cell.!!Then!double!click!on!the!bottom!right!corner!of!cell!A2!(the!cursor!should!become!a!black!cross!if!you!are!in!the!right!spot).!This!will!apply!the!concatenate!function!for!the!rest!of!the!dataset!(it!may!take!a!few!moments!to!do!so!depending!on!the!size!of!the!dataset).!!Save!your!file!as!a!new!file!(eg.!Record_with_ID.xlsx)!!
#
STEP2#In!Access!create!a!new!blank!database!(Figure!3):!1. Click!on!Blank2Database!2. Write!a!file!name!under!File2Name!on!the!right!3. Click!Create!
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!
Figure#3#!Import!excel!spreadsheet!in!MS!Access!by!following!these!steps:!1. Click!on!external2data!tab!–>!excel!icon!under!Import!tabY>!click!on!Browse!and!select!path!where!the!file!you!just!created!“Record_with_ID.xlsx”2is!located.!!2. This!will!open!a!wizard!window.!3. Select!“Import2the2source2data2into2the2new2table2in2the2current2database”!and!click!OK.!!4. In!the!first!page!please!tick!on!First2Row2Contains2Column2Headings!(if!an!error!message!opens!just!click!OK)!and!click!Next.!!5. Under!tab!field!name!write!NameID!and!click!Next!6. On!the!next!page!select!No2primary2key!then!click!Next.!7. Click!on!Finish!then!Close!(this!will!add!Sheet1:Table!on!the!menu!on!the!left).!!Assign!a!unique!ID:!
• Select!the!Tab!Create!and!then!Query2Design!(under!Other).!When!a!wizard!entitled!“Show2
table”!opens!add!the!table!with!the!name!you!gave!it!when!you!imported!the!data!(there!should!be!only!one!table!with!data!in!it!at!this!stage!–!we!named!it!Practice!in!this!example),!then!click!on!close!in!the!Show2table!window.!!
• Then!click!on!the!design!tab!at!the!top!(arrow!1)!and!on!ΣTotals!(arrow!2).!This!will!take!you!to!the!window!shown!in!Figure#4.!DoubleYclick!on!NameID!TWICE!(arrow!3!Y!this!will!add!NameID!TWICE!in!the!panel!at!the!bottom.!Then!click!where!indicated!by!arrow!4!(in!the!row!called!Total:!of!the!second!column!–!it!should!say!Group2by!at!this!stage!but!once!you!click!on!it!a!scroll!down!menu!should!open)!and!select!Count.!Then!click!on!save!(and!OK!in!the!save!window!that!opens)!and!Run!(arrows!5!and!6)!–!see!Figure!4!as!a!guide.!
• Once!you!run!the!query!it!will!give!your!NameID!columns!and!a!Count!column!(each!number!corresponds!to!the!times!each!horse!is!entered!in!the!records).!!
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!
Figure#4#!
• Copy!and!paste!the!column!NameID!by!RIGHT!clicking!where!indicated!by!Figure!5!(arrow!1)!and!selecting!copy!in!the!menu!that!opens.!Then!click!on!the!Create!tab!and!select!Table!(steps!2!and!4!of!figure!5).!!!
!
Figure#5#!
• On!the!menu!on!the!left,!LEFT!click!on!Table1:Table!and!select!Design2view.!Name!the!new!table!“ID2number”!when!asked.!
• On!the!new!tab!window!that!opens,!type!ID2number!in!the!first!row!of!column!Field2name!and!leave!AutoNumber!in!the!Data2Type!column.!In!the!second!row!write!ID2name!in!the!first!and!select!text!in!the!second!column!respectively.!After!saving,!RIGHT!click!on!ID2
number!tab!and!select!datasheet2view!(use!figure!6!as!a!guide).!
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!!!!! !
Figure#6#!
• Now,!RIGHT!click!on!ID2name!and!select!paste.!Click!on!yes!if!Access!asks!if!you!are!sure!to!paste!the!XXX!record(s)!(Figure!7).!This!will!add!all!the!ID!name!content!in!the!ID!name!column!and!assign!automatically!an!ID!number!in!the!ID!number!column.!!!
!
Figure#7#!
• Now,!create!a!query!(Create!Y>!Query2Design)!and!include!both!(double!click!on!each)!initial!table!with!dataset!(“Practice”!in!this!example)!and!the!newly!created!table!(“ID!number”)!then!select!close.!!
• Drag!ID2name!from!the!ID!number!window!to!NameID!on!the!left!(be!precisely!right!on!NameID).!Use!Figures!8Y9Y10!as!a!guide.!!
		
250	
	
!
!
!
Figure#8:!Drag!ID2Name!from!ID!precisely!onto!Name2ID!in!the!Practice!window.!This!will!create!a!link!(black!line!between!these!two).!
Figure#9:!double!click!on!the!black!link!line!and!the!Join2Properties!window!will!open.!Here!select!the!option!that!says:!Include2ALL2records2
from2‘Practice’2and2only2those2from2‘ID2
number’2where2the2joined2fields2are2
equal!Y>!this!is!option!3!in!this!example.!Then!click!OK.!
Figure#10:!If!these!steps!were!done!correctly!the!black!link!line!will!become!a!black!arrow.!
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• Double!click!on!ID2number!in!ID!number!window,!to!add!ID!number!in!the!first!column!at!the!bottom.!Select!all!the!content!in!Practice!window!and!drag!to!second!column!at!the!bottom!(this!will!add!each!of!them!in!each!column).!See!figure!11!for!reference.!!
!
Figure#11#!
• Click!on!Run!and!obtain!something!like!this!in!Figure!12!(The!original!Practice!table!with!the!first!column!containing!unique!ID!numbers!–!same!horse!has!same!ID!number!when!revisited).!!!
!
Figure#12#!Now!only!few!more!clicks!and!we!are!done.!!Click!on!External!Data!and!Excel!in!the!Export!tab.!This!opens!the!export!wizard.!Select!a!filename!(maybe!the!name!of!your!veterinary!practice)!and!location!and!tick!the!first!2!options!(Export2data2with2formatting2and2layout!and!open2the2destination2file)!and!click!on!OK!(Figure!13!as!reference).!!
		
252	
	
!
Figure#13#!This!will!then!open!an!excel!spreadsheet!containing!the!records!with!the!new!anonymous!ID!numbers!in!the!first!column.!If!an!error!message!shows!just!click!on!yes2or!ok.!If!the!file!opens!as!a!read!only!please!“save!as”!with!another!name!in!order!to!be!able!to!modify!it.!!
STEP3#Now!we!have!only!to!remove!the!columns!containing!owners’!details!to!anonymise!the!dataset.!To!do!so!LEFT!click!on!the!letter!at!the!top!of!the!column!you!want!to!delete!(Name!ID!and!the!one!with!owner!last!name,!address!and!animal!name)!whilst!pressing!on!the!CTRL!key!on!your!keyboard.!This!will!select!each!column!in!its!entire!length.!Finally!one!RIGHT!click!on!the!Last!column!and!select!delete!(blue!arrow).!This!will!delete!all!the!selected!columns!and!shift!all!the!others!to!the!left.!Alternatively!you!can!delete!each!column!individually!(right!click!and!select!delete!at!the!point!of!each!read!arrow!in!figure!14).!
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!
Figure#14#!Finally!save!the!file!and!you!are!done.!Hopefully!it!will!be!small!enough!to!be!sent!by!email.!!!!Thank!you!very!much!again!for!all!your!effort!and!help.!May!you!not!succeed!with!these!instructions!(eg.!your!access/excel!version!is!remarkably!different!from!mine),!call!me!(07717330610)!or!alternatively!I!am!quite!happy!to!come!there!in!person!to!sort!it!out!in!the!near!future.!!Kind!regards,!Marco!!!
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Appendix	3.3		
NSAIDS INCLUSION DICTIONARY 
ABS/NSAIDS  
ALSODANILON  
ANTI-INFLAMMATORIES  
ANTIINFLAM  
ARQUEL  
ASPIRIN  
ASPSOL  
BINIXIN  
BUSCA  
BUSCO  
BUSCOPAN  
BUSCOPAN_CO  
BUSCOPAN_COMPOSITUM  
BUTE  
BUTEEQUIP 
BUTEINJ 
BUTEPASTE  
COMPOSITUM  
CRONY  
CRONYXIN  
DANIL  
DANILON  
DANILON-PER  
DANILONAS  
DYNAM  
EQUIDOX  
EQUIOXX  
EQUIPAL  
EQUIPALAZONE  
FELDENE  
FINAD  
FINADNE  
FINADYNE  
FLUN  
FLUNIXIN  
KETOFEN  
KETOPROFEN  
MELOXICAM  
METACAM  
METCAM  
NOROCARP  
NSAIDS  
PAINKILLERS  
PBZ  
PBZ?  
PBZ/DANILON  
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PHENYLBUTAZONE  
PRO-DYNAM  
PRODYNAM  
REST/BUTE  
SACHETSBUTE  
TELZENAC  
TOLFINE  
 
NSAIDS EXCLUSION_DICTIONARY 
BUSC  
BUSCA  
BUSCOPAN  
BUSCO  
     
NSAIDS RE-INCLUSION_DICTIONARY 
BUSCOPAN_CO  
BUSCOPAN_COMPOSITUM  
BUSC_CO  
BUSC_COMPOSITUM  
  
COLIC INCLUSION_DICTIONARY 
?COLIC.HR40,PULSE  
?COLICKY  
ADB_DISCOMFORT  
CHOKE  
CLINICAL_NOTE_SEVERE_PAIN_ON_ARRIVAL.  
COLIC  
COLIC  
COLIC,PARAMETERS  
COLIC.  
COLIC.  
COLICING  
COLICING.  
COLICKING  
COLICKING  
COLICKY  
COLICKY.  
COLICY  
COLICY,  
COLICY.PASSED  
COLITIS  
COLOUR,?COLIC  
CONSTIPATION  
DISPLACED  
DISPLACEMENT  
DISPLACEMENT/IMPACTION_FELT.STOMACH  
DISTENDED_LARGE_INTESTINE  
DROPPINGS_PASSED._LYING_DOWN  
ENTEROCOLITIS  
EPISODE_OF_ROLLING  
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EPSOM  
FLANK_WATCHING  
FLANK_WATCHING.  
GASSEOUS_DISTENDEN  
GASTRIC  
GASTROSCOPY  
HAVE_BEEN_RESTLESS_AND_PAWING_BEDDING.  
IMOPACTION  
IMPACTION  
MASSIVELY_IMPACTED  
MILDLY_UNCOMFY  
NEFROSPLENIC  
NEPHRO_SPLENIC_ENTRAPM.  
PARAFFIN  
PASSSTOMACHTUBE  
PELVIC_FLEXURE_IMPACTION.  
PSYLLIUM  
REFLUX  
RETROFLEXION_OF_LARGE_COLON.  
ROLLING  
SAND  
SANDOUT  
SHOWING_SIGNS_OF_ABDOMINAL_PAIN  
SIGNS_OF_ABDOMINAL_PAIN  
SPASMODIC  
SPASMOLYTIC  
SPASMOTIC SQUAMOUS  
TWIST  
STARTD  
UNCOMFORTABLE._GUT_SOUNDS_-VE.  
UNSETTLED_IN_BOX  
  
COLIC EXCLUSION_DICTIONARY 
!TRANSPORT_STRESS/VIRAL  
-03-14_LAB:_INFLAMMATORY_PROFILE  
-04-20_JOURNEY  
-09-28_SAND_OUT  
...LAMINITIS,_V_DULL  
0.5LTR_REFLUX  
1999-09-28_SAND_OUT  
1____EQUINE_INTRAVENOUS  
?TRANSPORT_STRESS/VIRAL  
ATTEMPTS_TO_STOMACH_TUBE_FAILED  
BURPS._LIKELY_GASTRIC_IN_ORIGIN  
CAER_RE_IMPACTION  
CHECKED_TEETH  
CLEAR_IMPACTED_DIASTEMATA  
CLINICAL_NOTE_NO_NET_REFLUX  
COFFIN  
COLIC_ON_THE_29.01.10  
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D++_BUT_NO_COLIC_SIGNS  
DENTAL_EXAM  
DEPRESSED_BUT_NOT_COLIC  
DEPRESSED_BUT_NOT_COLIC.  
DIASTERMA  
DIDN'T_NEED_TO_STOMACH_TUBE_TODAY  
DISCUSSED_POSS_CAUSES_AND_POSS_GASTRIC_ULCERATION  
DISPLACED  
DISPLACED,_MONITOR_AS_ERUPTS  
DISUCSSED_COLIC_AND_FEET  
DOLX_COLITIS,  
EQH_BAXC_BAXTER_DRAPE-_COLIC  
EQH_COLIC_GOWN  
EQH_HICU_INTENSIVE_CARE_DAILY_FEE_HICU_INCL_MULTIPLE_ST
OMACH_TUBE  
EQH_HICU_INTENSIVE_CARE_DAILY_FEE_INCL._MULTIPLE_STOMAC
H_TUBE  
EQH_HICU_INTENSIVE_CARE_DAILY_FEE_INCLUDING_MULTIPLE_ST
OMACH_TUBE  
EQH_SEDAL_SEDALIN_GEL_GIVE_1/3_TUBE_ORALLY_TWICE_DAILY
_FOR_5_DAYS  
EQO_EPS2_MAGNESIUM_SULPHATE_EPSOM_SALTS_2KG_0.25_0.25_
BOXES_0  
EQO_EPSOM_EPSOM_SALTS_100G_1_1_BOX_0  
EQO_HST_STOMACH_TUBE  
EQO_THST_STOMACH_TUBE  
EQUINE_STOMACH_TUBE  
FAECAL_BALLS_PRESENT  
FAECES_IN_RECTUM_-_NO_OTHER_ABNS  
FIBRE  
FLUSHED_ABDOMEN_AND_TUBED_HORSE  
FRACTURE  
GUTS_QUITE_GURGLY_BUT_NO_CSX_OF_COLIC  
GUT_SOUNDS_REDUCED_ALL_ROUND,  
G_VENTIPULMIN_2_1/2_SCOOPS_TWICE_DAILY_BATCH:0256358  
HOCK_DISPLACED  
DIFFICULTY_SWALLOWING  
HOOF  
HR_32,_MM_PINK,_CRT_2SECS,_GUT_SOUNDS_NORMAL_TO_LOUD,  
HST_STOMACH_TUBE  
IF_COLICS_THEN_REFLUX  
ILIAL_WINGWHICH_WAS_DISPLACED  
IMPACTION_CLEARED,  
INFLAMMATORY_PROFILE_-_LAB  
INTERMITTENT_D+._NO_WEIGHT_LOSS._BRIGHT_INSELF._STILL_H
AS_GRADE_III_SYSTOLIC_MUMUR_AND_ARRHYTHMIA  
LAB:PARASITOLOGY_-_LAB_REF  
LAB:_INFLAMMATORY_PROFILE_LAB_REF:_A167_A167_MILD  
LAME  
LAMENESS  
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LAST_DONE_FOR_LARVAL_STAGES.NAD_ON_RECTAL.HAS_PASSED  
LATERALLY_DISPLACED  
LATERALLY_DISPLACED_TOOTH  
LHS_AFTER_30_MINUTES  
LIKELY_GASTRIC_IN_ORIGIN.  
LIQUID_PARAFFIN_5_LITRE  
LIQUID_PARAFFIN_X_1LT_LA  
LYING_DOWN_NOT_COLICING.  
LYING_DOWN_NOT_COLLIDING  
MAKE_COMFORTABLE_RECTAL_NAD_'RETCHING'_TYPE  
NA_PAID_BY_VISA_T_PAYMENTS:_15.42_USERID:_CY_BISHOPTON  
NON-MALODEROUS_PURULENT_L_SIDED_DISCHARGE  
NOTE_FLUSHED_ABDOMEN_AND  
NOT_SHOWING_ANY_COLIC  
NOT_SHOWING_ANY_COLLIC_SIGNS  
NO_ABDOMINAL_HEAVE_BUT_INC_ADVENTIOUS_SOUNDS  
NO_ACTIVE_COLIC_SIGNS  
NO_COLIC_SIGNS  
NO_COLIC_SIGNS,  
NO_COLIC_SIGNS.  
NO_CSX_OF_COLIC.  
NO_FBS_DETECTED_&_STOMACH_TUBE_PASSED_FINE  
NO_IMPACTION_FELT_SOME_REDUCED_AMNT_FAECES_ADV_PROB_
URTI  
NO_SIGNS_CHOKE  
NO_SIGNS_OF_COLIC  
NO_SIGNS_OF_COLIC.  
NO_SIGN_OF_COLIC  
OF_CONSTIPATION_AND_POOR_APPETITE.  
OF_CONSTIPATION_AND_POOR_APPETITE._EYE_LOOKS_AS_BEFOR
E,  
OVERNIGHT_COMFORTABLE_NO_SIGNS_OF_COLIC  
OWNER_CONCERNED_HORSE_HAS_BEEN_ACTING_STRANGELY._ON  
OWNER_CONCERNED_RE:_SQUAMOUS_CELL_CARCINOMA.  
PASSEDNG_TUBE  
PASS_STOMACH_TUBE_1_PFEE  
POLE?STOMACH_TUBE_-_NO_REFLUX  
POOR_INCISORS,_208_LARGE_SHARP_POINT  
PRESENT,STOMACH_TUBE_REFLUX_APPROX  
PREVNT_IMPACTION  
PSYLLIUM_500GM  
RECTAL_EXAM:_IMPACTION_CLEARED  
RECTAL_EXAM:_IMPACTION_GONE  
REMOVE_FOOD_PACKING,  
RESTRICTED_FEED,_IF_COLICKY_OR  
SAND_CRACK  
SAND_ON_R_CIRCLE  
SEDATED_TO_MAKE_COMFORTABLE_RECTAL_NAD_'RETCHING'_TYP
E  
SHARED_VISIT  
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SINUS  
SL_DISPLACED._ON_SCOPE_-_DUE_TO_SWELLING_ONLY_POSS_TO  
SOFT_F+_PRESENT_IN_RECTUM  
SOFT_F+_PRESENT_IN_RECTUM_NO_IMPACTION_PALPABLE  
SOME_FORAGE_IMPACTION  
SO_SIGNS_CHOKE.  
SQUAMOUS_CELL_CARCINOMA_SHEATH_HAS_A_LOT_OF_SMEGMA  
STOMACH_TUBE_REFLUX_APPROX_1L  
STOMACH_TUBE_THIS_AM.ALSO_ONTO_B-SURE_AS_POSS_MORE  
STOMACH_TUBING_MIDDAY_AND_FIRST_LITTLE_MASH  
ST_LINE_SAND_ON  
PROB_URTI_COS_OF_TRAVELLING  
TOPAZ_HAD_RADIOGRAPHS_OF_HER_TEETH_AND_SINUSES  
TO_STOMACH_TUBE_FAILED.DISCUSSED,ADV  
TUBED_AGAIN_WITH_5_L_ELECTROLYTES_AND_PARAFIN  
UNSTABLE_SANDCRACK  
VALLEY_VETS_SAND_SUPP  
VENTIPULMIN_2_1/2_SCOOPS_TWICE_DAILY_BATCH:0256358  
WELL_NO_COLIC_SIGNS,  
WENSUM_1_1_LIQUID_PARAFFIN_2_LITRES  
WENSUM_BUTEINJ_15_MLS_INJECT_EQUIPALAZONE_INJ_WENSUM  
WEN_SUM_SANDOUNT_1_TUB_SAND-OUT_908G  
WORMS/STABLING/GASTRIC_ULCERATION/MOTILITY_CHANGES  
WOUND_SLIGHT_ODEMA  
 
COLIC RE-INCLUSION DICTIONARY 
FLUSHED ABDOMEN AND REFLUXED HORSE AGIAN THIS PM 
FLUSHED ABDOMEN AND TUBED HORSE 
BUSCOPAN. POSS SPASMODIC COLIC 
MILD COLIC. NORMAL DROPPINGS 
COLON NOT DISTENDED SO ADVISE PROB MILDLY DISPLACED 
 
RIGHT DORSAL COLITIS INCLUSION 
RIGHT DORSAL COLITIS, 
RDC EPISODE 
RD_COLITIS 
RD COLITIS. 
NSAID_INDUCED 
?NSAIDS INDUCED 
 
RENAL_FAILURE INCLUSION DICTIONARY 
KIDNEY_DISEASE  
KIDNEY_FAIL  
KIDNEY_INSUF  
KIDNEY_INSUFFICIENCY  
PAPILLARY_NECROSIS  
RENAL_DISEASE  
RENAL_FAIL  
RENAL_FAILURE  
KIDNEY_FAILURE  
	 260	
RENAL_INSUF  
RENAL_INSUFFICIENCY  
URINARY_DISEASE  
URINARY_FAILURE  
      
RENAL_FAILURE EXCLUSION DICTIONARY 
ACUTE_RENAL_FAILURE_NO_URINE_RECTAL  
RENAL_DISEASE_?_!_C/EXAM_NAD.  
SG_LOW_1.040_DISCUSS_DILUTE_URINE  
SEVERE_DEHYDRATION_AND_PRE_RENAL_FAILURE 
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Appendix	4		
ASPIRIN INCLUSION DICTIONARY 
              ACETYLSALICYLIC 
              ACETYLSALICYLIC_ACID 
              ASPIRIN 
              ASPRIN 
              ASPSOL 
 
PHENYLBUTAZONE INCLUSION DICTIONARY 
              BIZOLIDIN 
              BUTATRON 
              BUTAZOLIDIN 
              BUTE 
              BUTEEQUIP 
              BUTEINJ 
              BUTEPASTE 
              BUTEQUINE 
              COMPANAZONE 
              DYNAM 
              EQUIBUTE 
              EQUIBUTE 
              EQUIPA 
              EQUIPAL 
              EQUIPAL 
              EQUIPALA 
              EQUIPALAZ 
              EQUIPALAZO 
              EQUIPALAZONE 
              EQUIPALAZONE 
              EQUIPALAZONE 
              EQUIPALIZONE 
              EQUIPALOZONE 
              EQUIPALZONE 
              EQUIPHEN 
              EQUIZONE 
              MBUTAZOLIDIN 
              PBZ, 
              PBZ. 
              PBZ/DANILON 
              PBZ? 
              PHEMYLBUTAZONE 
              PHEN_BUTA 
              PHENBUTA 
              PHEN-BUTA 
              PHENYBUTAZONE 
              PHENYLBUATZONE 
              PHENYLBUTASONE 
              PHENYLBUTAZONE 
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              PHENYLBUTE 
              PHENYLZONE 
              PRIBUTAZONE 
              PRO_DYNAM 
              PRODYNAM 
              PRO-DYNAM 
              REST/BUTE 
              ROBIZONE 
              RXBUTE 
              SACHETSBUTE 
              SUPERIORBUT 
              TEVCODYNE 
              THERAZONE 
 
SUXIBUZONE INCLUSION DICTIONARY 
              ALSODANILON 
              DALILON 
              DANALON 
              DANALONE 
              DANEQ 
              DANEQUIB 
              DANI 
              DANIDOL 
              DANIL 
              DANILAN 
              DANILAON 
              DANILLON 
              DANILON 
              DANILONAS 
              DANILON-PER 
              DANILONE 
              DANILONSID 
              DANION 
              DANOLIN 
              DANOLONE 
              DNAILON 
              SAXIBUZON 
              SUXIBUZONE 
              SUXILON 
              VET-DANILON 
              XDANILON 
 
SUXIBUZONE EXCLUSION DICTIONARY 
              ASPHALT_DANI 
              BY_DANI 
              CC_DANI 
              CHIP_DANI 
              DANI_-_BASIC 
              DANI_-_LAMENESS_EVAL 
              DANI_..._BEHAVE 
	 263	
              DANI_APPEARS 
              DANI_BUHLER 
              DANI_CALLED 
              DANI_DAUGHTER 
              DANI_FROM 
              DANI_HAS 
              DANI_IS 
              DANI_LACERATION 
              DANI_MADILL 
              DANI_OSTER 
              DANI_RINDFLEISCH 
              DANI_VOLK 
              FOR_DANI 
              HAVE_DANI 
              OSTER_DANI 
              DANI_RINDFLIESCH 
              PALPATED_DANI 
              PER_DANI 
              TEETH_DANI 
              WITH_DANI 
              SHOES_ON_DANI 
 
FIROCOXIB INCLUSION DICTIONARY 
              EQUIOOX 
              EQUIOX 
              EQUIOXX 
              FIBROCOX 
              FIBROCOXIB 
              FIROCOXIB 
              PREVACOX 
              PREVICOX 
              PREVICOXX 
 
FLUNIXIN MEGLUMINE INCLUSION DICTIONARY 
              BANA 
              BANAMIN 
              BANAMINE 
              BANMINE 
              BANNAMINE 
              BINIXIN 
              CRONIXIN 
              CRONY 
              CRONYXIN 
              EQUINIXIN 
              FINAD 
              FINADINE 
              FINADNE 
              FINADYN 
              FINADYNE 
              FINADYNE/BUSCO 
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              FINDYNE 
              FLUN 
              FLU_NIX 
              FLUNAZINE 
              FLUNIX 
              FLU-NIX 
              FLUNIXAMINE 
              FLUNIXIN 
              FLUNIXIN_MEGLUMINE 
              FLUNXIN 
              FYNADINE 
              HEXASOL 
              MBANAMINE 
              MEFLOSYL 
              MEGLUMINE 
              NOXIRIN 
              OXYCOMPLEX 
              RESFLOR 
              RXBANAMINE 
 
KETOPROFEN INCLUSION DICTIONARY 
              ANAFEN 
              AXORID 
              COMFORION 
              DANIDOL 
              DINALGEN 
              KELAPROFEN 
              KETOCID 
              KETODALE 
              KETOFEN 
              KETOPHEN 
              KETOPROFEN 
              KETOPROPIG 
              KETOVAIL 
              ORUDIS 
              ORUVAIL 
              POWERGEL 
 
MELOXICAM INCLUSION DICTIONARY 
              ADOCAM 
              ANIMELOX 
              FLEXICAM 
              LOXICOM 
              MELOSUS 
              MELOVEM 
              MELOXICAM 
              MELOXIVET 
              MELOXORAL 
              MELOXYDYL 
              METAC 
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              METACAM 
              METACINJ 
              METACJ 
              METCAM 
              METCAMMETAC 
              MOBIC 
              NOVEM 
              RECOCAM 
              RHEUMOCAM 
 
METAMIZOLE_UK INCLUSION DICTIONARY 
              BUSC 
              BUSCA 
              BUSCAPAN 
              BUSCAPAN 
              BUSCO 
              BUSCO 
              BUSCOPAN 
              BUSCOPAN 
              COMPOSITE 
              COMPOSITION 
              COMPOSITUM 
              DIPIRONE 
              DIPYRONE 
              DYPIRONE 
              DYPIRONE 
 
METAMIZOLE INCLUSION DICTIONARY 
              _CO 
              _CO. 
              _COMP 
              _CO, 
              _COMP. 
 
METAMIZOLE_UK EXCLUSION DICTIONARY 
              ADV_CO 
              ALL_3_COMP. 
              BANDAGE_-_CO 
              BEAN&CO._ 
              COLAST10_CO_ 
              COMP_ID_DRAW 
              CO_BACTAN 
              FOR_A_WEEK,_CO 
              INCREASE_CO 
              INDIVIDUALLY_SO_NO_COMP. 
              INSURANCE_CO, 
              INSURANCE_CO_ 
              I_WILL_CO_ 
              PRESENT._CO_ 
              RELUCTANT_CO_X_ 
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              TJHIS_IS_CO_ 
              TO_BE_CO_ 
              REX_HORSE_CO_ 
              TO_IMPROVE_CO_ 
              TRIMMING_TO_CO 
              _CO_PLUS. 
 
METAMIZOLE NORTH AMERICA INCLUSION DICTIONARY 
              COMPOSITUM 
              DIPIRONE 
              DIPYRONE 
              DYPIRONE 
              METAMIZOLE 
 
ACETAMINOPHEN INCLUSION DICTIONARY 
              ACETAMINOPHEN 
              NOXIRIN 
              NOXPIRIN 
 
CARPROFEN INCLUSION DICTIONARY 
              CARPROFEN 
              CARPROFENL 
              NOROCARP 
              RYMADIL 
              RIMADYL 
 
DERACOXIB INCLUSION DICTIONARY 
              DERACOXIB 
              DERAMAX 
              DERAMAXX 
 
DICLOFENAC INCLUSION DICTIONARY 
              DICLOFENAC 
              DICLOFINEC 
              SURPASS 
 
ELTENAC INCLUSION DICTIONARY 
              ELTENAC 
              TELZENAC 
 
MECLOFENAMIC_ACID INCLUSION DICTIONARY 
              ARQ 
              ARQUEL 
              ARQUELL 
              MECLOFENAMIC_ACID 
              MECLOFENAMATE 
 
TOLFENAMIC_ACID INCLUSION DICTIONARY 
              TOLFENAMIC 
              TOLFINE 
	 267	
 
VEDAPROFEN INCLUSION DICTIONARY 
              QUADRASOL 
              QUADRISOL 
              VEDAPROFEN 
               
COLIC INCLUSION DICTIONARY 
    ABDOCENTESIS 
              ABDOMINOCENTHESIS 
              ADBOMINOCENTESIS 
              CELIOTOMY 
              CHOKE 
              CHOKED 
              CHOKES 
              CHOKING 
              CHOLIC 
              COELIOTOMY 
              COILC 
              COLCI 
              COLCIKY 
              COLCKY 
              COLIC 
              COLICAGAIN 
              COLICALLY 
              COLICCS 
              COLICCY 
              COLICD 
              COLICE 
              COLICED 
              COLICER 
              COLICERY 
              COLICEXAM 
              COLICFY 
              COLICI 
              COLICIING 
              COLICIKY 
              COLICING 
              COLICK 
              COLICKE 
              COLICKED 
              COLICKED 
              COLICKER 
              COLICKEY 
              COLICKING 
              COLICKLY 
              COLICKS 
              COLICKY 
              COLICKYING 
              COLICL 
              COLICLY 
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              COLICN 
              COLICS 
              COLICSTRIC 
              COLICTHAT 
              COLICY 
              COLICY 
              COLICYING 
              COLIIC 
              COLIITIS 
              COLIKED 
              COLIKING 
              COLIKY 
              COLILC 
              COLILCY 
              COLITIS 
              COLLIC 
              COLLICED 
              COLLICKED 
              COLLICKING 
              COLLICKY 
              COLLICS 
              COLLICT 
              COLLICY 
              COLONIC 
              COLONIC 
              CONSTIPATED 
              CONSTIPATION 
              DISPLACED 
              DISPLACEMENT 
              DISPLACEMENTS 
              DISPLACMENT 
              DISTENDED_LARGE 
              DISTENDED_SI 
              DISTENDED_SMALL_INTESTINE 
              DOCUSOL 
              ENTERITIS 
              ENTEROCOLITIS 
              ENTEROLYTH 
              ENTEROLYTHIASIS 
              ENTEROTOMY 
              EPIPLOIC 
              EPSOM 
              EPSOM_SALTS 
              ESOPHAGEAL_DIVERTICULUM 
              ESOPHAGEAL_FOREIGN_BODY 
              ESOPHAGEAL_OBSTRUCTION 
              ESOPHAGEAL_RUPTURE 
              ESOPHAGEAL_STENOSIS 
              ESOPHAGEAL_STRICTURE 
              ESOPHAGEAL_TEAR 
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              EXPLORATORY 
              FECALITH 
              FLANK_WATCHING 
              GASEOUS_DISTENDEN 
              GASSY_COLIC 
              GASTRIC 
              GASTRIC_ULCER 
              GASTROSCOPY 
              GAS_COLIC 
              GLANDULAR 
              GUT_INFLAMMATION 
              IBD 
              IMOPACTION 
              IMPACTED 
              IMPACTION 
              IMPACTION 
              INFLAMMATORY_BOWEL 
              INTESTINAL_ISCHAEMIA 
              INTESTINAL_ISCHEMIA 
              INTRALUMINAL_OBSTRUCTION 
              ISOGEL 
              LAXATIVE 
              LDD 
              LIQUID_PARAFFIN 
              MARGO_PLICATUS 
              MEED 
              NEFROSPLENIC 
              NEMATODES 
              NEPHORSPLENIC 
              NEPHROPLENIC 
              NEPHROSLENIC 
              NEPHROSPENIC 
              NEPHROSPLENIC 
              NEPHRO_SPLENIC 
              NOT_IN_THE_RIGHT_PLACE 
              PARAFFIN 
              PASSSTOMACHTUBE 
              PAWINGAND 
              PAWINGS 
              PAWINIG 
              PSYLLIUM 
              PYLORIC 
              PYLORUS 
              RDD 
              REFLUX 
              REFLUXING 
              RESECTION 
              RETROFLEXION_OF_LARGE_COLON 
              ROLLING 
              SAND 
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              SANDOUT 
              SANDOUT 
              SPAMODIC 
              SPASMODIC 
              SPASMODICS 
              SPASMOLYTIC 
              SPASMOLYTICS 
              SPASMOTIC 
              SPASMOTIC 
              PAWING 
              STANGULATION 
              STOMACH_TUBE 
              STOMACH_ULCER 
              STRANGULATED 
              STRANGULATING 
              TIPHLITIS 
              TORSION 
              TUBED 
              TWIST 
              TYMPANTIC 
              SQUAMOUS 
              TYPHLITIS 
              VOLVOLUS 
              VOLVO 
              VOLVULUS 
              WINDY_COLIC 
              WIND_COLIC 
              ?COLIC.HR40,PULSE 
              ?COLICKY 
              ADB_DISCOMFORT 
              CHOKE 
              CLINICAL_NOTE_SEVERE_PAIN_ON_ARRIVAL. 
              COLIC,PARAMETERS 
              COLICY.PASSED 
              COLOUR,?COLIC 
              CONSTIPATION 
              DISPLACEMENT/IMPACTION_FELT.STOMACH 
              DISTENDED_LARGE_INTESTINE 
              DROPPINGS_PASSED._LYING_DOWN 
              ENTEROCOLITIS 
              EPISODE_OF_ROLLING 
              EPSOM 
              FLANK_WATCHING 
              FLANK_WATCHING. 
              HAVE_BEEN_RESTLESS_AND_PAWING_BEDDING. 
              UNCOMFORTABLE._GUT_SOUNDS_-VE. 
              UNSETTLED_IN_BOX 
 
COLIC EXCLUSION DICTIONARY 
              3RD_EYELID_REMOVAL_SQUAMOUS_CELL 
	 271	
              ABAXIAL_DISPLACEMENT 
              APICAL_DISPLACEMENT 
              ARCH 
              ARCH_DISPLACEMENT 
              AREA_OF_DISPLACEMENT 
              ARYEPIGLOTTIC 
              ASSESSMENT_ON_ORAL_EXAM 
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              LORDOSIS 
              LUMBAR 
              LUMBARS 
              LUMBOSACRAL 
              LUXATION 
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              MALEOLUS 
              MALLEOLUS 
              MCII 
              MCIII 
              MEADIAL 
              MEDIALL 
              MEDIOLATERAL 
              MEDRONE 
              MENISCAL 
              MENISCUS 
              MESOTENDON 
              METACARPAL 
              METACARPOPHALANGEAL 
              METACARPUS 
              METATARSAL 
              METATARSUS 
              MIDBRACHIUM 
              MIDCARPAL 
              MIDSOLE 
              MRI 
              MTIII 
              MTPJ 
              NAVIC 
              NAVICULAR 
              NAVICULARS 
              NAVILOX 
              NERVE-BLOCK 
              NERVEBLOCK 
              NERVE_BLOCK 
              NERVE_BLOCK 
              NEUROPATHY 
              N_BLOCK 
              N_BLOCK 
              OCD 
              OLECRANON 
              ORTHO 
              ORTHOPAEDIC 
              OSTECTIS 
              OSTEITIS 
              OSTEOARTHERITIS 
              OSTEOARTHRITIC 
              OSTEOARTHRITIS 
              OSTEOCHONDRAL 
              OSTEOCHONDROMA 
              OSTEOCHONDROSIS 
              OSTEODENSITY 
              OSTEOLYSIS 
              OSTEOMYELITIS 
              OSTEOPATH 
              OSTEOPHYTE 
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              OSTEOPHYTES 
              OSTEOPHYTOSIS 
              OSTITIS 
              OVERGROWING 
              OVERREACHED 
              OVERRIDING 
              P3_DISPLACEMENT 
              PALMAR 
              PALMAR-DIGITAL 
              PALMARDIGITAL 
              PALMARODISTAL 
              PALMAROLATERAL 
              PALMAROMEDIAL 
              PALMAR_N.B 
              PALMAR_NB 
              PALMER 
              PARALUMBAR 
              PARATENDON 
              PARATENON 
              PASTERN 
              PASTERNS 
              PATELA 
              PATELLA 
              PATELLAE 
              PATELLAR 
              PATELLAS 
              PDNB 
              PEDAL 
              PELVIC 
              PELVIS 
              PELVIS_DISPLACEMENT 
              PERIARTICULAR 
              PERILIGAMENTOUS 
              PERINEURAL 
              PERIOSTEAL 
              PERIOSTEUM 
              PERIOSTITIS 
              PERITARSAL 
              PERITENDINOUS 
              PERITENDONOUS 
              PERONEUS 
              PEROREUS 
              PHALANGEAL 
              PHALANX 
              PHYSIOTHERAPIST 
              PHYSITIS 
              PI 
              PII 
              PIII 
              PLANTAR 
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              PLANTARO 
              PLANTAROLATERAL 
              PLANTAROMEDIAL 
              POSTURAL 
              POTTERING 
              POULTICE 
              PUNCTURE 
              PUS_IN_THE_FOOT 
              QUADRICEPS 
              RADIAL 
              RADIALIS 
              RADIUS 
              REINJURED 
              REINJURY 
              RETINACULUM 
              RIDGE 
              RING-BONE 
              RINGBONE 
              RING_BONE 
              ROSTROVENTRAL 
              ROTAION 
              ROTATES 
              ROTATING 
              ROTATION 
              ROTATIONAL 
              ROTATIONS 
              RUMP 
              SACRAL 
              SACRALE 
              SACRALIS 
              SACROILEAC 
              SACROILIAC 
              SACROILIACS 
              SACROILIAE 
              SACROILLIAC 
              SACRUM 
              SAGGITAL 
              SAGITAL 
              SAGITTAL 
              SANDCRACK 
              SCAPULA 
              SCAPULAS 
              SCOUT 
              SDFT 
              SEMIMEMBRANOSUS 
              SEMITENDINOSUS 
              SEMITENDINOUS 
              SEQUESTRAE 
              SEQUESTRIUM 
              SEQUESTRUM 
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              SESAMOID 
              SESAMOIDEAN 
              SESAMOIDIAN 
              SESAMOIDITIS 
              SESAMOIDS 
              SESMOID 
              SHOCK-WAVE 
              SHOCKWAVE 
              SHOCKWAVED 
              SHOLDER 
              SHOULDER 
              SKELETAL 
              SKELETON 
              SOLAR 
              SOLESUPP 
              SPAVIN 
              SPAVINS 
              SPINE 
              SPINOUS 
              SPLINT 
              SPLINTS 
              SPONDYLOSIS 
              SPRAIN 
              STERNEBRA 
              STIFEL 
              STIFFEN 
              STIFFENED 
              STIFFENING 
              STIFFENS 
              STIFFF 
              STIFFLE 
              STIFLE 
              STIFLES 
              STIFNESS 
              STILES 
              STILFE 
              STRAIN 
              STRINGHALT 
              SUB-LUXATION 
              SUB-SOLEAR 
              SUBCARPAL 
              SUBCHONDRAL 
              SUBLUX 
              SUBLUXATING 
              SUBLUXATION 
              SUBSOLAR 
              SUBSOLEAR 
              SUBTARSAL 
              SUPENSORY 
              SUPRASCAPULAR 
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              SUPRASPINOUS 
              SUSPENSORIES 
              SUSPENSORY 
              SUSPENSORYS 
              SYNOVIA 
              SYNOVIAL 
              SYNOVILA 
              SYNOVIOCENTESIS 
              SYNOVIOCOELE 
              SYNOVITIS 
              SYNOVIUM 
              TARSAL 
              TARSO 
              TARSOCRUAL 
              TARSOCRURAL 
              TARSOCURAL 
              TARSOCURUAL 
              TARSOMETATARSAL 
              TECHNOVIT 
              TENDINITIS 
              TENDON 
              TENDONITIS 
              TENDONOUS 
              TENDONS 
              TENDONSHEATH 
              TENDON_SCAN 
              TENDON_SHEATH 
              TENOSINOVITIS 
              TENOSYNOITIS 
              TENOSYNOVITIS 
              TESTERS 
              THORACOLUMBAR 
              THORACOLUMBER 
              THORN 
              THOROUGHPIN 
              TIBIA 
              TIBIAL 
              TIBIOTARSAL 
              TILDREN 
              TILUDRONATE 
              TMJ 
              TMT 
              TMTINJECTION 
              TMTS 
              TRAPEZIUS 
              TROCHANTER 
              TROCHLEA 
              TROTED 
              TROTING 
              TROTUP 
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              TUBER 
              TUBERCLE 
              TUBERCOXEA 
              ULNAR 
              VALGUS 
              VERSATRON 
              VERTEBRAL 
              VETCAST 
              VOLUVEN 
              WEIGHBEARING 
              WEIGHTBEAR  
              WEIGHTBEARING 
              WEIGHTSHIFTING 
              WHITELINE 
              WITHERS 
              _OA_ 
              OBLIQUES 
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              AURICOLOPALPEBRAL_NERVE_BLOCK 
              BLOCK_EYE 
              CANTOS_OF_THE_EYE 
              CAUTERY_OPTHALMIC_NERVE_BLOCK 
              CEVA_OPEN_-_FARRIER_WORK 
              DORM_GELS_FOR_DONKEYS_AND_FARRIER_WORK 
              EYE_EXAM 
              EYE_NERVE_BLOCK 
              EYE_TUMOR 
              EYE_ULCER 
              FARRIER_WORK_-_OUTSIDE_FARRIER 
              FARRIER_WORK_APPOINTMENTINFO 
              FARRIER_WORK_[DR_DOUGLAS_LANGER 
              FROG_SUPPORT_IN_PLACE 
              FRONTAL_NERVE_BLOCK 
              IF_BO_BECAME_LAME_SORE_SWOLLEN 
              IS_A_NICE_FREE_MOVER_IN_ALL_4_LIMBS 
              NORMAL_FARRIER_WORK 
              NOTE_FARRIER_WORK_TODAY 
              NO_EVIDENCE_OF_LAMENESS 
              OPHTHALMIC_EXAM 
              OPHTHALMIC_NERVE_BLOCK 
              PALPEBRAL_NERVE_BLOCK 
              PALP_TEXT_RESULT_SARCOID._LIKE_2_CM._LESION_ON_PASTERN 
              REDUCED_DORM/TORB_-_.4/.4CC_-_FARRIER 
              REDUCED_DORM/TORB_-_.5/.5CC_-_FARRIER 
              REDUCED_DORMOSEDAN_-_.35CC_-_FARRIER 
              REDUCED_DORMOSEDAN_-_.4CC_-_FARRIER 
              REDUCED_DORMOSEDAN_-_.5CC_-_FARRIER 
              REGULAR_DORMOSEDAN_.3CC_-_FARRIER 
              RIGHT_EYE_HAS_MILD_AMOUNT_OF_WHITE_DISCHARGE 
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              SHOE_CYCLE 
              TRANQ_FOR_FARRIER 
              SUPRAORBITAL_NERVE_BLOCK 
              ABRASIONS_ON_WITHERS 
              BRIEF_WITHERS_WNL 
              AUROCOLOPALPEBRAL_NERVE_BLOCK 
              CUT_ON_WITHERS 
              DISCHARGE_OUT_OF_WITHERS 
              EXCORIATED_L_WITHERS 
              FISTULOUS_WITHERS 
              FRONTAL_NERVE_BLOCK 
              INFECTED_WITHERS 
              INFECTION_OF_WITHERS 
              LLIAN_BIOPSY 
              LUMP_ON_WITHERS 
              OCULAR_NERVE_BLOCK 
              OVER_WITHERS 
              PALPEBRAL_NERVE_BLOCK 
              PRESSURE_SORE_WITHERS 
              PRURITIC_AREA_ALL_OF_NECK 
              PYODERMA_AROUND_WITHERS 
              RUB_ON_WITHERS 
              SOME_ON_WITHERS 
              STAPLES_REMOVED_FROM_SURGICAL_WITHERS 
              SUPRAORBITAL_NERVE_BLOCK 
              WHITE_HAIR_@_WITHERS 
              WITHERS_-_MOIST_DERMATITIS 
              WITHERS_INFECTION 
              WITHERS_WOUND_HEALING 
              WOUNDS_ON_WITHERS 
              WOUND_DORSAL_WITHERS 
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              A/BS 
              ABS 
              ABX 
              AB’S 
              ABS 
              AGRIMYCIN 
              AIVLOSIN 
              ALAMYCIN 
              AMIKACIN 
              AMIKIN 
              AMOXICILLIN 
              AMOXINSOL 
              AMOXLA 
              AMOXYCILLIN 
              AMPEQUINE 
              AMPICILLIN 
              AMPROLIUM 
              ANIMEDAZON 
              ANITBIOTICS 
              ANTBX 
              ANTI B 
              ANTIB 
              ANTIBACTERIAL 
              ANTIBIOSIS 
              ANTIBIOTCS 
              ANTIBIOTIC 
              ANTIBIOTICS 
              ANTIBOTICS 
              ANTIOBIOTICS 
              ANTIROBE 
              ANTI_BIOTICS 
              APRALAN 
              APRAMYCIN 
              AQUATET 
              ATBS 
              AUREOMYCIN 
              AUROFAC 
              AZIMYCIN 
              AZITHROMYCIN 
              BACTRIM 
              BANTIBIOTIC 
              BAYCOX 
              BAYRIL 
              BAYT 
              BAYTIL 
              BAYTRIL 
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              BAYTRIL 
              BAYTRILL 
              BENZATHINE 
              BENZYLPENICILLIN 
              BETAMOX 
              BIMECTIN 
              BIMOTRIM 
              BINIXIN 
              BIOMYCIN 
              BORGAL 
              CEFA 
              CEFALAC 
              CEFALACK 
              CEFALAK 
              CEFA-LAK 
              CEFALEXIN 
              CEFAPIRIN 
              CEFAZOLIN 
              CEFELAK 
              CEFENIL 
              CEFGUARD 
              CEFITOFUR 
              CEFOTAXIME 
              CEFOVECIN 
              CEFPODOXIME 
              CEFQUINOME 
              CEFTAZIDIME 
              CEFTIFLEX 
              CEFTIOCYL 
              CEFTIOFUR 
              CEFTRIAXONE 
              CEFUROXIME 
              CEPHAGUARD 
              CEPHALAC 
              CEPHALAK 
              CEPHALEXIN 
              CEPHALOTIN 
              CEPHAPIRIN 
              CEPHE 
              CEPOREX 
              CEPRAVIN 
              CEVAXEL 
              CHLO 
              CHLO 
              CHLOR 
              CHLORAM 
              CHLORAMPHEN 
              CHLORAMPHENICAL 
              CHLORAMPHENICOL 
              CHLORBIOTIC 
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              CHLOREPHENICAL 
              CHLOROMPHENICOL 
              CHLOROMYCETIN 
              CHLOROPHENICOL 
              CHLORSOL 
              CHLORTETRACYCLINE 
              CHLPO 
              CILASTATIN 
              CILOXAN 
              CIPROFLOXACIN 
              CLAMOXYL 
              CLARITHROMYCIN 
              CLAVAMOX 
              CLAVUCILL 
              CLAVULANIC_ACID 
              CLINDACYL 
              CLINDAMYCIN 
              CLORTETRACYCLINE 
              CLOXACILLIN 
              CLYNDAMYCIN 
              COBACTAN 
              COBACTIN 
              CRYSTAPEN 
              CYCLOSOL 
              DAILYTMPS 
              DELVOPRIM 
              DEPCILLIN 
              DEPO 
              DEPOCCILIN 
              DEPOCIILIN 
              DEPOCILIN 
              DEPOCILL 
              DEPOCILLIN 
              DEPOCILLING 
              DEPOCILLLIN 
              DEPOCILLON 
              DEPOCOLLIN 
              DEPOMYB 
              DEPOMYCIN 
              DEPOMYCN 
              DEPOMYJ 
              DFOXYCYCLINE 
              DIMYCIN 
              DOXICYLINE 
              DOXY 
              DOXYC 
              DOXYCYCLENE 
              DOXYCYCLINE 
              DOXYCYLCINE 
              DOXYCYLINE 
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              DOXYSEPTIN 
              DRAXXIN 
              DTRIMPASTE 
              DUPGRAN 
              DUPHACILLIN 
              DUPHACYCLINE 
              DUPHAMOX 
              DUPHAPEN 
              DUPHAPEN 
              DUPHATRIM 
              DUPHATRIM 
              DUPLOCILIN 
              DUPLOCILLIN 
              ENGEMYC 
              ENGEMYCIN 
              ENGYMYCIN 
              ENROFLAXACIN 
              ENROFLAXCECIN 
              ENROFLAXCIN 
              ENROFLOXACIN 
              ENROX 
              ENROXIL 
              EQUIFUR 
              EQUITRIM 
              EQUITRS 
              ERYTHROCIN 
              ERYTHROMICIN 
              ERYTHROMYCIN 
              ETHICILIN 
              EXCENEL 
              EXENEL 
              FENOFLOX 
              FLOROCOL 
              FLO_CILLIN 
              FLOCILLIN 
              FLORFENICOL 
              FLUORQUINOLONES 
              FORCYL 
              FORTAZ 
              FRAMOMYCIN 
              GENOTCIN 
              GENT 
              GENTA 
              GENTACIN 
              GENTAJECT 
              GENTAMAX 
              GENTAMICIN 
              GENTAMYCIN 
              GENTICIN 
              GENTOCIN 
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              GSULPHADIAZINE 
              HEXASOL 
              HYDRODOXX 
              IMIPENEM 
              KARIDOX 
              KLARICID 
              KPEN 
              LINCOCIN 
              LIQUAMYCIN 
              MARBIFLOX 
              MARBOCYL 
              MARBOFLOXACIN 
              MARBOX 
              METORNIDAYOLE 
              METRO 
              METRONDIAZOLE 
              METRONEX 
              METRONIDAOLE 
              METRONIDAZLOE 
              METRONIDAZOL 
              METRONIDAZOLE 
              METRONIDAZOLEL 
              METRONIDOZOLE 
              METRONITAZOLE 
              MICOTIL 
              MILIMYCIN 
              MINOCYCLINE 
              MINOCYLINE 
              MMETRONIDAZOLE 
              MOXIFLOXACIN 
              MOXYFLOXACIN 
              MTRIMETHOPRIM 
              NAXC 
              NAXCEL 
              NAXCELL 
              NAXEL 
              NAXIV 
              NEOMYACIN 
              NEOMYCIN 
              NEOPEN 
              NEOPEN 
              NISAMOX 
              NITROFURANTOIN 
              NORADINE 
              NORDINE 
              NOROCILLIN 
              NOROCILLINLAINJ 
              NOROCLAV 
              NORODINE 
              NOROG 
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              NOROTYL 
              NUFLOR 
              OPTICLOX 
              ORBENIN 
              ORNICURE 
              OXACILLIN 
              OXYMYCIN 
              OXYMYCINE 
              OXYTET 
              OXYTETRA 
              OXYTETRACYCLIN 
              OXYTETRACYCLINE 
              OXYTETRIN 
              OXYTETS 
              OXYTOCIN 
              OXYTRACYCLINE 
              PEN&STREP 
              PENCILLIN 
              PENICILLI 
              PENICILLIN 
              PENICLLIN 
              PENLA 
              PENSTR1 
              PENSTREP 
              PETERCILLIN 
              PIPERACILLIN 
              POWERFLOX 
              PROCAINE 
              PULMODOX 
              READYCEF 
              RIFADIN 
              RIFAMPICIN 
              RIFAMPIN 
              RONAXAN 
              SMZ 
              SMZS 
              SMZT 
              SOLUDOX 
              SPECTAM 
              SPECTIN 
              SPECTINOMICIN 
              SPECTINOMYCIN 
              SPECTOGARD 
              SPECTRAMAST 
              SPECTROMAST 
              STOMORGYL 
              STREPTOMYCIN 
              STREPTOPEN 
              SULFADIAZINE 
              SULFADIAZONE 
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              SULFADOXINE 
              SULFAMETHOXAZOLE 
              SULFATRIM 
              SULPHADIAZINE 
              SULPHADOXINE 
              SULPHAMETHOXAZOLE 
              SULPHANILAMIDE 
              SULPHATHIAZOLE 
              SULPHONAMIDE 
              SULPHONAMIDES 
              SYNULOX 
              SYNUTRIM 
              TAZICEF 
              TAZOBACTAM 
              TAZOBACTUM 
              TERRAMYCIN 
              TETRACYCLINE 
              TETRAMIN 
              THIOSTREPTON 
              TIACIL 
              TICARCILLIN 
              TIMENTIN 
              TMPS 
              TMS 
              TRIBISSEN 
              TRIBRESSEN 
              TRIBRESSIN 
              TRIBRISSAN 
              TRIBRISSEN 
              TRIBRISSON 
              TRICARCILLIN 
              TRIMEDIAZINE 
              TRIMETHOPRIM 
              TRIMETOPRIM 
              TRIMS 
              TRIVETRIN 
              TUCAPRIM 
              TUCAPRIME 
              TUCCOPRIM 
              TUCOPRIM 
              TULATHROMYCIN 
              TULOSIN 
              TYLAN 
              TYLAN 
              TYLUVET 
              UBIFLOX 
              UBROLEXIN 
              ULTRAPEN 
              ULTRAPEN 
              UNIPRIM 
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              VANCOMYCIN 
              VETRIMYCIN 
              VIGAMOX 
              ZIMYCIN 
              ZITHROMAX 
              ZYMICIN 
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              ABX_INDUCE 
              ABX_INDUCED 
              ABX-INDUCED 
              ANTIBIOTIC_INDUCED 
              ANTIBIOTIC-INDUCED 
              ANTIMICROBIAL_INDUCED 
              ANTIMICROBIAL-INDUCED 
              BIOSPONGE 
              CHARCOAL 
              COCCIDIA 
              CODEINE 
              COLITIS 
              COWPAT 
              COW_PATCH 
              COW_PIE 
              COW-PATCH 
              COW-PIE 
              CYATH 
              CYATHOSTOME 
              CYATHOSTOMES 
              CYATHOSTOMIASIS 
              D+ 
              D++ 
              D++. 
              D+++ 
              DARRHOEA 
              DIAAHORREA 
              DIAARRHOEIC 
              DIAFFHOEA 
              DIAHOREEA 
              DIAHORREA 
              DIAOHHREA 
              DIAOHROEA 
              DIAORRHEA 
              DIARHAEA 
              DIARHEA 
              DIARHHOEA 
              DIARHOEA 
              DIARHOEE 
              DIARHORRA 
              DIARHORREA 
              DIAROEAH 
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              DIAROHEEA 
              DIAROHHEA 
              DIAROHOEA 
              DIAROOHEA 
              DIARR 
              DIARRAHEA 
              DIARREHA 
              DIARREHEA 
              DIARRH 
              DIARRHAE 
              DIARRHAEA 
              DIARRHEA 
              DIARRHEOA 
              DIARRHIAEA 
              DIARRHOA 
              DIARRHOAE 
              DIARRHOE 
              DIARRHOEA 
              DIARRHOEAL 
              DIARRHOEAPAINFUL 
              DIARRHOEIA 
              DIARRHOEIC 
              DIARRHOERA 
              DIARRHOES 
              DIARRHORA 
              DIARRHOREA 
              DIARRHOSIN 
              DIARROEA 
              DIARROEAH 
              DIARROHEA 
              DIARROHEOA 
              DIARROHOEA 
              DIARRORHAEA 
              DIARRORHEA 
              DIOROHEA 
              DIORREAH 
              DIORRHAEA 
              DIORRHEOA 
              DIORRHOEA 
              ENTEROCOLITIS 
              FORGASTRIN 
              FROM_ANTIMICROBIAL_TREATMENT 
              FROM_NSAID_TREATMENT 
              KAOGEL 
              KOLIN 
              LOOSE_FAECES 
              LOOSE_FECES 
              LOOSE_MANURE 
              LOOSE_TOOLS 
              NSAID_INDUCED 
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              NSAID-INDUCED 
              NSAIDS_INDUCED 
              NSAIDS-INDUCED 
              PEPTO 
              PEPTOBISMOL 
              POST_NSAID_ADMINISTRATION 
              REDWORM 
              REDWORMS 
              SALMONELLA 
              SCOUR 
              SCOURING 
              SOFT_FAECES 
              SOFT_FECES 
              SOFT_MANURE 
              SOFT_TOOLS 
              THICK_COLON 
              THICKENED_COLON 
              WATERY_FAECES 
              WATERY_FECES 
              WATERY_MANURE 
              WATERY_TOOLS 
    FROM_NSAID_TREATMENT 
              NSAID_INDUCED 
              NSAID-INDUCED 
              NSAIDS_INDUCED 
              NSAIDS-INDUCED 
              POST_NSAID_ADMINISTRATION 
              RD_COLITIS 
              RDC_EPISODE 
              RIGHT_DORSAL,COLITIS 
              RIGHT_DORSAL_COLITIS 
              RIGHT_DORSAL_COLITIS, 
              RIGHT_DORSAL_COLITS, 
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              ALSO_MONITOR_FOR_DIARRHEA_AS_WELL 
              BREAKS_WITH_DIARRHEA_HIS_PROGNOSIS_GOES_DOWN 
              BUT_TAPEWROM_AND_TX_LARVAL_CYATH 
              CALL_IF_ANY_DIARRHEA 
              CALL_IF_COLT_GETS_DIARRHEA 
              CALL_IF_DIARRHEA_OR_DECREASED_MANURE 
              CALL_IF_DIARRHEA_OR_OTHER_CONCERNS 
              CALL_IF_HE_HAS_DIARRHEA 
              CALL_IF_HORSE_HAS_DIARRHEA 
              CALL_IF_HORSES_HAVE_DIARRHEA 
              CALL_IF_PAIN_RETURNS_APPETITE_DROPS_FEVER_DIARRHEA 
              CALL_IF_SHE_HAS_DIARRHEA 
              CAN_COME_AFTER_THE_DIARRHEA_PHASE 
              CHARCOAL_DRESS 
              CHARCOAL_DRESSING 
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              CHARCOAL_HAS_BEEN_PREVENTING_MORE_EXCESS_PROUD 
              CHARCOAL_STUCK_ON_WITH_E-BAND 
              CONTINUE_MONITORING_FOR_SIGNS_OF_COLIC_DIARRHEA 
              CSSOTP_IF_DIARRH 
              CSSTOP_IF_DIARRHEA 
              DEVELOPS_DIARRHEA 
              DEVELOPS_LOOSE_MANURE_AND_CALL_US 
              DEVELOPS_SOFT_MANURE 
              DIARRHEA_DEVELOPS_STOPS_EATING 
              DIARRHEA_DISCONTINUE 
              DIARRHEA_GONE 
              DIARRHEA_HAS_NOT_COME_BACK 
              DIARRHEA_OR_FOR_ANY_CONCERNS 
              DIARRHEA_OR_SIGN_OF_COLIC 
              DID_NOT_SEE_ANY_MORE_DIARRHEA 
DISCONTINUE_USE_IMMEDIATELY_IF_SMOLE_SHOWS_SIGNS_OF_DIAR
RHEA 
              DISCUSSED_WITH_OWNER_POSSIBILITY_OF_DIARRHEA 
              DISPENSED_FOR_DIARRHEA_IN_FUTURE 
              DOES_NOT_HAVE_A_HX_OF_DIARRHEA 
              EGG_COUNT_-VE 
              EPG_-_NEEDS_WORMED_ADVISE_TO_USE_BIMECTIN 
FROM_THE_PROBLEM_LIST_WE_CAN_REMOVE_FEVER_AND_DIARRHE
A 
              HAS_NOT_HAD_ANY_HISTORY_OF_DAIRRHEA 
              HAS_NOT_HAD_DIARRHEA_SINCE 
              HAS_NOT_HAD_WATERY_DIARRHEA 
              HE_MAY_BECOME_OVERLY_DROWSY_OR_DEVELOP_DIARRHEA 
              I.E._WATCH_FOR_DAIRRHEA 
              IE_RECURRENCE_DIARRHEA_OR_SIGN_OF 
              IF DIARRHEA DEVELOPSN 
              IF DIARRHEA IS OBSERVED 
              IF DIARRHEA IS SEEN 
              IF DIARRHEA SEEN 
              IF DIARRHEA SHOULD DEVELOP 
              IF DIARRHEA STARTS 
              IF_ANY_DIARRHEA_PLEASE_CALL 
              IF_ANY_SIGNS_OF_ULCERS_OR_DIARRHEA_PRESENT 
              IF_CONCERNED_CAN_CHECK_DUNG_SAMPLE 
              IF_DIARRHEA_BEGINS_AGAIN 
              IF_DIARRHEA_DEVELOPS 
              IF_DIARRHEA_INAPPETENCE_ETC 
              IF_DIARRHEA_OCCURS 
              IF_FOAL_GETS_DIARRHEA 
              IF_HE_BREAKS_WITH_DIARRHEA 
              IF_LOOSE_MANURE_DEVELIOPS 
              IF_LOOSE_MANURE_DEVELOPS 
              IF_THE_HORSE_DEVELOPS_DIARRHEA 
              IF_YOU_NOTCIE_ANY_DIARRHEA 
              IF_YOU_NOTICE_DIARRHEA 
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              IF_YOU_NOTICE_LOOSE_MANURE 
              IF_YOU_NOTICE_SOFT_MANURE 
              KGSTOP_IF_DIARRHEA 
              LARVAL_COUNT_NEGATIVE 
              MAY_CAUSE_DIARRHEA 
MONITOR_BOTH_HORSES_FOR_A_DECREASE_IN_APPETITE_DEPRESSI
ON_A_FEVER_ABOVE_102.5_DIARRHEA 
              MONITOR_DAILY_FOR_DAIRRHEA 
              MONITOR_FOR_ANY_DIARRHEA 
              MONITOR_FOR_COLIC_DIARRHEA_SORENESS_IN_FEET 
              MONITOR_FOR_COUGH_NASAL_DISCHAGE_DIARRHEA 
              MONITOR_FOR_DIARRHEA 
              MONITOR_FOR_INCREASED_FOOT_SORENESS_DIARRHEA 
              NOT_PASSED_ANY_DROPPINGS_SINCE_YESTERDAY 
              NO_COUGH_SNEEZE_DIARRHEA 
              NO_COUGHING_SNEEZING_DIARRHEA 
              NO_CYATH_TX._ADVISE_EQUESTS_FOR_MOST_PAN_GAURD 
              NO_D+ 
              NO_D++ 
              NO_DIARRHEA 
              NO_EVIDENCE_OF_DIARRHEA 
              NO_FEVER_OR_DIARRHEA 
              NO_HX_OF_DIARRHEA 
              NO_LOOSE_MANURE 
              NO_MANURE_DIARRHEA 
              NO_MORE_DIARRHEA_NOTED 
              NO_MORE_DIARRHEA_PRESENT 
              NO_NEW_MANURE_DIARRHEA 
              NO_NEW_MANURE_OR_DIARRHEA 
              NO_RECURRENCE_OF_THE_DIARRHEA 
              NO_SIGN_OF_DIARRHEA 
              NO_SIGNS_COLIC_OR_RECURRENT_DIARRHEA 
              NO_SIGNS_OF_ANY_DIARRHEA 
              NO_SIGNS_OF_COLIC_OR_DIARRHEA 
              NO_SIGNS_OF_DIARRHEA 
              NO_SIGNS_OF_LAMENESS_OR_DIARRHEA 
              NORMAL DEFECATION 
              NORMAL_MANURE 
              NORMAL_MANURE 
              NOT ISOLATED 
              PKSTOP_IF_DIARRHEA 
              PLANNING_ 
              RCSTOP_IF_DIARRHEA 
              RGSTOP_IF_DIARRHEA 
RISKS_WITH_OXYTET_INJECTIONS_INCLUDING_RESP._DISTRESS_COL
IC_DIARRHEA 
              SHOWS_SIGNS_OF_COLIC_OR_DIARRHEA 
              SIGNS_OF_LAMINITIS_WORSENING_SKIN_IRRITATION_DIARRHEA 
              SOFT_FAECES_PALPABLE_IN_RECTUM 
              SOFT_FECES_FILLING_THE_RECTUM 
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              SPECTAM_SCOUR 
              STOPPED_SCOURING_YESTERDAY 
              SWAB_STANDARD_CHARCOAL 
              SWELLING_ABOVE_THE_WRAP_DECREASED_APPETITE_DIARRHEA 
              THERE_IS_SOME_RISK_OF_DIARRHEA 
              THIS_MEDICATION_CAN_CAUSE_DIARRHEA 
              THIS_MEDICATION_CAN_CAUSE_LOOSE_MANURE 
WATCH_FOR_ANY_DIARRHEA_AND_CALL_IMMEDIATELY_AND_DISCO
NTINUE_MEDS_IF_IT_HAPPENS 
              WATCH_FOR_ANY_SIGN_OF_DIARRHEA 
              WATCH_FOR_DIARRHEA 
              WATCH_FOR_DIARRHEA 
              WATCH_FOR_DIARRHEA_LACK_OF_FECES 
              WATCH_FOR_DIARRHEA_TEETH_GRINDING_COLIC 
              WILL_LIKELY_PASS_SOME_SOFT_MANURE 
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              ADCORTYL 
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